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1 Introduction and Goals 
Our ecosystem is severely tested by the ever increasing needs of today’s “society of consumers” 
and the continuously growing population. The concept of sustainable development strives for an 
evolution in balance with the ecosystem which implies that the current and future use of energy 
and natural resources does not exceed the carrying capacity of the Earth. It would be foolish to 
think that this can be achieved without switching to a less energy- and resource-consuming way 
of producing and consuming. 
A lot of research these days is focussed on the use of bioresources as a source of raw material in 
the chemical industry.1 Whether resources for the chemical industry are renewable or not is 
irrelevant to the fact that one always has to try to achieve a specific chemical transformation in 
the most efficient way in order to limit the amount of waste and used energy. It is in this 
perspective that the use of catalysts has to be seen. A catalyst is a substance that makes a 
reaction go faster, by decreasing the activation energy, without being consumed in this reaction. 
In this way certain processes can be achieved that otherwise would demand an immense energy 
input or would not be possible at all. 
 
Uncatalyzed reaction
Catalyzed reaction
time
energy
activation energy
 
Figure 1: Difference in activation energy between catalyzed and uncatalyzed reaction. 
 
Almost 80% of all processes in the chemical industry use catalysts. Famous examples are the 
production of NH3 in the Haber process (Fe catalyst, 140 million tonnes per year), the synthesis 
of nitric acid (Pt/Rh catalyst, 60 million tonnes per year), the synthesis of sulfuric acid (V2O5 
catalyst, 140 million tonnes per year) and the production of margarine by hydrogenation of 
vegetable oils (Ni catalyst, 2 million tonnes per year).2 Catalysts are found in many different 
forms. Roughly, catalysis can be divided in three classes: homogeneous catalysis, heterogeneous 
catalysis and biocatalysis. The best known biocatalysts are called enzymes which are responsible 
for many fundamentally important reactions in living organisms. In heterogeneous catalysis the 
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catalyst and the involved reaction components are present in a different phase (e.g. solid catalyst 
in liquid). In homogeneous catalysis both the catalyst and reaction components are distributed to 
the molecular level in a single phase. 
 
It is the goal of this work to use homogeneous catalysis for the synthesis of fine chemicals. More 
precise, compounds will be targeted that are very difficult to synthesize in a non-catalytic way 
and that are biologically important or closely related to a biologically important group of 
compounds. Attention will be focussed on three major groups: pyrroles, hydantoins and benzo-
fused heterocycles. Since the synthesis of new molecules almost always consists of many 
different synthetic steps, it is virtually impossible to perform every single transformation in a 
catalytic way. Therefore, in this thesis, only the key transformation will be performed using 
homogeneous catalysis. The work in this thesis is based on ring-closing metathesis (RCM), a 
catalytic process in which two carbon-carbon double bonds are broken and one new carbon-
carbon double bond is formed. Furthermore, attempts will be made to achieve multiple 
transformations (both catalytic and non-catalytic) in a single synthetic operation thus decreasing 
the amount of steps needed to obtain a certain compound. 
 
During previous research at our department using a novel bimetallic catalyst 1,3 it was found that 
diallylamines 2 are converted to pyrroles 3 instead of to the expected pyrrolines 4. 
 
N
R
N
R
N
R
Ru CHPh
Cl
Ru
O
N
Cl
1
Cl
2 examples
10% 110% 1
2 34
 
 
Since the importance of the pyrrole nucleus is evident by its presence in both natural and 
synthetic biologically active compounds,4 the abovementioned new entry towards this interesting 
heterocycle has to be further explored. Some examples of physiologically active pyrroles are 
pyrrolnitrin 5 (antifungal) and derivative fenpiclonil 6,5 viminol 76 (analgesic), the antibacterial 
heterocycle 87 and antimycobacterial compound 98 to name but a few. 
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N
H
R1
R2
R3
5 R1 = R3 = Cl, R2 = NO2
6 R1 = CN, R2 = R3 = Cl
N
Cl
N
OH
N
N S
F
7 8
N
N
F
OO
N
H
O
9
 
 
The prime goal will be to establish the general nature of this pyrrole formation and develop a 
standard protocol that can be used for the synthesis of a variety of mono- and polycyclic 
pyrroles. Once a workable protocol for the catalytic synthesis of pyrroles has been developed, an 
attempt will be made to use this methodology for the synthesis of phosphonylated pyrroles. 
Phosphonylated azaheterocycles are an important class of compounds with high biological 
potential as conformationally restricted bioisosteres of amino acids. Some interesting activities 
are shown by azaheterocyclic five-membered rings with phosphonates at various positions like 
compound 10 (bactericidal, fungicidal, herbicidal) and compound 11 (antibiotic).9 
 
N
H
P(O)(OH)2HOHN
10
N
11
OH
O OH
(HO)2(O)P
 
 
Only a limited amount of research on the synthesis of the aromatic counterpart of 
phosphonylated five-membered rings has been performed, however, leaving much room for new 
developments in this field. An attempt will be made to convert imines 12, versatile compounds in 
organic synthesis,10 to α-aminophosphonates 13. 
 
R1 H
R2
N
R3
12
R1 P(OMe)2
R2
N
O
R3Ph
N P(OMe)2
R2
Ph
R3
O
N P(OMe)2
R2
Ph
R3
O
13 14
15  
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Under standard RCM conditions these compounds should be converted to pyrrolines 14 whereas 
the ‘to be developed protocol’ should be able to convert them to pyrroles 15. 
 
Next to this sequence, a ring-closing enyne metathesis (RCEYM) approach will also be envisaged 
which also leads to phosphonylated pyrroles and pyrrolines. RCEYM is even more atom-efficient 
than RCM since all atoms from the starting material are retained in the end product. For this, 
suitable imines 16 have to be converted to α-aminophosphonates 17. These compounds can 
then be converted to pyrrolines 18 or to pyrroles 19, depending on the conditions used. Since 
intramolecular RCEYM reactions between a terminal alkyne and a non-terminal alkene have not 
been systematically studied in the literature, an extra effort will be made in order to unravel the 
details concerning the precise reaction mechanism. 
 
R1 H
R2
N
16
R1 P(OMe)2
R2
N
O
Ph
N P(OMe)2
R2
Ph
O17
18
R1
N P(OMe)2
R2
Ph
O
R1
19  
 
Preliminary research at our department has shown that pyroglutamates 20 undergo an 
interesting ring-transformation upon reaction with isocyanates 21 leading to hydantoins 22.11  
 
N
H
O
O
OR1
CX N
R2
20
HN N
O
X
R2
R1OOC
22
NaH
THF, RT
21  
 
Hydantoins have been extensively studied and are reported to possess a wide range of biological 
activities. Phenetoin 23, for example, was already synthesized in 190812 and is now still the drug 
of choice for the treatment of certain types of epileptic seizures. Compounds with general 
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structure 24 are known for their fungicidal, herbicidal and bactericidal properties. Dibromantin 
(R1 = R2 = Br) for example is a disinfectant used for water purification and glycoserve (R1 = R2 = 
CH2OH) is a pesticide used in paints. A well known fungicide containing the hydantoin nucleus is 
iprodione 25. Allantoin 26 was originally isolated from the comfrey plant (Symphytum officinale 
L., Dutch: smeerwortel) and is used for its healing and anti-irritating properties in a lot of 
skincare products like shaving cream, to help heal minor cuts. It is also frequently used in 
toothpaste, shampoos, lipsticks, lotions, ... Dantrolene 27 is a muscle relaxant that is used in 
cases of muscle spasticity for example for persons with ecstasy (XTC) intoxication. Finally, 
fosphenytoin 28 is a water soluble prodrug of phenetoin. In the body it is hydrolyzed to yield 
phosphate, formaldehyde and phenetoin 23. 
 
HN NH
O
O
23
Ph
Ph
N N
O
O
24
R1 R2
R1, R2 = Cl, Br, CH2OH, H
N N
O
O
25
Cl
Cl
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O
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Furthermore, several hydantoin derivatives with an extra fused ring show some interesting 
medicinal properties. Bicyclic compound 29 is an inhibitor for the LFA-1/ICAM interactions 
(Leukocyte Function-Associated antigen-1 / InterCellular Adhesion Molecule).13 Derivatives 30 
are androgen receptor antagonists and may play an important role in the treatment of prostate 
cancer.14 Finally, hydantoins 31 bind selectively to certain receptors involved in regulating a 
variety of neurotransmitters in the central nervous system.15 
 
N N
O
O
29
Cl
Cl
Br
N N
O
O
31
RN N
O
O
30
R
H
 
 
Attempts will be made to synthesize polycyclic hydantoin derivatives 33 starting from 
pyroglutamates 20. Functionalization of the pyroglutamate at the 2-position, subsequent ring-
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transformation and N-functionalization should lead to 32. With the two double bonds ready for 
cyclization, treatment with a metathesis catalyst should produce derivatives 33. Reaction of 20 
with allylisocyanate followed by N-functionalization should yield 34. Ring-closing of 34 could lead 
to derivatives 35 containing a seven-membered ring. Also the reaction of pyroglutamates with 
diisocyanates leading to derivatives 36 will be investigated. Bis-hydantoins, usually dimers of 
phenetoin or related compounds, have been tested as analogues of HMBA 38 
(hexamethylenebis(acetamide)) and might prove effective in cancer treatment.16,17 The problem 
with these compounds is their poor water solubility, requiring high doses. Since derivatives 36 
have an ester moiety on a side chain, the increased polarity might lead to an activity at lower 
concentrations. Attempts will be made to cyclize these compounds to macrocyclic derivatives 37. 
N
H
O COOR1
33
N N
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N
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O
O
R1OOC
R3
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Finally, a new entry will be developed towards benzo-annulated heterocycles. Benzo-fused 
compounds, and especially seven-membered ring systems, have received a lot of attention over 
the years because of their ubiquitous appearance in natural products and modern 
pharmaceuticals.18 Two important examples are diazepam 39 (Valium®) and flurazepam 
(Dalmadorm®) 40, mostly used in psychotherapy. Other commercially available drugs include 
capsazepine 41, used to treat respiratory disorders like astma,19 benazepril 42, used to lower 
blood pressure in case of hypertension, hart failure and stroke and finally fenoldopam 43, a rapid 
vasodilator. 
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Derivatives of type 44 are inhibitors of acetylcholinesterase and may find application in the 
treatment of Alzheimer’s disease.20 
NCl
O
R
O
NMe2O
X
44
N
COOH
O
NH
EtOOC
Ph
42
NH
HO
43
HO
Cl
HO
 
 
So far only one entry to 1H-2-benzazepine-1-ylphosphonates 45 has been reported in the 
literature.21 Furthermore, only a few papers have been published in the field of seven-membered 
azaheterocyclic phosphonates, although some of these compounds show interesting biological 
properties like bone-resorption inhibitory activity.22 An attempt will be made to synthesize these 
compounds starting from α-aminophosphonates 46 or 47 using a tandem enyne-metathesis—
cross metathesis with an alkene. 
 
4546
alkene (R2) alkene (R1)
N
P(O)(OMe)2
PG
47
N
P(O)(OMe)2
PGN
PG(MeO)2(O)P
R1 R2
 
 
The same methodology will be used to try to synthesize other benzo-annulated phosphonylated 
heterocycles like benzoxazonines and benzoxazepines. 
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2 Literature Overview on Ring-Closing Metathesis 
2.1 History of RCM 
In 2005, the Nobel Prize in Chemistry was awarded jointly to Yves Chauvin, Robert H. Grubbs 
and Richard R. Schrock “for the development of the metathesis method in organic synthesis”. 
The discovery of catalyzed metathesis dates from the 1950s in industry when Ziegler observed 
the polymerization of ethylene. Later on, polymers were obtained starting from norbornene, 
cycloheptene, cyclooctene, cyclododecene and it was observed that propene was converted to 
ethylene and butene. The mechanisms behind these reactions were not understood and instead 
of defined catalysts mixtures of compounds (like MoO3 on alumina combined with LiAlH4 or 
AliBu3, WCl6 combined with Et3Al, Et2AlCl or EtAlCl2) were used to achieve these conversions. 
Several mechanistic hypotheses were formulated to explain these results like the metal-
coordinated ‘quasicyclobutane’ model of Calderon23,24 who proposed a pairwise exchange of 
alkylidenes (48-51) and the metallacyclopentane model of Grubbs (52-56).25  
 
R2
R2
R1
R1
M
R1
R1
R2
R2
M
R1
R1
R2
R2
M M
R1
R2
R2
R1
48 49 50 51  
 
R
R
M M
R
R
M
R
R M
R
R
R
M
R
52 53 54 55 56  
 
In 1971 Chauvin proposed a non-pairwise mechanism with a metal carbene as the acting catalyst 
which connects two terminal alkenes into an internal alkene with the formation of ethylene.26 
Every step in the reaction is an equilibrium, but the removal of ethylene drives the reaction to 
completion. The metal alkylidene plays a central role in this mechanism. In a first step the metal 
methylidene 57 reacts with an alkene 58 to form a metallacyclobutane 59. This four-membered 
ring cleaves with the formation of a new metal alkylidene 60 and ethylene 61. The ethylene 
formed contains one methylene from the catalyst and one from the starting alkene. The metal 
alkylidene 60 again reacts with a molecule of alkene 58 to form a new metallacyclobutane 62. 
Literature Overview 
-9- 
Upon decomposition, the internal alkene 63 is formed and the methylidene carbene 57 is 
regenerated. 
 
[M]
R1
M
R1
[M]
M
R1 R1
R1
R1
R1
R1
57
60
58
59
6158
62
63
 
 
After extensive experimental work, this mechanism became accepted as the mechanism for 
metathesis. A famous experiment performed by Grubbs lies at the basis of this acceptance. A 1:1 
mixture of 1,1,8,8-tetradeutero-1,7-octadiene 64 and 1,7-octadiene 65 was treated with a 
catalyst to produce cyclohexene 66 and a statistical mixture of deuterium labeled ethylenes. 
Statistical analysis had shown that the kinetic products formed in the non-pairwise mechanism 
(Chauvin) should appear in a 1:2:1 ratio whereas in the pairwise mechanism (Calderon) a 1:1.6:1 
mixture should be formed. It was found that a 1:2:1 mixture was formed, which could only be 
explained by the Chauvin mechanism.27 Experiments carried out later with other labeled 
compounds also pointed towards the Chauvin mechanism.28,29 
CD2
CD2
CH2
CH2
+
H2C CH2
H2C CD2
D2C CD2
+
non-pairwise pairwise
1
2
1
1
1.6
1
64
65
66
catalyst
 
 
This insight in the reaction mechanism prompted chemists to try to synthesize stabile alkylidene 
carbenes that could catalyze metathesis reactions, rather than working with the in situ generated 
undefined catalysts used up to that time. It wasn’t until the mid 1980s however that a stable 
metal carbene was synthesized by Schrock and his co-workers that showed metathesis activity.30 
The work of Schrock resulted in the synthesis of a whole family of Mo and W based catalysts 
possessing very high metathesis activity with general formula 67, some of them are commercially 
available like 68.31,32,33 
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M
NAr
RO
RO
H
tBu Mo
N
Ph
iPriPr
O
CF3
F3C
O
F3C
F3C
67 68
 
 
Although Schrock’s catalysts are stable and well defined, they are very sensitive to moisture and 
air. In 1992 Grubbs and co-workers reported the first well defined ruthenium carbene complex 
69 that did not only show good metathesis activity, but was also air-stable and could be used 
under standard lab conditions.34 Three years later, the PPh3 ligands were replaced by PCy3 
(tricyclohexylphosphine) ligands and the vinylidene carbene by a benzylidene carbene; catalyst A 
which would later be called the “first-generation Grubbs’ catalyst” was born.35 In order to 
increase both the activity of the catalyst and its lifetime, one of the phosphine ligands was 
replaced by a cyclic bis-amino carbene ligand.36 This catalyst B with greater thermal stability is 
now known as the “second-generation Grubbs’ catalyst”. 
 
N N
RuCl
Cl
PCy3
PCy3
RuCl
Cl
PCy3
PPh3
RuCl
Cl
PPh3
Ph
Ph
Ph
Mes
Ph
Mes
69 A B  
 
The Grubbs’ catalysts, with their ease of handling and tolerance to a wide variety of functional 
groups, have offered synthetic chemists opportunities to explore a whole range of new reactions. 
These reactions can be classified into different classes. In this thesis ring-closing metathesis 
(RCM), cross metathesis (CM) and ring-closing enyne metathesis (RCEYM) are used. 
 
n
n
R1
R2
R1 R2
+
+
R1 R2+
R1
R2
+
R2
R1
R1
R1
R1
R2
+
Ring-opening metathesis polymerization (ROMP)
Acyclic diene metathesis polymerization (ADMEP)
Ring-opening cross metathesis (ROCM)
Cross metathesis (CM)
Ring-closing metathesis (RCM)
Ring-closing enyne metathesis (RCEYM)
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As a consequence of the ‘ease of handling’ of these catalysts, the number of articles dealing with 
metathesis has grown exponentially over the years. To illustrate this, figure 2 shows the 
cumulative amount of articles found in Web of Knowledge containing the term ‘ring-closing 
metathesis’ in the title, keywords or abstract between 1995 and 2005. 
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Figure 2: Cumulative amount of articles found in Web of Knowledge containing 
the term ‘ring-closing metathesis’ in the title, keywords or abstract between 
1995 and 2005. 
2.2 RCM in organic synthesis; a short appetizer 
2.2.1 The Chauvin mechanism applied to the Grubbs’ catalysts 
The Grubbs’ catalysts are Ru(II) based 16 valence-electron complexes with a general formula like 
70 (L = ligand). In this form, they are stable and inert and can be stored for years without 
decomposition. When brought in solution, however, a phosphine ligand can dissociate to form the 
active 14 valence-electron complex 71. An alkene, present in the solution, can act as a new 
ligand to form another 16 valence-electron complex 72. A [2+2] cycloaddition results in the 
formation of ruthenacyclobutane 73, with 14 valence-electrons and the oxidation state of 
ruthenium changes to IV.37 The dissociation of the phosphine ligand, the initiation step, occurs 
much faster (about two orders of magnitude) in the first generation complex (L = PCy3) than in 
the second generation complex (L = SIMES, Saturated Imidazole N-Mesityl, 1,3-dimesityl-4,5-
dihydroimidazol-2-ylidene). This is more than compensated, however, by the selectivity towards 
alkenes versus phosphines (about four orders of magnitude) for the second generation complex 
compared to the first generation complex. This results in an overall greater activity of the catalyst 
bearing a N-heterocyclic carbene (NHC) ligand. In a series of experiments, Grubbs was able to 
determine the rate constants k1 and k2 of the different Ru-complexes in reaction with 
ethylvinylether as well as the Gibbs free activation energies for phosphine dissociation (Table 
1).38,39 
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L
RuCl
Cl
PCy3
R
L
RuCl
Cl R
+PCy3
-PCy3
16 e- Ru(II) 14 e- Ru(II)
L
RuCl
Cl R
O
16 e- Ru(II)
L
RuCl
Cl
14 e- Ru(IV)
O
R
70 71 72 73
k1 k2
ΔG
 
 
 Table 1: rate constants k1 and k2 of reaction with ethylvinylether and Gibbs free 
activation energies for phosphine dissociation of different Ru-complexes 
 
 L = PCy3 L = SIMES  
 ΔG = 83.2 kJ/mol ± 0.3 kJ/mol ΔG = 96.2 kJ/mol ± 1.7 kJ/mol  
 k1/k2 = 1.3x104 k1/k2 = 1.25  
 
From these results it is clear that although the formation of the active species is quite slow for 
the second generation catalyst (larger ΔG), the association with an alkene occurs extremely fast 
resulting in an overall much greater activity (in this case about four orders of magnitude). 
 
The complete catalytic cycle for ring-closing of 1,6-heptene 75 is depicted in the scheme below. 
After the active species 74 is formed by dissociation of the phosphine ligand, the alkene can 
associate with one of its double bonds. For clarity reasons, the ruthenium with all its remaining 
ligands is depicted as [Ru]. A [2+2] cycloaddition produces ruthenacyclobutane 76 which forms 
styrene 78, as a side product, and new carbene 77 after cycloreversion. 
 
[Ru]
[Ru]
61
79
[Ru]
[Ru]
Ph
[Ru]
Ph
[Ru]
Ph
75
74
76 78
77
80
81
82
75
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Now the other double bond can associate with the ruthenium and another cycloaddition leads to 
bicyclic compound 79. Cycloreversion forms the end product cyclopentene 81 and methylidene 
carbene 80. This carbene is considered as the propagating species that is continuously 
regenerated during the course of the reaction. The cycle continues with association and 
subsequent cycloaddition of another molecule of substrate, forming 82, which decomposes with 
formation of 77 and ethylene 61. Since all steps in this reaction sequence are in fact equilibria, 
removal of ethylene from the mixture drives the reaction to completion. 
2.2.2 Ring-closing metathesis in action 
As stated before, the number of reports on the use of RCM has grown exponentially. Therefore, a 
systematic overview of this subject can not be presented here. The interested reader is kindly 
invited to consult following reviews for more information: olefin metathesis,40,41,42,43,44 non-
metathetic behaviour of Grubbs’ carbenes,45 Ru complexes with bidentate carbenes,46 enyne 
metathesis,47,48 group-selective ring-closing enyne metathesis,49 Ru complexes with bidentate 
Schiff base ligands for organic and polymer synthesis,50 tandem and stepwise metathesis/non-
metathesis processes,51,52 molybdenum and tungsten catalysts,53 metathesis in total synthesis,54 
RCM for the construction of aromatic compounds,55 the evolution of metathesis,56,57 synthesis of 
oxygen- and nitrogen-containing heterocycles by RCM,58 synthesis of phosphorus and sulfur 
heterocycles by RCM,59 metathesis/hydrogenation tandems,60 synthesis of peptidomimetics, 
sugars and alkaloids by RCM,61 factors influencing ring-closure,62 cross-metathesis.63 In what 
follows, a very short summary of some interesting examples of RCM in organic synthesis will be 
given, although this is merely ‘scratching the surface’. Two important developments, namely the 
use of RCM for the synthesis of aromatic compounds and RCM in a tandem reaction sequence will 
be dealt with in more detail later. 
 
Pentalongin 86 is a natural product from the Central-East African medicinal plant Pentas 
longiflora Oliv., which is used in the region for treatment of malaria and certain skin diseases. 
Starting from dimethoxynaphthalene derivative 83, the RCM substrate 84 was synthesized in two 
steps; the first being isomerization of the allylic double bond and the second vinylation of the 
primary alcohol. Treatment of this precursor with first generation catalyst A resulted in the 
formation of 85, the reduced and protected form of pentalongin. This compound was 
transformed in 3 additional steps to the target compound 86.64 
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OMe
OMe
O
OMe
OMe
O
OMe
OMe
1. 3 equiv KOtBu
    THF, RT, 3h
    
2. 5 equiv vinyl acetate
    0.6 equiv Na2CO3
     0.001 equiv [IrCl(cod)2]
    toluene, 100°C, 12h
7% cat. A
toluene, RT, 12h
then 100°C, 12h
O
O
O
OH
83 84 91% 85 86%
86 49%  
An elegant approach to the piperidine alkaloid (−)-halosaline 90 using a combination of ring-
opening metathesis and ring-closing metathesis, also called ring shuffling metathesis, was 
developed by Blechert.65 Functionalized cyclopentene derivative 87 was treated with first 
generation catalyst A resulting in opening of the five-membered ring and the formation of two 
less strained six-membered rings 88. After cleavage of the O-Si bond, 89, the double bonds 
were reduced and the N-atom was deprotected to yield 90. 
 
5% cat. A
O
N
Si
Tos
N
H
Tos
Si
O
N
H
Tos
OHTBAF
-78°C to RT N
H H
OH1. H2, Pd/C
2. Na/Hg
87 88 8978% over both steps
90 81%
 
 
The alkaloid (−)-balanol 96, with a hexahydroazepine nucleus, is a new lead structure in the 
quest for protein kinase C inhibitors. A total synthesis to form the seven-membered core of this 
compound was developed by Fürstner.66 Commercially available alcohol 91 was converted to the 
RCM substrate 92 in four steps in 89% yield. Treatment of this compound with catalyst 95 
effects the formation of the seven-membered ring 93 which is converted to 94 in three steps in 
50% yield. 
NH
O H
N O
OH
O
OH
HO
OH
OH
O
96
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5% cat. 95
N
OBn
OH
Boc
Ru
PCy3
PCy3 Ph
Cl
Cl
N
OBn
OH
Boc
N
OBn
Boc
H
N O
OBn
OH
91
92 89% 93 87% 94 50%
95  
 
Coumarins are widespread in nature as physiologically active components of plants and show 
interesting biological properties like antimicrobial, anticancer and anti-HIV activity. Commercially 
available phenols 97 were transformed in four straightforward steps to α,β-unsaturated esters 
98. When subjected to the action of the second generation catalyst B, these compounds were 
cyclized to coumarins 99.67 A similar approach to coumarins, with substituents at the α,β-
unsaturated bond, was independently developed by Grubbs.68 
 
5% cat. B
CH2Cl2, Δ, 24h
O
O
R1
R2
R3
R4
O
O
R1
R2
R3
R4
OH
R1
R2
R3
R4
97 98
5 examples: 70-90%
99  
 
The odour compound of animal origin (R)-(−)-muscopyridine 103, has attracted a lot of 
attention from organic chemists but was only recently very efficiently synthesized by Fürstner.69 
The synthesis is based on two key reactions. The first one being an alkyl-aryl cross-coupling 
catalyzed by an iron-salen complex and the second being RCM. Functionalized pyridine 100 is 
transformed in two iron-salen catalyzed cross-couplings to open chain derivative 101 in about 
65% yield. Treatment of the HCl salt of 101 with catalyst 95 gives 102 as an E/Z mixture. This 
crude mixture was placed under a high pressure H2 atmosphere and after a basic workup 
muscopyridine 103 was obtained in 57%. 
N OTfCl
N N
H
Cl
N1. HCl, Et2O
2. 5% cat. 95
    THF/NMP, 0°C
1. H2, 50atm
2. aq. NaHCO3
102 103 57%101 65%
100
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In relay metathesis, an acyclic precursor containing two double and several triple bonds is 
cyclized to a polycyclic entity. A very nice example of this was reported by Grubbs and truly 
shows the power of this technique.70 Thus (dienyl)polyalkyne 104 was transformed in a single 
step to the tetracyclic compound 108 possessing the steroid skeleton. The catalyst initiates at 
the terminal double bond and then reacts with the nearest triple bond to form a new ring 105. 
Every triple bond acts as an anchor that keeps the catalyst attached to the molecule. The 
catalysts moves from one triple bond to the next, from 105 to 106 to 107, and after the final 
cyclization the catalyst is split off and ready to react with another molecule of 104. 
 
4-8% cat. A
C6H6, 40-45°C
OTBS
OTBS
108 70%
[Ru]
OTBS
[Ru]
OTBS
[Ru]
OTBS
104
105 106 107
 
 
Recently the first ever use of RCM for production scale synthesis was described by German 
researchers at Boehringer Ingelheim.71,72 The fifteen-membered macrocycle 110 is a precursor 
of the antiviral drug BILN 2061 ZW, which has been developed against the Hepatitis C virus. In 
total, 400 kg of compound 110 was needed and this was achieved by conducting the cyclization 
of 109 in batches of 20.2 kg diene in toluene at 80 °C. 
 
N
O
NH
O
O
O
H
N
O
O N
O
NH
O
O
O
H
N
O
O
Ru
O
Cl
Cl
NMesMesN
3% cat. 111
toluene, 80°C
109 110 83%111
OR OR
 
 
In order to prevent dimerization instead of cyclization, the reaction has to be run at a very low 
concentration of 14.64 mmol/l, i.e. 7.3 g of diene 109 per litre toluene. The second generation 
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Hoveyda-Grubbs catalyst 111 was used with a loading set to about 3 mol%. This means that 
about 493 g of catalyst was needed for each reaction run! 
 
A relatively new chapter in metathesis is the synthesis of chiral Ru complexes like catalyst 112.73 
The usefulness of this kind of catalysts is shown by several examples like the asymmetric ring-
opening/cross metathesis of substrate 113 in the presence of an alkene 58. After the reaction, 
the catalyst can be recovered up to 96%. The ring-opened compounds 114 are obtained in 
reasonable yield and good enantioselective excess. The same catalyst was used for the 
enantioselective ring-closing of ether 115. Dihydro pyran 116 was obtained in excellent yield 
with reasonable enantiomeric excess. 
 
MesN N
Ru
O
Ph
Cl
O
112
OO O
2 equiv.
0.5-10% cat. 112
THF, 50°C
R1 58
O
R1
O O
113 80-82% ee
57-71%
114
O
O
H
10% cat. 104
ClCH2CH2Cl, 60°C
76% ee, 98%
116115  
 
Very recently Grubbs reported on the synthesis and evaluation of the new catalyst 117, with a 
poly(ethylene glycol) (PEG) chain attached to the nondissociating NHC ligand.74 This very polar 
side chain makes the catalyst soluble in methanol and water. The remarkable stability of the 
ruthenium carbene was again proven by conducting RCM in water. Thus quaternary ammonium 
salt 118 could by cyclized to 119 in excellent yield. Also cross metathesis proved to be possible, 
shown by dimerization of allyl alcohol 120 to 121. The use of PEG as support for metathesis 
catalysts has also been reported by other research groups.75 
 
Ru
O
Cl
Cl
NMesMesN
5% cat. 117
H2O, 45°C, 12h
117
OPEG-Me
NCl
N
Cl
118 119 >95%
5% cat. 117
H2O, 45°C, 12h
OH OH
HO
120 121 >95%  
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2.3 RCM as a basis for the synthesis of aromatic compounds 
2.3.1 Introduction 
At the beginning of this PhD in august 2003, there was no general route to aromatic compounds 
using RCM. In the following years, however, this became a new ‘hot topic’ in organic synthesis. 
The strategy developed in this work is based on a one-pot combination of ring-closing metathesis 
and oxidation in which both the ruthenium catalyst and the oxidant are present at the beginning 
of the reaction. To this date, no other research group has developed a similar protocol. In what 
follows an overview is presented of the different strategies developed in recent years used to 
synthesize aromatic compounds by RCM. 
2.3.2 Direct formation of aromatic compounds by RCM 
Evidently, the easiest way to construct aromatic compounds by RCM is choosing the correct 
starting material that upon cyclization immediately leads to the aromatic compound. Although 
this strategy leads directly to the desired compounds, it has limited use due to the non-
availability and stability of suitable starting materials. This strategy was applied for the synthesis 
of benzofurans 123 using a Mo based catalyst for the cyclization of enol ethers 122.76 A very 
similar strategy can be applied for the synthesis of indoles 125. In this case the second 
generation Grubbs’ catalyst B was used to cyclize enamines 124.77 These enamines were 
obtained by isomerization of the double bond using catalyst B modified with 1 equivalent of 
vinyloxytrimethylsilane. The second generation catalyst was later used for the synthesis of a 
number of phenanthrenes78,79 and ring-fused carbazoles.80 
 
O R O
R N N
TosOMe
MeO
MeO
TosOMe
MeO
MeO
122 123, 87% 124 125, 83%
Mo cat.
hexane, 60°C
cat. B
toluene, Δ
 
 
2.3.3 RCM followed by elimination of a leaving group 
Another strategy used to obtain aromatic compounds is incorporating a proper leaving group in 
the ring that upon elimination leads to aromatization. This strategy was used for the first time in 
2001 for the synthesis of a number of naphthalene derivatives 128.81 The diene precursors 126 
were cyclized to 127 using the first generation Grubbs’ catalyst A and aromatized by dehydration 
using silica gel. A very similar combination of cyclization and elimination of water was used for 
the synthesis of a benzimidazole in the presence of TsOH.82 
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126
cat. A
CH2Cl2, RT
OR1
MeO
R2
OH 127
OR1
MeO
R2
OH
silica gel
128, 80-92%
OR1
MeO
R2
 
 
A general approach to pyrroles was developed by Lamaty and coworkers.83 They observed that 
trimethylsilylethanesulfonyl (SES)-protected84 pyrrolines 130, formed by cyclization of 129 using 
second generation catalyst B, aromatize to the corresponding pyrroles 131 upon base-induced 
deprotection of the N-atom. The same group had previously observed the formation of pyridines 
upon fluoride-induced deprotection of the PEG-supported SES-group on tetrahydropyridines.85 
 
N
SES
Ar
MeOOC
N
MeOOC
Ar
SES
N
H
MeOOC
Ar
5% cat. B
CH2Cl2, RT
KOtBu
DMF
129 130, 90-98% 131, 66-88% 
 
Donohoe and coworkers came up with an approach to furans and pyrroles by TFA promoted 
elimination of methanol after cyclization.86 In a first step, diene precursors 132 and 135 were 
treated with second generation catalyst B in refluxing CH2Cl2. When this mixture was treated with 
TFA, the ring-closed products 133 and 136 aromatized to the corresponding furan 134 and 
pyrrole 137. The main drawback of this procedure, however, was the purification of these 
aromatic compounds. Therefore, the reaction had to be performed in two steps with intermediate 
purification of 133 and 136. 
 
OMeO OMeO O
10% cat. B
CH2Cl2, Δ
TFA
132 133 134, 59-81%
Ar
COOMe
Ar
COOMe
Ar
COOMe
N N N
10% cat. B
CH2Cl2, Δ
135 136 137, 74%
OMe
Ph
OMe
Ph Ph
Tos Tos Tos
TFA
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2.3.4 RCM followed by oxidation 
The new entry to pyrroles developed in this work is based on a combination of RCM and 
oxidation and will be described in detail later on. Here, an overview is presented of other 
oxidation methods recently described. 
 
In 2000, Robertson and co-workers were able to construct the bis-aromatic compound 140 in 
two steps starting from pyrrole 138.87 They used a NiO2 promoted oxidation of compound 139 
but obtained only 8% of the desired compound after 5 days of reflux in cyclohexane. 
 
N
Tos
N
3% cat. A
C6H6, RT, 88%
138 139 140, 8%
N
Tos O O Tos O
NiO2
C6H12, Δ, 5days
 
 
Two different research groups were able to obtain quinolines after removal of the protecting 
group on the N-atom followed by spontaneous oxidation. In the first strategy compound 141 is 
cyclized towards 142 and subsequently the benzyl group is split off during chromatography. The 
N-deprotected form of 142 spontaneously oxidized to 143.88 
 
5% cat. B
CH2Cl2, Δ, 99%
141 142 143
SiO2 / air
100%N
Bn
N
Bn
N
 
 
In 2004, De Kimpe and co-workers disclosed a new entry to anthraquinones 146 in two high-
yielding steps starting from diallylated naphthoquinones 144. The first step is ring-closing 
catalyzed by first generation complex A and the second an oxidative aromatization of 145 by 
treatment with Pd/C in refluxing toluene.89 
 
O
O
R3O
O
R3O
O
7% cat. A
toluene, RT, 12h
then 100°C, 12h
Pd/C
toluene, Δ, 2-12h
R3R1
R2 R2
R1 R1
R2
5 examples: 88-94% 5 examples: 88-96%
145144 146  
 
Another research group used a very similar strategy to obtain quinolines 149. The cyclized 
compound 148 is refluxed in THF under O2 atmosphere in the presence of Pd/C resulting in 
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aromatization and deprotection of nitrogen.90 A similar strategy with another protecting group 
(CO2Me) was later used by the same research group.91 
 
6% cat. B
toluene, 80°C
147a R = H
147b R = Me
148a R = H, 75%
148b R = Me, 45%
149a R = H, 80%
149b R = Me, 85%
5% Pd/C, O2
THF, ΔN
Boc
R N
Boc
NR R
 
 
Recently another Pd/C promoted aromatization was disclosed by heating cyclized compounds 
151 and 154 to 220 °C in decalin. In this fashion, pyrrole 152 and quinoline 155 could be 
obtained. The authors report that during the cyclization of 153 the acetyl group is spontaneously 
split off and the double bond isomerizes.92 
5% cat. A
C6H6, 60°C
79%
150 151 152
Pd/C
decalin, 220°C
89%
N
F
N
F
N
F
 
N
O
5% cat. A
C6H6, 60°C
52%
H
N Pd/C
decalin, 220°C
92%
N
153 154 155  
 
A new benzoannulation protocol leading to various quinone derivatives consists of RCM followed 
by oxidation with DDQ. An example is 5,12-naphthacenedione 158 which is obtained in a one-
pot two-step protocol starting from 156.93 The sequence has to be performed in two steps 
because of incompatibility between the metathesis catalyst and DDQ. 
 
OMe
OMe
O
O
OMe
OMe
O
O
OMe
OMe
O
O
cat. A
CH2Cl2, RT, 24h
DDQ
C6H6, Δ
156 157 158 49% overall  
 
Finally, there are some reports in the literature of spontaneous aromatization upon prolonged 
heating of the reaction mixtures. Generally decomposition products of the metathesis catalyst are 
thought to be responsible for this. Examples include the formation of pyrroles,94,95 furans96 and 
indenones.97 It should be noted, however, that the aromatizations in the first two cases are side 
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reactions observed with only one or a few derivatives whereas the metathesis of compounds 159 
can be directed towards the indenols 160 or indenones 161 depending on the applied 
conditions. 
 
OiPr
MeO
OH
R2
R1
OH
R1
R2OiPr
MeO
O
R1
R2OiPr
MeO
5% cat. B
CH2Cl2, RT
5-15% cat. B
toluene, 60-110°C
159160 161
6 examples: 47-89%6 examples: 43-87%
 
 
2.3.5 RCM combined with tautomerization 
The first compound to be synthesized by a combination of RCM and tautomerization was 
naphthol 164 reported by de Koning.98 When α,β-unsaturated ketone 162 was treated with 
second generation catalyst B it was immediately converted to 164 without a trace of 
intermediate 163. 
 
O
OiPr
MeO
O
OiPr
MeO
OH
OiPr
MeO
5% cat. B
CH2Cl2, RT
162 163
Not observed
164 69%
 
 
A similar strategy was used for the synthesis of phenols 167. The only limitation is the number 
of substituents, as it was observed that an acyclic precursor 165 bearing more than three 
substituents did not cyclize.99 
 
2.5-7.5% cat. B
CH2Cl2, RT-Δ
O
R3
R2 R1
R4
R5
O
R1
R5
R4
R3
R2
OH
R1
R5
R4
R3
R2
165 166 167
40-97%  
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2.4 RCM in a tandem reaction sequence 
2.4.1 Tandem metathesis/hydrogenation 
The first reaction to be performed in a tandem sequence with RCM was hydrogenation. To 
achieve this, the mixture obtained after the ring-closing step is simply placed under a H2 
atmosphere which turns the ruthenium catalyst into a metal-hydride species, able to reduce 
double bonds. One of the most famous examples, the synthesis of (R)-muscone 171, was 
published by Grubbs.100 In a first step the secondary alcohol 168 is cyclized towards 169 which 
is converted to ketone 170 by transfer hydrogenation in the presence of 3-pentanone and NaOH. 
Finally the mixture is placed under a H2 atmosphere which results in the chemoselective 
reduction of the double bond. It is important to notice that a single Ru source is used for all three 
transformations. 
 
OOOHOH
cat. B
74%
3-pentanone
NaOH
76%
169 170 171168
H2
100%
 
 
2.4.2 Combination of RCM and isomerization 
The isomerization of a double bond can be achieved either before or after the metathesis step. A 
lot of work based on a combination of isomerization catalyzed by 172101,102 and RCM has been 
performed by van Otterlo and co-workers. In a series of papers they describe the synthesis of 
benzo[1,4]dioxins 175a, benzoxazines 175b, benzofurans 178 and a 1,5-benzothiazepine 181, 
all based on the same strategy.103,104,105 
 
O
X
R1
R2
O
X
R1
R2
O
X
R1
R2
RuClH(CO)(PPh3)3 172
173a X = O
173b X = NTos
174a X = O
174b X = NTos
175a X = O, 70-90%
175b X = NTos, 71-90%
5% cat. 172
toluene, Δ
5% cat. B
toluene, Δ
 
 
In some cases the reaction is performed without isolation nor purification of the isomerized 
compounds. 
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OR2
R3
R1
R4
OR2
R3
R1
R4
R2
R3
R1
R4
O
S
N
O O
Tos
S
N
O O
Tos
N
S
O O
Tos
176 177 178 20-100%
179 180 59% 181 41%
5% cat. 172
toluene, Δ
5% cat. B
toluene, Δ
5% cat. 172
toluene, Δ
5% cat. B
toluene, 50°C
 
 
Isomerization after cyclization can be performed by adding certain additives to the reaction 
mixture in order to convert the metathesis catalyst to a Ru-H species, or by applying more drastic 
reaction conditions. The first additive used to create the hydride species was a mixture of H2 and 
N2 (5/95).106 A more practical approach was developed by Schmidt who used organic (ethyl vinyl 
ether, triethylsilane and isopropanol in combination with NaOH) and inorganic (NaH and NaBH4) 
additives to achieve this conversion.107,108 In this way 3,4-dihydro-2H-pyrans 184 and 2,3-
dihydro-furans 186 could be obtained without isolation of the metathesis products 183 and 185. 
 
ORORO OR R additive
Δ
5% cat. A
toluene, RT
n = 1182 183 184
65-91%
186
61-74%
185
R O
n
5% cat. A
toluene, RT
n = 0
additive
Δ
 
 
The addition of an extra reagent can be avoided by allowing the metathesis catalyst to 
decompose after cyclization has occurred. Upon decomposition, the catalyst is transformed into 
an undefined Ru-H species which is able to bring about isomerization. This strategy was used for 
the synthesis of a variety of five- to eight-membered rings. Depending on the applied reaction 
conditions, fluorinated amides 187 are converted to 189 or to the isomerized compounds 
188.109 
 
N
O
RFF
N
O
RFF N
O
RFF5-10% cat. A
CH2Cl2, Δ
5-10% cat. B
toluene, Δ
187
4 examples: 70-95%
189
6 examples: 70-93%
188  
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2.4.3 Combination of a Grignard or Wittig reaction with RCM 
During research on the mitosene skeleton, it was found that certain intermediates in the 
envisaged reaction sequence are unstable. This meant that either a new strategy had to be 
adopted or the isolation of these intermediates had to be avoided. It was found that compounds 
191, created by a Wittig reaction on 190, are very unstable and break down rapidly. It proved 
possible, however, to perform an RCM on the unpurified reaction mixture (after extraction and 
changing of solvent) and obtain 192 in very good overall yield. After the ring-closing, the double 
bond of the newly formed five-membered ring spontaneously shifts towards the N-atom. The 
same group reported the instability of the secondary alcohol obtained by a Grignard reaction 
between 190a and allylmagnesium bromide. Again this problem was circumvented by 
immediately performing the metathesis reaction. The overall yield of 193 is excellent.110 Another 
research group performed an enantioselective Grignard reaction, using a BINAP ligand, in the 
presence of Cu in combination with RCM.111 
 
N H
OR
N
R
N
R
Ph3P=CH2 / KHMDS
THF, RT
5 % cat. A
CH2Cl2, RT
190a R = H
190b R = MeO
191a R = H
191b R = MeO
192a R = H, 65%
192b R = MeO, 79%
N
R OH
1)
2) 5% cat. A
MgBr
193 R = H, 95%  
2.4.4 Combination of RCM and dihydroxylation or α-ketohydroxylation 
The first report of a metathesis/dihydroxylation sequence was made by Blechert.112 After the 
metathesis, the ruthenium carbene is converted to the oxidative RuO4 species by treatment with 
1.2-1.6 equivalents of NaIO4 (the stoichiometric oxidant) and a catalytic amount of YbCl3.6H2O in 
a 3:3:1 mixture of MeCN/EtOAc/H2O. A number of six- and seven-membered nitrogen and 
oxygen heterocycles were prepared in this fashion such as piperidine 195, obtained in excellent 
yield starting from 194. Instead of RCM also cross metathesis is possible, in this case acyclic 
dihydroxylated compounds are obtained. 
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N
Tos
N
Tos
OH
OHCOOMe
MeOOC
1) 1% cat. A
    CH2Cl2, Δ
    
2) NaIO4, YbCl3.6H2O
    MeCN/EtOAc/H2O, 0°C
195 88%194  
 
The main disadvantage of this approach is the fact that both steps have to be performed in 
different solvents since the dihydroxylation didn’t work in CH2Cl2. This technique was refined and 
expanded, however, by Snapper and co-workers.113 By performing the RCM in EtOAc and 
afterwards pouring this mixture in MeCN/H2O (6:1) containing a catalytic amount of CeCl3 and a 
stoichiometric amount of NaIO4, the need for solvent removal was avoided. By changing NaIO4 to 
oxone, they were able to achieve α-ketohydroxylation instead of dihydroxylation. In this way a 
number of five- six- and seven-membered α-hydroxyketones were produced as well as linear 
ones when used in combination with cross metathesis. Compound 196 could thus be converted 
to 197 or to 198 depending on the oxidant used. 
 
1) 5% cat. B
    EtOAc, RT
    
2) NaIO4, CeCl3
    MeCN/EtOAc/H2O, RT
N
HO OH
Tos
N
O OH
Tos
N
Tos
1) 5% cat. B
    EtOAc, RT
    
2) Oxone, NaHCO3
    MeCN/EtOAc/H2O, RT
196 197 65%198 65%  
 
Control experiments showed that the oxidation does not occur in the absence of the Ru-complex, 
proving that this is really necessary for the oxidation. The dihydroxylation reaction can proceed 
with high diastereoselectivity when a stereocenter is proximal to the olefin. This is proven by the 
selective conversion of 199 to 201. When the α-ketohydroxylation was performed on the same 
unsymmetrical substrate, however, regioisomers 200 are obtained. 
 
1) 5% cat. B
    EtOAc, RT
    
2) NaIO4, CeCl3
    MeCN/EtOAc/H2O, RT
1) 5% cat. B
    EtOAc, RT
    
2) Oxone, NaHCO3
    MeCN/EtOAc/H2O, RT
199 201 81%200 60%
(2:1)
OBzOBz
O
OH
OBz
OH
OH
 
2.4.5 RCM followed by cyclopropanation 
The same research group that developed the α-ketohydroxylation also came up with a 
combination of ring-closing enyne metathesis with cyclopropanation.114 Treatment of a precursor 
like 202 containing an yne and an ene moiety with first generation catalyst A under ethylene 
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atmosphere, the so called Mori conditions,115 results in the formation of intermediate 1,3-dienes 
like 203. Subsequently, the ethylene atmosphere was changed into a N2 atmosphere and 5 
equivalents of a suitable diazo compound were added. This results in cyclopropanation at the 
more accessible olefin. The obtained compounds 204 are the (E)- and (Z)-cyclopropyl 
stereoisomers. 
N
Tos
10% cat. A
C6H6, 75°C, 10min
H2C=CH2 atm
N
Tos
5 equiv
 
C6H6, 75°C, 10h
N2 atm
N
Tos
N
Tos
ROOC ROOC
+
202 203 204a R = Et, 65%, E/Z 2.2/1
204b R = tBu, 71%, E/Z 2.7/1
N2 COOR
 
 
A complementary reaction sequence, cyclopropanation at the least accessible olefin, was 
developed by Dixneuf and co-workers.116,117 They didn’t use a Grubbs-type catalyst for the ring-
closing of 206, however, but catalyst 205. This catalyst is in fact a pre-catalyst; treatment with a 
diazocompound turns it into a ruthenium carbene species that is able to perform ring-closing 
enyne metathesis. The cyclopropane is formed because the intermediate ruthenacyclobutane 
208 favours reductive elimination leading to 207 rather than [2+2] cycloreversion. 
 
Ru N
R
5% cat. 205
dioxane, 100°C
N
R
206a R = Cbz
206b R = Tos
207a R = Cbz, 60%
207b R = Tos, 80%
N2 COOEt
MeOOC
F3C
H
COOEt
MeOOC
F3CCl
205
1.2 equiv
N
R
MeOOC
F3C
Ru
COOEt
Cl
208  
2.4.6 RCM combined with radical atom transfer cyclization 
It was not long after Quayle118,119 reported that the Grubbs’ catalysts act as efficient catalysts in 
intramolecular Kharasch reactions, that Schmidt used this in a tandem sequence with RCM.120 
The tandem sequence is based on the fact that RCM occurs at ambient temperature whereas the 
generation of radicals requires reflux conditions. It was expected that cyclization of 209 would 
lead to intermediate 211 which could undergo a radical cyclization to yield trichlorinated 
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compound 212. The isolated compound of this sequence, however, was 210 apparently 
resulting from dechlorination and double bond migration. With an extra substituent on the alkyl 
chain, like in 213, the isolated compound was the expected trichlorinated bicyclic lactone 214. 
 
O O
CCl3
O O
CCl3
O
O
ClCl
O
O
ClCl
Cl
209 210 n = 1, 63%
211 212
O O
CCl3
O
O
BnO
BnO
Cl
H
H Cl
Cl
213
214
5% cat. A
toluene, RT, 1h
then Δ
5% cat. B 
toluene, RT, 1h
then Δ
n
n n
n
RCM
Kharasch
Rearrangement?
 
 
Quayle was able to reveal the true nature of this rearrangement. By running an experiment in 
deuterated toluene inside an NMR, he was able to follow the exact course of the reaction.121 As a 
test substrate, 215 was treated with second generation catalyst B resulting in cyclopentene 216. 
This compound is extremely labile and fragments into trichloroacetic acid 217 and 
cyclopentadiene 218. Upon heating, an intermolecular Kharasch reaction takes place between 
these two compounds resulting in the formation of 219 and 220. Both compounds then further 
react to the observed product 221 by SN2 or SN2’. The same mechanism is applicable for the 
formation of derivative 210. 
 
O
Cl3C O
O
Cl3C O
HO
O
CCl3
Cl
HO
O
ClCl
HO
O
ClCl
Cl
OCl
Cl
O
Intermolecular
Kharasch
215 216 217 218
219 220221
5 % cat. B Fragmentation
SN2 or SN2'
 
 
Strangely enough, the catalyst used can determine the course of the reaction. It was found that 
subjecting 222 to the tandem RCM/Kharasch sequence can lead either to 224 or 225. When the 
first generation catalyst A is used, the ring-closed product 223 rearranges to give unsaturated 
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lactone 224. When the second generation catalyst B is used, on the other hand, intramolecular 
Kharasch reaction takes place to yield trichlorinated compound 225. Very similar work was 
performed by Snapper.122 
O
OCl3C
OO
CCl3O
O
Cl
O
O
Cl
Cl ClH
H
Cl
222
223 224225
5% cat. A or B
toluene, RT, 3h
cat. A
toluene, 110°C
cat. B
toluene, 110°C
 
2.4.7 RCM combined with 1,3-dipolar cycloaddition 
Two research groups developed a new Pd(0) catalyzed three component process involving 
allenylation of aryl iodides to generate palladium species which react with nitrogen nucleophiles 
to afford 1,6- and 1,7-dienes.123,124 Thus, for example, tertiary amine 229 could be prepared by 
reacting iodobenzene 226 with secondary amine 227 under an atmosphere of allene 228. In a 
second step, this amine could be cyclized to pyrroline 230 using second generation catalyst B. 
 
I
N
Tos
NH
Tos
C
10% Pd(OAc)2, 20% PPh3
2 equiv K2CO3
toluene, 80°C, 18h
226 227 228 229 79%
N
Tos
5% cat. B
toluene, 80°C, 3h
230 74%  
 
This process was transformed to a four component reaction by working under an atmosphere of 
CO (1 atm) and allene (1 atm).125 Thus compound 232, containing an α,β-unsaturated ketone, 
was obtained and in a separate step cyclized towards 233. 
I
N
Tos
NH
Tos
C
10% Pd(OAc)2, 20% PPh3
2 equiv K2CO3
toluene, 80°C, 32h
226 227 228 232 74%
N
Tos
5% cat. B
toluene, 70°C, 2-4h
233 88%
CO
O
O
231  
 
The obtained unsaturated compounds proved to be ideal substrates for 1,3-dipolar cycloadditions 
with imines and nitrones. It was even possible to perform the RCM and the cycloaddition in one 
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pot.126 Thus, a mixture of secondary amine 234 and nitrone 235 was treated with the second 
generation catalyst for 1 hour at 70 °C and then for 17 hours at 90 °C. The diastereomeric 
mixture of 236 was isolated in 59% yield. 
N
Tos
234
N
Tos
5% cat. B
toluene, 70°C, 1h
then 90°C, 17h
236 59%
O
S
N
O
N
O
H
O
S
235  
2.4.8 RCM followed by a Diels-Alder reaction 
A lot of reports have been published regarding the combination of ring-closing enyne metathesis 
and Diels-Alder reactions.127,128 A nice example is the synthesis of polycyclic β-lactams via a one-
pot reaction sequence.129 Treatment of β-lactam 237 in a pressure tube with first generation 
catalyst A results in the formation of diene 238. Subsequently, different dienophiles (like 1,4-
benzoquinone 239, dimethylacetylene dicarboxylate 240 or N-phenyl maleimide 241) can be 
added, the temperature is raised to 80 °C and tricyclic 243 or tetracyclic compounds 242 and 
244 are formed in high yields. 
N
O
OTBS
N
O
OTBS
N
O
OTBS
N
O
OTBS
N
O
OTBS
COOMe
COOMe
OH
OH
N
O
O
Ph
COOMeMeOOC
O
O
N
O
O
Ph
5% cat. A
CH2Cl2, 50°C
237 238
239
240
241 244 99%
243 92%
242 90%
 
 
A combination of RCEYM with an intramolecular Diels-Alder was used for the synthesis of a 
bicyclo[5.3.1]undecene, a structural subunit of taxol. Unsaturated ketone 245 was treated with 
second generation catalyst B to form triene 246 via cross-metathesis with ethylene. Upon 
prolonged heating, this compound cyclizes to form the desired bicyclic skeleton 247.130 
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10% cat. B
toluene, 80°C, 48h
H2C=CH2 atm.
OO
O
OO
O
O
O
O
245 246 247 62%  
 
Finally, a three component tandem enyne metathesis, diene-ene metathesis followed by Diels-
Alder reaction was used to synthesize very complex tricyclic compounds with four stereocenters. 
A mixture of 202 and 5 equivalents of an alkene 58 was treated with second generation catalyst 
B in refluxing CH2Cl2. The produced diene 248 is then treated with 10 equivalents of dienophile 
241 resulting in very slow conversion to 249.131 
N
Tos
N
Tos
R
N
Tos
N
O
O
PhR H
H
H
N
O
O
Ph
R+
10% cat. B
CH2Cl2, Δ, 3-5h
10 equiv
CH2Cl2, Δ, 3-5 days
202 58 248 249
6 examples 71-83%
241
 
2.4.9 RCM followed by Si-O bond cleavage 
Kozmin reported on the use of RCM followed by cleavage of a Si-O bond for the synthesis of 
functionalized enones starting from readily accessible precursors.132 In a first step, ester 250 was 
transformed to the corresponding dibromoketone 251 by treatment with LiCHBr2. 
 
OMe
O
LiCHBr2
THF, -78°C, 59%
OTIPS
3-10% cat. B
C6H6, 60°C, 1h
OTIPSO 1M HF in CH3CN
RT, 30min
250 252
253254 81%
O
Br
Br
LiHMDS, nBuLi
THF, -78°C
TIPSOTf, 83%251
 
Next, this product was subjected to a Kowalski rearrangement133,134 by treatment with a mixture 
of LiHMDS and BuLi and silylated using triisopropylsilyl trifluoromethanesulfonate (TIPSOTf) to 
obtain enyne 252. After cyclization using second generation catalyst B, the O-protecting group in 
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253 was removed using HF in CH3CN and unsaturated ketone 254 was obtained in 81% yield. 
By this procedure, a variety of highly functionalized enones could be prepared in high yield. 
 
Several groups have used a combination of RCM and Si-O bond cleavage to obtain a cis carbon-
carbon double bond.135,136 An attempted cross-metathesis between 255 and 256 led to 257 in 
poor yield (max 42%) and as an E/Z-mixture (ratio from 4:1 to 6:1). If the coupling is aided by a 
silicon tether, like in 258, the RCM results in the formation of eight-membered ring 259 which 
can be opened with TBAF to yield 260 with a double bond exclusively in the Z-configuration.137 
 
NHTos
BnO
OAc
OAc
NHTos
BnO
OAc
OAc
10% cat. A
CH2Cl2, Δ, 5h
+
255 256 257 15-42% E/Z 4:1-6:1  
 
NHTos
BnO
O
Si
O
PhPh
5% cat. A
CH2Cl2, Δ, 5h
NHTos
BnO
OSi
O
Ph
Ph
NHTos
BnO
OH
OH
TBAF
THF, RT
258 259 86% 260 84%  
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3 Results and Discussion 
3.1 Introduction 
The results in this thesis are divided into 3 chapters: the synthesis of pyrroles by an 
RCM/oxidation strategy, the synthesis of polycyclic hydantoins and the synthesis of benzo-fused 
heterocycles. This thesis is partly based on eight papers, published in peer-reviewed SCI-journals, 
referred to in the text by the Roman numerals I-VIII. In the following chapters, a comprehensive 
overview of the published results will be given and the main conclusions will be highlighted. More 
details regarding the experimental set-up, additional mechanistic considerations, exact reaction 
conditions and specific introductions can be found in the papers. 
 
Part 1: synthesis of pyrroles by an RCM/oxidation strategy: 
 
I. N. Dieltiens, C. V. Stevens, D. De Vos, B. Allaert, R. Drozdzak, F. Verpoort, Tetrahedron 
Lett. 2004, 45, 8995–8998. Pyrrole synthesis using a tandem Grubbs’ carbene-RuCl3 
catalytic system. (SCI Impact Factor 2.477) 
 
II. N. Dieltiens, C. V. Stevens, B. Allaert, F. Verpoort, Arkivoc 2005, i, 92-97. A new protocol 
for pyrrole synthesis by a combination of ring-closing metathesis and in situ oxidative 
aromatization. (SCI Impact Factor 0.694) 
 
III. K. Moonen, N. Dieltiens, C. V. Stevens, J. Org. Chem. 2006, 71, 4006-4009. Synthesis of 
2-Phosphonopyrroles via a One-Pot RCM/Oxidation Sequence. (SCI Impact Factor 3.675) 
 
IV. N. Dieltiens, K. Moonen, C. V. Stevens, Chem. Eur. J. 2007, 13, 203-214. Enyne 
Metathesis-Oxidation Sequence for the Synthesis of 2-Phosphono Pyrroles, Proof of the 
“Yne-then-Ene” Pathway. (SCI Impact Factor 4.907) 
 
Part 2: synthesis of polycyclic hydantoins: 
 
V. N. Dieltiens, D. D. Claeys, V. V. Zhdankin, V. N. Nemykin, B. Allaert, F. Verpoort, C. V. 
Stevens, Eur. J. Org. Chem. 2006, 2649-2660. The Pyroglutamate Hydantoin 
Rearrangement. (SCI Impact Factor 2.548) 
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VI. N. Dieltiens, D. D. Claeys, C. V. Stevens, J. Org. Chem. 2006, 71, 3863-3868. Synthesis 
of N(3),N'(3)-Polymethylene-bis-hydantoins and Their Macrocyclic Derivatives. (SCI Impact 
Factor 3.675) 
 
Part 3: synthesis of benzo-fused heterocycles: 
 
VII. N. Dieltiens, C. V. Stevens, Synlett 2006, 17, 2771-2776. Domino Ring-Closing Enyne 
Metathesis—Cross-Metathesis Approach to 1-Phosphonylated Benzazepines. (SCI Impact 
Factor 2.693) 
 
VIII. N. Dieltiens, C. V. Stevens, Org. Lett. 2007, 9, 465-468. Metal-Free Entry to 
Phosphonylated Isoindoles by a Cascade of 5-exo-dig Cyclization, a [1,3]-Alkyl Shift, and 
Aromatization under Microwave Heating. (SCI Impact Factor 4.368) 
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3.2 Synthesis of pyrroles by an RCM/oxidation strategy 
3.2.1 Introduction 
Due to the omnipresent nature and the wide variety of biological activities of the pyrrole nucleus, 
this ring system has been the subject of intense investigation over the years. Next to the classical 
methods like the Knorr, Paal-Knorr and Hantzsch syntheses, many new entries to functionalized 
pyrroles like cyanopyrroles,138 halogenated pyrroles,139,140,141,142,143 annulated pyrroles144 and 
others145 have been developed. These new methods include microwave synthesis,146 ruthenium 
catalyzed synthesis,147 palladium catalyzed multicomponent coupling,148 titanium catalyzed 
synthesis,149 and many more. The interested reader is kindly requested to consult some 
interesting reviews for more detailed information regarding pyrrole syntheses.4,150,151 
 
The taxonomy used in this work is based on the flowchart outlined below.152 In order to classify a 
one-pot process with multiple catalytic transformations a number of questions have to be 
answered: 
 
Is a single catalyst / precatalyst used?
Yes
No Yes
Orthogonal Catalysis Tandem Catalysis
Is > 1 catalytic mechanism required?
Yes
No
Domino Catalysis
Are all precatalysts present at outset?
No
One-pot Reaction
 
The transformations can be roughly categorized into four groups depending on criteria like the 
presence of the catalysts at the beginning of the reaction, the number of catalytic mechanisms 
and the number of catalysts used. 
3.2.2 Orthogonal tandem catalysis for pyrrole synthesis (Paper I) 
Initial experiments focused on the use of bimetallic complex 1.153 A number of diallylamines 2 
were prepared under straightforward conditions either by refluxing the corresponding amines 
261 with allylbromide in CH3CN with NEt3 as a base, or by reacting diallylamine 262 with 
electrophiles. 
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N
R
2a-h
NH2
R
261
Br2.5 equiv
CH3CN, Δ, NEt3
N
R
2i-k
N
H
262
0.9 equiv electrophile
CH3CN, Δ, NEt3
 
Table 2: Synthesis of diallylamines 2a-k 
2 R Yield (%) 
a p-FC6H4 95 
b o,o-Cl2C6H3 92 
c Bn 99 
d CH(CH3)COOEt 96 
e CH2COOMe 88 
f CH(Ph)COOEt 82 
g CH2P(O)(OEt)2 47 
h o-MeOC6H4 98 
i CH2CH2CH2Ph 75 
j CH2CN 94 
k CH2CH2CN 74 
 
A final group of diallylamines with an R-group attached to a double bond was made by alkylation 
of secondary amines 263 with a proper electrophile. Secondary amines 263 were made by a 
reductive amination from benzaldehyde and allylamine or by allylation of methyl glycinate. Amine 
2q was made by treating 2o with morpholine. 
 
HN
R2 N
R2
R1
2l-q263a R
2 = Bn
263b R2 = CH2COOMe
1 equiv electrophile
CH3CN, Δ, NEt3
 
Table 3: Synthesis of diallylamines 2l-q 
2 R1 R2 Yield (%) 
l CH3 Bn 92 
m Cl Bn 79 
n Br COOMe 80 
o CH2Cl Bn 68¥ 
p COOEt Bn 82 
q CH2morpholine Bn 75 
  ¥ 3 eq. electrophile were used 
 
Although the synthesis of these amines is very straightforward, most of them were purified using 
column chromatography in order to remove trace amounts of secondary amines which would 
poison the catalyst. A selection of these amines (a, b, d, e, f, g and i) were treated with 
complex 1 and heated to 60 °C in chlorobenzene for 14 hours. Not in a single case, however, 
could pyrrole formation be observed, even after numerous repetitions, extra purification of the 
substrates and resynthesizing the catalyst. In most cases only starting material and 
decomposition products could be detected. The fact that no pyrroles were formed could not be 
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attributed to the change of substrates since 2e and 2g were exactly the same compounds as 
used in previous research. The only reasonable explanation would be that the pyrrole formation 
in the original experiments could not be attributed to complex 1. At a very early stage, this work 
seemed to be a dead-end street. 
Rationalizing these observations in combination with literature data, led to the belief that another 
ruthenium species might have been responsible for the oxidative aromatization and that the 
original starting point of this research, namely the special activity of complex 1, was wrong. It 
was proposed that maybe some RuCl3, used in the synthesis of 1, was still present in the catalyst 
and caused the oxidative aromatization. According to this hypothesis two different catalytic 
processes were active; the first being ring-closure catalyzed by the metathesis catalyst and the 
second being oxidative dehydrogenation catalyzed by RuCl3. Indeed, it was found that subjecting 
a variety of amines 2 in a pressure tube to a tandem catalytic system of the ‘standard’ second 
generation metathesis catalyst B in combination with RuCl3 under ultrasound conditions results in 
the production of pyrroles 3. The ultrasound was used to obtain a fine dispersion of the RuCl3 
since this additive is poorly soluble. Although reasonable conversions are obtained, the 
purification on a silica column causes a significant drop in yield. Unfortunately, compounds 2m 
and 2n bearing a vinylic halogen or 2p bearing an ester on the double bond could not be 
converted to the corresponding pyrroles. In these cases a mixture was formed of dimerized 
material, product with the allyl group split off and remaining starting product. Compounds 2o 
and 2q were converted to the pyrroles but the presence of a good leaving group caused 
decomposition during purification, probably by formation of aza-fulvenes. 
 
N
R1
N
R1
R2R2 5% cat. B, 1% RuCl3 x H2O
ClCH2CH2Cl, 60°C, 12h
32  
Table 4: Synthesis of pyrroles 3 by combination of 2nd gen. Grubbs’ and RuCl3 
R1 R2  Conversion Yield  
Bn H 74% 3a 55% 
CH(CH3)COOEt H 78% 3b 57% 
CH2COOMe H 91% 3c 63% 
CH2P(O)(OEt)2 H 71% 3d 60% 
o-MeOC6H4 H 95% 3e 74% 
CH2CN H 30% 3f 0% 
CH2CH2CN H 44% 3g 30% 
Bn CH3 69% 3h 50% 
Bn CH2morpholine 82% 3i 0% 
Bn Cl 0% 3k 0% 
COOMe Br 0% 3l 0% 
Bn CH2Cl 56% 3m 0% 
Bn COOEt 0% 3n 0% 
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Already in 1974, Japanese scientists had noticed that RuCl3 x H2O can act as hydrogen transfer 
catalyst in the oxidation of isopropanol 264 to acetone 265 with simultaneous reduction of 
chloranil 266 (tetrachloroquinone, TCQ) to the corresponding hydroquinone 267.154 They also 
observed that the speed of this reaction was greatly increased (73% conversion) using 
RuCl2(PPh3)3, a more soluble Ru-complex. 
OH O
OH
OH
Cl
ClCl
Cl
O
O
Cl
ClCl
Cl
[Ru] [RuH2]
chlorobenzene
170°C, 2h
264 265 26%
266267  
 
Very recently both German155 and English156 researchers reported that RuCl3, in the presence of 
various phosphine ligands, is able to oxidize alcohols to the corresponding ketones in the absence 
of a hydrogen acceptor. This means that the ruthenium-hydride intermediates decompose with 
the formation of hydrogen gas. In our case, the phosphine ligand is in situ released by the 
Grubbs’ catalyst creating a catalytic system very similar to the one described by these 
researchers. A strange observation was, however, that some pyrrole formation is also observed 
when no RuCl3 is added. In this case the oxidation of the pyrroline to the pyrrole is much slower 
and no complete conversion is obtained. This can be explained by assuming that not only RuCl3 
but also decomposition products of the catalyst act as hydrogen acceptors. This hypothesis is 
supported by the discovery that metathesis catalysts form metal-hydride compounds upon 
prolonged heating.157 It should also be noted that no pyrrole is formed when an electron 
withdrawing group is present at nitrogen. Thus 2r and 2s were very rapidly and quantitatively 
converted to pyrrolines 4r and 4s. This explains why no direct pyrrole formation was observed 
by researchers working with a tosyl-, Boc-, or SES-protecting group on nitrogen. 
 
N
R1
N
R1
2r R1 = Boc
2s R1 = Tos
4r R1 = Boc
4s R1 = Tos
5% cat. B, 1% RuCl3 x H2O
ClCH2CH2Cl, 60°C, 30min
 
 
When the conversion of diallylamines to pyrroles is monitored by NMR, both the pyrroline 4 and 
the pyrrole 3 are observed next to the starting material. This proofs that the ring-closing step 
proceeds quite slow and the oxidation from the pyrroline to the pyrrole occurs very slow. 
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N
R1
N
R1
R2R2 5% cat. B
N
R1
R2
[Ru] [RuH2]
H2
'Slow'
'Very Slow'
2 4 3
 
Usually it takes about 12 hours to obtain a reasonable conversion to the pyrrole. This slow 
conversion might be attributed to catalyst poisoning by the substrate 2 and/or pyrroline 4. 
 
3.2.3 Domino reaction sequence for pyrrole synthesis (Paper II) 
In order to accelerate the conversion of the pyrroline to the pyrrole, a hydrogen acceptor was 
added to the reaction mixture to increase the speed by which the [RuH2] species is converted 
back to the [Ru] species. The oxidation of pyrrolines to pyrroles is usually performed with 
DDQ.158,159,160 Evaluation of three different quinones (DDQ, duroquinone and TCQ) showed that 
the last one is the best oxidant since the first one destroys the metathesis catalyst and the 
second one doesn’t affect the oxidation rate at all. In a comparative test, it was also found that 
RuCl3 is not really required as a hydrogen transfer catalyst since the reaction works equally well 
in the absence of this reagent. Thus, diallylamines could be very rapidly converted to pyrroles in 
a one-pot domino reaction sequence. In this case, obviously, a stoichiometric amount of oxidant 
is required. The intermediate pyrrolines 4 were never observed, proving that the oxidation to the 
pyrroles occurs very fast. Another observation was that the ring-closing step from 2 to 4 also 
occurs faster. This is probably because the pyrroline, which poisons the catalyst, is quickly 
removed from the reaction mixture by conversion to the pyrrole which does not contaminate the 
catalyst. In this case only the remaining starting material will diminish the activity of the catalyst. 
Usually it takes only about 2 hours to obtain reasonable conversion to the pyrrole. 
 
N
R1
N
R1
R2R2 5% cat. B
N
R1
R2
'Fast'
OH
OH
Cl
Cl Cl
Cl
O
O
Cl
Cl Cl
Cl
'Very Fast'
2 4 3
266 267  
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Table 5: Synthesis of pyrroles 3 by combination of 2nd gen. 
Grubbs’ and TCQ 
R1 R2  Conversion 
Bn H 3a 100% 
CH2COOMe H 3c 96% 
CH2P(O)(OEt)2 H 3d 95% 
o-MeOC6H4 H 3e 100% 
Bn CH3 3h 93% 
Bn CH2morpholine 3i 90% 
 
A possible mechanism for this reaction sequence is outlined below. After ring-closing metathesis, 
the electron lone pair on nitrogen of the intermediate 3-pyrroline 4 initiates the aromatization by 
expelling a hydride which immediately reacts with quinone 266. This assumption is consistent 
with the observation that diallylamines with strong electron withdrawing groups on nitrogen do 
not aromatize. Possibly, both donor and acceptor are coordinated to the transition metal centre in 
this step, thus facilitating the H-transfer. In the next step, the intermediate iminium-ion 268 
loses a proton and aromatizes to the pyrrole 3. In a final step, a keto-enol tautomeric shift 
converts 270 to hydroquinone 267. 
 
O
O
Cl
ClCl
Cl
N
R2
H
R1
N
R1
R2
O
O
Cl
Cl Cl
Cl
H
N
R2
R1
O
OH
Cl
Cl Cl
Cl
N
R2
R1
OH
OH
Cl
Cl Cl
Cl
H-shift
2
4
266 267
268
3
269
270
 
 
3.2.4 Attempted synthesis of furans 
An attempt was made to expand this methodology for the synthesis of furans. In a first step 
alcohol 271 was obtained in 96% yield by treating benzaldehyde with vinylmagnesium chloride. 
This alcohol was allylated at oxygen using allylbromide and KOtBu as a base. Treatment of 272 
with the second generation catalyst B resulted in very fast conversion to dihydrofuran 273. It 
proved impossible, however, to oxidize this compound to furan 274 using RuCl3 or TCQ. 
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H
O OH O
MgCl
THF, -78°C, 3h
271 96% 272 98%
KOtBu
allylbromide
ether, RT, 16h
O
O
5% cat. B
RuCl3 or TCQ
273 88%
274
 
3.2.5 Attempted synthesis of bicyclic pyrroles 
Having established this new entry to pyrroles, an attempt was made to use this methodology for 
the synthesis of bicyclic derivatives such as 279 and 280. Azabicyclic compounds with a nitrogen 
at a bridgehead position have attracted the attention of synthetic chemists for many years.161,162 
The 2,3-dihydro-1H-pyrrolizine skeleton 279 is present in a number of Maillard components 
285a and 285b, formed by heating a model system of L-proline and 1,3-dihydroxyacetone.163,164 
It can also be found in ketorolac 286, an anti-inflammatory agent with analgesic and antipyretic 
properties. The 5,6,7,8-tetrahydro-indolizine 280 nucleus can be found for example in natural 
compounds, present in herbs used in traditional Chinese medicine, that delay replicative 
senescence in certain human cells.165 
Retrosynthetic analysis shows that these compounds can be obtained by oxidative aromatization 
of 277 and 278 which are obtained by RCM of derivatives 275 and 276. Alternatively they could 
also be obtained by oxidative aromatization of cyclic enamines 281 and 282 which are obtained 
by ring-closing of 283 and 284. 
 
NN N NN
nnn n n
279 n = 1
280 n = 2
277 n = 1
278 n = 2
275 n = 1
276 n = 2
281 n = 1
282 n = 2
283 n = 1
284 n = 2
N
COOH
O
Ph
N
O
R
285a R = CH3
285b R = CH2OH 286  
 
Derivatives of type 283 were targeted starting from pyroglutamate 287, since some expertise on 
pyroglutamate chemistry was present at our department166,167 and pyroglutamates can be easily 
functionalized at various positions.168 Treatment of 287 with butanal in the presence of P2O5 in a 
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Dean-Stark trap led to enamide 288 after column chromatography and bulb-to-bulb 
distillation.169 Reduction of the ester function using NaBH4 in methanol gave alcohol 289. 
 
N
H
COOEtO N
COOEtO NO
OH1 equiv butanal1.05 equiv P2O5
toluene, Δ, 12h
288 81% 289 80%
3.3 equiv NaBH4
MeOH, Δ, 16h
287
 
 
The alcohol function was converted to different leaving groups (290, 291, 292) under 
straightforward conditions in order to substitute this with a Grignard reagent (vinylmagnesium 
chloride) to introduce the second double bond. Not in a single case, however, the desired 
compound 293 could be obtained in pure form. A number of competing reactions, namely 
opening of the lactam ring and elimination of the leaving group with formation of a double bond, 
caused the formation of inseparable mixtures. 
 
NO
OTos
NO
NO
OMs
NO
I
NO
NO
1.1 equiv TosCl
1.2 equiv pyridine
CH2Cl2, RT, 16h
289
289
289
1.5 equiv PPh3
3 equiv imidazole
1.3 equiv I2
toluene, Δ, 30min
290 98%
1.05 equiv MsCl
1.2 equiv pyridine
CH2Cl2, RT, 16h
291 94%
292 48%
MgCl
MgCl
MgCl
1 equiv. CuI
2 equiv. P(OEt)3
2 equiv. DMPU
THF, -35°C
293
293
293
THF, -78°C
THF, -94°C
 
 
Two different routes to obtain derivatives of type 275 were designed starting from prolinol 294 
and methyl prolinate 299, respectively. After protection of the N-atom of 294 with a Boc-group, 
the alcohol 295 was oxidized to the aldehyde 296. A Wittig reaction completed the synthesis of 
the first double bond. Upon deprotection of compound 297 a volatile secondary amine would be 
formed, therefore this compound was isolated as its TFA salt 298.  
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N
Boc
H
O
N
Boc
N
H H
TFA
N
275
Decomposition
N
H
OH
N
Boc
OH
1.1 equiv (tBoc)2O
0.1 equiv DMAP
CH2Cl2, RT, 16h
295 98%
3.5 equiv NEt3
3.5 equiv SO3-pyridine
DMSO, 0°C, 2.5h
296 99%
1.5 equiv Ph3PCH3I
1.5 equiv KOtBu
THF, RT, 16h
297 70%
3 equiv TFA
CH2Cl2/MeOH (10/1)
Δ, 6h
3 equiv NEt3
2 equiv allylbromide
THF, RT, 48h
294
298
 
 
Treatment of this salt with triethylamine and allylbromide in THF resulted in the formation of the 
desired compound 275. Unfortunately, this compound proved to be extremely unstable and 
decomposed within minutes upon concentration. Because the crude mixture still contains 
allylbromide, TFA and a large amount of triethylamine, direct RCM on this mixture is probably not 
possible. 
 
Therefore, a second route to 275 was evaluated. This strategy was planned to end with a Wittig-
reaction. Since this reaction can be combined in a tandem sequence with RCM, this strategy 
could possibly avoid the problems associated with the instability of 275. Thus, 299 was allylated 
at the N-atom and the ester 300 was reduced to 301. Unfortunately, the oxidation of alcohol 
301 to the corresponding aldehyde 302 proved to be a problem. Although some aldehyde was 
formed, judging from the crude 1H NMR spectrum, the main part of the reaction mixture proved 
to consist of decomposition material. 
 
N
N
H
COOMe
N COOMe N
OH
N
O
H
1.2 equiv pyridine
1.1 equiv allylbromide
CH3CN, Δ, 4h
300 78%
1 equiv LiAlH4
THF, 0°C, 4h
301 89%
3.5 equiv NEt3
3.5 equiv SO3-pyridine
DMSO, 0°C, 2.5h
302
299
RCM
N
275
277
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A final attempt was made to access the 5,6,7,8-tetrahydro-indolizine 280 skeleton by 
RCM/oxidation from derivatives 276. A strategy very similar to the one attempted for the 
synthesis of derivatives 275 was followed. In a first route, the N-atom of ethyl pipecolinate 303 
was protected with a Boc-group. Ester 304 was reduced to alcohol 305 using NaBH4 and a 
catalytic amount of LiCl. Oxidation to aldehyde 306 and subsequent Wittig olefination gave 
derivative 307. Deprotection of 307 and subsequent allylation of the TFA salt 308 gave 276 
that unfortunately decomposed rapidly as was the case for compound 275. 
 
TFA
276
Decomposition
1.1 equiv (tBoc)2O
0.1 equiv DMAP
CH2Cl2, RT, 16h 305 33%
3.5 equiv NEt3
3.5 equiv SO3-pyridine
DMSO, 0°C, 2.5h
306 97%
1.5 equiv Ph3PCH3I
1.5 equiv KOtBu
THF, RT, 16h
307 76%
3 equiv TFA
CH2Cl2/MeOH (10/1)
Δ, 6h
3 equiv NEt3
2 equiv allylbromide
THF, RT, 48h
N
H
COOEt N
Boc
OH
N
Boc
O
H
N
Boc
N
H H
N
N COOEt
Boc
304 99%
3 equiv NaBH4
0.15 equiv LiCl
EtOH, Δ, 8h
303
308
 
 
The second route also ran into the same problems as encountered during the synthesis of 275. 
Although allylation of 303 to 309 and subsequent reduction with LiAlH4 to 310 proceeded 
smoothly, the attempted oxidation to 311 brought an early end to this route since mostly 
decomposition material was formed. The attempts to synthesize bicyclic pyrroles were 
abandoned in this stage to pursue other, hopefully more fruitful routes. 
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276
1.2 equiv pyridine
1.1 equiv allylbromide
CH3CN, Δ, 4h
1 equiv LiAlH4
THF, 0°C, 4h
310 98%
3.5 equiv NEt3
3.5 equiv SO3-pyridine
DMSO, 0°C, 2.5h
N
H
COOEt N COOEt
309 96%
N
OH
N N
O
H
303
311 98%
RCM
N
278
 
3.2.6 Synthesis of 2-phosphonopyrroles via an RCM/oxidation sequence (Paper III) 
Bearing in mind the developed RCM/oxidation methodology, both phosphonylated pyrrolines 14 
and pyrroles 15 should be accessible from the same α-aminophosphonate 13 depending on the 
reaction conditions used. The problem in obtaining compounds 13 is that they need to be formed 
by a regioselective 1,2-addition of a phosphorus nucleophile onto imines 12, followed by 
alkylation of the N-atom. Initial experiments using silylated phophites as a nucleophile resulted in 
the formation of a mixture of a variety of compounds that could not be purified or properly 
analyzed at that time. Ongoing research at our department revealed, however, that both the 
phosphorus nucleophile used and the steric hindrance of the substituents greatly affect the 
course of this reaction and allow the selective synthesis of 1,2-adducts, 1,4-adducts or even 
tandem 1,4-1,2-addition products.170,171,172 This insight and research paved the way for the 
straightforward synthesis of compounds 13. 
R1 P(OMe)2
R2
N
O
R3Ph
R1
R2
N
R3
H
1. 1,2-addition
2. alkylation
1312  
 
Thus, imines 12 could simply be phosphonylated with complete 1,2-regioselectivity by refluxing 
in methanol in the presence of two equivalents of dimethyl phosphite. An acid/base extraction 
proves sufficient to purify compounds 312. Since secondary amines are well known to poison the 
Grubbs’ catalysts, the nitrogen had to be protected prior to metathesis. Due to the electron 
withdrawing nature of the phosphonate in combination with the steric hindrance, these 
compounds are very poor nucleophiles, so that alkylation requires long reaction times, good 
electrophiles (like benzylbromide) and the use of NaI as a catalyst. 
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R1 H
R2
N
R3 R1 P(OMe)2
R2
HN
O
R3
12
R1 P(OMe)2
R2
N
O
R3Ph
2 equiv HP(O)(OMe)2
MeOH, Δ, 2-4h
312 13
1.5 equiv BnBr
0.5 equiv NaI
4 equiv K2CO3
acetone, Δ, 24h
 
 
Table 6: Synthesis of α-aminophosphonates 312 and 13 
Entry R1 R2 R3 312 (%) 13 (%) 
a Ph H H 95 61 
b Ph Me H 90 50 
c Me Bn H 27 50 
d Ph isoamyl H 88 54 
e Me Ph H 80 35 
f Me CH2CH2Ph H 44 92 
g Ph H Me 74 86 
 
The domino reaction sequence using in situ oxidative aromatization with TCQ proved to work 
excellent on these substrates. Both pyrrolines 14 and pyrroles 15 could be formed in good yield 
at room temperature upon treatment with second generation catalyst B. The fact that these 
substrates could be cyclized under such mild conditions can most probably be attributed to the 
electron withdrawing nature of the phosphonate group, which lowers the nucleophilicity of the N-
atom. As a consequence the substrate is less likely to poison the catalyst. In a control 
experiment, it was demonstrated that oxidation of the isolated pyrrolines 14 with TCQ in the 
absence of second generation catalyst B proceeds significantly slower than in the domino 
reaction. Probably both hydrogen donor and acceptor are brought together by simultaneous 
coordination to the metal centre, followed by direct hydrogen transfer from the pyrroline to the 
TCQ. 
R1 P(OMe)2
R2
N
O
R3Ph
N P(OMe)2
R2
Ph
R3
O
N P(OMe)2
R2
Ph
R3
O
5% cat. B
CH2Cl2, RT, 3-5h
1314 15
5% cat. B
1 equiv TCQ
CH2Cl2, RT, 5-7h
 
 
Table 7: Synthesis of 2-phosphonylated pyrrolines 14 by RCM and pyrroles 15 
by RCM/oxidation sequence using TCQ 
Entry R1 R2 R3 14 (%) 15 (%) 
a Ph H H 44 75 
b Ph Me H 58 84 
c Me Bn H 62 72 
d Ph isoamyl H 70 70 
e Me Ph H 54 75 
f Me CH2CH2Ph H - 71 
g Ph H Me - - 
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As mentioned before, secondary amines poison the Grubbs’ catalysts because they coordinate too 
strong to the central ruthenium metal. When the RCM was attempted on amines 312 the 
reaction stops at about 30% conversion. This proves that especially pyrrolines 313 tend to 
poison the catalyst. This comes as no surprise since cyclic amines are always much more 
nucleophilic than their acyclic counterparts due to the lowered steric hindrance of the alkyl chains 
which are tightly held back in the ring. In the pyrrole ring, however, the nitrogen lone pair is not 
nucleophilic anymore since it is part of the aromatic system. 
P(OMe)2
HN
O
N
H
P(OMe)2
O
N
H
P(OMe)2
O
N
H
P(OMe)2
O
312 313
313 315a R = H, 39%
315b R = isoamyl, 27%
R
R
R R
max. 30% conversion
5% cat. B
CH2Cl2, Δ
N N
Ru CHRCl
Cl
MesMes
N
P(OMe)2
O
R
H
N N
Ru CHRCl
Cl
MesMes
+
Inactive Complex 314
5% cat. B
1 equiv TCQ
CH2Cl2, Δ
 
 
When TCQ is added to the secondary amines 312 together with second generation catalyst B, 
the ‘poisonous’ pyrrolines 313 are immediately oxidized to the ‘benign’ pyrroles 315. In this 
fashion, the formation of inactive complexes like 314 is inhibited and 100% conversion is 
obtained. Unfortunately, an immense drop in yield is observed during purification by column 
chromatography. 
 
The substrates 13 and 312 bear one terminal and one non-terminal alkene. Initiation of the 
metathesis occurs, for steric reasons, on the terminal double bond. The cyclobutane 316 
fragments with formation of a new carbene 317 and styrene 78. The new carbene cyclizes to 
318 which forms the pyrroline 14 and regenerates the active species of catalyst B upon 
cycloreversion. No ethylene is formed in this cycle which is very strange since the formation of 
ethylene is considered to be crucial to shift the equilibrium to the end product. Styrene 78 builds 
up in the reaction mixture, however, and starts to compete with the substrate for reaction with 
the catalyst. Thus in a second catalytic cycle, styrene is dimerized to stilbene 320, which 
precipitates from the mixture, and methylidene carbene 321 is generated. This carbene can 
react either with styrene to 322 or with substrate to 323. Both cyclobutanes generate ethylene 
upon cycloreversion. Thus in contrast to the normal metathesis cycle, in this case ethylene is 
generated in two secondary catalytic pathways. 
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P(OMe)2
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(MeO)2P Ph
O
[Ru]
N
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P(OMe)2
Bn
O
[Ru]
Ph [Ru]
Ph
Ph
Ph
Ph
[Ru]
N
Bn
P(OMe)2
Ph
O
[Ru]
Ph
Ph
Ph
Pyrroline 14
Substrate
Substrate
B
316
317
78
318
78
319
320
321
78
322
323
 
3.2.7 Synthesis of 2-phosphonopyrroles via an RCEYM/oxidation sequence (Paper IV) 
As stated before, ring-closing metathesis has been applied for the synthesis of a wide variety of 
ring systems. The very related enyne metathesis, involving the reaction between an alkene and 
an alkyne, has received far less attention. Unlike olefin metathesis, all carbon atoms from the 
starting material are retained in the end-product which contains a synthetically useful 1,3-diene 
moiety. In the literature overview, a number of sequential reactions using RCM has been 
presented. Such sequential reactions have hardly been developed for enyne metathesis. So far, 
only a one-pot combination of enyne metathesis with a Diels-Alder reaction or a cyclopropanation 
has been reported. 
As previously described, suitable diallylamines can be converted to the corresponding 3-pyrrolines 
upon treatment with the second generation Grubbs’ catalyst and in situ oxidized to the pyrrole 
nucleus in a one-pot protocol by the addition of tetrachloroquinone (TCQ). The correct choice of 
the oxidizing agent, however, is crucial, since DDQ caused decomposition of the metathesis 
catalyst, illustrating the delicate balance of this one-pot reaction sequence. Since enyne 
metathesis involves different ruthenium-species intermediates, it was hard to predict if TCQ 
would be able to oxidize the pyrrolines to the corresponding pyrroles while not affecting the 
metathesis reaction. 
Thus α,β-unsaturated N-propargyl aldimines 16 were phosphonylated with complete 
regioselectivity, using the same protocol as for the synthesis of derivatives 312, resulting in the 
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formation of aminophosphonates 324 in good yield. Subsequent benzylation provided the 
substrates 17 for the ring-closing/oxidation step. 
 
R1 H
R2
N
R1 P(OMe)2
R2
HN
O
16
R1 P(OMe)2
R2
N
O
2 equiv HP(O)(OMe)2
MeOH, Δ, 2-3h
324 17
1.5 equiv BnBr
0.1 equiv NaI
4 equiv K2CO3
acetone, Δ, 24h
Ph
 
 
Table 8: Synthesis of α-aminophosphonates 324 and 17 
Entry R1 R2 324 (%) 17 (%) 
a 2-furyl H 69 54 
b CH3 Ph 82 68 
c Ph CH3 92 65 
d propyl H 95 60 
e Ph H 70 64 
f isopropyl H 65 46 
 
It was found, however, that conversion of these derivatives to pyrrolines 18 upon treatment with 
second generation catalyst B in refluxing CH2Cl2 is very slow. More than 12h were needed to 
achieve complete conversion. When the reaction was carried out in refluxing benzene, however, 
complete conversion was achieved in less than 30 minutes. The addition of 1 equivalent TCQ to 
the reaction mixture resulted in complete conversion to pyrroles 19 in about the same time. 
Large substituents R2 are not very well tolerated in these reactions. In the case of 17b, no 
metathesis was observed but only catalytic deprotection of the propargyl amine. 
 
R1 P(OMe)2
R2
N
O
N P(OMe)2
R2
Ph
O
N P(OMe)2
R2
Ph
O
5% cat. B
C6H6, Δ, 1h
1718 19
5% cat. B
1 equiv TCQ
C6H6, Δ, 1h
Ph
R1 R1
 
 
Table 9: Synthesis of 2-phosphonylated pyrrolines 18 by RCEYM and pyrroles 19 
by RCEYM/oxidation sequence using TCQ 
Entry R1 R2 18 (%) (E:Z) 19 (%) (E:Z) 
a 2-furyl H 68 (78:22) 78 (75:25) 
b CH3 Ph 0 0 
c Ph CH3 88 (100:0) 85 (100:0) 
d propyl H 78 (100:0) 48 (79:21) 
e Ph H 86 (82:18) 82 (82:18) 
f isopropyl H 75 (64:36) ‡ 
        ‡the pyrrole could not be obtained in sufficient purity 
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Because of the formation of an (E/Z)-mixture in combination with the phosphorus coupling, the 
spectra of these compounds can sometimes be quite difficult to interpret. In order to be sure that 
indeed an (E/Z)-mixture is formed, compound 19e was treated with Pd(C) under a hydrogen 
atmosphere. The reduction of the double bond led, as expected, to the formation of 325 as the 
only compound. 
 
N P(OMe)2
Ph
O
325
Pd(C) / H2
EtOH
Ph
N P(OMe)2
Ph
O
19e
Ph
 
 
In order to investigate the effect of other substituents on the double bond, enynes 327 were 
prepared by alkylation of 326. It was shown that a variety of substituents are tolerated with no 
significant effect on the yield of the cyclization. Due to the electron withdrawing properties of the 
tosyl group, the pyrrolines 328 cannot be oxidized to the pyrroles. 
N
5% cat. B
C6H6, Δ, 1h
R3
Tos
N
Tos
R3HN
Tos
326 327 328
1.5 equiv electrophile
4 equiv K2CO3
acetone, Δ, 16-20h
 
Table 10: Synthesis of N-Tos pyrrolines 328 by RCEYM 
Entry R3 Yield 328 (%) E:Z 
g CH2Cl 86 100/0 
h CH2Br 76 100/0 
i 4-chloro-phenoxymethyl 73 63/37 
j Ph 89 100/0 
 
The history of RCM is laced with experiments designed to determine the exact mechanism of a 
certain reaction. Since enyne metathesis reactions of acyclic olefins, other than terminal olefins, 
with terminal alkynes have not been studied systematically, research to determine this 
mechanism can contribute to a better understanding of RCEYM. More precisely, the question 
whether the reaction proceeds via the “yne-then-ene” or the “ene-then-yne” mechanism is still 
often raised. The “yne-then-ene” mechanism is commonly postulated for the Ru-catalyzed enyne 
RCM reaction. In this pathway, the reaction starts at the alkyne moiety with formation of a 
metallacyclobutene. Recent kinetic studies, however, have brought up evidence for the “ene-
then-yne” pathway in cross enyne metathesis173 and enyne metathesis with terminal olefins.174 In 
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this pathway, the reaction starts at the alkene with formation of a metallacyclobutane. This has 
created a gap in the mechanistic insights of RCEYM that has to be addressed. 
 
R1 P(OMe)2
R2
N
O
17
Bn
Initiation here?
Initiation here?
R1 P(OMe)2
R2
N
O
Bn
[Ru]
Ph
P(OMe)2
N
O
Bn
[Ru] R2
R1
Ph
Easy approach
Formation cyclobutene
Difficult approach
Formation cyclobutane
329330  
 
This is exemplified by the possible reaction pathways of compound 17. When the catalyst 
initiates at the triple bond, there is little steric hindrance but cycloaddition forms a cyclobutene 
329. In case of initiation at the double bond, the approach is more difficult due to steric 
hindrance but a less strained cyclobutane 330 is formed. As mentioned before, when both 
multiple bonds are terminal (R1 = H) and as a consequence steric hindrance is comparable for 
both pathways, the catalyst chooses the formation of the cyclobutane over the cyclobutene. 
Since both pathways lead to the same final product, other information is necessary in order to 
distinguish between these two mechanisms. 
In case of initiation at the triple bond, cyclobutene 329 opens with formation of 331. 
Intramolecular cycloaddition and subsequent cycloreversion leads to pyrroline 332 and new 
catalyst 333. This pyrroline has got a phenyl group where the R1 group was expected to be. This 
phenyl group used to be attached to the catalyst and was transferred to the substrate during the 
reaction. Next to this pyrroline, a new carbene 333 is formed with the R1 group attached to it as 
alkylidene ligand. This new catalyst can continue the catalytic cycle and transfer the R1 group to 
a newly formed pyrroline. 
 
R1 P(OMe)2
R2
N
O
Bn
[Ru]
Ph
329
R1 P(OMe)2
R2
N
O
Bn
331
[Ru]
Ph
N
R2
Ph
Bn
[Ru]
R1
+
333332  
 
In case of initiation at the double bond, cyclobutane 330 opens with formation of 334 and side 
product 335. Carbene 334 cyclizes to 336 which has to do a cross metathesis with another 
molecule of substrate 17 in order to create pyrroline 18 and to regenerate carbene 334. In this 
case, no pyrroline side product like 332 or a new carbene like 333 are formed. 
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Careful analysis of the reaction mixtures revealed the presence of side product 332 in every 
case, in about the same amount as the catalyst loading (about 5%). Not in a single case, 
products like 335 could be observed. This was a first indication that the “yne-then-ene” pathway 
is active. In order to obtain further evidence, an attempt was made to detect the newly formed 
carbenoid species 333 since this is only formed in the first pathway. To detect this compound, 
derivative 327h was dissolved in C6D6 treated with first generation catalyst A and the reaction 
was performed inside the NMR. The reaction could easily be monitored using 31P NMR. In the 
beginning of the reaction one strong signal is observed at 36.9 ppm which belongs to the Grubbs’ 
catalyst. Next this signal slowly decreased and at the same time a new signal appeared at 33.7 
ppm. In order to attribute this signal to 337, allylbromide was treated in a separate experiment 
with first generation catalyst A resulting in the appearance of the same signal. This proves that it 
was indeed this ruthenium species that was formed during enyne metathesis of 327h. 
 
5% cat. A
N
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Br
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Br
[Ru] 33.7 ppm
decreasing signal at 36.9 ppm
increasing signal at 33.7 ppm
327
337  
 
In order to obtain additional proof for the mechanism, enediyne 338 was synthesized since this 
compound would, depending on the reaction pathway, lead to a different compound. Treatment 
of this compound with 5 mol% of the second generation catalyst B in refluxing benzene led to 
the formation of conjugated triene 339 in 74% yield after purification with concomitant 
formation of 5% 328j. This result can only be explained by accepting the “yne-then-ene” 
pathway. This reaction also represents the first example of a conjugated triene being formed by 
enyne-metathesis. 
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This result can only be obtained when the “yne-then-ene” pathway is active since the “ene-then-
yne” pathway does not lead to the formation of the observed end product as outlined in the 
scheme below. 
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Finally, evaluating 13g as a substrate showed that no metathesis occurred at all when a 2-
methylallyl substituent is introduced at nitrogen. Initiation at either double bond would result in a 
ruthenium species 350 or 351 with limited steric hindrance at the other double bond, especially 
compared to intermediates like 331. Even switching of solvent to refluxing toluene (110 °C) or 
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chlorobenzene (132 °C) did not result in any metathesis activity. This shows that removing the 
yne-moiety has a very dramatic effect on the reactivity of these compounds. 
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All these observations lead to the proposal of a complete catalytic cycle as depicted below. In the 
initiation phase, the substrate reacts with the Grubbs’ carbene to yield, after a sequence of 
cycloadditions and cycloreversions, the byproduct and the new carbene. This new carbene can 
then react further with another molecule of substrate to produce the final product with 
regeneration of the carbene, after a sequence of cycloadditions and cycloreversions. In the case 
of complete initiation of the metathesis catalyst, x% of catalyst gives rise to a mixture of x% 
byproduct and (100-x)% of product upon completion of the reaction. 
 
 
3.2.8 Conclusion 
In the first part of this thesis a new entry towards pyrroles was developed using a combination of 
ring-closing metathesis mediated by the second generation Grubbs’ catalyst and oxidative 
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aromatization. At first, RuCl3 was used as an additive for the conversion of the intermediate 
pyrrolines to the corresponding pyrroles. Although this reaction works fine, it usually takes more 
than 12 hours to obtain satisfactory conversion at 60 °C under ultrasound conditions. The 
reaction time could be dramatically reduced by adding a strong hydrogen acceptor, namely 
tetrachloroquinone, to the reaction mixture. In this case RuCl3 is no longer required as a 
hydrogen transfer catalyst. The reaction time is reduced to about 2 hours in this fashion. 
Substrates bearing a strong electron withdrawing group on the N-atom, however, could not be 
oxidized. The application of this methodology on α-aminophosphonates containing two double 
bonds allowed the straightforward synthesis of phosphonylated pyrroles. This conversion also 
occurs in a one-pot fashion and under very mild conditions. In a control experiment, it was 
demonstrated that oxidation of the isolated pyrrolines with TCQ in the absence of the second 
generation catalyst B proceeds significantly slower than in the domino reaction. Probably both 
hydrogen donor and acceptor are brought together by simultaneous coordination to the metal 
centre, followed by direct hydrogen transfer from the pyrroline to the TCQ. It seems that the 
phosphonate group is just electron withdrawing enough to lower the nucleophilicity of the N-
atom to allow the RCM to occur at room temperature while still allowing oxidation of the 
pyrrolines to the corresponding pyrroles. The first combination of ring-closing enyne metathesis 
with oxidation was developed by treatment of α-aminophosphonates containing a double and a 
triple bond with the second generation Grubbs’ catalyst in refluxing benzene in the presence of 
TCQ. This reaction sequence allows the synthesis of highly functionalized 2-phosphonylated 
pyrroles. A detailed mechanistic investigation revealed that the reaction follows the “yne-then-
ene” pathway. The proof of this reaction mechanism is based on the formation of certain end and 
sideproducts, spectroscopic data and finally on the difference in reactivity of different substrates. 
During the initiation phase, the Grubbs’ carbene is converted to a new ruthenium-carbene which 
continues the propagation cycle. 
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3.3 Synthesis of polycyclic hydantoins 
3.3.1 Introduction 
The story of hydantoin starts in 1861 when Adolph von Baeyer discovered this compound by 
hydrogenolysis of allantoin, hence it’s name.175 The first classical synthetic pathway, known as 
the Urech reaction, comprises to reaction of amino acids with potassium cyanate and allows the 
synthesis of 5-monosubstituted hydantoins.176 Another famous method is known as the Bucherer-
Bergs method, comprising the condensation of carbonyl compounds with potassium cyanide and 
ammonium carbonate.177 This reaction allows the synthesis of both 5-mono and 5,5-disubstituted 
hydantoins. Since then a vast amount of new entries towards this interesting heterocycle have 
been described. This interest is driven by the discovery of a wide variety of biological activities 
like anticonvulsant, neuro-protective, antihypertensive, antibacterial, antiviral, analgesic,... 
activities and many, many more. The recent developments in hydantoin chemistry have been 
excellently reviewed by Gütschow.178 
3.3.2 Synthesis of bicyclic hydantoin derivatives (Paper V) 
At first the reaction of pyroglutamates 20 with isocyanates 21 was misinterpreted as leading to 
perhydro-1,3-diazepine-2,4-diones 356.179 It was found that when a mixture of 20 with an 
isocyanate is treated with NaH in diethylether, a precipitate is formed during the reaction, which 
after workup proved to be the sodium salt of the expected carbamoyllactam 352 in high purity. 
If the reaction is performed in THF on the other hand, no precipitate is formed and after workup 
a compound was isolated which gave a different but very similar 1H NMR spectrum. It was 
assumed that intermediate 352, which is apparently soluble in THF, reacts intramolecularly by a 
nucleophilic attack on the lactam ring with formation of the unstable intermediate 353. This 
intermediate decomposes with loss of ring-strain to form the seven-membered ring anions 354 
and 355. 
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These anions are in equilibrium with each other, causing racemization of the chiral centre (this 
was proven by quenching the reaction with D2O) and upon workup resulted in what was thought 
to be 356 as a 1:1 mixture of its enantiomers. 
 
In the past, 1-carbamoyl-2-pyrrolidinones 352 were incorrectly identified as perhydro-1,3-
diazepine-2,4-diones 356. For example the natural product squamolone was originally identified 
as a seven-membered ring (of type 356) but later turned out to be a five-membered ring (of 
type 352).180 Also a claim of the preparation of these seven-membered rings by cyclization of 4-
ureidobutyric acids with thionyl chloride181 was later corrected by another research group.182 This 
last research group gave some spectroscopic guidelines which would allow discrimination 
between compounds 352 and 356. In the 2D-correlated spectra, certain long range correlations 
should be visible in case of the seven-membered ring that are not present in the five-membered 
ring. Since we believed we had both derivatives in hands, we could compare all spectral data. 
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Indeed we observed the predicted HMBC (Heteronuclear Multiple Bond Correlation) couplings 
between the CH2 of the benzyl group on the tertiary nitrogen atom to the urea and the lactam 
carbonyl in the compound with proposed structure 356e. Also a COSY (Correlated Spectroscopy) 
coupling between the NH and the proton in α-position of the ester was observed. All these 
couplings could not be found for the carbamoylated lactam 352e and as a consequence these 
and other derivatives were identified as seven-membered rings.183 
 
X-ray analysis that was carried out later proved, however, that the compounds produced are in 
fact hydantoin derivatives 22. Apparently the intermediate 352 performs an intramolecular 
nucleophilic attack on the ester carbonyl with formation of bicyclic intermediate 357 and 
expulsion of an alkoxide anion. The alkoxide anion in turn can open this bicyclic intermediate with 
formation of anions 358 and 359. These anions are in equilibrium with each other, causing 
racemization of the chiral centre and upon work up resulted in hydantoin derivatives 22 as a 1:1 
mixture of their enantiomers. 
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Table 11: Synthesis of hydantoins 22 by ring-transformation from pyroglutamates 20 
Entry R1 X R2 Yield 22 (%) 
a Bn O Ph 56 
b Bn O CH2CH2Cl 50 
c Bn S Ph 42 
d Et O Ph 89 
e Et O Bn 87 
f Et O CH2CH2Cl 81 
g Et O allyl 48 
h Me O Ph 81 
 
The same methodology was performed on different combinations of pyroglutamate esters and 
isocyanates. We were pleased to find that different esters underwent the same reaction, 
although, in some cases, traces of carbamoyllactam could be observed due to the poor solubility 
of this intermediate in THF. It is important to notice, however, that in diethylether the sodium 
salts of intermediates 352 precipitate. As a consequence the end product formed depends on the 
solvent used. 
As shown below, all the predicted and observed HMBC- and COSY-couplings for the seven-
membered ring are also present in case of the hydantoin derivative, this explains the 
misinterpretation of the spectral data. 
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The attractiveness in using pyroglutamates as a building block lies in the fact that the site of 
alkylation can be directed by changing the protecting group on nitrogen. Alkylation of N-Boc 
protected pyroglutamates 360 results in C(4) functionalized derivatives 363 whereas alkylation 
of N-benzyl 361 or N-unprotected 20 pyroglutamates occurs at the 2-position, resulting in 364 
and 365.184,185 The regioselectivity of the alkylation of N-Boc protected pyroglutamates was 
explained by the formation of a stabilized Li-salt 362 which directs the alkylation to the 4-
position. This stabilized intermediate cannot be formed in N-benzyl or N-unprotected derivatives, 
thus resulting in alkylation at the 2-position. 
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The first step in the sequence towards the bicyclic derivatives 33 is alkylation of the 
pyroglutamate at the 2-position. As mentioned above, alkylation of pyroglutamates at this 
position has been described before, but this method is rather unpractical with the need for 
stringent time and temperature control. During a series of experiments, the alkylation of benzyl 
pyroglutamate with allylbromide was optimized. In each experiment benzyl alcohol was formed 
by fragmentation of the ester. This kind of fragmentation in the absence of water has been 
observed before.167 The main conclusion of these experiments is that the anion at C(2) is quite 
unstable and the time it is present in the mixture should be kept to a minimum. In order to 
realize this, the electrophile can already be mixed with the pyroglutamate prior to deprotonation. 
It was found that excellent results can be obtained when a mixture of the pyroglutamate and the 
electrophile is treated with 2.1 equivalents of LiHMDS at –40 °C.186 Even when using several 
equivalents of electrophile, no N-alkylation was observed. This methodology can not be followed, 
however, when base-sensitive electrophiles are used (e.g. in case of 365e and 365f). The 
electrophile used for entry d, (1-bromomethyl-vinyl)-benzene, was obtained following a literature 
procedure.187 Compound 365i was obtained by treating 365b with morpholine but is added to 
the table for the sake of completion. 
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Table 12: Alkylation of pyroglutamates 20 at the 2-position towards 365 
Entry R1 R2 Yield 365 (%) 
a Et H 72 
b Et CH2Cl 62 
c Et CH3 84 
d Et Ph 70 
e Et Cl 46 
f Et Propyne at C(2) 20 
g Bn H 83 
h Bn CH2Cl 40 
i Et CH2morpholine 60 
 
All following reactions were carried out on the ethyl ester since working with the benzyl esters 
often caused decomposition and subsequent purification problems. Furthermore, the ring-
transformation to the hydantoins gives lower yields for these derivatives. The ring-transformation 
of compounds 365 to the hydantoins was then performed using different isocyanates. 
Unfortunately, bulky substituents at the 2-position prevent the substrate from reacting with the 
isocyanate, even at elevated temperatures. In these cases only unreacted starting material could 
be recovered. Also compound 365f, with a propyne substituent at C(2), gave a mixture of 
compounds upon reaction with isocyanates and was therefore not used further. 
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Table 13: Synthesis of hydantoins 368 by ring-transformation from 
pyroglutamates 365 
Entry R2 R3 Yield 368 (%) 
a H Pr 61 
b H Ph 70 
c H Bn 45 
d Cl Pr 66 
e CH3 Pr 63 
 
When compound 365b was treated with propyl isocyanate and NaH in THF, the bicyclic 
hydantoin derivative 370 is formed. The intermediate carbamoylated lactam 367b cyclizes as 
expected to compound 369 with formation of ethoxide. This bicyclic compound is opened by 
ethoxide to give anion 368b. Normally this anion is stable and quenched by the addition of 
water. In this case, however, a good leaving group is present and an intramolecular substitution 
of the allylic chloride leads to the tetrahydro-pyrrolo[1,2-c]imidazol-7a-yl derivative 370 in 34% 
yield after purification. 
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The 1H NMR and 13C NMR spectra of compounds 368 are again not completely conclusive to 
determine whether or not the rearrangement has indeed taken place. In order to distinguish 
these compounds from the intermediate lactams 367, the 2D spectra are extremely useful. In 
the HMBC spectrum the protons of the allyl substituent, of the benzyl group and on the 
secondary N-atom all couple to the same carbon at 175.0 ppm. These couplings could never be 
observed in case of the carbamoylated lactams. 
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The next step in the reaction sequence is the introduction of a second double bond by alkylation 
of N(1). Normally, when N-unsubstituted hydantoins are treated with alkyl halides, reaction 
occurs at N(3). Functionalization of both nitrogen atoms, or of N(1) in case N(3) already bears a 
substituent, requires very harsh conditions. It was found that the only way to alkylate these 
compounds cleanly at N(1) in good yield was to reflux them with 2 equivalents of electrophile 
and 5 equivalents of finely ground K2CO3 in acetone for several days. The compounds 32 are 
obtained pure after filtration of the solids and evaporation of the volatiles. In some cases, column 
chromatography was necessary to remove the excess of electrophile. 
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Table 14: Alkylation at N(1) of hydantoins 368 towards 32 
Entry R2 R3 R4 Yield 32 (%) 
a H Pr H 98 
b H Ph H 98 
c H Bn Cl 70 
d H Ph CH3 99 
e H Bn CH2Cl 72 
f H Bn COOEt 45 
g Cl Pr H 83 
h CH3 Pr H 98 
 
The last step in the sequence is the ruthenium catalyzed cyclization. Treatment of these 
compounds with 5% second generation catalyst B in refluxing CH2Cl2 resulted in clean conversion 
to the desired compounds 33. When a halogen is present at the double bond, 32c and 32g, 
more drastic conditions are required.188,189 In this case switching to refluxing benzene is 
necessary to obtain cyclization. Since compound 32f has a very electron poor double bond, it is 
in fact an α,β-unsaturated ester, the second generation Hoveyda-Grubbs catalyst 111 was used 
because this catalyst proved to be superior with electron deficient olefins.190 
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Table 15: Synthesis of bicyclic hydantoin derivatives 33 by RCM on substrates 32 
Entry R2 R3 R4 Yield 33 (%) 
a H Pr H 93 
b H Ph H 88 
c H Bn Cl 75 
d H Ph CH3 79 
e H Bn CH2Cl 85 
f H Bn COOEt 55¥ 
g Cl Pr H 77 
h CH3 Pr H 86 
     ¥the second generation Hoveyda-Grubbs catalyst 111 was used 
 
It was possible to obtain single crystals from compound 33b which made it possible to perform 
X-ray analysis (Fig. 3). 
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Figure 3: X-ray structure of compound 33b. 
 
In conclusion, it can be stated that a straightforward four-step protocol for the synthesis of 
bicyclic hydantoin derivatives starting from pyroglutamates was developed. This procedure starts 
with alkylation of the pyroglutamate at the 2-position, followed by ring-transformation to the 
hydantoin nucleus upon reaction with an isocyanate. Next, N-alkylation and ring-closing 
metathesis provides the heavily substituted bicyclic compounds (Fig. 4). 
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Figure 4: Four-step approach towards bicyclic hydantoin derivatives. 
3.3.3 Attempted synthesis of other bicyclic hydantoin derivatives 
Attempts were made to synthesize two other diazabicyclic compounds using the same 
methodology. First, compound 373 was targeted. A mixture of functionalized pyroglutamate 
365a and allylisocyanate was treated with NaH in THF to produce hydantoin 371. This 
compound was alkylated using benzylbromide to 372 in refluxing acetone and K2CO3 as a solid 
base. When compound 372 was treated with 5% second generation catalyst B in refluxing 
CH2Cl2 a mixture of different compounds was obtained. Probably, the envisaged compound 373 
is too strained resulting in polymerization of 372 rather than in cyclization. Compound 373 could 
not be purified from this mixture. Lowering the concentration of the reaction in order to favour 
cyclization over polymerization gave no better result. 
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Secondly, compound 35 was targeted. A mixture of ethyl pyroglutamate 287 and allyl isocyanate 
was treated with NaH in THF. The obtained compound 22g was alkylated using allylbromide in 
refluxing acetone in the presence of K2CO3. Treatment of compound 374 at room temperature 
with 5% second generation catalyst B in CH2Cl2 did not result in any reaction. Raising the 
temperature of the mixture to reflux did result in reaction. Spectroscopic analysis of the crude 
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reaction mixture revealed certain signals that could be attributed to compound 35, however, a 
great number of undesired compounds, probably resulting from polymerization, were also formed 
and the targeted structure could not be purified from this mixture. 
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3.3.4 Synthesis of bis-hydantoins and their macrocyclic derivatives (Paper VI) 
The pyroglutamate-hydantoin rearrangement could prove a very powerful method to make 
N(3),N’(3)-polymethylene-bis-hydantoins with general structure 375. In the past, this kind of 
compounds has been made by reaction of a hydantoin with an α,ω-dihaloalkane under basic 
conditions.191 As mentioned before, the functionalization of hydantoins at the 3-position occurs 
quite easily, but side reactions at N(1) also occur resulting in mixtures of compounds that are 
difficult to purify and usually result in quite low yields. Starting from pyroglutamates would avoid 
the problem of N(3)-selectivity and also allows the synthesis of highly functionalized derivatives 
since pyroglutamates can easily be derivatised. 
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When the developed method was applied to a mixture of pyroglutamate 287 and diisocyanate 
376b, however, a mixture of a variety of compounds was formed. The formation of this mixture 
can be explained by taking a closer look at the reaction mixture. Once a pyroglutamate has 
reacted with one of the isocyanate moieties, the intermediate 377 can react in different ways. 
Route A is active in the normal rearrangement and leads to the bicyclic intermediates. The 
intermediate can also avoid forming this strained bicyclic compound by reacting towards the 
second isocyanate moiety, route B. A third possibility, route C, is that ethoxide anions, formed by 
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route A, react with the isocyanate instead of opening the bicyclic compound. Besides these three 
reactions also others can be proposed. 
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An earlier observation, namely that the sodium salts of the carbamoylated lactams precipitate in 
diethylether, came to rescue. When a mixture of pyroglutamate 287 and diisocyanate 376 in 
ether was treated with NaH, a white precipitate is formed. This precipitate dissolves during acidic 
workup using aqueous NH4Cl and the dimers 379 were isolated in high yield and purity. 
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Table 16: Synthesis of bis-carbamoylated lactams 379 
Entry n Yield 379 (%) 
a 0 97 
b 2 99 
c 4 99 
d 8 99 
 
The most convenient way to achieve the ring rearrangement towards the bis-hydantoins was to 
dissolve these dimers in absolute ethanol followed by treatment with 2.2 equivalents of KOtBu. 
Two reaction pathways can be proposed for this rearrangement. In the first pathway, the lactam 
rings of 379 are opened by ethoxide resulting in acyclic compound 380. This dianion is in 
equilibrium with dianion 381 and cyclization of the latter with expulsion of ethoxide leads to the 
bis-hydantoins 382. Alternatively, the rearrangement can also follow the same course as when 
performed in THF. Deprotonation of nitrogen and cyclization of 383 leads to intermediate 384 
Results and Discussion 
-67- 
which is opened by ethoxide to give 382. Possibly, both pathways may be active, but this isn’t a 
problem since they both lead to the same compound. 
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Table 17: Synthesis of bis-hydantoins 382 
Entry n Yield 382 (%) 
a 0 98 
b 2 97 
c 4 99 
d 8 99 
 
Again straightforward 1H NMR and 13C NMR measurements are not sufficient to distinguish 
between compounds 379 and 382, as can be seen from figures 5-8. However, having both 
compounds in hand, 2-dimensional spectroscopy clearly allowed the unambiguous determination. 
In the case of 379, there is a coupling in the COSY spectrum between the NH-protons and the 
CH2 next to the nitrogen. On the other hand, the NH protons of 382 show a coupling to the 
proton next to the carbonyl and not to the CH2, proving that this methylene is connected to a 
tertiary nitrogen. Furthermore, the protons of the CH2 next to nitrogen of 379 only couple to the 
urea carbonyl in the HMBC spectrum, whereas in the case of 382 they couple to both the urea 
and the lactam carbonyl. Another distinctive feature is the shift of the NH-protons. Intramolecular 
hydrogen bridge formation in 379 to the lactam carbonyl causes a downfield shift, resulting in a 
typical value of 8.3 ppm whereas the value in the case of 382 is typically around 6.3 ppm. 
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Figure 5: 13C spectrum of 379c. 
 
 
Figure 6: 13C spectrum of 382c. 
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Figure 7: 1H spectrum of 379c. 
 
Figure 8: 1H spectrum of 382c. 
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Alkylation at N(1) was performed by the same procedure as for the synthesis of compounds 32. 
Thus compounds 36 were obtained clean and in good yield after filtration and evaporation of the 
solids or column chromatography. 
 
382
4 equiv electrophile
5 equiv K2CO3
acetone, Δ
N NnHN NH
O
O
O
O COOEtEtOOC
N NnN N
O
O
O
O COOEtEtOOC
RR
36  
 
Table 18: Alkylation at N(1) of bis-hydantoins 382 towards 36 
Entry n R Yield 36 (%) 
a 0 allyl 98 
b 2 allyl 98 
c 2 CH2CCCH3 99 
d 4 allyl 98 
e 4 o-bromobenzyl 84 
f 4 m-fluorobenzyl 86 
g 8 allyl 98 
 
In order to prevent free rotation around the central polymethylene axis, we wanted to evaluate 
the possibility to use ring-closing metathesis for the macrocyclization of derivatives 36a, b, d and 
g. Treatment of these compounds with 5% second generation catalyst B resulted in reasonably 
clean conversion to tricyclic compounds 37. Due to the great polarity of these compounds quite a 
drop in yield was observed during purification. 
36
N NnN N
O
O
O
O COOEtEtOOC
N Nn
N N
O OOO
EtOOC COOEt37
5% cat. B
CH2Cl2, Δ, 16h
 
 
Table 19: Synthesis of macrocycles 37 by RCM on substrates 36 
Entry n Outer ringsize Yield 37 (%) 
a 0 16 46 
b 2 18 58 
c 4 20 54 
d 8 24 41 
 
Spectral analysis of compounds 37 revealed that they are present in two forms (1:1 ratio). This 
could indicate that an (E,Z)-mixture around the double bond is formed during the metathesis. It 
was also possible that the two forms are diastereoisomers since these compounds have two 
racemic centres. Since these compounds are symmetrical entities, the 3JHH coupling constant 
between the two alkene protons is absent because they are magnetically equivalent. It was, 
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however, possible to separate the two forms of compound 37c by column chromatography. Now 
it was possible to prove whether they were diastereoisomers or (E,Z)-isomers. Firstly, it was 
observed that treatment with base of one form of 37c resulted in equilibration to the mixture of 
both forms. Secondly, hydrogenation of the two forms gave two different compounds 385a en 
385b. These results can only be explained by assuming that the two compounds were 
diastereoisomers. 
 
However, the question then arose whether the trans- or cis-fused cycles were produced. As 
mentioned before, the 3JHH couplings are absent and cannot be used to determine the 
configuration of the double bond. The symmetry of the molecule could be circumvented, 
however, by taking the 13C satellites of the alkene protons into account of one pair of 
enantiomers of 37c. When one of the two alkene carbon atoms is a 13C isotope, the symmetry is 
lost due to the presence of a magnetically active 13C in place of an inactive 12C. In this case, the 
two isotopomers give two separate signals (br d, 5.14 ppm, 14.3 Hz and br d, 5.12 ppm, 14.9 
Hz). They are not each other’s mirror image because of the two other chiral centres. A 3JH,H 
coupling of 14.3 and 14.9 Hz is observed, pointing to the trans-geometry. 
 
37c n = 4
isotopomer 1
37c n = 4
isotopomer 2
3J(H,H) = 14.3 Hz
N N
n
13CN N
O OOO H
H
3J(H,H) = 14.9 Hz
N N
n
13CN N
O OOO H
HEtOOC COOEt EtOOC COOEt
 
 
One could argue that these macrocyclic compounds could also be obtained by reaction of 
derivatives 382 with an α,ω-dihaloalkane. Treatment of 382c with cis-1,4-dichloro-2-butene 
resulted in a mixture, however, of starting material, mono-alkylated product 386 and cyclized 
material (<10%). In order for a ring to be formed, an energy activation barrier ΔG has to be 
taken. This barrier is comprised of two parts namely the enthalpy of activation ΔH, which is 
associated with the energy required to bring the reacting atoms together against the ring strain 
and repulsive forces and the entropy of activation ΔS which is associated with the ease by which 
an ordered transition state is formed from a randomly moving molecule. In this case a very large 
ring is formed thus ΔH is very small since no ring strain is present. On the other hand ΔS is very 
negative since mono-alkylated compound 386 has to give up a lot of freedom to adopt the right 
conformation 387 which can react. 
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The fact that these derivatives are so difficult to cyclize in this fashion, again proves the 
importance of RCM as macrocyclization method. Probably, chelation complexes of type 388 are 
formed during metathesis, effectively bringing the two alkene moieties in the correct position. 
Complexation of the ruthenium centre with functional groups across the molecule lowers the ΔS 
needed to achieve the proper conformation. This illustrates the essential role of functional groups 
as a relay in order to form macrocyclic compounds by RCM.192,193 
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N
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N
O
O
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388  
3.3.5 Anti-invasive activity on human breast cancer cell lines 
3.3.5.1 Introduction 
Cancer is the result of a number of genetic mutations that lead to functional alterations of certain 
cells. Cancer cells differ from their normal counterparts in the following aspects: growth, 
differentiation, tissue integrity and anoikis. When a cancer develops, the cells start to divide in an 
uncontrolled way and penetrate and damage the surrounding tissue. The causes of cancer can be 
divided into internal factors and external factors. The most important internal factors are errors in 
the DNA and a weakened immune system. The most important external factors include smoking, 
drinking, viruses, several chemical substances, radiation etc. In Flanders every day 84 people are 
diagnosed with cancer, which equals about 30000 per year. After cardiac affections, cancer is the 
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most important cause of death. Among the male population prostate cancer is the most occurring 
(28,6 %), followed by lung cancer (17,9 %) and colon cancer (13,6 %). Among the female 
population breast cancer is the most occurring (35,5 %), followed by colon cancer (13,9 %) and 
uterus cancer (5,4 %).194 Treatment of cancer is done by surgery, radiotherapy, chemotherapy 
or a combination of those. 
As mentioned in the introduction of this work, bis-hydantoins have in the past been tested as 
analogues of HMBA 38. HMBA is an agent that induces differentiation of certain types of tumor 
cells to nonmalignant phenotypes. This implies that it works not by killing the cancer cells but by 
inducing them to differentiate and to express characteristics of the normal nontransformed 
counterpart. This is a promising approach to cancer therapy, potentially without many of the 
disadvantages of cytotoxic agents. HMBA has even had some modest success in clinical trials. 
The doses required to achieve sufficient blood levels in human patients, however, led to some 
undesirable side effects. It was found that compounds 375a and 375c were 10 times more 
potent than HMBA itself. The activity of 375b was low, probably due to its insolubility.16,17,195 
Since derivatives 36 have an ester moiety on a side chain, the increased polarity might lead to an 
activity at lower concentrations. 
 
N NnHN NH
O
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O O
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3.3.5.2 The chick heart invasion essay 
The screening of several hydantoin derivatives for their anti-invasive activity was performed in 
cooperation with the department of Gynaecological Oncology and the department of 
Experimental Cancerology at the Ghent University Hospital.  
The screening assay chosen, is based on the in vitro confrontation of cancer cells with a fragment 
of normal tissue (Fig. 9). Heart tissue fragments are 
dissected from 9-days old chicken embryos and 
precultured to obtain living spheres with a standard 
diameter of 0.4 mm. These precultured heart fragments 
(PHF’s) are confronted with standard aggregates 
(diameter 0.2 mm) of invasive test cells like human MCF-
7/6 mammary carcinoma cells. The aggregates become 
attached to the PHF’s by incubation on a semi-solid agar 
bed overnight and are then transferred as individual 
Figure 9: Protocol for the chick heart
               invasion assay.
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pairs into Erlenmeyer flasks for suspension culture in liquid medium. The cultures are treated 
with the compounds at concentrations ranging from 100 μm to 1 μm. After 8 days of incubation 
on a Gyrotory shaker, the cultures are fixed and embedded in paraffin for histology. After serial 
sectioning and staining of the sections with hematoxylin and eosin, the interaction of the tumor 
cells with the PHF can be reconstructed tri-dimensionally from microscopic analysis of all 
sections.196 
 
The invasion was scored as follows: 
• Grade 0: only PHF can be found and no confronting cells can be observed 
• Grade 1: the confronting test cells are attached to the PHF and do not occupy the heart 
tissue 
• Grade 2: occupation of the PHF is limited to the outer fibroblast-like and myoblast cell 
layers 
• Grade 3: the confronting cells have occupied the PHF but have left more than half of the 
original amount of heart tissue intact 
• Grade 4: the confronting cells have occupied more than half of the original volume of the 
PHF 
3.3.5.3 Results 
A total number of 15 compounds were selected for screening in the in vitro tests. These include 
N(3) functionalized hydantoins (22a, 22c, 22e, 22h), hydantoins functionalized at N(3) and 
N(1) (32c, 32e, 389, 370), bis-hydantoins (382a, 382b, 382c, 382d) and functionalized bis-
hydantoins (36a, 36e, 36f). 
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In a first screening, 13 compounds were added to the liquid medium containing the PHF and the 
human MCF-7/6 mammary carcinoma cells in a concentration of 100 μm. In every batch of tests 
a number of control experiments are included in order to check the activity of the cancer cells. 
This is necessary because after a number of cell divisions mutations start to accumulate that can 
alter the normal activity of the cancer cells. As can be seen from these results (table 20) a 
number of compounds completely block the invasion of the cancer cells into the heart tissue 
whereas in the control experiments the heart fragments have almost completely been destroyed 
(Fig. 10). The compounds showing the highest activity (score 1) do not immediately show 
structural resemblance. Sometimes a great difference in activity is observed depending on the 
substituents present on the hydantoin nucleus. This is the case for 36e and 36f where the only 
difference is the nature and position of the halogen. Although this test is performed at a very 
high concentration, it is well suited for selecting active compounds and detect toxicity towards 
the benign cells as is the case for compounds 22c and 22e. 
 
Table 20: Anti-invasive activity of several 
hydantoin derivatives at 100 μm 
Product Invasion Grade Remark 
22a 4  
22c 1 Toxic for PHF 
22e 1 Toxic for PHF 
22h 3  
32c 1  
389 2  
382a 4  
382b 2  
382c 1  
382d 3  
36a 3  
36e 3  
36f 1  
Control 4  
Control 4  
 
In a second series of experiments, the most active non-toxic compounds from the previous test 
and the untested compounds were screened for activity at a concentration of 10 μm. It should be 
noted that in these tests the control experiments clearly showed a decrease in the activity of the 
cancer cells. This means that it’s difficult to compare these results with the previous tests and 
draw conclusions. It can still be seen, however, that some compounds also prevent invasion at 
Grade 4
Grade 2
Grade 1
Heart tissue
Cancer cells
Figure 10: Example PHF's with invasion grades
                 4, 2 and 1.
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this lower concentration. A rather strange result is obtained from compound 382d that showed 
an activity of only 3 at 100 μm but seems to be more active at 10 μm. 
 
Table 21: Anti-invasive activity of several hydantoin derivatives 
at 10 μm 
Product Invasion Grade batch 1 
Invasion 
Grade batch 2 
32e 1  
370 2  
382c 1  
382d 1 0 
36f 1 2 
389 1  
Control 2 2 
 
The final experiments were performed at 1 μm. Also in this case, a decreased activity of the 
cancer cells was observed. The fact, however, that a strong invasion (score 3) was observed in 
some cases, shows that the cancer cells are still reasonably active. It is clear that the activity at 
this low concentration is rather poor. 
 
Table 22: Anti-invasive activity of 
several hydantoin derivatives at 1 μm 
Product Invasion Grade 
382c 3 
382d 2 
36f 3 
Control 2 
 
3.3.5.4 Predicting the activity 
Quantitative structure-activity relationships (QSAR’s) have been used in the past to develop 
models in order to estimate and predict biological or toxicological behaviour of organic molecules 
using computational descriptors solely derived from chemical structures. Very recently an artificial 
neural network was constructed that used a nonlinear combination of a large number of 
descriptors derived from 93 anti-invasive compounds. This model was able to predict accurately 
the anti-invasive activity of 46 other compounds.197 If this model is able to predict the activity of 
the synthesized hydantoins, this would provide the opportunity to screen compounds prior to 
their synthesis. This would give the chance to target new compounds that are predicted to be 
active rather than randomly synthesize derivatives. The model calculates an anti-invasive activity 
score (I_index) representing the activity of the compounds at different concentration. The 
compounds are classified using this I_index depending on the concentration at which they inhibit 
invasion of the cancer cells into the PHF (grade 0 or grade 1). 
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Table 23: I_index in relation to concentration needed for anti-ivasive activity 
Concentration (μm) Activity Anti-invasive activity score (I_index) 
>100 Low 1 
100 Fair 2 
10 Good 3 
1 Active 4 
 
Unfortunately, the model proved to be completely useless for the compounds prepared in this 
thesis. As can be seen in the table below products 36a, 36e and 36f are all predicted to possess 
very low activity while in reality 36f shows good activity. Compounds 382a, 382c and 382d are 
all predicted to be very active while in fact 382a is completely inactive. 
 
Table 24: Predicted anti-invasive activity score of several 
hydantoin derivatives 
Product Predicted anti-invasive activity score (I_index) 
36a 1.39 
36e 1.16 
36f 1.09 
382a 3.51 
382c 3.56 
382d 3.53 
 
For other derivatives there was also no correlation between the predicted and observed activity. 
Although this model is based on a wide variety of compounds including chalcones, chromenones, 
catechins, (poly)phenolics, methoxyflavones, pyrazoles, oxazoles, indolones and others, the 
hydantoins seem to be a bridge too far. 
3.3.6 Conclusion 
In the second part of this thesis entries towards new polycyclic hydantoin derivatives were 
developed starting from pyroglutamates. A short four-step approach was successful for the 
synthesis of hydantoin derivatives that are annelated to a six-membered ring. Also a new entry 
towards bis-hydantoins was developed by reaction of pyroglutamates with bis-isocyanates and 
subsequent ring-transformation. The compounds could be converted to their macrocyclic 
derivatives using the second generation Grubbs’ catalyst in refluxing CH2Cl2. A number of the 
synthesized compounds were screened for their anti-invasive activity on human breast cancer cell 
lines. It can be stated that some of the synthesized bis-hydantoins show some good anti-invasive 
activity and are non-toxic to the heart tissue used in the in vitro tests. Unfortunately, the activity 
of these compounds cannot be accurately predicted using a nonlinear QSAR model. Therefore, 
further research is needed to shed light on the mode of action of these structures in order to 
allow the synthesis of more active compounds. In a further stage in vivo tests will have to be 
performed to validate these results. 
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3.4 Synthesis of benzo-fused heterocycles 
3.4.1 Synthesis of 1-phosphonylated benzazepines (Paper VII) 
Seven-membered azaheterocyclic phosphonates are very rare in literature. As mentioned in the 
introduction, only one entry to 1-phoshonylated benzazepines has been described.21 This 
rearrangement involves the reaction of a dialkyl phosphite and amines with bicyclic aromatic nitro 
compounds 390 to afford compounds 391. 
 
X
NO2 HP(O)(OMe)2, NHR
1R2
MeONa, MeOH X
N
(MeO)2(O)P
N
R1
R2
390 391
6 examples: 65-82%  
 
The lack of straightforward entries towards this interesting heterocyclic scaffold provides the 
opportunity to develop new pathways targeting related compounds. Ring-closing enyne 
metathesis seems a very attractive method to obtain these compounds since it is not only very 
atom-efficient but it also provides the possibility of immediately functionalising the intermediately 
formed diene by cross-metathesis with an alkene. Thus α-aminophosphonates 46 and 47 have 
to be synthesized and treated with a metathesis catalyst to produce vinylic carbenes 392 and 
393. These intermediates can undergo cross-metathesis with an alkene to form 394 and 395. 
The advantage of this strategy is that only two compounds, 46 and 47, have to be used as 
starting material. These compounds can be transformed to a variety of benzazepines depending 
on the addition of a certain alkene to the reaction mixture. 
 
P(O)(OMe)2
N
PG
P(O)(OMe)2
N
PG
N
PG(MeO)2(O)P
R
N
PG(MeO)2(O)P
[Ru]
N
PG(MeO)2(O)P
N
PG(MeO)2(O)P
[Ru]
R
RCEYM RCEYM
CM CM
4746
392 393
394 395  
Results and Discussion 
-79- 
The first building block 46 was synthesized in four steps starting from commercially available 
aldehyde 396. In the first step, the aldehyde was converted to an alkene via a Wittig reaction 
using methyltriphenylphosphonium bromide and KOtBu as a base. The formylation of alkene 397 
was performed with DMF after Li-halogen exchange with BuLi at -78 °C. The obtained aldehyde 
398 was converted to imine 399 by treatment with propargylamine and MgSO4 in CH2Cl2. This 
imine was immediately phosphonylated using dimethyl phosphite in methanol and isolated using 
an acid-base extraction. The N-atom of 400 was protected using p-bromobenzylbromide and 
K2CO3 as a solid base in refluxing acetone. The first building block 46 was isolated in 69% yield 
after column chromatography. 
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Br
Ph3PCH3Br, KOtBu
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396 397 91% 398 73%
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A very similar approach towards the second building block 47 was attempted. When 
commercially available aldehyde 401 was treated with primary amines in the presence of MgSO4 
in CH2Cl2, a complex reaction mixture was formed instead of the expected imines 402. 
Apparently these imines are quite unstable. An attempt was made to form the imine followed by 
an immediate reaction with dimethyl phosphite by running the imination reaction in dry methanol 
in the presence of MgSO4. Although 31P NMR revealed the formation of an α-aminophosphonate, 
this reaction was far from clean and the desired compound could not be purified from this 
mixture. Recently, Asao and co-workers revealed the nature of the instability of imines 402.198 
Apparently an intramolecular 6-endo-dig reaction takes place by attack of the nitrogen lone pair 
onto the inactivated triple bond. This results in the formation of zwitterionic intermediate 403. 
When the reaction is performed in chloroform, a proton is abstracted from the solvent to produce 
404. Subsequent attack of −CCl3 provides 1,2-dihydroisoquinolines 405. 
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In order to circumvent the instability of imines 402, a one-pot three-component coupling 
mediated by LiClO4 was attempted.199 Thus, a mixture of aldehyde 401 and two equivalents of 
amine 263a was treated with LiClO4 in ether. This results in the formation of iminium ion 406 
which is stabilized by LiClO4. Subsequent addition of trimethyl phosphite to this mixture results in 
the formation of the desired compound 47. Although this reaction work fine, a difficult 
purification is necessary to remove the excess of amine resulting in a decreased yield of the 
aminophosphonate. The second building block 47 was isolated in 68% yield after column 
chromatography. 
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Having both building blocks in hands, a first reaction was performed to test the envisaged route. 
Thus compound 47 was treated with 5 equivalents of styrene and 10% second generation 
catalyst B in refluxing CH2Cl2. Spectroscopic analysis of the reaction mixture after 30 minutes 
revealed that the major compound present was 407. The conversion of this compound to the 
desired compound 395a proceeded extremely slow. It was found, however, that the addition of 
an extra five equivalents of styrene speeds up this conversion significantly. 
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This reaction pattern can be explained by looking at the complete reaction cycle of this 
conversion. In a first step, vinylic carbene 393 is formed. This compound can react with the 
alkene in two different ways: with the R-group pointing away from the metallic centre (408) or 
with the R-group towards the metallic centre (409). In the first case the desired end product 
395 is produced after the cycloreversion. In the second case the unwanted byproduct 407 is 
formed after cycloreversion which can react in three different ways: 1) conversion to 393 via 
409, 2) conversion to 393 by reaction with the methylidene carbene and production of ethylene 
or 3) conversion to 395 after reaction with the alkylidene carbene via 410. During the course of 
the reaction, the alkene is not only incorporated in the end product but also dimerized in the 
“alkene sink” with regeneration of the methylidene carbene and production of ethylene. This 
explains the fact that adding an extra amount of alkene speeds up the conversion of 407 to 395 
since the dimerized alkene remains relatively inert in the reaction mixture. In all cases, however, 
about 10% of 407 remained present which had to be removed by flash chromatography. 
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Upon evaluation of the reaction between 46 and styrene, it was found that in this case it is not 
necessary to add an extra amount of alkene. Only very small signals were present in the 1H NMR 
spectrum that could tentatively be attributed to 411. This can be explained in two ways. The first 
possibility is that the formation of metallacyclobutanes of type 408 is favoured, immediately 
leading to the end products. The second possibility is that the intermediate product 411 is 
converted much faster to the final compound than the alkene is being dimerized. 
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A total of six 1-phosphonylated benzazepines of type 394 and 395 could be obtained in 
reasonable yield after column chromatography in this fashion. In two cases an (E/Z)-mixture was 
obtained. The (E/Z)-ratio observed does not provide any information about the configuration of 
the intermediate metallacyclobutanes or of the initial metathesis products since Grubbs has 
proven that isomerization of double bonds can occur by secondary metathesis reactions leading 
to the thermodynamically favoured configuration.200 
N
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394 395
Br
 
Table 25: Synthesis of 1-phosphonylated benzazepines 394 and 395 
Substrate Product R Yield (%) E/Z 
46 394a Ph 69 100/0 
46 394b CH2CH2Br 50 100/0 
46 394c CH2CH2CH2CH3 70 100/0 
47 395a Ph 78 100/0 
47 395b CH2Si(CH3)3 74 66/34 
47 395c CH2CH2COCH3 68 67/33 
 
3.4.2 Synthesis of 1-phosphonylated benzazocines 
In closely related research, a very similar methodology was used for the synthesis of previously 
undescribed 1-phosphonylated benzazocines.201 Thus α-aminophosphonates 412a and 412b 
were prepared and treated with the second generation Grubbs’ catalyst B in refluxing benzene. 
The benzo-fused eight-membered rings 413a and 413b were isolated in reasonable yield. 
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3.4.3 Attempted synthesis of other benzo-fused heterocycles by RCEYM or RCM 
In a first pathway, phosphonylated benzoxazonines were targeted, nine-membered rings 
containing one oxygen and one nitrogen atom fused with an aromatic six-membered ring. In a 
first step, 2-bromo-4-methylphenol 414 was allylated at oxygen using allylbromide and K2CO3 in 
refluxing acetone. After a basic workup compound 415 was obtained in 91% yield. This 
compound was formylated with DMF after Li-halogen exchange resulting in 416 in 50% yield 
after column chromatography. Conversion of the aldehyde to imine 417 with propargylamine and 
subsequent phosphonylation gave 418 in excellent yield after acid/base extraction. Finally 
benzylation gave substrate 419. 
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O
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O
Bn(MeO)2(O)P
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420
5% cat. B
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No reaction was observed when enyne 419 was treated with 10 mol% second generation 
catalyst B and 5 equivalents of styrene in refluxing CH2Cl2 for an overnight period. When the 
solvent was changed to refluxing benzene, however, almost complete consumption of the 
starting material was obtained after 16 hours. Unfortunately, a complex mixture was obtained 
which proved impossible to purify. Switching to 4-bromobutene as an alkene gave no better 
result. When no alkene was added, only unreacted starting material was recovered. Derivatives 
420 could never be obtained. 
The formation of these mixtures can be explained by mechanistic work done by Hansen and 
Lee.202,203 The problem with the use of RCEYM for the synthesis of macrocycles is the control of 
exo or endo ring-closure. The initially formed carbene 421 normally reacts in an exo-mode with 
Results and Discussion 
-84- 
the formation of bicyclic intermediate 422a. When this opens and reacts further, the expected 
product 423 is observed. 
[Ru]
[Ru]
[Ru]
n
n
n+1
exo
endo
n
n
421
422a
422b
423
424  
When n is large, however, reaction can also proceed via the endo-mode leading to intermediate 
422b. When this compound reacts further, another compound 424 is formed having a larger 
ring than expected. It is possible that in this case both the exo and endo pathways are occurring 
leading to the observed mixtures. Furthermore, cross-metathesis with the alkene could lead to 
(E/Z)-mixtures as was observed for derivatives 395. 
 
This route was abandoned and an attempt was made to obtain benzoxazepines, seven-
membered rings containing one oxygen and one nitrogen atom fused with an aromatic six-
membered ring, via an isomerization-RCM sequence. Compound 430, the required substrate, 
was obtained in a very similar way used to synthesize 419. 
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In a first step, 2-bromophenol 425 was allylated at oxygen using allylbromide and K2CO3 in 
refluxing acetone. After a basic workup compound 426 was obtained in 99% yield. This 
compound was formylated with DMF after Li-halogen exchange resulting in 427 in 72% yield 
after column chromatography. Conversion of the aldehyde to imine 428 with allylamine and 
subsequent phosphonylation gave 429 in excellent yield after acid/base extraction. Finally 
benzylation gave substrate 430. The idea was to treat 430 with catalyst 172 in order to 
isomerize the double bonds and then cyclize 431 with the RCM catalyst towards the envisaged 
structure 432. Unfortunately, only compound 433 could be isolated from the reaction mixture 
resulting from decomposition of 431. It seems that especially the enamine is unstable. This 
problem might be solved by placing an electron withdrawing group on the N-atom, but this route 
was not pursued. 
 
3.4.4 Microwave induced synthesis of phosphonylated isoindoles (Paper VIII) 
In a previous chapter, it was explained how compound 47 was used in a domino enyne 
metathesis—cross-metathesis with an alkene for the synthesis of benzazepines 395. In extension 
of this research an enyne metathesis with a non-terminal alkene 434a was attempted, as was 
very successful in paper IV. This would avoid the need of adding a great number of equivalents 
of alkene to the reaction mixture. It was found, however, that 434a was quite inert towards the 
second generation Grubbs’ catalyst, even in refluxing benzene. After two weeks of refluxing, 
however, spectroscopic analysis revealed the formation of a trace amount of new compound with 
a 31P NMR shift around 15 ppm. This was recognized as a phosphorus attached to an sp2-carbon. 
The trace amount was isolated and identified as isoindole 435a. 
 
N
P(O)(OMe)2
Bn N
R2
Bn(MeO)2(O)P
R2
10 % cat. B
CH2Cl2, Δ
39547 R
1 = H
434a R1 = Ph
R1
R1 = H
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N
P(O)(OMe)2
Bn
Ph
R1 = Ph
C6H6, Δ
 
 
Phosphonylated isoindoles and related compounds are rarely described in the literature. In fact, 
only one entry to phosphonylated isoindoles could be found from the reaction of 2,3-benzoxazin-
1-ones 436 with trialkyl phosphites at high temperature. This reaction results in the formation of 
a mixture containing about 30% 437, about 10% 438 and 439. From this mixture, the 
isoindoles 439 could be purified in a rather low yield.204 
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Few entries towards phosphonylated dihydro isoindoles and isoindolinones have been reported in 
the literature. The latter are known for their plant growth regulating properties. Compound 440 
is effective against the weed cocklebur (Xanthium pennsylvanicum Wallr., Dutch: stekelnoot) at 
56 kg/ha.205 Compound 441 can alter some growth-related properties (like stature reduction and 
axillary bud development) in soybean plants at 0.35 kg/ha.206 Isoindoles possessing an 
alkoxycarbonyl group, the bio-isosteric counterpart of the phosphonate, on the 1-position 442 
have been patented as appetite depressants.207 
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In light of this interesting range of biological activities, an attempt was made to develop an easy 
protocol for the synthesis of phosphonylated isoindoles starting from compounds like 434a. 
Since the transformation of 434a to 435a is obviously not a metathesis process, the reaction 
was repeated in refluxing benzene without a metal catalyst. It required several days, however, to 
achieve some conversion to 435a. At first, it was thought that the reaction proceeded via a 
[1,5]-shift of the acidic proton in α-position of the phosphonate of 434a followed by 5-endo-dig 
attack of the nitrogen atom onto the central allene carbon atom of 443. The zwitterionic form 
444 could then fragment into anion 445 and cations 446a and 446b. The anion can then react 
with 446b at the phenylated position to yield 435a. Next, the rearrangement was evaluated in 
CH3CN since the formation and stability of ionic intermediates might be improved in a more polar 
solvent. It was found that the reaction indeed proceeds faster, but it takes still several days to 
obtain reasonable conversion. The first step in this sequence is assumed to be rate determining 
since aromaticity of the benzene ring is lost. The addition of NEt3 to a refluxing solution of 434a 
in CH3CN, in order to facilitate the proton shift, did not result in an increased reaction rate and 
caused decomposition (appearance of signals in the 0-5 ppm region in the 31P NMR). Also the 
addition of NEt(iPr)2 did not result in a more efficient conversion. These observations may 
suggest that the reaction does not proceed via the proposed pathway. 
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If the reaction is thermally driven, increasing the temperature should result in a faster conversion 
to 435a. Unfortunately, refluxing in DMF, DMSO or NMP did not result in a clean reaction; again 
the appearance of signals in the 0-5 ppm region in the 31P NMR was noticed. Finally a high-
temperature short-time approach was evaluated using microwave technology. When using 
benzene, a quite apolar solvent, very slow heating was observed. Polar solvents, on the other 
hand, are heated very fast as their component molecules are forced to rotate with the field and 
lose energy in collisions. Thus it was observed that CH3CN heats up very rapidly, but the reaction 
was not as clean as expected. After a number of experiments, a mixture of benzene/CH3CN in a 
1/1 ratio at 165 °C proved to be the ideal solvent system for the ring-transformation. The first 
step in this transformation probably involves a direct addition of the nitrogen lone pair onto the 
triple bond in a 5-exo-dig fashion to 447. Although endo dig cyclizations are more favoured than 
exo dig cyclizations, in this case the endo cyclization would lead to a less stable secondary anion 
448. Although the anion 448 is benzylic, the electron pair resides in an sp-orbital that is 
perpendicular to the p-orbitals of the aromatic system. As a consequence no additional 
stabilization by conjugation with this aromatic system is to be expected. Indeed it is found in the 
literature that this kind of exo cyclizations are the most common pathways followed by substrates 
bearing terminal alkynes.208,209 
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The zwitterionic intermediate 447 subsequently fragments with formation of anion 449 and 
cations 446a and 446b. Anion 449 reacts with 446b with formation of 450. The overall result 
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of the fragmentation and recombination corresponds to a [1,3]-alkyl shift. The rearrangement 
ends with a [1,5]-H shift resulting in aromatization towards 435a. 
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In order to prove the general nature of this rearrangement, a number of α-aminophosphonates 
like 434a had to be prepared. A number of secondary amines 454a-h were prepared by a 
straightforward reductive amination between suitable unsaturated aldehydes 452 and amines 
451.210 Thus the formed imines 453 were treated with NaBH4 in methanol for an overnight 
period and the produced secondary amines were isolated using a simple extraction. These 
amines were converted to the α-aminophosphonates 434a-i using the three component coupling 
mediated by LiClO4. Although this reaction works fine, a very difficult purification is necessary in 
order to remove the excess of amine. Very often column chromatography is not possible since 
both the aminophosphonate and the amine have a very similar Rf value. In some cases, the 
aminophosphonates could be crystallised from the mixture; in other cases the excess amine could 
be removed by washing with acidified water since the protonated aminophosphonates are poorly 
water soluble and remained in the organic phase. It was also observed that during the synthesis 
of compounds 434 sometimes some isoindole (<10%) was formed if the reaction was allowed to 
stir for a prolonged time, probably by activation of the triple bond by LiClO4. All the synthesized 
α-aminophosphonates could be converted to the isoindoles by heating to 165 °C in a 1/1 mixture 
benzene/CH3CN under microwave conditions. In order to assure that complete conversion 
occurred, a sample can be taken directly from the reaction mixture and analyzed using 31P NMR. 
When this revealed the presence of remaining starting material, the pressure tube was put back 
in the microwave for an additional period of time. In every case the recombination of the anion 
occurs with the most stabile resonance form of the cation. 
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Table 26: Synthesis of secondary amines 454 and α-aminophosphonates 434 
Entry R1 R2 R3 R4 Yield 454 (%) 
Yield 434 
(%) 
a Bn H Ph H 98 68 
b Bn H H H 99‡ 68 
c Pr H p-MeOC6H4 H 97 81 
d p-MeBn H CH3 CH3 68 48 
e CH2CH2Ph H iPr H 86 56 
f m-FC6H4 H H H 94 72 
g CH2CH2p-ClPh -CH2CH2CH2CH2- H 88 59 
h Bu CH3 Ph H 49 88 
i Allyl H H H - 79¥ 
              ‡ allylamine was used in combination with benzaldehyde 
              ¥ commercially available diallylamine was used 
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Table 27: Microwave induced rearrangement of 434 towards isoindoles 435 
Substrate Time (min) Yield 435a-i (%) 
434a 90 82 
434b 70 76 
434c 90 68 
434d 95 47 
434e 80 71 
434f 150 63 
434g 180 40 
434h 80 40 
434i 60 98 
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During all these rearrangements, allylic cations are formed. In order to check if this is really a 
prerequisite, amines 454j-k were prepared by reductive amination from functionalized 
benzaldehydes and primary amines and subsequent conversion to aminophosphonates 434j-k. 
 
2-ethynylbenzaldehyde
LiClO4, ether, RT
P(OMe)3
N
P(O)(OMe)2
R2
R1
HN
R2
R1
454j R1 = Bu, R2 = m-FBn
454k R1 = Pr, R2 = p-MeOBn 434j R1 = Bu, R2 = m-FBn, 65%
434k R1 = Pr, R2 = p-MeOBn, 71% 
 
It was found that these compounds require higher temperatures in order to react. This can be 
explained by the necessity of forming a less stabilized benzylic cation 456 instead of an allylic 
cation. Furthermore, next to the expected products 459j-k also side products were formed that 
were identified as 461j-k. Normally, route A is followed in which anions 457 recombine with 
cations 456 and produce 459 after the proton shift. Apparently, benzylic cations 456 are not 
stable enough and decompose in the reaction mixture. As a consequence, there is a shortage of 
reaction partners for the anions 457. These anions can then abstract a proton from a molecule 
of substrate or from a trace amount of water to form compounds 460 (route B). These 
compounds also aromatize via a [1,5]-H shift to produce the observed side products 461. 
Depending on the applied time/temperature profile a different ratio of 459/461 is obtained. It 
proved impossible, however, to separate these two compounds. It should be noted that not in a 
single case migration of the alkyl chain was observed. 
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The fact that alkyl migration does not occur in combination with the observation that LiClO4 can 
slightly activate the triple bond, allowed the ‘trapping’ of a zwitterionic intermediate. Thus, a 
mixture of 2-ethynylbenzaldehyde 401 and pyrrolidine 462 was stirred in a concentrated 
solution of LiClO4 in ether and treated with trimethyl phosphite resulting in the formation of 
aminophosphonate 463. By activation of the triple bond by LiClO4, a small amount of zwitterionic 
compound 464 is formed. Under these conditions, this intermediate did not fragment, since a 
non-stabilized primary cation would have been formed. After four hours, this mixture was 
quenched by the addition of 3N HCl. The zwitterionic intermediate reacted with HCl producing 
compound 466 by aromatization of 465. This compound could be purified by column 
chromatography and was obtained pure in 8% yield. 
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Figure 11: 13C spectrum of isoindole 466. 
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Figure 11 shows the typical 13C pattern displayed by these phosphonylated isoindoles. All four 
carbon atoms (A, B, D and H) from the five-membered ring appear as doublets as is the case for 
the phosphonylated pyrroles. A very large C-P coupling of about 235 Hz is observed for carbon H 
which is attached to the phosphonate function. A remarkable deshielding is observed for carbon 
C. This can probably be attributed to the 1,4-relationship with the electron withdrawing 
phosphonate. 
 
When the allylic group that migrates is incorporated in an extra ring, the anion and cation will 
remain attached to each other during the reaction. Thus compounds 434l-m were easily 
prepared from the commercially available amines 467a-b. 
 
2-ethynylbenzaldehyde
LiClO4, ether, RT
P(OMe)3
N
P(O)(OMe)2
R
434l R = Ph, 75%
434m R = p-FPh, 62%
N
H
R
467a R = Ph
467b R = p-FPh  
 
As expected, heating 434l-m under microwave conditions resulted in the formation of tricyclic 
compounds 471a-b. The fragmentation of the zwitterionic intermediate 468 results in the 
formation of 469a and resonance form 469b. An intramolecular attack forms an additional six-
membered ring 470. Finally, aromatization produces isoindoles 471a-b. 
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Derivative 435i proved to be an excellent substrate for ring-closing metathesis. It was converted 
to azepino isoindole 472 in high yield by treatment with 2 mol% second generation catalyst B in 
refluxing benzene. 
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Some attempts were made to convert the phosphonates to the free phosphonic acids. Thus 
compound 471b was treated with 3 equivalents of TMSBr in dry dichloromethane. After 1 hour, 
water was added and all solvents were removed. Analysis by 31P NMR revealed the formation of a 
1:1 mixture of two compounds. At first it was thought that the starting material was only partially 
deprotected. The same mixture was obtained, however, when the reaction was repeated with 5, 
10 or 15 equivalents of TMSBr. Possibly, a diasteriomeric isoindolium salt 473 is formed during 
this reaction. Unfortunately, due to the poor solubility of this compound, no complete 
spectroscopic analysis could be performed. The hypothesis of the formation of this 
diastereomeric salt is supported by the fact that the multiplicity disappears upon addition of NEt3. 
The presumably formed salt 474, however, could also not be fully characterized due to its 
insolubility in a variety of solvents. 
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Further evidence for the formation of a isoindolium salt was obtained by treating 471a with 4 
equivalents HBr in H2O (33% w/w). After stirring for 10 minutes at room temperature, the 
volatiles were removed and the 31P NMR showed the presence of four compounds which were 
tentatively identified as diastereomers 475 and diastereomers 476. If the compound was stirred 
for 2 hours in the presence of HBr, complete conversion to 476 was obtained. Also in this case, 
however, a practically insoluble compound was obtained. 
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3.4.5 Conclusion 
In the third and final part of this thesis two new entries to benzo-fused azaheterocyclic 
phosphonates have been developed. The first protocol uses a combination of enyne-metathesis 
with cross-metathesis and leads to phosponylated benzazepines. The advantage of this strategy 
is that it required the synthesis of only two substrates, with a terminal double and triple bond, 
that depending on the addition of a certain alkene to the reaction mixture are transformed into 
different seven-membered rings. The treatment of very similar substrates containing a non-
terminal double bond with a metathesis catalyst did not lead to the expected seven-membered 
rings but produced phosphonylated isoindoles instead. This thermally driven rearrangement 
starts with an attack of a tertiary nitrogen on a non-activated carbon-carbon triple bond in a 5-
exo-dig fashion, followed by a [1,3]-alkyl shift with eventual aromatization. This pathway 
represents the first high yielding entry to phosphonylated isoindoles. The same strategy could 
also be used for the synthesis of compounds containing an additional six- or seven-membered 
ring. 
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4 Supplementary Experimental Part 
4.1 General methods 
4.1.1 NMR spectroscopy 
High resolution 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra were run on a Jeol JNM-EX 
300 NMR. Peak assignments were obtained with the aid of DEPT, HSQC, COSY, DQFCOSY, HMBC 
spectra. The compounds were diluted in deuterated solvents and the used solvent is indicated for 
each compound. As internal standard tetramethylsilane (TMS) was used. Multiplicities are 
described by using the following abbreviation: s = singlet, d = doublet, t = triplet, q = 
quadruplet, p = pentuplet, m = multiplet, br = broad, ps = pseudo. 
4.1.2 Mass spectroscopy 
Low resolution mass spectra were recorded on an Agilent 1100 Series VS mass spectrometer 
using a direct inlet system (ES, 4000V). Some volatile samples were recorded on a HP 6890 GC 
coupled with a HP 5973 MSD (Mass selective detector; quadrupole). High resolution mass spectra 
were recorded on a Finnigan MAT 95 XP-API-GC-Trap tandem mass spectrometer system. 
4.1.3 Infrared spectroscopy 
IR spectra were obtained from a Perkin Elmer Spectrum One infrared spectrometer. For liquid 
samples the spectra were collected by preparing a thin film of compound between two sodium 
chloride plates. The crystalline compounds were mixed with potassium bromide and pressed until 
a transparent potassium bromide plate was obtained. 
4.1.4 Melting point 
Melting points of crystalline compounds were measured with a Büchi 540 apparatus. 
4.1.5 Column chromatography 
The purification of reaction mixtures was performed by column chromatography using a glass 
column with silica gel (particle size 0.035-0.070 mm, pore diameter ca. 6 nm). Solvent systems 
were determined via initial TLC analysis (Merck Kieselgel 60F254, precoated 0.25 mm). As 
detection methods UV light, adsorption with iodine vapours or colouring with KMnO4 was used. 
4.1.6 Dry solvents 
Diethyl ether, tetrahydrofuran and toluene were distilled from sodium and sodium benzophenone 
ketyl, while dichloromethane was distilled from calcium hydride before use. Methanol was 
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refluxed in the presence of magnesium metal for two hours, then distilled and kept over 
molecular sieves. 
4.1.7 Microwave reactions 
All microwave reactions were performed in the CEM Focused MicrowaveTM Synthesis System, 
Model Discover, with a selectable power output from 0-300 watts. The reactions were performed 
in 10 ml thick walled Pyrex reaction vessels closed with a Septa cap and equiped with a small 
stirring bar. The temperature control system uses a non-contact infrared sensor to measure 
temperature on the bottom of the vessel and is used in a feedback loop with the on-board 
computer to regulate the temperature from 25-250 °C by adjusting the power output (1 watt 
increments). The pressure control, IntelliVentTM Pressure Control System, uses an indirect 
measurement of the pressure by sensing changes in the external deflection of the septa on the 
top of the sealed pressure vessel. Stirring is performed by a rotating magnetic plate located 
below the floor of the microwave cavity. Cooling of the vessel after the reaction is performed by 
a stream of clean air onto the vessel which decreases the temperature of a 2 ml solution from 
~150 °C to ~40 °C in less then 120 seconds. A ramp time of maximum 5 minutes is used during 
which the temperature increases from RT to the desired temperature. This temperature is 
maintained during the course of the reaction for the indicated time. 
4.2 Synthesis of diallylamines 
4.2.1 Alkylation of amines using allylbromide 
Amines 2a-h were prepared by alkylation of the corresponding amines with allylbromide. To a 
solution of 20 mmol amine in 100 ml CH3CN was added 50 mmol allylbromide and 70 mmol NEt3. 
This mixture was refluxed until TLC analysis showed complete consumption of the starting 
material. After cooling this mixture was poured into a separation funnel containing 150 ml 
NaHCO3 (aq, sat). This mixture was extracted three times with 50 ml ethyl acetate and dried with 
MgSO4. After removal of the volatiles an additional purification using column chromatography 
was sometimes necessary. 
 
N,N-diallyl-4-fluoroaniline (2a) 
1H-NMR (300 MHz, CDCl3) δ: 3.86-3.88 (m, 4H, 2 x NCH2), 5.13-5.20 (m, 4H, m, 2 
x HC=CH2), 5.77-5.89 (m, 2H, 2 x HC=CH2), 6.59-6.65 (m, 2H, CHarom), 6.84-6.92 (m, 
2H CHarom). 13C-NMR (75 MHz, CDCl3) δ: 55.54 (2 x NCH2), 113.73 (d, J = 7 Hz, 
CHarom), 115.54 (d, J = 22 Hz, CHarom), 116.3 (2 x HC=CH2), 134.2 (2 x HC=CH2), 
145.6 (NCq,arom), 155,46 (d, J = 235 Hz, FCq,arom). 19F-NMR (282 MHz, CDCl3) δ: -
N
F
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129.2 IR (cm-1) νmax: 1513. MS: m/z (%): 191 (M+,100), 164 (97), 148 (42), 122 (63), 95 
(45), 75 (13), 41 (26). Yield: 95%. 
 
N,N-diallyl-2,6-dichloroaniline (2b) 
1H-NMR (300 MHz, CDCl3) δ: 3.74-3.77 (m, 4H, 2 x NCH2), 5.00-5.20 (m, 4H, 2 x 
HC=CH2), 5.80-5.93 (m, 2H, 2 x HC=CH2), 6.98 (dd, J = 3.0 Hz, J = 7.7 Hz, 1H, 
CHCHCH), 7.25-7.27 (m, 2H, CHCHCH). 13C-NMR (75 MHz, CDCl3) δ: 55.37 (2 x 
NCH2), 116.87 (2 x HCH=CH2), 126,38 (CHarom), 129.00 (CHarom), 136.09 (2 x 
HC=CH2), 136,72 (Cq,arom), 144.72 (Cq,arom). IR (cm-1) νmax: 1641. MS: m/z (%): 245/243/241 
(M+,41), 214 (45), 206 (100), 171,9 (49), 164 (45). Yield: 92%. 
 
Diallyl benzylamine (2c) 
1H-NMR (300 MHz, CDCl3) δ: 3.10 (dt, J = 6.4 Hz, J = 1.2 Hz, 4H, 2 x NCH2CH), 
3.60 (s, 2H, NCH2Ph), 5.06-5.28 (m, 4H, 2 x HC=CH2), 5.91 (ddt, J = 6.4 Hz, J = 10.3 
Hz, J = 16.9 Hz, 2H, 2 x HC=CH2), 6.98-7.27 (m, 5H, Ph). 13C-NMR (75 MHz, 
CDCl3) δ: 56.46 (2 x NCH2CH), 57.59 (NCH2Ph), 117.75 (2 x HC=CH2), 127,01 (CHarom), 128.31 
(2 x CHarom), 129.08 (2 x CHarom), 135,72 (2 x HC=CH2), 139.21 (Cq,arom). IR (cm-1) νmax: 1643 
(C=C). MS: m/z (%): 187 (M+,100), 91 (49). Yield: 99%. 
 
Ethyl 2-(diallylamino)propanoate (2d) 
1H-NMR (300 MHz, CDCl3) δ: 1.27 (d, J = 7.2 Hz, 3H, CH3CH), 1.28 (t, J = 7.2 
Hz, 3H, CH2CH3), 3.14 (dd, J = 7.0 Hz, J = 14.4 Hz, 2H, 2 x NCHAHB), 3.27 (ddt, J 
= 1.4 Hz, J = 5.5 Hz, J = 14.4 Hz, 2H, 2 x NCHAHB), 3.58 (q, J = 7.2 Hz, 1H, 
CHCH3), 4.08-4.23 (m, 2H, CH2CH3), 5.09-5.23 (m, 4H, 2 x HC=CH2), 5.75-5.88 (m, 2H, 2 x 
HC=CH2). 13C-NMR (75 MHz, CDCl3) δ: 14.35 (CH3), 14.88 (CH3), 53.49 (2 x NCH2), 57.23 
(CH2CH3), 60.04 (CHCH3), 116.95 (2 x HC=CH2), 136.55 (2 x HC=CH2), 173.78 (C=O). IR (cm-1) 
νmax: 1732 (C=O), 1643 (C=C). MS: m/z (%): no M+, 156 (9), 124 (100), 41 (17). 
Chromatography: EtOAc (100) Rf = 0.65. Yield: 99%. 
 
Methyl diallylamino acetate (2e) 
1H-NMR (300 MHz, CDCl3) δ: 3.24 (d, J = 6.6 Hz, 4H, 2 x NCH2CH), 3.32 (s, 
2H, NCH2COOMe), 3.69 (s, 3H, CH3), 5.13-5.24 (m, 4H, 2 x HC=CH2), 5.86 (ddt, J 
= 6.6 Hz, J = 10.2 Hz, J = 17.2 Hz, 2H, 2 x HC=CH2), 6.98-7.27 (m, 5H, Ph). 13C-
NMR (75 MHz, CDCl3) δ: 51.39 (NCH2COOMe), 57.27 (2 x NCH2CH), 118.20 (2 x HC=CH2), 
135,24 (2 x HC=CH2), 171.75 (C=O). IR (cm-1) νmax: 1643 (C=C), 1741 (C=O). MS: m/z (%): 
169 (M+, 0.6), 110 (M+-COOMe, 100). Chromatography: Hex/EtOAc (70/30) Rf = 0.34. Yield: 
88%. 
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Ethyl diallylaminophenylacetate (2f) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 7.2 Hz, 3H, CH2CH3), 3.22 (d, J = 6.3 
Hz, 4H, 2 x NCH2), 4.11-4.29 (m, 2H, CH2CH3), 4.59 (s, 1H, CHPh), 5.11-5.20 (m, 
4H, 2 x HC=CH2), 5.76-5.90 (m, 2H, 2 x HC=CH2), 7.26-7.43 (m, 5H, Ph). 13C-
NMR (75 MHz, CDCl3) δ: 14.24 (CH2CH3), 53.19 (NCH2), 60.23 (CH2CH3), 67.50 (CHPh), 
117.34 (2 x HC=CH2), 127.84 (CHarom), 128.34 (CHarom), 128.63 (CHarom), 135.78 (2 x HC=CH2), 
137.00 (Cq,arom), 171.72 (C=O). IR (cm-1) νmax: 1736 (C=O), 1642 (C=C). MS: m/z (%): no 
M+, 186 (100), 104 (7), 91 (9), 41 (12). Yield: 82%. 
 
Diethyl diallylaminomethylphosphonate (2g) 
1H-NMR (300 MHz, CDCl3) δ: 1.32 (t, J = 7.1 Hz, 3H, CH2CH3), 1.33 (t, J = 
6.9 Hz, 3H, CH2CH3), 2.87 (d, J = 10.9 Hz, 2H, NCH2P(O)(OEt)2), 3.25 (d, J = 
6.3 Hz, 4H, 2 x NCH2CH), 4.06-4.20 (m, 4H, 2 x CH2CH3), 5.17-5.23 (m, 4H, 2 x 
HC=CH2), 5.76-5.96 (m, 2H, 2 x HC=CH2), 6.98-7.27 (m, 5H, Ph). 13C-NMR (75 MHz, CDCl3) 
δ: 16.50 (d, J = 4.8 Hz, 2 x CH2CH3), 48.19 (d, J = 163.6 Hz, NCH2P(O)(OEt)2), 58.09 (d, J = 7.3 
Hz, 2 x NCH2CH), 61.90 (d, J = 3.6 Hz, 2 x CH2CH3), 118.17 (d, J = 7.3 Hz, 2 x HC=CH2), 135,04 
(2 x HC=CH2), 171.75 (C=O). 31P-NMR (121 MHz, CDCl3) δ: 26.35. IR (cm-1) νmax: 1030 (P-
O), 1260 (P=O), 1643 (C=C). MS: m/z (%): 247 (M+, 3), 110 (M+-P(O)(OEt)2, 100). 
Chromatography: Hex/EtOAc (30/70) Rf = 0.30. Yield: 47%. 
 
N,N-diallyl-N-(2-methoxyphenyl)amine (2h) 
1H-NMR (300 MHz, CDCl3) δ: 3.75 (dd, J = 1.1 Hz, J = 6.4 Hz, 4H, 2 x NCH2), 
3.87 (s, 3H, OCH3), 5.09-5.19 (m, 4H, 2 x HC=CH2), 5.82 (ddt, J = 6.4 Hz, J = 10.2 
Hz, J = 17.1 Hz, 2H, 2 x HC=CH2), 6.84-6.99 (m, 4H, CHarom). ). 13C-NMR (75 
MHz, CDCl3) δ: 54.67 (2 x NCH2), 55.48 (OCH3), 111.83 (CHarom), 117.22 (2 x 
HC=CH2), 117.33 (CHarom), 120.76 (CHarom), 121.31 (CHarom), 122.63 (CHarom), 135.61 (2 x 
HC=CH2), 139.85 (Carom), 153.59 (Carom). IR (cm-1) νmax: 1594, 1642. MS: m/z (%): 203 
(M+,100), 176 (53), 162 (47), 134 (35). Chromatography: Hex/EtOAc (95/5) Rf = 0.28. Yield: 
98%. 
4.2.2 Alkylation of diallylamine 
Amines 2i-k were prepared by alkylation of commercially available diallylamine with 
electrophiles. To a solution of 30 mmol diallylamine in 100 ml CH3CN was added 10 mmol 
electrophile and 30 mmol NEt3. This mixture was refluxed until TLC analysis showed complete 
consumption of the starting material. After cooling this mixture was poured into a separation 
funnel containing 150 ml NaHCO3 (aq, sat). This mixture was extracted three times with 50 ml 
N
COOEtPh
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ethyl acetate and dried with MgSO4. After removal of the volatiles an additional purification using 
column chromatography was sometimes necessary. 
 
N-allyl-N-(3-phenylpropyl)-2-propen-1-amine (2i) 
1H-NMR (300 MHz, CDCl3) δ: 1.55-1.70 (m, 2H, NCH2CH2), 2.45-2.51 (m, 2H, 
NCH2CH2), 2.58-2.63 (m, 2H, CH2Ph), 3.07-3.10 (m, 4H, 2 x NCH2CH), 5.09-5.19 (m, 
4H, 2 x HC=CH2), 5.78-5.92 (m, 2H, 2 x HC=CH2), 7.14-7.30 (m, 5H, CHarom). 13C-
NMR (75 MHz, CDCl3) δ: 28.87 (NCH2CH2), 33.80 (NCH2CH2), 52.93 (CH2Ph), 
56.93 (2 x NCH2CH), 117.54 (2 x HC=CH2), 125.85 (CHarom), 128.41 (CHarom), 128.52 (CHarom), 
135.75 (2 x HC=CH2), 142.45 (Carom). IR (cm-1) νmax: 1642. MS: m/z (%): 215 (M+,3), 110 
(100), 91 (13), 41 (14). Yield: 75%. 
 
(Diallylamino)acetonitrile (2j) 
1H-NMR (300 MHz, CDCl3) δ: 3.17 (d, J = 6.6 Hz, 4H, 2 x NCH2CH), 3.56 (s, 2H, 
NCH2CN), 5.22-5.36 (m, 4H, 2 x HC=CH2), 5.72-5.85 (m, 2H, 2 x HC=CH2). 13C-NMR 
(75 MHz, CDCl3) δ: 40.73 (NCH2CN), 57.02 (2 x NCH2CH), 114.60 (CN), 119.31 (2 x 
HC=CH2), 134.14 (2 x HC=CH2). IR (cm-1) νmax: 1644 (C=C), 2232 (CN). MS: m/z (%): 136 
(M+, 32), 135 (11), 121 (22), 109 (97), 107 (30), 96 (31), 95 (39), 68 (59), 67 (25), 42 (100), 41 
(94). Chromatography: Hex/EtOAc (1/1) Rf = 0.52. Yield: 94%. 
 
3-(Diallylamino)propanenitrile (2k) 
1H-NMR (300 MHz, CDCl3) δ: 2.45 (t, J = 7.0 Hz, 2H, CH2CN), 2.80 (t, J = 7.0 Hz, 
2H, NCH2CH2), 3.14 (dt, J = 1.2 Hz, J = 6.6 Hz, 4H, 2 x NCH2CH), 5.15-5.25 (m, 4H, 2 
x HC=CH2), 5.77-5.91 (m, 2H, 2 x HC=CH2). 13C-NMR (75 MHz, CDCl3) δ: 16.27 
(CH2CN), 48.39 (NCH2CH2), 56.64 (2 x NCH2CH), 117.73 (2 x HC=CH2), 118.96 (CN), 135.24 (2 x 
HC=CH2). IR (cm-1) νmax: 1643 (C=C), 2249 (CN). MS: m/z (%): 150 (M+, 4), 123 (10), 110 
(100), 81 (9), 68 (10), 42 (11), 41 (40). Yield: 74%. 
4.2.3 Alkylation of allylbenzylamine 
Amines 2l-q were prepared by alkylation of allylbenzylamine or methyl N-allylglycine with 
electrophiles. To a solution of 30 mmol secondary amine in 100 ml CH3CN was added 33 mmol 
electrophile and 45 mmol NEt3. This mixture was refluxed until TLC analysis showed complete 
consumption of the starting material. After cooling this mixture was poured into a separation 
funnel containing 150 ml NaHCO3 (aq, sat). This mixture was extracted three times with 50 ml 
ethyl acetate and dried with MgSO4. After removal of the volatiles an additional purification using 
column chromatography was sometimes necessary. 
 
N
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N-allyl-N-benzyl-2-methyl-2-propen-1-amine (2l) 
1H-NMR (300 MHz, CDCl3) δ: 1.76 (s, 3H, CH3), 2.93 (s, 2H, NCH2C), 3.01 (dd, J = 
1.1 Hz, J = 6.2 Hz, 2H, NCH2CH), 3.53 (s, 2H, CH2Ph), 4.85 (d, J = 0.8 Hz, 1H, 
C=CHAHB), 4.94 (d, J = 0.8 Hz, 1H, C=CHAHB), 5.11-5.23 (m, 2H, HC=CH2), 5.81-5.94 
(m, 1H, HC=CH2), 7.20-7.36 (m, 5H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 20.93 (CH3), 56.46 
(NCH2CH), 57.88 (CH2Ph), 60.67 (NCH2C), 112.72 (C=CH2), 117.18 (HC=CH2), 126.84 (CHarom), 
128.29 (CHarom), 128.81 (CHarom), 136.29 (HC=CH2), 140.06 (Cq,arom), 144.12 (Cq). IR (cm-1) 
νmax: 1644 (C=C), 1698 (C=C). MS: m/z (%): 201 (M+, 18), 160 (70), 91 (100). 
Chromatography: Hex/EtOAc (95/5) Rf = 0.23. Yield: 92%. 
 
N-allyl-N-benzyl-2-chloro-2-propen-1-amine (2m) 
1H-NMR (300 MHz, CDCl3) δ: 3.13 (d, J = 6.1 Hz, 2H, NCH2CH), 3.22 (s, 2H, 
NCH2C), 3.65 (s, 2H, NCH2Ph), 5.15-5.26 (m, 2H, HC=CH2), 5.34 (s, 1H, ClC=CHAHB), 
5.48 (s, 1H, ClC=CHAHB), 5.80-5.94 (m, 1H, HC=CH2), 7.22-7.37 (m, 5H, Ph). 13C-
NMR (75 MHz, CDCl3) δ: 56.33 (NCH2), 57.63 (NCH2Ph), 59.75 (NCH2CCl), 113.96 (ClC=CH2), 
117.89 (HC=CH2), 127.21 (CHarom), 128.48 (CHarom), 128.87 (CHarom), 135.54 (HC=CH2), 139.87 
(Carom or CCl), 140.44 (Carom or CCl). IR (cm-1) νmax: 1635 (C=C). MS: m/z (%): 222.2/224.2 
(M+H+, 100). Chromatography: Hex/EtOAc (95/5) Rf = 0.23. Yield: 79%. 
 
Methyl [allyl(2-bromo-2-propenyl)amino]acetate (2n) 
1H-NMR (300 MHz, CDCl3) δ: 3.34 (dt, J = 1.2 Hz, J = 6.6 Hz, 2H, NCH2CH), 
3.45 (s, 2H, CH2COOMe), 3.52 (s, 2H, NCH2CBr), 3.70 (s, 3H, CH3), 5.14-5.26 (m, 
2H, HC=CH2), 5.58 (dd, J = 0.8 Hz, J = 1.4 Hz, 1H, BrC=CHAHB), 5.78-5.91 (m, 
1H, HC=CH2), 5.90 (dd, J = 1.4 Hz, J = 2.8 Hz, 1H, BrC=CHAHB). 13C-NMR (75 MHz, CDCl3) δ: 
51.43 (CH3), 53.11 (NCH2COOMe), 56.58 (NCH2CH), 61.52 (NCH2CBr), 118.18 (HC=CH2), 118.69 
(CBrCH2), 131.57 (CBr), 135.35 (HC=CH2), 171.70 (C=O). IR (cm-1) νmax: 1629 (br. C=C), 1741 
(br. C=O). MS: m/z (%): no M+, 188/190 (100, M+-COOMe), 128 (48), 41 (35). 
Chromatography: Hex/EtOAc (7/3) Rf = 0.66. Yield: 80%. 
 
N-allyl-N-benzyl-N-[2-(chloromethyl)prop-2-enyl]amine (2o) 
1H-NMR (300 MHz, CDCl3) δ: 2.98-3.05 (m, 2H, NCH2CH), 3.13 (s, 2H, NCH2C), 
3.54 (d, J = 10.7 Hz, 1H, NCHAHBPh), 3.54 (d, J = 10.7 Hz, 1H, NCHAHVPh), 4.13 (s, 
2H, CH2Cl), 5.10-5.27 (m, 4H, HC=CH2 + C=CH2), 5.80-5.94 (m, 1H, HC=CH2), 7.22-
7.39 (m, 5H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 46.30 (CH2Cl), 56.53 (NCH2), 56.57 (NCH2), 
58.09 (NCH2), 117.12 (HC=CH2), 117.83 (C=CH2), 128.43 (CHarom), 128.57 (CHarom), 128.99 
(CHarom), 135.88 (HC=CH2), 139.54 (C=CH2), 143.83 (Carom). IR (cm-1) νmax: 1644 (C=C). MS: 
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m/z (%): 237 (M+, 3), 235 (M+, 10), 200 (28), 160 (60), 91 (100). Chromatography: 
Hex/EtOAc (8/2) Rf = 0.77. Yield: 68%. 
 
Ethyl 2-{[allyl(benzyl)amino)]methyl}acrylate (2p) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (dt, J = 1.7 Hz, J = 7.2 Hz, 3H, CH2CH3), 3.04 
(dd, J = 1.0 Hz, J = 6.2 Hz, 2H, NCH2CH), 3.33 (s, 2H, NCH2C), 3.57 (s, 2H, CH2Ph), 
4.17 (dq, J = 1.4 Hz, J = 7.2 Hz, 2H, CH2CH3), 5.09-5.21 (m, 2H, HC=CH2), 5.78-
5.91 (m, 2H, HC=CH2 + C=CHaHb), 6.23 (dd, J = 1 Hz, J = 2.1 Hz, 1H, C=CHaHb), 7.18-7.36 (m, 
5H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 14.32 (COOCH2CH3), 53.89 (NCH2C), 56.64 (NCH2CH), 
57.98 (CH2Ph), 60.62 (COOCH2CH3), 117.36 (HC=CH2), 125.76 (C=CH2), 126.95 (CHarom), 128.29 
(CHarom), 128.64 (CHarom), 135.83 (HC=CH2), 138.67 (Carom), 139.56 (C=CH2), 167.09 (C=O). IR 
(cm-1) νmax: 1717 (C=O), 1640 (C=C). MS: m/z (%): 259 (M+, 1), 218 (16), 168 (83), 160 
(17), 146 (28), 122 (19), 91 (100). Chromatography: Hex/EtOAc (95/5) Rf = 0.29. Yield: 
82%. 
 
N-allyl-N-benzyl-N-[2-(morholin-4-ylmethyl)prop-2-enyl]amine (2q) 
Compound 2o (0.32 g, 1.36 mmol) is dissolved into CH3CN (10 ml), morpholine (0.35 g, 4.08 mmol) is 
added and the mixture is refluxed until TLC analysis showed that all starting material was consumed. 
The mixture is cooled and aqueous NaHCO3 (15 ml) is added. The mixture is extracted with EtOAc, 
and the organics are dried (MgSO4) and filtered. The solvent is removed in vacuo, and the residue is 
purified by column chromatography. The compound was obtained in 75% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 2.35 (t, J = 4.6 Hz, 4H, 2 x NCH2morph.), 2.93 (s, 2H, 
NCH2C), 3.00 (s, 2H, NCH2C), 3.01-3.03 (m, 2H, NCH2CH), 3.53 (s, 2H, NCH2Ph), 3.63 
(t, J = 4.6 Hz, 4H, 2 x OCH2), 5.05-5.29 (m, 4H, HC=CH2 + C=CH2), 5.80-5.94 (m, 
1H, HC=CH2), 7.19-7.35 (m, 5H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 53.77 (2x 
NCH2morph.), 56.61 (NCH2), 57.48 (NCH2), 58.09 (NCH2), 62.41 (NCH2), 67.22 (2x 
CH2O), 114.90 (C=CH2), 117.07 (HC=CH2), 126.81 (CHarom),128.22 (CHarom),128.78 (CHarom), 
136.26 (HC=CH2), 139.99 (Cq.arom), 144.00 (C=CH2). IR (cm-1) νmax: 1651 (C=C). MS: m/z 
(%): 287 (M+H+, 100). Chromatography: Hex/EtOAc (8/2) Rf = 0.32. Yield: 75%. 
 
4.3 Synthesis of pyrroles using the RuCl3 or the TCQ method 
The general procedure for the synthesis of pyrroles using a combination of the second generation 
Grubbs’ catalyst and RuCl3 is presented in paper I. The general procedure for the synthesis of 
pyrroles using a combination of the second generation Grubbs’ catalyst and TCQ is presented in 
paper II. The spectral data of pyrroles 3a (Hex/EtOAc (9/1) Rf = 0.55), 3c (Hex/EtOAc (1/1) Rf = 
N
Bn
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0.7), 3d (Hex/EtOAc (2/8) Rf = 0.3), 3e (Hex/EtOAc (9/1) Rf = 0.4) and 3h (Hex/EtOAc (9/1) Rf 
= 0.6) can also be found in paper II. 
 
Ethyl 2-(1H-pyrrol-1-yl)propanoate (3b) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 7.2 Hz, 3H, CH2CH3), 1.72 (d, J = 7.3 Hz, 
3H, CHCH3), 4.18 (q, J = 7.2 Hz, 2H, CH2CH3), 4.75 (q, J = 7.3 Hz, 1H, CHCH3), 6.19 
(t, J = 2.2 Hz, 2H, 2 x NCHCH), 6.76 (t, J = 2.2 Hz, 2H, 2 x NCH). 13C-NMR (75 
MHz, CDCl3) δ: 14.18 (CH2CH3), 18.42 (CHCH3), 57.14 (CH2CH3), 61.65 (CHCH3), 108.61 (2 x 
NCHCH), 119.79 (2 x NCH), 171.36 (C=O). IR (cm-1) νmax: 1741 (br. C=O). MS: m/z (%): 
167 (M+, 45), 95 (10), 94 (100). Chromatography: Hex/EtOAc (6/4) Rf = 0.77. 
 
3-(1H-pyrrol-1-yl)propanenitrile (3g) 
1H-NMR (300 MHz, CDCl3) δ: 2.77 (t, J = 6.7 Hz, 2H, CH2CN), 4.20 (t, J = 6.7 Hz, 2H, 
NCH2), 6.20 (t, J = 2.1 Hz, 2H, 2 x NCHCH), 6.71 (t, J = 2.1 Hz, 2H, 2 x NCH). 13C-NMR 
(75 MHz, CDCl3) δ: 20.97 (CH2CN), 45.17 (NCH2), 109.63 (2 x NCHCH), 117.37 (CN), 
120.46 (2 x NCH). IR (cm-1) νmax: 2250 (CN). MS: m/z (%): 120 (M+, 79), 80 (100), 78 (12), 
53 (23). Chromatography: Hex/EtOAc (6/4) Rf = 0.65. 
 
Tert-butyl 2,5-dihydro-1H-pyrrole-1-carboxylate (4r) 
1H-NMR (300 MHz, CDCl3) δ: 1.48 (s, 9H, tBu), 4.11 (dt, J = 12.9 Hz, J = 2.1 Hz, 4H, 2 
x CH2), 5.73-5.81 (m, 2H, HC=CH). 13C-NMR (75 MHz, CDCl3) δ: 28.61 (tBu), 52.93 
(CH2), 53.19 (CH2), 79.37 (Cq), 125.85 (CH), 125.96 (CH), 154.42 (C=O). IR (cm-1) νmax: 1625 
(C=C), 1705 (br. C=O). MS: m/z (%): 169 (M+, 6), 114 (24), 113 (32), 112 (40), 96 (40), 69 
(28), 68 (65), 57 (100), 41 (41). 
 
1-[(4-Methylphenyl)sulfonyl]-2,5-dihydro-1H-pyrrole (4s) 
1H-NMR (300 MHz, CDCl3) δ: 2.43 (s, 3H, CH3), 4.12 (br s, 4H, 2 x CH2), 5.65 (br s, 2H, 
HC=CH), 7.32 (J = 8.1 Hz, 2H, 2 x CHarom), 7.72 (dt, J = 1.9 Hz, J = 8.1 Hz, 2H, 2 x 
CHarom). 13C-NMR (75 MHz, CDCl3) δ: 21.61 (CH3), 54.93 (2xCH2), 125.53 (CHarom.), 127.50 
(CHarom.), 129.86 (C), 134.31 (C), 143.54 (HC=CH). IR (cm-1) νmax: 1595 (C=C). MS: m/z 
(%): 223 (50), 155 (50), 91 (100), 68 (85), 41 (16). Chromatography: Hex/EtOAc (1/2) Rf = 
0.74. Mp. (°C): 126. 
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4.4 Attempted synthesis of furans 
4.4.1 Synthesis of 1-phenylprop-2-en-1-ol (271) 
In dry THF (10 ml) benzaldehyde (1 g, 9.43 mmol) is dissolved and the flask is cooled to -78 °C 
under N2 atmosphere. Via a syringe vinylmagnesium chloride (6.12 ml of a 15% solution, 9.91 
mmol) is added and the mixture is slowely heated to room temperature over a period of 3 hours. 
After this time NH4Cl (5 ml, aq, sat) and water (10 ml) are added and the mixture is extracted 
with ether (3 x 20 ml). After drying with MgSO4 and evaporation of the solvent, the alcohol is 
obtained pure in 96% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 2.00 (br s, 1H, OH), 5.18-5.21 (m, 2H, HC=CH2), 
5.35 (dt, J = 17.1 Hz, J = 1.3 Hz, 1H, CHOH), 6.00-6.11 (m, 1H, HC=CH2), 7.35-
7.37 (m, 5H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 75.27 (CHOH), 115.18 (HC=CH2), 
126.81 (2 x CHarom), 127.77 (CHarom), 128,69 (2 x CHarom), 140.72 (HC=CH2), 143.10 (Carom). IR 
(cm-1) νmax: 1643 (C=C), 3246 (br OH). MS: m/z (%): 134 (M+, 53), 133 (100), 115 (35), 105 
(64), 92 (50), 91 (29), 79 (55), 77 (58). 
4.4.2 Synthesis of [1-(allyloxy)prop-2-enyl]benzene (272) 
Alcohol 271 (0.5 g, 3.73 mmol) is dissolved in dry ether (10 ml) and KOtBu (0.47 g, 4.1 mmol) is 
added after which the mixture is stirred for 30 minutes. Next allylbromide (0.99 g, 8.2 mmol) is 
added and stirring is continued for 16 hours. After this time NH4Cl (5 ml, aq, sat) and water (10 
ml) are added and the mixture is extracted with ether (3 x 20 ml). After drying with MgSO4 and 
evaporation of the solvent, the ether is obtained pure in 98% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 3.93-4.05 (m, 2H, OCH2), 4.81 (d, J = 6.6 Hz, 
1H, OCH), 5.16-5.33 (m, 4H, 2 x HC=CH2), 5.88-6.01 (m, 2H, 2 x HC=CH2), 7.24-
7.36 (m, 5H, Ph). 13C-NMR (75 MHz, CDCl3) δ: 69.34 (OCH2), 82.23 (OCH), 
116.41 (HC=CH2), 116.95 (HC=CH2), 127.04 (2 x CHarom), 127.80 (CHarom), 128.61 (2 x CHarom), 
134.99 (CH2HC=CH2), 139.07 (CHHC=CH2), 141.15 (Carom). IR (cm-1) νmax: 1645 (C=C), 1687 
(C=C). MS: m/z (%): no M+, 133 (45), 117 (67), 115 (52), 105 (100), 91 (24). 
4.4.3 Synthesis of 2-phenyl-2,5-dihydrofuran (273) 
Ether 272 (0.1 g, 0.57 mmol) is dissolved in dry CH2Cl2 (5 ml) and the second generation 
Grubbs’ catalyst (0.005 g, 0.0057 mmol) is added after which the mixture is refluxed for 30 
minutes. Next the mixture is filtered over a small silica plug and after evaporation of the solvent 
dihydrofuran is obtained pure in 88% yield. 
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1H-NMR (300 MHz, CDCl3) δ: 4.78 (dddd, J = 1.7 Hz, J = 2.5 Hz, J = 4.1 Hz, J = 
12.8 Hz, 1H, HC=CH), 4.87 (dddd, J = 1.7 Hz, J = 2.5 Hz, J = 6.0 Hz, J = 12.8 Hz, 
1H, HC=CH), 5.80 (ddd, J = 1.7 Hz, J = 4.1 Hz, J = 7.9 Hz, 1H, CHPh), 5.75-5.92 
(m, 1H, OCHAHB), 6.02-6.06 (m, 1H, OCHAHB), 7.28-7.38 (m, 5H, Ph). 13C-NMR (75 MHz, 
CDCl3) δ: 75.92 (OCH2), 88.00 (OCH), 126.49 (2 x CHarom), 126.73 (HC=CH), 127.91 (CHarom), 
128.60 (2 x CHarom), 130.05 (HC=CH), 142.11 (Carom). IR (cm-1) νmax: 1680 (C=C), 1725 (C=C). 
MS: m/z (%): 146 (M+, 62), 145 (58), 117 (40), 115 (61), 105 (100), 77 (29). 
4.5 Synthesis of 2-phosphonopyrroles 
The general procedure for the synthesis of α-aminophosphonates like 312a-g and 324a-f by 
phosphonylation of an aldimine is described in paper IV. The benzylation of 312a-g towards 
13a-g and the conversion of these compounds to 2-phosphonopyrrolines 14a-e and 2-
phosphonopyrroles 15a-f is described in paper III. Paper III also contains the spectroscopic data 
of 13a, 14a and 15a. Paper IV contains the complete spectroscopic characterization and general 
procedure for the synthesis of all compounds obtained by RCEYM and RCEYM in combination with 
oxidation. 
 
Dimethyl (2E)-1-allylamino-3-phenylprop-2-enylphosphonate (312a) 
1H NMR (300 MHz, ppm) δ: 1.91 (br s, 1H, NH), 3.21 (dd, J = 14.0 Hz, J 
= 6.3 Hz, 1H, NCHAHB), 3.41 (dd, J = 14.0 Hz, J = 5.2 Hz, 1H, NCHAHB), 
3.72-3.84 (m, 7H, CHP + 2 x OMe), 5.12-5.22 (m, 2H, HC=CH2), 5.86 (dddd, J = 17.2 Hz, J = 
10.3 Hz, J = 6.7 Hz, J = 5.2 Hz, 1H, HC=CH2), 6.10 (ddd, J = 15.9 Hz, J = 8.7 Hz, J = 5.8 Hz, 
CHCHPh), 6.62 (dd, J = 15.9 Hz, J = 4.7 Hz, 1H, CHPh), 7.23-7.42 (m, 5H, Ph). 13C NMR (75 
MHz, ppm) δ: 50.09 (d, J = 16.2 Hz, NCH2), 53.57 (d, J = 6.9 Hz, OMe), 53.73 (d, J = 8.1 Hz, 
OMe), 57.72 (d, J = 156.9 Hz, CHP), 116.96 (HC=CH2), 123.91 (d, J = 6.9 Hz, CHCHPh), 126.64 
(CHarom), 128.09 (CHarom), 128.72 (CHarom), 134.70 (d, J = 6.9 Hz, CHPh), 135.97 (HC=CH2), 
136.34. 31P NMR (121 MHz, ppm) δ: 26.77. IR  (cm-1) νmax: 3308 (NH), 1247 (P=O), 1033 
(br P-O). MS m/z (%): 282 (M+H+, 100). MP (°C): 54.1. Yield: 95%. 
 
Dimethyl (2E)-1-allylamino-2-methyl-3-phenylprop-2-enylphosphonate (312b) 
1H NMR (300 MHz, ppm) δ: 1.90 (br s, 1H, NH), 1.99 (dd, J = 3.3 Hz, J = 
1.4 Hz, 3H, CH3), 3.13 (dd, J = 13.9 Hz, J = 6.9 Hz, 1H, NCHAHB), 3.33 (dd, 
J = 13.9 Hz, J = 5.2 Hz, 1H, NCHAHB), 3.70 (d, J = 21.5 Hz, 1H, CHP), 3.78 
(d, J = 10.5 Hz, 3H, OMe), 3.83 (d, J = 10.7 Hz, OMe), 5.12-5.29 (m, 2H, HC=CH2), 5.81-5.94 
(m, 1H, HC=CH2), 6.55 (d, J = 4.1 Hz, CHPh), 7.21-7.37 (m, 5H, Ph). 13C NMR (75 MHz, ppm) 
δ: 15.40 (CH3), 49.86 (d, J = 18.5 Hz, NCH2), 53.48 (d, J = 6.9 Hz, OMe), 53.65 (d, J = 8.1 Hz, 
OMe), 62.97 (d, J = 153.5 Hz, CHP), 116.99 (HC=CH2), 126.84 (CHarom), 128.28 (CHarom), 129.07 
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(CHarom), 130.48 (d, J = 12.7 Hz, CHPh), 132.67 (d, J = 4.6 Hz, C=CH), 136.05 (HC=CH2), 137.28 
(d, J = 2.3 Hz, Cq,arom). 31P NMR (121 MHz, ppm) δ: 26.98. IR  (cm-1) νmax: 3470 (NH), 1248 
(P=O), 1039 (br P-O). MS m/z (%): 296 (M+H+, 81), 186 (M+H+-P(O)(OMe)2, 100). Yield: 
90%. 
 
Dimethyl (2E)-1-allylamino-2-benzyl-but-2-enylphosphonate (312c) 
1H NMR (300 MHz, ppm) δ: 1.54 (br s, 1H, NH), 1.87 (dd, J = 6.3 Hz, J = 
5.8 Hz, 3H, CH3), 2.68 (dd, J = 14.0 Hz, J = 6.6 Hz, 1H, NCHAHB), 2.99 (dd, J 
= 14.0 Hz, J = 5.5 Hz, 1H, NCHAHB), 3.34-3.40 (m, 1H, CHAHBPh), 3.41 (d, J 
= 21.7 Hz, 1H, CHP), 3.68-3.82 (m, 1H, CHAHBPh), 3.73 (d, J = 10.5 Hz, 3H, OMe), 3.78 (d, J = 
10.5 Hz, OMe), 4.75-4.90 (m, 2H, HC=CH2), 5.49-5.63 (m, 1H, HC=CH2), 5.81 (ps p, J ≈ 6.3 Hz, 
CHCH3), 7.15-7.30 (m, 5H, Ph). 13C NMR (75 MHz, ppm) δ: 14.15 (CH3), 35.23 (CH2Ph), 49.57 
(d, J = 16.2 Hz, NCH2), 53.05 (d, J = 6.9 Hz, OMe), 53.86 (d, J = 6.9 Hz, OMe), 58.90 (d, J = 
154.6 Hz, CHP), 116.32 (HC=CH2), 124.93 (d, J = 11.5 Hz, HCCH3), 126.25, 128.46, 128.90, 
133.31 (d, J = 3.5 Hz, C=CH), 136.09 (HC=CH2), 139.41 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 
27.40. IR  (cm-1) νmax: 3321 (NH); 1238 (P=O), 1074, 1026 (P-O). MS m/z (%): 310 (M+H+, 
100). MP (°C): 78-80. Yield: 27%. 
 
Dimethyl 1-allylamino-2-isopentyl-3-phenyl-propenylphosphonate (312d) 
Mixture of two isomers: 79% E and 21% Z. 
Major and minor isomer are indicated as M and m respectively whenever possible. 
1H NMR (300 MHz, ppm) δ: 0.85-0.96 (m, 2 x 3H, CH3), 1.27-1.49 (m, 2 
x 5H, CH3 + CH + CHAHB), 1.53-1.71 (m, 2x1H, CHAHB), 1.89 (br s, 2x1H, 
NH), 2.11-2.20 (m, 1H, CCHAHB, M), 2.22-2.37 (m, 2H, CCH2, m), 2.50-2.60 
(m, 1H, CCHAHB, M), 2.84 (dd, J = 13.8 Hz, J = 6.3 Hz, 1H, NCHAHB, m), 
3.17 (dd, JAB = 14.0 Hz, J = 5.5 Hz, 1H, NCHAHB, M), 3.13-3.20 (m, 1H, NCHAHB, m), 3.40 (dd, 
JAB = 13.8 Hz, J = 3.9 Hz, 1H, NCHAHB, M), 3.66 (d, J = 20.6 Hz, 1H, CHP, M), 3.77 (d, J = 10.5 
Hz, 2 x 3H, OCH3), 3.78 (d, J = 10.5 Hz, 3H, OCH3, m), 3.83 (d, J = 10.5 Hz, 3H, OCH3, M), 4.25 
(d, J = 22.6 Hz, 1H, CHP, m), 4.83-4.90 (m, 2H, HC=CH2, m), 5.11-5.25 (m, 2H, HC=CH2, M), 
5.61-5.74 (m, 1H, HC=CH2, m), 5.81-5.94 (m, 1H, HC=CH2, M), 6.67 (d, J = 5.5 Hz, 1H, CHPh, 
M), 6.70 (br s, 1H, CHPh, m), 7.20-7.36 (m, 2 x 5H, Ph). 13C NMR (75 MHz, ppm) δ: 13.99 
(CH3, M), 14.08 (CH3, m), 22.34 (CH3, M), 22.74 (CH3, m), 27.83 (d, J = 2.3 Hz, CH2, M), 28.08 
(CH2, m), 30.58 (CCH2CH2, m), 30.89 (d, J = 2.3 Hz, CH2, M), 31.85 (CH, m), 32.00 (CH, M), 
49.62 (d, J = 16.2 Hz, NCH2, m), 49.84 (d, J = 16.2 Hz, NCH2, M), 52.95 (d, J = 6.9 Hz, OMe, m), 
53.26 (d, J = 6.9 Hz, OMe, M), 53.45 (d, J = 6.9 Hz, OMe, m), 53.87 (d, J = 6.9 Hz, OMe, M), 
54.78 (d, J = 156.9 Hz, CHP, m), 59.74 (d, J = 152.3 Hz, CHP, M), 116.60 (HC=CH2, m + M), 
126.63 (CHarom), 128.18 (CHarom), 128.22 (CHarom), 128.48 (CHarom), 128.60 (d, J = 13.9 Hz, 
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CHPh, M), 130.53 (d, J = 13.9 Hz, CHPh, m), 135.75 (HC=CH2, m), 136.24 (HC=CH2, M), 136.42 
(Cq), 137.34 (Cq), 137.38 (Cq), 137.43 (Cq), 137.49 (Cq). 31P NMR (121 MHz, ppm) δ: 26.94 
(M), 27.64 (m). IR (cm-1) νmax: 3329 (NH), 1246 (P=O), 1052, 1035 (P-O). MS: m/z (%): 352 
(M+H+, 53), 242 (M+H+-PO(OMe)2, 100). Yield: 88%. 
 
Dimethyl (2E)-1-allylamino-2-phenyl-but-2-enylphosphonate (E-(312e)) 
1H NMR (300 MHz, ppm) δ: 1.66 (dd, J = 6.6 Hz, J = 5.2 Hz, 3H, CH3), 
1.84 (br s, 1H, NH), 3.23 (dd, J = 13.7 Hz, J = 6.6 Hz, 1H, NCHAHB), 3.44 
(dd, J = 13.7 Hz, J = 5.2 Hz, 1H, NCHAHB), 3.64 (d, J = 10.5 Hz, 3H, OMe), 
3.66 (d, J = 10.7 Hz, 3H, OMe), 3.80 (d, J = 22.6 Hz, 1H, CHP), 5.10-5.22 (m, 2H, HC=CH2), 
5.80-5.97 (m, 2H, HC=CH2 + CHCH3), 7.22-7.40 (m, 5H, Ph). 13C NMR (75 MHz, ppm) δ: 
14.79 (d, J = 2.3 Hz, CH3), 49.70 (d, J = 17.3 Hz, NCH2), 52.88 (d, J = 6.9 Hz, OMe), 53.35 (d, J 
= 6.9 Hz, OMe), 60.82 (d, J = 156.9 Hz, CHP), 116.69 (HC=CH2), 127.86 (CHarom), 127.24 (d, J = 
10.4 Hz, CHCH3), 127.97 (2 x CHarom), 129.01 (2 x CHarom), 135.68 (br CPh), 136.05 (HC=CH2), 
138.83 (d, J = 3.5 Hz, Cq,arom). 31P NMR (121 MHz, ppm) δ: 26.87. IR (cm-1) νmax: 3469 
(NH), 1244 (P=O), 1039 (br P-O). MS: m/z (%): 296.3 (M+H+, 100), 186.2 (M+H+-PO(OMe)2, 
84). Chromatography: Hex/EtOAc (2/8) Rf = 0.20. Yield: 52%. 
 
Dimethyl (2Z)-1-allylamino-2-phenyl-but-2-enylphosphonate (Z-(312e)) 
1H NMR (300 MHz, ppm) δ: 1.86 (dd, J = 7.2 Hz, J = 4.7 Hz, 3H, CH3), 1.89 
(br s, 1H, NH), 3.00 (dd, J = 13.7 Hz, J = 6.9 Hz, 1H, NCHAHB), 3.18 (dd, J = 
13.7 Hz, J = 5.2 Hz, 1H, NCHAHB), 3.73 (d, J = 10.5 Hz, 3H, OMe), 3.79 (d, J = 
10.5 Hz, 3H, OMe), 4.29 (d, J = 26.4 Hz, 1H, CHP), 5.05-5.12 (m, 2H, HC=CH2), 5.71-5.84 (m, 
1H, HC=CH2), 5.97 (dq, J = 7.2 Hz, J = 4.1 Hz, 1H, CHCH3), 7.20-7.59 (m, 5H, Ph). 13C NMR 
(75 MHz, ppm) δ: 14.34 (CH3), 50.17 (d, J = 18.5 Hz, NCH2), 53.35 (d, J = 8.1 Hz, OMe), 53.82 
(d, J = 6.9 Hz, OMe), 54.62 (d, J = 160.4 Hz, CHP), 117.11 (HC=CH2), 127.17 (CHarom), 127.25 (2 
x CHarom), 128.36 (2 x CHarom), 130.56 (d, J = 11.5 Hz, CHCH3), 136.14 (HC=CH2), 136.76 (CPh), 
140.86 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 27.40. IR (cm-1) νmax: 3469 (NH), 1246 (P=O), 
1058, 1032 (br P-O). MS: m/z (%): 296.3 (M+H+, 100), 186.2 (M+H+-PO(OMe)2, 39). 
Chromatography: Hex/EtOAc (2/8) Rf = 0.24. Yield: 10%. 
 
Dimethyl (2E)-1-allylamino-2-(2-phenylethyl)but-2-enylphosphonate (312f) 
1H-NMR (300 MHz, CDCl3) δ: 1.71 (t, J = 6.05 Hz, 3H, CH3), 1.76 (s, 1H, 
NH), 2.28-2.81 (m, 4H, CH2CH2), 3.07 (dd, J = 14.1 Hz, J = 6.3 Hz, 1H, 
NCHAHB), 3.27 (dd, J = 14.1 Hz, J = 5.1 Hz, 1H, NCHAHB), 3.50 (d, J = 21.5 
Hz, 1H, CHP), 3.74 (d, J = 10.5 Hz, 3H, OCH3), 3.80 (d, J = 10.2 Hz, 3H, 
OCH3), 5.09-5.22 (m, 2H, C=CH2), 5.66 (dq, J = 6.6 Hz, J = 6.2 Hz, 1H, CH3CH), 5.77-5.88 (m, 
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1H, HC=CH2), 7.16-7.32 (m, 5H, Ph). 13C -NMR (75 MHz, CDCl3) δ: 13.43 (CH3), 31.42 
(CH2Ph), 34.42 (CCH2), 49.68 (d, J = 16.2 Hz, NCH2), 52.90 (d, J = 6.9 Hz, OCH3), 53.55 (d, J = 
6.9 Hz, OCH3), 60.17 (d, J = 154.6 Hz, CHP), 116.26 (C=CH2), 125.16 (d, J = 11.5 Hz, CH3CH), 
125.82 (2 x CHarom), 128.28 (2 x CHarom), 133.73 (d, J = 3.5 Hz, HC=CH2), 136.29 (Cq arom), 
141.97 (C=CH2). 31P NMR (121 MHz, ppm) δ: 27.56 IR (cm-1) νmax: 3324 (NH), 1246 (P=O), 
1031 (P-O). MS: m/z (%): 324.2 (M+H+, 100). Chromatography: Hex/EtOAc (2/8) Rf = 0,32. 
Yield: 44%. 
 
Dimethyl (2E)-1-[(2-methylprop-2-enyl)amino]-3-phenyl-prop-2-enylphosphonate 
(312g) 
1H-NMR (300 MHz, CDCl3) δ: 1.75 (s, 4H, NH + CH3), 3.16 (d, J = 14.3 
Hz, 1H, NCHAHB), 3.29 (d, J = 14.3 Hz, 1H, NCHAHB), 3.71 (ddd, J = 0.8 Hz, 
J = 8.5 Hz, J = 19.5 Hz, 1H, CHP), 3.80 (d, J = 9.6 Hz, 3H, OCH3), 3.83 (d, J = 9.6 Hz, 3H, 
OCH3), 4.88 (s, 1H, C=CHAHB), 4.90 (s, 1H, C=CHAHB), 6.11 (ddd, J = 5.6 Hz, J = 8.5 Hz, J = 
15.8 Hz, 1H, CHCHP), 6.62 (dd, J = 4.5 Hz, J = 15.8 Hz, 1H, PhCH), 7.23-7.42 (m, 5H, Ph). 13C -
NMR (75 MHz, CDCl3) δ: 20.68 (CH3), 53.22 (d, J = 16.1 Hz, NCH2), 53.51 (d, J = 6.9 Hz, 
OCH3), 53.80 (d, J = 7.0 Hz, OCH3), 57.45 (d, J = 156.9 Hz, CHP), 111.99 (C=CH2), 124.02 (d, J 
= 6.9 Hz, CHCHP), 126.64 (2 x CHarom), 128.05 (CHarom), 128.70 (2 x CHarom), 134.64 (d, J = 13.8 
Hz, PhCH), 136.37 (Cq arom), 143.03 (C=CH2). 31P-NMR (121 MHz, CDCl3) δ: 26.9 IR (cm-1) 
νmax: 1057 (P-O), 1244 (P=O), 3460 (NH). MS: m/z (%): 296.7 (M+H+, 100). Yield: 74%. 
 
Dimethyl (2E)-1-(allylbenzylamino)-2-methyl-3-phenyl-prop-2-enylphosphonate (13b) 
1H NMR (300 MHz, ppm) δ: 2.07 (s, 3H, CH3), 3.25 (dd, JAB = 14.2 Hz, J 
= 7.4 Hz, 1H, NCHAHB), 3.62-3.70 (m, 1H, NCHAHB), 3.72 (d, J = 10.5 Hz, 
3H, OMe), 3.72-3.86 (m, 2H, CHP + CHAHBPh), 3.84 (d, J = 10.5 Hz, 3H, 
OMe), 4.18 (dd, JAB = 13.8 Hz, J = 2.5 Hz, 1H, CHAHBPh), 5.15-5.26 (m, 2H, HC=CH2), 5.79-5.92 
(m, 1H, HC=CH2), 6.66 (br s, 1H, CHPh), 7.20-7.39 (m, 10H, Ph). 13C NMR (75 MHz, ppm) δ: 
18.63 (d, J = 6.9 Hz, CH3), 52.86 (d, J = 8.1 Hz, OMe), 52.98 (d, J = 6.9 Hz, OMe), 63.92 (d, J = 
153.5 Hz, CHP), 117.83 (HC=CH2), 126.82 (CHarom), 127.02 (CHarom), 128.21 (CHarom), 128.28 
(CHarom), 128.88 (CHarom), 129.12 (CHarom), 131.95 (d, J = 4.6 Hz, C=CH), 132.38 (d, J = 11.5 Hz, 
CHPh), 136.49 (HC=CH2), 137.40 (Cq,arom), 139.80 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 
27.35. IR (cm-1) νmax: 1247 (P=O), 1037 (br P-O). MS m/z (%): 386 (M+H+, 100). 
Chromatography: Hex/EtOAc (3/2) Rf = 0.26.  Yield: 50%. 
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Dimethyl (2E)-1-(allylbenzylamino)-2-benzyl-but-2-enylphosphonate (13c) 
1H NMR (300 MHz, ppm) δ: 1.83 (d, J = 6.6 Hz, 3H, CH3), 3.20 (d, J = 
14.9 Hz, 1H, CCHAHBPh), 3.34-3.39 (m, 2H, NCH2CH), 3.46 (d, J = 10.5 Hz, 
3H, OMe), 3.53 (d, J = 20.6 Hz, 1H, CHP), 3.66 (d, J = 10.5 Hz, 3H, OMe), 
3.68-3.74 (m, 1H, CCHAHBPh), 3.86-3.88 (m, 2H, NCH2Ph), 5.05-5.16 (m, 2H, HC=CH2), 5.73 
(ddt, J = 17.3 Hz, J = 10.2 Hz, J = 6.5 Hz, 1H, HC=CH2), 6.27 (q, J = 6.6 Hz, 1H, CHCH3), 6.92 
(d, J = 6.6 Hz, 2H, 2 x CHarom), 7.10-7.39 (m, 8H, Ph). 13C NMR (75 MHz, ppm) δ: 14.44 
(CH3), 35.74 (d, J = 11.5 Hz, CCH2Ph), 51.81 (d, J = 6.9 Hz, OMe), 52.65 (d, J = 6.9 Hz, OMe), 
54.20 (d, J = 3.5 Hz, NCH2CH), 54.91 (br NCH2Ph), 58.41 (d, J = 140.8 Hz, CHP), 117.6 
(HC=CH2), 126.06 (CHarom), 126.98 (CHarom), 127.71 (d, J = 5.8 Hz, CHCH3), 128.29 (CHarom), 
128.81 (CHarom), 129.2,2 (CHarom), 133.22 (d, J = 10.4 Hz, C=CH), 137.16 (HC=CH2), 139.45 
(CCH2Cq,arom), 140.29 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 28.84. IR (cm-1) νmax: 1236 
(P=O), 1053, 1030 (P-O). MS m/z (%): 400 (M+H+, 100). Chromatography: Hex/EtOAc 
(1/1) Rf = 0.45.  Yield: 50%. 
Dimethyl (2E)-1-(allylbenzylamino)-2-isopentyl-3-phenyl-prop-2-enylphosphonate (E-
(13d)) 
1H NMR (300 MHz, ppm) δ: 0.83-0.88 (m, 3H, CH3), 1.12-1.35 (m, 6H, 
CH3 + CH2 + CH), 2.05-2.17 (m, 1H, CHAHBC), 2.40-2.49 (m, 1H, CHAHBC), 
3.42-3.57 (m, 2H, NCH2), 3.75 (d, J = 10.5 Hz, 3H, OMe), 3.83 (d, J = 21.5 
Hz, 1H, CHP), 3.87 (d, J = 10.5 Hz, 3H, OMe), 3.96 (d, J = 13.7 Hz, 1H, 
CHAHBPh), 4.04 (dd, J = 13.7 Hz, J = 3.9 Hz, 1H, CHAHBPh), 5.15-5.28 (m, 2H, HC=CH2), 5.77-
5.90 (m, 1H, HC=CH2), 7.12 (br s, 1H, CHPh), 7.21-7.35 (m, 10H, Ph). 13C NMR (75 MHz, 
ppm) δ: 14.07 (CH3), 22.37 (CH3), 28.02 (CH2), 31.27 (d, J = 10.4 Hz, CCH2CH2), 31.81 (CH), 
52.05 (d, J = 6.9 Hz, OMe), 53.11 (d, J = 6.9 Hz, OMe), 54.25 (d, J = 4.6 Hz, NCH2), 55.08 (d, J 
= 4.6 Hz, NCH2Ph), 58.72 (d, J = 144.2 Hz, CHP), 117.68 (HC=CH2), 126.65 (CHarom), 126.97 
(CHarom), 128.17 (CHarom), 128.20 (CHarom), 128.74 (CHarom), 129.10 (CHarom), 131.36 (d, J = 5.8 
Hz, CHPh), 136.96 (HC=CH2), 137.15 (d, J = 8.1 Hz, C=CH), 137.68 (Cq,arom), 139.96 
(CH2Cq,arom). 31P NMR (121 MHz, ppm) δ: 28.72 IR (cm-1) νmax: 1247 (P=O), 1058, 1029 (P-
O), MS: m/z (%): 442 (M+H+, 100), 332 (M+H+-PO(OMe)2, 32). Chromatography: 
Hex/EtOAc (1/1) Rf = 0.50. Yield: 34%. 
 
Dimethyl (2Z)-1-(allylbenzylamino)-2-isopentyl-3-phenyl-prop-2-enylphosphonate (Z-
(13d)) 
1H NMR (300 MHz, ppm) δ: 0.84-0.96 (m, 3H, CH3), 1.32-1.46 (m, 4H, CH3 
+ CH), 1.61-1.72 (m, 2H, CH2), 2.40-2.63 (m, 2H, CH2C), 3.05 (dd, J = 14.3 Hz, 
J = 7.4 Hz, 1H, NCHAHB), 3.47-3.57 (m, 1H, NCHAHB), 3.55 (d, J = 14.0 Hz, 1H, 
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CHAHBPh), 3.69 (d, J = 10.7 Hz, 3H, OMe), 3.71 (d, J = 10.7 Hz, 3H, OMe), 4.05 (dd, J = 14.0 
Hz, J = 1.9 Hz, 1H, CHAHBPh), 4.54 (d, J = 24.8 Hz, 1H, CHP), 4.71-4.87 (m, 2H, HC=CH2), 5.52-
5.65 (m, 1H, HC=CH2), 6.70 (br s, 1H, CHPh), 7.07-7.35 (m, 10H, Ph). 13C NMR (75 MHz, 
ppm) δ: 14.22 (CH3), 22.84 (CH3), 28.60 (CH2), 32.01 (CH), 33.54 (CCH2CH2), 52.55 (d, J = 6.9 
Hz, OMe), 53.08 (d, J = 6.9 Hz, OMe), 54.74 (d, J = 8.1 Hz, NCH2), 55.55 (d, J = 8.1 Hz, 
NCH2Ph), 56.82 (d, J = 156.9 Hz, CHP), 117.28 (HC=CH2), 126.69 (CHarom), 128.06 (CHarom), 
128.37 (CHarom), 128.44 (CHarom), 128.89 (CHarom), 131.05 (d, J = 13.9 Hz, CHPh), 135.83 
(HC=CH2), 136.99 (C=CH), 137.92 (Cq,arom), 139.93 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 
27.79. IR (cm-1) νmax: 1249 (P=O), 1059, 1031 (P-O). MS: m/z (%): 442 (M+H+, 100), 332 
(19, M+H+-PO(OMe)2, 19). Chromatography: Hex/EtOAc (1/1) Rf = 0.58. Yield: 11%. 
 
Dimethyl (2E)-1-(allylbenzylamino)-2-phenyl-but-2-enylphosphonate (13e) 
1H NMR (300 MHz, ppm) δ: 1.69 (d, J = 6.3 Hz, 3H, CH3), 2.95 (dd, J = 
13.9 Hz, J = 7.6 Hz, 1H, NCHAHB), 3.43 (d, J = 13.5 Hz, 1H, CHAHBPh), 3.44-
3.51 (m, 1H, NCHAHB), 3.70 (d, J = 10.5 Hz, 3H, OMe), 3.82 (d, J = 10.7 Hz, 
3H, OMe), 4.03 (d, J = 24.5 Hz, 1H, CHP), 4.02-4.08 (m, 1H, CHAHBPh), 4.84-5.01 (m, 2H, 
HC=CH2), 5.60-5.74 (m, 1H, HC=CH2), 6.41 (qd, J = 6.8 Hz, J = 1.7 Hz, 1H, CHCH3), 7.04-7.36 
(m, 10H, Ph). 13C NMR (75 MHz, ppm) δ: 15.10 (CH3), 52.63 (d, J = 6.9 Hz, OMe), 53.27 (d, J 
= 6.9 Hz, OMe), 54.35 (d, J = 6.9 Hz, NCH2), 55.27 (d, J = 6.9 Hz, NCH2Ph), 60.81 (d, J = 156.9 
Hz, CHP), 117.58 (HC=CH2), 126.76 (CHarom), 127.95 (CHarom), 128.13 (CHarom), 128.95 (CHarom), 
129.09 (d, J = 4.6 Hz, CHCH3), 134.12 (d, J = 8.1 Hz, CPh), 136.47 (HC=CH2), 139.43 
(CH2Cq,arom), 141.51 (d, J = 13.9 Hz, Cq,arom). 31P NMR (121 MHz, ppm) δ: 27.19. IR (cm-1) 
νmax: 1246 (P=O), 1057, 1036 (P-O). MS: m/z (%): 386 (M+H+, 100), 276 (1M+H+-PO(OMe)2, 
10). Chromatography: Hex/EtOAc (1/1) Rf = 0.30. Yield: 25%. - The minor (2Z)-isomer could 
not be obtained in pure form. 
 
Dimethyl (2E)-1-(allylbenzylamino)-2-(2-phenylethyl)but-2-enylphosphonate (13f) 
1H-NMR (300 MHz, CDCl3) δ: 1.64 (d, J = 6.8 Hz, 3H, CH3), 2.23-2.33 (m, 
1H, CHAHBPh), 2.47-2.57 (m, 3H, CH2CHAHBPh), 3.32 (dd, J = 13.8 Hz, J = 
6.1 Hz, 1H, NCHAHBCH), 3.44 (ddd, J = 13.8 Hz, J = 6.6 Hz, J = 4.3 Hz, 1H, 
NCHAHBCH), 3.65-3.81 (m, 2H, CHP + NCHAHBPh), 3.68 (d, J = 10.6 Hz, 3H, 
OCH3), 3.83 (d, J = 10.7 Hz, 3H, OCH3), 3.92 (dd, J = 13.8 Hz, J = 1.1 Hz, 1H, NCHAHBPh), 5.11-
5.25 (m, 2H, C=CH2), 5.79 (ddt, J = 16.6 Hz, J = 10.5 Hz, J = 6.5 Hz, 1H, NCH2CH), 6.05 (q, J = 
6.8 Hz, 1H, CH3CH), 7.10-7.38 (m, 10H, Ph). 13C -NMR (75 MHz, CDCl3) δ: 13.69 (CH3), 32.95 
(d, J = 10.7 Hz, CH2Ph), 34.58 (CCH2), 52.10 (d, J = 8.1 Hz, OCH3), 52.87 (d, J = 7.0 Hz, OCH3), 
54.09 (d, J = 4.6 Hz, NCH2CH), 54.84 (d, J = 3.4 Hz, NCH2Ph), 59.23 (d, J = 143.1 Hz, CHP), 
117.76 (C=CH2), 125.89 (CHarom), 126.98 (CHarom), 127.38 (d, J = 5.8 Hz, CH3CH), 128.29 (2 x 
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CHarom), 128.38 (2 x CHarom), 128.52 (2 x CHarom), 129.10 (2 x CHarom), 133.48 (d, J = 8.0 Hz, 
HC=CH2), 137.12 (Cq arom), 140.17 (Cq arom), (141.97 (C=CH2). 31P-NMR (121 MHz, CDCl3) δ: 
29.01 IR (cm-1) νmax: 1028 (P-O), 1241 (P=O). MS: m/z (%): 414.2 (M+H+, 100). 
Chromatography: Hex/EtOAc (4/6) Rf = 0,41. Yield: 92%. 
 
Dimethyl (2E)-1-[benzyl(2-methylprop-2-enyl)amino]-3-phenylprop-2-enylphosphonate 
(13g)  
1H-NMR (300 MHz, CDCl3) δ: 1.79 (s, 3H, CH3), 3.02 (d, J = 12.7 Hz, 1H, 
NCHAHBPh), 3.47 (d, J = 13.8 Hz, 1H, NCHAHBC), 3.51 (d, J = 12.7 Hz, 1H, 
NCHAHBPh), 3.68 (d, J = 10.5 Hz, 3H, OCH3), 3.82 (d, J = 10.7 Hz, 3H, OCH3), 3.82 (dd, J = 9.8 
Hz, J = 23.7 Hz, 1H, CHP), 4.22 (dd, J = 13.8 Hz, J = 2.2 Hz, 1H, NCHAHBC),4.91 (s, 1H, 
C=CHAHB), 4.98 (s, 1H, C=CHAHB), 6.38 (ddd, J = 6.3 Hz, J = 9.8 Hz, J = 15.7 Hz, 1H, CHCHP), 
6.70 (dd, J = 3.0 Hz, J = 15.7 Hz, 1H, PhCH), 7.22-7.45 (m, 5H, Ph). 13C -NMR (75 MHz, 
CDCl3) δ: 20.64 (CH3), 52.85 (d, J = 6.9 Hz, OCH3), 53.31 (d, J = 6.9 Hz, OCH3), 55.14 (d, J = 
6.9 Hz, NCH2C), 57.84 (d, J = 8.1 Hz, NCH2Ph), 59.01 (d, J = 160.4 Hz, CHP), 113.63 (C=CH2), 
119.74 (CHCHP), 126.75 (2 x CHarom), 127.10 (CHarom), 128.22 (CHarom), 128.40 (2 x CHarom), 
128.75 (2 x CHarom), 128.84 (2 x CHarom), 136.40 (Cq arom), 137.28 (d, J = 15.0 Hz, PhCH), 139.57 
(Cq arom), 143.53 (C=CH2). 31P-NMR (121 MHz, CDCl3) δ: 27.48 IR (cm-1) νmax: 1029 (P-O), 
1246 (P=O). MS: m/z (%): 386.7 (M+H+, 100). Chromatography: Hex/EtOAc (4/6) Rf = 
0,47. MP (°C): 78.5. Yield: 86%. 
 
Dimethyl 1-benzyl-3-methyl-2,5-dihydro-1H-pyrrol-2-ylphosphonate (14b) 
1H NMR (300 MHz, ppm) δ: 1.86 (br s, 3H, CH3), 3.19-3.47 (m, 1H, NCHAHB), 
3.63 (d, J = 13.2 Hz, 1H, CHAHBPh), 3.63-3.74 (m, 1H, NCHAHB), 3.82 (d, J = 
10.7 Hz, 6H, 2 x OMe), 3.92 (m, 1H, CHP), 4.28 (d, J = 13.2 Hz, 1H, CHAHBPh), 
5.49-5.52 (m, 1H, HC=C), 7.21-7.39 (m, 5H, Ph). 13C NMR (75 MHz, ppm) δ: 14.81 (CH3), 
53.19 (d, J = 8.1 Hz, OMe), 53.36 (d, J = 6.9 Hz, OMe), 59.87 (d, J = 8.1 Hz, NCH2), 60.56 (d, J 
= 5.8 Hz, NCH2Ph), 70.84 (d, J = 174.2 Hz, CHP), 124.78 (d, J = 12.7 Hz, HC=C), 126.92 
(CHarom), 128.25 (CHarom), 128.60 (CHarom), 133.43 (d, J = 4.6 Hz, HC=C), 139.37 (Cq,arom). 31P 
NMR (121 MHz, ppm) δ: 24.69. IR (cm-1) νmax: 1249 (P=O), 1057, 1029 (P-O). MS m/z 
(%): 282 (M+H+, 100). Yield: 58%. 
 
Dimethyl 1-benzyl-3-benzyl-2,5-dihydro-1H-pyrrol-2-ylphosphonate (14c) 
1H NMR (300 MHz, ppm) δ: 3.20-3.34 (m, 1H, NCHAHB), 3.43 (br d, J = 16.2 
Hz, 1H, CCHAHBPh), 3.60 (d, J = 13.2 Hz, 1H, NCHAHBPh), 3.63-3.76 (m, 2H, 
NCHAHB, CCHAHBPh), 3.80 (d, J = 10.5 Hz, 3H, OMe), 3.82 (d, J = 10.5 Hz, 3H, 
OMe), 3.89-3.94 (m, 1H, CHP), 4.13 (d, J = 13.2 Hz, 1H, NCHAHBPh), 5.43-5.48 (m, 1H, HC=C), 
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7.20-7.34 (m, 10H, Ph). 13C NMR (75 MHz, ppm) δ: 35.33 (CH2Ph), 53.29 (d, J = 6.9 Hz, 
OMe), 53.39 (d, J = 8.1 Hz, OMe), 59.93 (d, J = 6.9 Hz, NCH2), 60.65 (d, J = 6.9 Hz, NCH2Ph), 
69.04 (d, J = 173.1 Hz, CHP), 125.76 (d, J = 11.5 Hz, HC=C), 126.37 (CHarom), 127.06 (CHarom), 
128.34 (CHarom), 128.49 (CHarom), 128.73 (CHarom), 129,15 (CHarom), 137.67 (d, J = 4.6 Hz, 
HC=C), 138.89 (Cq,arom), 139.24 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 24.69. IR (cm-1) νmax: 
1245 (P=O), 1056, 1029 (P-O). MS m/z (%): 358 (M+H+, 100), 248 (M+H+-PO(OMe)2, 34). 
Yield: 62%. 
 
Dimethyl 1-benzyl-3-isopentyl-2,5-dihydro-1H-pyrrol-2-ylphosphonate (14d) 
1H NMR (300 MHz, ppm) δ: 0.90 (ps t, J = 6.7 Hz, 3H, CH3), 1.25-1.38 (m, 
4H, CH3 + CH), 1.42-1.55 (m, 2H, CH2), 2.06-2.31 (m, 2H, CH2C), 3.20-3.34 (m, 
1H, NCHAHB), 3.63 (d, J = 13.2 Hz, 1H, NCHAHBPh), 3.65-3.78 (m, 1H, NCHAHB), 
3.80 (d, J = 10.2 Hz, 3H, OMe), 3.81 (d, J = 10.2 Hz, 3H, OMe), 3.93-3.99 (m, 
1H, CHP), 4.24 (d, J = 13.2 Hz, 1H, NCHAHBPh), 5.51 (br s, 1H, HC=C), 7.21-7.38 (m, 5H, Ph). 
13C NMR (75 MHz, ppm) δ: 14.15 (CH3), 22.59 (CH3), 27.28 (CH2), 28.76 (CCH2CH2), 31.64 
(CH), 53.36 (d, J = 6.9 Hz, 2 x OMe), 60.02 (d, J = 8.1 Hz, NCH2), 60.81 (d, J = 6.9 Hz, CH2Ph), 
69.87 (d, J = 174.2 Hz, CHP), 123.28 (d, J = 11.5 Hz, HC=C), 127.01 (CHarom), 128.34 (CHarom), 
128.67 (CHarom), 138.34 (d, J = 4.6 Hz, HC=C), 139.45 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 
24.91. IR (cm-1) νmax: 1249 (P=O), 1058, 1032 (P-O). MS m/z (%): 338 (M+H+, 100), 228 
(M+H+-PO(OMe)2, 17). Yield: 70%. 
 
Dimethyl 1-benzyl-3-phenyl-2,5-dihydro-1H-pyrrol-2-ylphosphonate (14e) 
Could only be isolated together with small amounts of pyrrole 15e because of spontaneous 
oxidation during the work-up procedure and product handling. Spectral data given below are 
determined from the mixture and are indicative. 
1H NMR (300 MHz, ppm) δ: 3.51 (d, J = 10.5 Hz, 3H, OMe), 3.52-3.60 (m, 
1H, NCHAHB), 3.64 (d, J = 10.5 Hz, 3H, OMe), 3.82 (d, J = 13.2 Hz, 1H, 
NCHAHBPh), 3.93-4.05 (m, 1H, NCHAHB), 4.15 (d, J = 13.2 Hz, 1H, NCHAHBPh), 
4.54-4.59 (m, 1H, CHP), 6.17-6.19 (m, 1H, HC=C), 7.19-7.45 (m, 10H, Ph). 13C NMR (75 MHz, 
ppm) δ: 53.20 (d, J = 6.9 Hz, 2 x OMe), 60.60 (d, J = 4.5 Hz, NCH2), 61.22 (d, J = 9.2 Hz, 
CH2Ph), 68.67 (d, J = 173.1 Hz, CHP), 126.98 (d, J = 11.5 Hz, CH), 127.06 (CHarom), 127.24 
(CHarom), 127.89 (CHarom), 128.25 (CHarom), 128.43 (CHarom), 128.84 (CHarom), 134.05 (Cq,arom), 
137.52 (d, J = 3.5 Hz, CPh), 139.12 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 24.64. 
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Dimethyl 1-benzyl-3-methyl-1H-pyrrol-2-ylphosphonate (15b) 
1H NMR (300 MHz, ppm) δ: 2.29 (d, J = 1.4 Hz, 3H, CH3), 3.53 (d, J = 11.7 
Hz, 6H, 2 x OMe), 5.38 (s, 2H, NCH2), 6.07-6.09 (m, 1H, CH), 6.82 (dd, J = 5.0 
Hz, J = 2.5 Hz, 1H, NCH), 7.07-7.35 (m, 5H, Ph). 13C NMR (75 MHz, ppm) δ: 
12.93 (CH3), 52.03 (d, J = 4.6 Hz, 2 x OMe), 52.46 (NCH2), 111.25 (d, J = 15.0 Hz, CH), 113.49 
(d, J = 226.1 Hz, CP), 126.91 (CHarom), 127.38 (CHarom), 128.54 (d, J = 12.7 Hz, NCH), 128.50 
(CHarom), 133.47 (d, J = 18.5 Hz, NCC), 138.6 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 14.82. IR 
(cm-1) νmax: 1249 (P=O), 1025 (br P-O). MS m/z (%): 280 (M+H+, 100). Chromatography: 
Hex/EtOAc (2/3) Rf = 0.27. Yield: 84%. 
 
Dimethyl 1,3-dibenzyl-1H-pyrrol-2-ylphosphonate (15c) 
1H NMR (300 MHz, ppm) δ: 3.47 (d, J = 11.6 Hz, 6H, 2 x OMe), 4.11 (s, 2H, 
CCH2Ph), 5.38 (s, 2H, NCH2), 6.02 (dd, J = 4.2 Hz, J = 2.5 Hz, 1H, CH), 6.84 
(dd, J = 5.0 Hz, J = 2.5 Hz, 1H, NCH), 7.07-7.35 (m, 10H, Ph). 13C NMR (75 
MHz, ppm) δ: 33.06 (CCH2Ph), 52.07 (d, J = 5.8 Hz, 2 x OMe), 52.48 (NCH2), 110.89 (d, J = 
16.2 Hz, CH), 113.47 (d, J = 226.0 Hz, CP), 125.70 (CHarom), 126.92 (CHarom), 127.43 (CHarom), 
128.19 (CHarom), 128.51 (CHarom), 128.73 (d, J = 11.5 Hz, NCH), 128.80 (CHarom), 137.15 (d, J = 
18.5 Hz, NCC), 138.44 (Cq,arom), 141.78 (Cq,arom). 31P NMR (121 MHz, ppm) δ: 14.39. IR (cm-
1) νmax: 1240 (P=O), 1023 (br P-O). MS m/z (%): 356 (M+H+, 100). Chromatography: 
Hex/EtOAc (2/3) Rf = 0.29. Yield: 72%. 
 
Dimethyl 1-benzyl-3-isopentyl-1H-pyrrol-2-ylphosphonate (15d) 
1H NMR (300 MHz, ppm) δ: 0.87-0.92 (m, 3H, CH3), 1.28-1.40 (m, 4H, CH + 
CH3), 1.54-1.64 (m, 2H, CH2), 2.69 (t, J = 7.8 Hz, 2H, CCH2CH2), 3.52 (d, J = 
11.6 Hz, 6H, 2 x OMe), 5.38 (s, 2H, NCH2), 6.13 (dd, J = 4.1 Hz, J = 2.8 Hz, 
1H, CH), 6.84 (dd, J = 5.1 Hz, J = 2.8 Hz, 1H, NCH), 7.06-7.32 (m, 5H, Ph). 13C 
NMR (75 MHz, ppm) δ: 14.18 (CH3), 22.67 (CH3), 26.96 (CCH2CH2), 31.03 
(CH2), 31.89 (CH), 52.08 (d, J = 5.8 Hz, 2 x OMe), 52.47 (NCH2), 109.86 (d, J = 15.0 Hz, CH), 
112.92 (d, J = 226.1 Hz, CP), 126.95 (CHarom), 127.42 (CHarom), 128.55 (CHarom), 128.71 (d, J = 
12.7 Hz, NCH), 138.78 (Cq,arom), 139.38 (d, J = 19.6 Hz, NCC). 31P NMR (121 MHz, ppm) δ: 
14.87. IR (cm-1) νmax: 1250 (P=O), 1025 (br P-O). MS m/z (%): 336 (M+H+, 100). 
Chromatography: Hex/EtOAc (2/3) Rf = 0.46. Yield: 70%. 
 
Dimethyl 1-benzyl-3-phenyl-1H-pyrrol-2-ylphosphonate (15e) 
1H NMR (300 MHz, ppm) δ: 3.36 (d, J = 11.6 Hz, 6H, 2 x OMe), 5.57 (s, 2H, 
NCH2), 6.29 (dd, J = 4.0 Hz, J = 2.5 Hz, 1H, CH), 6.94 (dd, J = 5.0 Hz, J = 2.5 
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Hz, 1H, NCH), 7.19-7.46 (m, 10H, Ph). 13C NMR (75 MHz, ppm) δ: 52.09 (d, J = 5.8 Hz, 2 x 
OMe), 52.95 (NCH2), 110.98 (d, J = 13.9 Hz, CH), 113.79 (d, J = 226.1 Hz, CP), 126.88 (CHarom), 
127.32 (CHarom), 127.58 (CHarom), 128.57 (CHarom), 128.66 (d, J = 12.7 Hz, NCH), 129.46 
(CHarom), 135.99 (Cq,arom), 137.46 (d, J = 18.5 Hz, NCC), 138.28 (Cq,arom). 31P NMR (121 MHz, 
ppm) δ: 13.77. IR νmax (cm-1): 1249 (P=O), 1053, 1028 (br., P-O). MS m/z (%): 342 (M+H+, 
100). Chromatography: Hex/EtOAc (2/3) Rf = 0.30. Yield: 75%. 
 
Dimethyl 1-benzyl-3-(2-phenylethyl)-1H-pyrrol-2-ylphosphonate (15f) 
1H-NMR (300 MHz, CDCl3) δ: 2.87-2.92 (m, 2H, CH2Ph), 3.01-3.06 (m, 2H, 
CH2CH2Ph), 3.47 (d, J = 11.6 Hz, 6H, 2 x OCH3), 5.37 (s, 2H, NCH2), 6.13 (dd, J 
= 4.1 Hz, J = 2.5 Hz, 1H, NCHCH), 6.84 (dd, J = 5.0 Hz, J = 2.5 Hz, 1H, NCH), 
7.03-7.35 (m, 10H, Ph). 13C -NMR (75 MHz, CDCl3) δ: 29.19 (CH2CH2Ph), 
37.89 (CCH2), 52.11 (d, J = 5.8 Hz, 2 x OCH3), 52.52 (NCH2), 110.12 (d, J = 16.2 Hz, NCHCH), 
113.32 (d, J = 225.0 Hz, CP), 125.81 (CHarom), 126.87 (2 x CHarom), 127.47 (CHarom), 128.29 (2 x 
CHarom), 128.58 (2 x CHarom), 128.62 (d, J = 12.7 Hz, NCH), 128.75 (2 x CHarom), 138.24 (d, J = 
19.6 Hz, NCC), 138.75 (Cq arom), 142.32 (Cq arom). 31P-NMR (121 MHz, CDCl3) δ: 14.52 IR (cm-
1) νmax: 1025 (P-O), 1248 (P=O). MS: m/z (%): 370.2 (M+H+, 100). Chromatography: 
Hex/EtOAc (6/4) Rf = 0,27. Yield: 71%. 
 
Dimethyl 1H-pyrrol-2-ylphosphonate (315a) 
1H-NMR (300 MHz, ppm) δ: 3.73 (d, J = 11.6 Hz, 6H, 2 x OMe), 6.29-6.33 
(m, 1H, CH), 6.73-6.76 (m, 1H, NCCH), 7.07-7.10 (m, 1H, NCH). 13C-NMR (75 
MHz, ppm) δ: 53.00 (d, J = 5.8 Hz, 2 x OMe), 109.93 (d, J = 15.0 Hz, CH), 115.16 (d, J = 230.8 
Hz, CP), 118.65 (d, J = 17.3 Hz, NCCH), 124.59 (d, J = 12.7 Hz, NCH). 31P-NMR (121 MHz, 
ppm) δ: 15.01. IR ν (cm-1): 3199 (NH), 1244 (P=O), 1029 (br P-O). MS m/z (%): 175 
(M+H+, 100). Chromatography: EtOAc Rf = 0.20. Yield: 39%. 
 
Dimethyl 3-isopentyl-1H-pyrrol-2-ylphosphonate (315b) 
1H-NMR (300 MHz, ppm) δ: 0.86-0.92 (m, 3H, CH3), 1.25-1.41 (m, 4H, CH + 
CH3), 1.52-1.63 (m, 2H, CH2), 2.58 (t, J = 7.8 Hz, 2H, CCH2CH2), 3.71 (d, J = 
11.6 Hz, 6H, 2 x OMe), 6.18-6.21 (m, 1H, CH), 6.93-6.97 (m, 1H, NCH). 13C-
NMR (75 MHz, ppm) δ: 14.04 (CH3), 22.54 (CH3), 26.28 (CCH2CH2), 30.64 
(CH2), 31.70 (CH), 52.44 (d, J = 5.8 Hz, 2 x OMe), 110.82 (d, J = 15.0 Hz, CH), 111.74 (d, J = 
229.6 Hz, CP), 123.35 (d, J = 11.5 Hz, NCH), 135.21 (d, J = 18.5 Hz, NCC). 31P-NMR (121 
MHz, ppm) δ: 16.21. IR ν (cm-1): 3215 (NH), 1245 (P=O), 1030, 1053 (P-O). MS m/z (%): 
246 (M+H+, 100). Chromatography: Hex/EtOAc (2/3) Rf = 0.23. Yield: 27%. Purity: 90%. 
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Dimethyl 1-benzyl-4-[2-phenylethyl]-1H-pyrrol-2-ylphoshonate (325) 
Compound 19e (70 mg, 0.19 mmol) was dissolved in absolute ethanol (10 ml) and subjected to 
catalytic reduction using H2 (3 bar) and Pd/C (5%) at room temperature for 16 hours. After this 
time the mixture was filtered over a small silica plug and the solvent was removed in vacuo. The 
reduced compound is obtained quantitatively. 
 
1H-NMR (300 MHz, CDCl3) δ: 2.73-2.88 (m, 4H, CH2CH2), 3.58 (d, 6H, J = 
11.3 Hz, 2 x OCH3), 5.26 (s, 2H, NCH2), 6.62 (dd, 1H, J = 1.9 Hz, J = 5.5 Hz, 
NCH), 6.69 (dd, 1H, J = 1.9 Hz, J = 3.3 Hz, NCCH), 7.05-7.33 (m, 10H, 2 x 
Ph). 13C -NMR (75 MHz, CDCl3) δ: 28.59 (CH2CH2Ph), 37.37 (CH2CH2Ph), 
52.30 (NCH2), 52.72 (d, J = 5.8 Hz, 2 x OCH3), 116.99 (d, J = 238.4 Hz, CP), 122.15 (d, J = 17.3 
Hz, NCCH), 124.25 (d, J = 13.8 Hz, NCHC), 125.91 (CHarom), 127.06 (d, J = 9.2 Hz, NCH), 127.12 
(2 x CHarom), 127.62 (CHarom), 128.31 (2 x CHarom), 128.60 (2 x CHarom), 128.63 (2 x CHarom), 
138.14 (Carom), 142.02 (NCH2Carom). 31P-NMR (121 MHz, CDCl3) δ: 13.8. IR (cm-1) νmax: 1255 
(P=O), 1023. MS: m/z (%): 370.8 (M+H+, 100). 
4.6 Attempted synthesis of bicyclic pyrroles 
4.6.1 Synthesis of (5S)-ethyl 1-(but-1-enyl)-5-oxopyrrolidine-2-carboxylate (288) 
In a dry flask ethyl pyroglutamate (5 g, 32 mmol) and butanal (2.31 g, 32 mmol) are dissolved 
into toluene (40 ml). To this mixture is added P2O5 (4.78 g, 33.7 mmol) and the flask is fitted 
with a Dean-Stark apparatus. After 12 hours of refluxing the mixture is cooled and carefully 
poured into a separation funnel containing 200 ml NaHCO3 (aq, sat). This mixture is extracted 
with diethyl ether (3 x 100 ml) and dried with MgSO4. After removal of the solids the product is 
distilled (Kugelrohr, 155-160 °C, 3 mmHg) and further purified using column chromatography 
(diethyl ether, Rf = 0.44). The compound is obtained as an oil in 52% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 0.99 (t, J = 7.4 Hz, 3H, CH2CH3), 1.27 (t, J = 
7.2 Hz, 3H, COOCH2CH3), 2.02-2.17 (m, 3H, CH2CH3 + COCH2CHAHB), 2.29-2.50 
(m, 2H, COCHAHBCHAHB), 2.55-2.70 (m, 1H, COCHAHB), 4.23 (q, J = 7.2 Hz, 2H, 
COOCH2CH3), 4.36 (dd, J = 1.8 Hz, J = 9.2 Hz, 1H, NCH), 4.90 (dt, J = 6.9 Hz, J 
= 14.7 Hz, 1H, NCH=CH), 6.83 (d, J = 14.7 Hz, 1H, NCH=CH). 13C -NMR (75 MHz, CDCl3) δ: 
13.46 (CH3), 13.98 (CH3), 22.70 (CH2), 23.14 (CH2CH3), 29.60 (COCH2), 58.43 (COOCH2CH3), 
61.34 (NCH), 114.00 (NCH=CH), 122.05 (NCH=CH), 171.39 (C=O), 172.69 (C=O). IR (cm-1) 
νmax: 1667 (C=C), 1712 (C=O), 1743 (C=O). MS: m/z (%): 212 (M+H+, 100). 
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4.6.2 Synthesis of (5S)-1-[(1E)-but-1-enyl]-5-(hydroxymethyl)pyrrolidin-2-one (289) 
In a dry flask enamide 288 (1.42 g, 6.73 mmol) is dissolved into dry methanol (15 ml). Carefully 
NaBH4 (0.28 g, 7.4 mmol) is added and the mixture is refluxed for 2 hours. After this period, the 
flask is cooled and again very carefully NaBH4 (0.28 g, 7.4 mmol) is added and the mixture is 
again refluxed for 2 hours. After this again very carefully a final amount of NaBH4 (0.28 g, 7.4 
mmol) is added and the mixture is again refluxed for 2 hours. After cooling, 50 ml of NaHCO3 
(aq, sat) is added and the methanol is removed in vacuo. The remaining part is extracted with 
CH2Cl2 (3 x 25 ml) and dried with MgSO4. After evaporation of the solvent the alcohol is purified 
by column chromatography and obtained as an oil in 72% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 1.02 (t, J = 7.4 Hz, 3H, CH3), 1.95-2.23 (m, 4H, 
CH2CH3 + CH2), 2.26-2.40 (m, 1H, COCHAHB), 2.62 (dt, J = 2.6 Hz, J = 8.5 Hz, 
1H, COCHAHB), 3.64 (dd, J = 2.5Hz, J = 11.4 Hz, 1H, CHAHBOH), 3.78 (dd, J = 4.8 
Hz, J = 11.4 Hz, 1H, CHAHBOH), 4.00-4.03 (m, 1H, NCH), 4.65 (br s, 1H, OH), 
5.15 (dt, J = 7.0 Hz, J = 14.9 Hz, 1H, NCH=CH), 6.69 (d, J = 14.9 Hz, 1H, NCH=CH). 13C -NMR 
(75 MHz, CDCl3) δ: 14.24 (CH3), 21.55 (CH2), 23.43 (CH2CH3), 30.62 (COCH2), 58.26 (CH2OH), 
60.53 (NCH), 114.93 (NCH=CH), 121.47 (NCH=CH), 173.90 (C=O). IR (cm-1) νmax: 1663 
(C=C), 1682 (br. C=O), 3391 (br. OH). MS: m/z (%): 170 (M+H+, 100). Chromatography: 
CH2Cl2/MeOH 93/7 Rf = 0.31. 
 
4.6.3 Synthesis of {(2S)-1-[(1E)-but-1-enyl]-5-oxopyrrolidin-2-yl}methyl 4-methyl 
benzenesulfonate (290) 
In a dry flask alcohol 289 (0.59 g, 3.49 mmol) is dissolved into dry CH2Cl2 (10 ml). To this 
solution tosylchloride (0.80 g, 4.18 mmol) and pyridine (0.33 g, 4.18 mmol) are added and the 
mixture is stirred for 16 hours at room temperature. Next the mixture is poured into a separation 
funnel containing 50 ml NaHCO3 (aq, sat), extracted with CH2Cl2 (3 x 10 ml) and dried with 
MgSO4. After evaporation of the solvent the product is purified by column chromatography and 
obtained as a white solid in 98% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 0.92 (t, J = 7.1 Hz, 3H, CH3), 1.91-2.67 (m, 
6H, CH2CH3 + CH2CH2), 2.46 (s, 3H, PhCH3), 4.07-4.15 (m, 3H, NCH + CH2O), 
4.73 (dt, J = 7.1 Hz, J = 14.9 Hz, 1H, NCH=CH), 6.50 (d, J = 14.9 Hz, 1H, 
NCH=CH), 7.36 (d, J = 8.1 Hz, 2 x CHarom), 7.74 (d, J = 8.1 Hz, 2 x CHarom). 13C 
-NMR (75 MHz, CDCl3) δ: 14.22 (CH3), 21.51 (CH2), 21.71 (PhCH3), 23.42 (CH2CH3), 30.09 
(COCH2), 54.84 (CH2O), 67.34 (NCH), 114.50 (NCH=CH), 121.10 (NCH=CH), 128.03 (2 x CHarom), 
130.08 (2 x CHarom), 132.19 (SCq,arom), 145.35 (Cq,arom), 172.66 (C=O). IR (cm-1) νmax: 1664 
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(C=C), 1689 (C=O). MS: m/z (%): 324.2 (M+H+, 100). Chromatography: EtOAc Rf = 0.53. 
MP (°C): 62.5-63. α589nm = -37.2° (c = 11.02 mg/ml in CH2Cl2). 
 
4.6.4 Synthesis of {(2S)-1-[(1E)-but-1-enyl]-5-oxopyrrolidin-2-yl}methyl methane 
sulfonate (291) 
In a dry flask alcohol 289 (1 g, 5.92 mmol) is dissolved into dry CH2Cl2 (20 ml) and placed into 
an ice bath. To this solution pyridine (0.51 g, 6.5 mmol), mesylchloride (0.48 ml, 6.21 mmol) and 
DMAP (0.07 g, 0.59 mmol) are added and the mixture is stirred for 16 hours at room 
temperature. Next the mixture is poured into a separation funnel containing 50 ml NaHCO3 (aq, 
sat), extracted with CH2Cl2 (3 x 10 ml) and dried with MgSO4. After evaporation of the solvent 
the product is purified by column chromatography and obtained as an oil in 94% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 1.04 (t, J = 7.4 Hz, 3H, CH3), 1.76-2.69 (m, 6H, 
CH2CH3 + CH2CH2), 3.01 (s, 3H, SCH3), 4.18-4.25 (m, 1H, NCH), 4.31 (dd, J = 
2.6 Hz, J = 10.5 Hz, 1H, CHAHBO), 4.37 (dd, J = 4.7 Hz, J = 10.5 Hz, 1H, 
CHAHBO), 5.11 (dt, J = 6.7 Hz, J = 14.7 Hz, 1H, NCH=CH), 6.78 (d, J = 14.7 Hz, 
1H, NCH=CH). 13C -NMR (75 MHz, CDCl3) δ: 14.28 (CH3), 21.40 (CH2), 23.40 (CH2CH3), 29.98 
(COCH2), 37.26 (SCH3), 54.94 (NCH), 67.42 (OCH2), 114.89 (NCH=CH), 121.22 (NCH=CH), 
172.80 (C=O). IR (cm-1) νmax: 1694 (br C=C + C=O). MS: m/z (%): 248.3 (M+H+, 100). 
Chromatography: Hex/EtOAc 2/8 Rf = 0.33. 
4.6.5 Synthesis of (5S)-1-[(1E)-but-1-enyl]-5-(iodomethyl)pyrrolidin-2-one (292) 
In a dry flask alcohol 289 (1 g, 5.92 mmol) is dissolved into dry toluene (60 ml). To this solution 
triphenylphosphine (2.33 g, 8.88 mmol) is added and the mixture is refluxed for 15 minutes. 
After this time 10 ml of toluene is removed by distillation. The mixture is cooled to room 
temperature and imidazole (1.21 g, 17.8 mmol) and iodine (1.95 g, 7.69 mmol) are added. The 
mixture is refluxed for 30 minutes after which the solvent is removed in vacuo. Next EtOAc (75 
ml) is added and the organic layer is washed with brine (25 ml). After drying with MgSO4 the 
remainder is dissolved in a 1:1 mixture of EtOAc:hexanes and placed in the freezer. The liquid 
layer is decanted from the white precipitate (Ph3PO) and purified by column chromatography. 
The compound is obtained as an oil in 48% yield. 
 
1H-NMR (300 MHz, CDCl3) δ: 1.03 (t, J = 7.4 Hz, 3H, CH3), 1.73-2.70 (m, 6H, 
CH2CH3 + CH2CH2), 3.16-3.45 (m, 2H, CH2I), 4.09 (t, J = 8.3 Hz, 1H, NCH), 5.04 
(dt, J = 7.0 Hz, J = 14.9 Hz, 1H, NCH=CH), 6.73 (d, J = 14.9 Hz, 1H, NCH=CH). 
13C -NMR (75 MHz, CDCl3) δ: 8.74 (CH2I), 14.39 (CH3), 23.45 (CH2), 24.03 
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(CH2CH3), 29.72 (COCH2), 56.61 (NCH), 114.46 (NCH=CH), 121.15 (NCH=CH), 172.05 (C=O). 
IR (cm-1) νmax: 1691 (br C=C + C=O). MS: m/z (%): 280.2 (M+H+, 100). Chromatography: 
Hex/EtOAc 8/2 Rf = 0.24. 
 
4.6.6 Synthesis of tert-butyl (2S)-2-hydroxymethyl-pyrrolidine-1-carboxylate (295) and 
tert-butyl (2S)-2-formyl-pyrrolidine-1-carboxylate (296) 
Both compounds were obtained following a literature procedure and the obtained spectroscopic 
data was in agreement with the reported data.211 
4.6.7 Synthesis of tert-butyl (2S)-2-vinylpyrrolidin-1-carboxylate (297) 
In a dry flask methyltriphenylphosphonium iodide (4.57 g, 11.3 mmol) is dissolved in 30 ml dry 
THF and KOtBu (2.62 g, 11.6 mmol) is added. This mixture is stirred for 15 minutes under inert 
N2 atmosphere. Next aldehyde 296 (1.5 g, 7.54 mmol) is dissolved into dry THF (20 ml) and 
added to the mixture which is stirred for an overnight period. After this time 30 ml of water is 
added and the mixture is extracted with ether (3 x 50 ml). The organic layer is washed with brine 
(20 ml) and dried with MgSO4. After removal of the solvent, the remainder is dissolved in a 1:1 
mixture of ether:hexanes and placed in the freezer. The liquid layer is decanted from the white 
precipitate (Ph3PO) and purified by column chromatography. The compound is obtained as an oil 
in 70% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 1.44 (s, 9H, tBu), 1.66-2.13 (m, 4H, 2 x CH2), 3.63 
(br s, 2H, NCH2), 4.25 (br s, 1H, NCH), 5.02 (br s, 1H, HC=CHAHB), 5.06 (br s, 1H, 
HC=CHAHB), 5.73 (br s, 1H, HC=CH2). 13C-NMR (75 MHz, CDCl3): δ 22.29 (CH2), 
27.93 ((CH3)3), 31.61 (CH2), 45.72 (NCH2), 58.67 (NCH), 78.11 (Cq), 113.02 (HC=CH2), 138.70 
(HC=CH2), 153.73 (C=O). IR (cm-1) υmax: 1644 (C=C), 1692 (C=O). MS (ESI): m/z (%): 
198.3 (M+H+, 100). Chromatography: Hex/EtOAc 9/1 Rf = 0.23. α589nm = -14.4° (c = 10.40 
mg/ml in CH2Cl2). 
 
4.6.8 Synthesis of methyl (2S)-1-allylpyrrolidine-2-carboxylate (300) 
Methyl prolinate 299 (5 g, 39 mmol) is dissolved in acetonitrile (50 ml). To this solution pyridine 
(3.67 g, 47 mmol) and allylbromide (5.16 g, 43 mmol) are added. The mixture is refluxed for 4 
hours. After this time all the volatiles are removed in vacuo and the residue is dissolved in EtOAc 
(50 ml) and saturated aqueous NaHCO3 (50 ml). After extracting with EtOAc (3 x 25 ml) and 
drying with MgSO4 the compound is obtained pure as an oil in 78% yield. 
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1H-NMR (300 MHz, CDCl3): δ 1.79-2.22 (m, 4H, 2 x CH2), 2.38 (dd, J = 7.7 Hz, 
J = 16.0 Hz, 1H, NCHAHBCH2), 3.09-3.18 (m, 3H, NCH + NCHAHBCH2 + 
NCHAHBCH), 3.71 (dd, J = 6.5 Hz, J = 13.1 Hz, 1H, NCHAHBCH), 3.72 (s, 3H, CH3), 
5.07-5.21 (m, 2H, HC=CH2), 5.85-5.99 (m, 1H, HC=CH2). 13C-NMR (75 MHz, 
CDCl3): δ 22.74 (CH2), 29.06 (CH2), 51.17 (OCH3), 52.99 (NCH2CH2), 57.25 (NCH2CH), 64.65 
(NCH), 116.81 (HC=CH2), 135.06 (HC=CH2), 173.93 (C=O). IR (cm-1) υmax: 1644 (C=C), 1736 
(C=O). MS (ESI): m/z (%): 170.2 (M+H+, 100). α589nm = -99.8° (c = 11.32 mg/ml in CH2Cl2). 
 
4.6.9 Synthesis of [(2S)-1-allylpyrrolidin-2-yl]methanol (301) 
Ester 300 (5.1 g, 30.1 mmol) is dissolved in dry THF (50 ml) and placed in an ice bath under N2 
atmosphere. Very carefully LiAlH4 (1.14 g, 30.1 mmol) is added. The mixture is stirred for 4 hours 
at 0 °C. After this time water (2 ml) is added drop wise and the solution is stirred for an 
additional hour at room temperature. The mixture is filtered over MgSO4 and the solvent is 
removed. The compound is obtained pure as an oil in 89% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 1.66-1.96 (m, 4H, 2 x CH2), 2.30 (dd, J = 7.3 Hz, J 
= 15.8 Hz, 1H, NCHAHBCH2), 2.60-2.77 (m, 2H, NCH + NCHAHBCH), 2.92 (dd, J = 7.3 
Hz, J = 13.6 Hz, 1H, NCHAHBCH), 3.05-3.17 (m, 1H, NCHAHBCH2), 3.36-3.44 (m, 2H, 
NCHAHBOH + NCHAHBCH2), 3.63 (dd, J = 10.8 Hz, J = 3.6 Hz, 1H, NCHAHBOH), 5.10 (dd, J = 1.2 
Hz, J = 9.5 Hz, 1H, HC=CHAHB), 5.19 (dd, J = 1.2 Hz, J = 17.2 Hz, 1H, HC=CHAHB), 5.89 (dddd, 
J = 5.5 Hz, J = 7.3 Hz, J = 9.5 Hz, J = 17.2 Hz, 1H, HC=CH2). 13C-NMR (75 MHz, CDCl3): δ 
22.77 (CH2), 27.63 (CH2), 54.26 (NCH2CH2), 57.75 (NCH2CH), 62.85 (OCH2), 64.47 (NCH), 
116.78 (HC=CH2), 135.76 (HC=CH2). IR (cm-1) υmax: 1644 (C=C), 3400 (br OH). MS (ESI): 
m/z (%): 142.5 (M+H+, 100). α589nm = -36.8° (c = 10.34 mg/ml in CH2Cl2). 
 
4.6.10 Synthesis of tert-butyl 2-(hydroxymethyl)piperidine-1-carboxylate (305) 
Ester 304 (5 g, 19.5 mmol) is dissolved in dry ethanol (50 ml) and placed in an ice bath under N2 
atmosphere. Very carefully NaBH4 (2.21 g, 58.4 mmol) and LiCl (0.12 g, 2.92 mmol) are added. 
The mixture is refluxed for 8 hours. After this time 1N HCl is added until the pH is 7. The mixture 
is extracted with EtOAc (3 x 30 ml) and dried with MgSO4. After removal of the solvent the 
residue is redissolved in CH2Cl2 (15 ml) and the precipitates are removed by filtration. The 
solvent is removed from the filtrate and the compound is obtained pure after column 
chromatography as a solid in 33% yield. 
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1H-NMR (300 MHz, CDCl3): δ 1.40-1.52 (m, 2H, CH2), 1.46 (s, 9H, tBu), 1.55-
1.71 (m, 4H, 2 x CH2), 2.87 (t, J = 12.3 Hz, 1H, NCHAHB), 3.61 (dd, J = 5.8 Hz, J = 
10.9 Hz, 1H, OCHAHB), 3.82 (dd, J = 9.2 Hz, J = 10.9 Hz, 1H, OCHAHB), 3.94 (br d, J 
= 12.3 Hz, 1H, NCHAHB), 4.26-4.31 (m, 1H, NCH). 13C-NMR (75 MHz, CDCl3): δ 19.74 (CH2), 
25.31 (CH2), 25.37 (CH2), 28.51 ((CH3)3), 40.03 (NCH2), 52.64 (NCH), 61.89 (OCH2), 79.94 (Cq), 
156.43 (C=O). IR (cm-1) υmax: 1680 (br C=O), 3436 (br OH). MS (ESI): m/z (%): 238.3 
(M+Na+, 100). MP (°C): 64-66. 
 
4.6.11 Synthesis of tert-butyl 2-formylpiperidine-1-carboxylate (306) 
Alcohol 305 (1.35 g, 6.27 mmol) is dissolved in DMSO (10 ml) and placed in an ice bath under Ar 
atmosphere. To this solution NEt3 (3.08 ml, 22 mmol) is added and the mixture is stirred for 15 
minutes. After this time SO3-pyridine complex (3.49 g, 21.9 mmol) is added in three portions over 
40 minutes at room temperature. Next the reaction is placed in an ice bath and stirring is 
continues for 2.5 hours. After this period ice is added (25 g) and the mixture is extracted with 
CH2Cl2 (4 x 20 ml). The organic phase is washed consecutively with citric acid (20 ml, 50% in 
water), water (20 ml), NaHCO3 (20 ml, aq, sat) and water (20 ml). After drying with MgSO4 and 
removal of the solvent the compound is obtained pure in 97% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 1.02-1.63 (m, 14H, tBu + CHAHB+ 2 x CH2), 2.01-
2.11 (m, 1H, CHAHB), 2.79 (br s, 1H, NCHAHB), 3.89 (br s, NCHAHB), 4.47 (br s, 1H, 
NCH), 9.47 (s, 1H, HCO). 13C-NMR (75 MHz, CDCl3): δ 20.96 (CH2), 23.60 (CH2), 
24.73 (CH2), 28.42 ((CH3)3), 43.14 (br NCH2), 61.51 (br NCH), 80.33 (Cq), 155.00 (br C=O), 
201.32 (C=O). IR (cm-1) υmax: 1694 (C=O), 1735 (C=O). MS (GCMS): m/z (%): 184 (M+-
COH, 20), 140 (M+-OtBu, 20), 128 (100). 
 
4.6.12 Synthesis of tert-butyl 2-vinylpiperidine-1-carboxylate (307) 
In a dry flask methyltriphenylphosphonium iodide (3.41 g, 8.44 mmol) is dissolved in 25 ml dry 
THF and KOtBu (0.98 g, 8.53 mmol) is added. This mixture is stirred for 15 minutes under inert 
N2 atmosphere. Next aldehyde 306 (1.2 g, 5.63 mmol) is dissolved into dry THF (15 ml) and 
added to the mixture which is stirred for an overnight period. After this time 30 ml of water is 
added and the mixture is extracted with ether (3 x 40 ml). The organic layer is washed with brine 
(20 ml) and dried with MgSO4. After removal of the solvent, the remainder is dissolved in a 1:1 
mixture of ether:hexanes and placed in the freezer. The liquid layer is decanted from the white 
precipitate (Ph3PO) and purified by column chromatography. The compound is obtained as an oil 
in 76% yield. 
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1H-NMR (300 MHz, CDCl3): δ 1.24-1.82 (m, 15H, tBu + 3 x CH2), 2.83 (br t, J = 
13.1 Hz, 1H, NCHAHB), 3.95 (br d, J = 13.1 Hz, 1H, NCHAHB), 4.79 (br s, 1H, NCH), 
5.04 (dt, J = 1.4 Hz, J = 17.1 Hz, 1H, HC=CHAHB), 5.17 (dt, J = 1.4 Hz, J = 10.6 Hz, 
1H, HC=CHAHB), 5.75 (ddd, J = 4.1 Hz, J = 10.6 Hz, J = 17.1 Hz, 1H, HC=CH2). 13C-NMR (75 
MHz, CDCl3): δ 19.57 (CH2), 25.64 (CH2), 28.51 ((CH3)3), 29.02 (CH2), 39.78 (NCH2), 52.56 
(NCH), 79.34 (Cq), 115.54 (HC=CH2), 137.00 (HC=CH2), 155.75 (C=O). IR (cm-1) υmax: 1640 
(C=C), 1694 (C=O). MS (ESI): m/z (%): 212.3 (M+H+, 100). Chromatography: Hex/EtOAc 
9/1 Rf = 0.43. 
4.6.13 Synthesis of ethyl 1-allylpiperidine-2-carboxylate (309) 
Ethyl pipecolinate 303 (4 g, 25 mmol) is dissolved in acetonitrile (40 ml). To this solution 
pyridine (2.42 g, 30.6 mmol) and allylbromide (3.39 g, 28 mmol) are added. The mixture is 
refluxed for 4 hours. After this time all the volatiles are removed in vacuo and the residue is 
dissolved in EtOAc (50 ml) and saturated aqueous NaHCO3 (50 ml). After extracting with EtOAc 
(3 x 25 ml) and drying with MgSO4 the compound is obtained pure as an oil in 96% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 1.28 (t, J = 7.2 Hz, CH3), 1.33-2.19 (m, 6H, 3 x 
CH2), 2.89-3.35 (m, 5H, 2 x NCH2 + NCH), 4.11-4.23 (m, 2H, OCH2), 5.12-5.18 (m, 
2H, HC=CH2), 5.83-5.97 (m, 1H, HC=CH2). 13C-NMR (75 MHz, CDCl3): δ 13.74 
(CH3), 22.07 (CH2), 24.90 (CH2), 29.09 (CH2), 49.81 (NCH2CH2), 58.91 (NCH2CH), 
59.54 (OCH2), 63.72 (NCH), 117.10 (HC=CH2), 134.67 (HC=CH2), 172.68 (C=O). IR (cm-1) 
υmax: 1643 (C=C), 1733 (C=O). MS (ESI): m/z (%): 198.2 (M+H+, 100). 
 
4.6.14 Synthesis of (1-allylpiperidin-2-yl)methanol (310) 
Ester 309 (4.1 g, 21 mmol) is dissolved in dry THF (35 ml) and placed in an ice bath under N2 
atmosphere. Very carefully LiAlH4 (0.79 g, 21 mmol) is added. The mixture is stirred for 4 hours 
at 0 °C. After this time water (1.5 ml) is added drop wise and the solution is stirred for an 
additional hour at room temperature. The mixture is filtered over MgSO4 and the solvent is 
removed. The compound is obtained pure as an oil in 98% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 1.22-1.85 (m, 6H, 3 x CH2), 2.18-2.37 (m, 2H, 
NCHAHBCH2 + NCH), 2.92-3.20 (m, 2H, NCHAHBCH2 + NCHAHBCH), 3.40-3.52 (m, 2H, 
NCHAHBCH + CHAHBOH), 3.78 (dd, J = 3.7 Hz, J = 11.0 Hz,1H, CHAHBOH), 5.12-5.22 
(m, 2H, HC=CH2), 5.80-5.94 (m, 1H, HC=CH2). 13C-NMR (75 MHz, CDCl3): δ 
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23.46 (CH2), 23.71 (CH2), 27.15 (CH2), 50.71 (NCH2CH2), 55.68 (NCH2CH), 60.40 (NCH), 61.52 
(CH2OH), 116.18 (HC=CH2), 133.48 (HC=CH2). IR (cm-1) υmax: 1643 (C=C), 3370 (br OH). MS 
(ESI): m/z (%): 156.2 (M+H+, 100). 
4.7 Synthesis of hydantoins by rearrangement of 
pyroglutamates 
Typical procedures for the synthesis and complete spectroscopic description of compounds 22a-
h, 365a-i, 368a-e, 32a-h and 33a-h can be found in paper V. 
4.7.1 Ethyl 3-(6-methylene-1,3-dioxo-2-propyltetrahydro-1H-pyrrolo[1,2-c]imidazol-
7a(5H)-yl)propanoate (370) 
1H-NMR (300 MHz, CDCl3) δ: 0.93 (t, J = 7.3 Hz, 3H, NCH2CH2CH3), 1.24 (t, J 
= 7.2 Hz, 3H, CH3), 1.65 (sextet, J = 7.3 Hz, 2H, NCH2CH2), 2.03-2.28 (m, 4H, 
CH2CH2), 2.43-2.73 (m, 2H, CCH2), 3.45 (dt, J = 7.3 Hz,  J = 13.3 Hz, 1H, 
NCHAHBCH2), 3.49 (dt, J = 7.3 Hz,  J = 13.3 Hz, 1H, NCHAHBCH2), 3.73 (d + small 
splitting, J = 15.5 Hz, 1H, NCHAHBC), 4.09 (dq, J = 7.2 Hz, J = 10.5 Hz, 1H, CHAHBCH3), 4.12 
(dq, J = 7.2 Hz, J = 10.5 Hz, 1H, CHAHBCH3), 4.32 (d + small splitting, J = 15.5 Hz, 1H, 
NCHAHBC), 5.11 (p, J = 2.1 Hz, 1H, C=CHAHB), 5.15 (p, J = 2.1 Hz, 1H, C=CHAHB). 13C-NMR 
(75 MHz, CDCl3) δ: 11.19 (CH3, pr), 14.18 (CH3), 21.35 (NCH2CH2), 29.16 (CH2), 29.42 (CH2), 
40.73 (NCH2CH2), 40.78 (CCH2C), 48.68 (NCH2C), 60.78 (OCH2), 71.78 (Cq), 110.12 (HC=CH2), 
144.93 (C=CH2), 159.73 (NC=ON), 172.42 (C=O), 175.03 (C=O). MS (ESI) m/z (%): 295.8 
(M+H+, 100). IR (cm-1, KBr) υmax: 1714 (C=O), 1774 (C=O). Chromatography: 
Hex/EtOAc/ether 7/3/2 Rf = 0.36. Yield: 34%. 
4.7.2 Ethyl 3-(1,4-diallyl-2,5-dioxo-imidazolidin-4-yl)propionate (371) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 7.1 Hz, 3H, CH3), 2.05-2.31 (m, 
4H, CH2CH2), 2.44 (dd, J = 7.4 Hz, J = 14.0 Hz, 1H, CHAHBCH), 2.52 (dd, J = 
7.6 Hz, J = 14.0 Hz, 1H, CHAHBCH), 4.07-4.16 (m, 2H, NCH2), 4.12 (q, J = 7.1 
Hz, 2H, CH2CH3), 5.16-5.28 (m, 4H, 2 x HC=CH2), 5.62-5.86 (m, 2H, 2 x 
HC=CH2). 13C-NMR (75 MHz, CDCl3) δ: 14.19 (CH3), 28.76 (CH2), 31.16 (CH2), 40.70 (NCH2), 
41.46 (CH2CH), 61.02 (OCH2), 64.59 (Cq), 118.23 (HC=CH2), 121.36 (HC=CH2), 130.03 
(HC=CH2), 131.15 (HC=CH2), 156.69 (NC=ON), 172.81 (C=O), 174.98 (C=O). MS (ESI) m/z 
(%): 281.2 (M+H+, 100). IR (cm-1, KBr) νmax: 1645 (C=C), 1714 (C=O), 1777 (C=O). 
Chromatography: Hex/EtOAc 6/4 Rf = 0.23. Yield: 55%. 
 
HN N
O
O
COOEt
N N
O
O
Pr
COOEt
Supplementary Experimental Part 
-122- 
4.7.3 Ethyl 3-(1,4-diallyl-3-benzyl-2,5-dioxo-imidazolidin-4-yl)propionate (372) 
 
1H-NMR (300 MHz, CDCl3) δ: 1.18 (t, J = 7.1 Hz, 3H, CH3), 1.73-2.15 (m, 
4H, CH2CH2), 2.47 (dd, J = 6.7 Hz, J = 14.2 Hz, 1H, CHAHBCH), 2.54 (dd, J = 
7.3 Hz, J = 14.2 Hz, 1H, CHAHBCH), 4.00 (q, J = 7.1 Hz, 2H, CH2CH3), 4.10 (dd, 
J = 5.2 Hz, J = 14.4 Hz, 1H, NCHAHB), 4.12 (dd, J = 5.9 Hz, J = 14.4 Hz, 1H, 
NCHAHB), 4.29 (d, J = 15.3 Hz, 1H, NCHAHBPh), 4.68 (d, J = 15.3 Hz, 1H, NCHAHBPh), 4.98-5.05 
(m, 2H, HC=CH2), 5.19-5.38 (m, 3H, HC=CH2), 5.74-5.87 (m, 1H, HC=CH2), 7.25-7.44 (m, 5H, 
Ph). 13C-NMR (75 MHz, CDCl3) δ: 14.21 (CH3), 27.97 (CH2), 29.87 (CH2), 39.60 (CH2CH), 
41.16 (NCH2), 43.77 (NCH2Ph), 60.68 (OCH2), 68.55 (Cq), 118.55 (HC=CH2), 121.09 (HC=CH2), 
128.15 (CHarom), 128.89 (2 x CHarom), 129.01 (2 x CHarom), 129.62 (HC=CH2), 131.24 (HC=CH2), 
137.19 (Cq,arom), 156.49 (NC=ON), 171.73 (C=O), 173.76 (C=O). MS (ESI) m/z (%): 371.2 
(M+H+, 100). IR (cm-1, KBr) νmax: 1710 (C=O), 1733 (C=O), 1769 (C=O). 
Chromatography: Hex/EtOAc 2/1 Rf = 0.40. Yield: 88%. 
 
4.7.4 Ethyl 3-(1,3-diallyl-2,5-dioxo-imidazolidin-4-yl)propionate (374) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 7.1 Hz, 3H, CH3), 2.02-2.14 (m, 
1H, CHCHAHB), 2.17-2.44 (m, 3H, COCH2 + CHCHAHB), 3.62 (dd, J = 7.7 Hz, J = 
15.7 Hz, 1H, NCHAHB), 4.04 (dd, J = 3.0 Hz, J = 6.6 Hz, 1H, CHCH2), 4.10 (dd, 
J = 1.7 Hz, J = 3.0 Hz, 1H, NCHAHB), 4.12 (dd, J = 1.4 Hz, J = 3.2 Hz, 1H, 
NCHAHB), 4.13 (q, J = 7.1 Hz, 2H, CH2CH3), 4.37 (ddt, J = 1.3 Hz, J = 5.0 Hz, J = 15.7 Hz, 1H, 
NCHAHB), 5.19-5.29 (m, 4H, 2 x HC=CH2), 5.34-5.95 (m, 2H, 2 x HC=CH2). 13C-NMR (75 MHz, 
CDCl3) δ: 14.24 (CH3), 23.80 (CH2), 28.22 (CH2), 41.07 (NCH2), 43.54 (NCH2), 57.81 (CH), 
60.93 (OCH2), 118.28 (HC=CH2), 119.51 (HC=CH2), 131.21 (HC=CH2), 131.73 (HC=CH2), 155.97 
(NC=ON), 172.20 (C=O), 172.37 (C=O). MS (ESI) m/z (%): 281.2 (M+H+, 100). IR (cm-1, 
KBr) νmax: 1646 (C=C), 1661 (C=C), 1713 (C=O), 1772 (C=O). Chromatography: 
Hex/EtOAc 1/1 Rf = 0.55. Yield: 99%. 
4.8 Synthesis of bis-hydantoins and derivatives 
4.8.1 Synthesis of bis-carbamoyl lactams 379 
The general procedure of this synthesis can be found in paper VI. 
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Ethyl 1-({[4-({[2-(ethoxycarbonyl)-5-oxopyrrolidin-1-yl]carbonyl}amino)butyl]amino} 
carbonyl)-5-oxopyrrolidine-2-carboxylate (379a) 
1H-NMR (300 MHz, CDCl3) δ: 1.29 (t, J = 7.2 Hz, 6H, 2 
x CH3), 1.60 (t, J = 3.0 Hz, 4H, 2 x NCH2CH2), 2.00-2.10 
(m, 2H, 2 x CHCHAHB), 2.25-2.45 (m, 2H, 2 x CHCHAHB), 
2.57 (ddd, J = 17.6 Hz, J = 3.4 Hz, J = 9.5 Hz, 2H, 2 x 
COCHAHB), 2.74 (ddd, J = 17.6 Hz, J = 9.9 Hz, J = 9.9 Hz, 2H, 2 x COCHAHB), 3.23-3.40 (m, 4H, 
2 x NCH2), 4.24 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 4.77 (dd, J = 9.5 Hz, J = 2.6 Hz, 2H, 2 x CH), 
8.31 (t, J = 5.5 Hz, 2H, 2 x NH). 13C-NMR (75 MHz, CDCl3) δ: 14.15 (2 x CH3), 21.28 (2 x 
CHCH2), 27.02 (2 x NCH2CH2), 31.87 (2 x COCH2), 39.51 (2 x NCH2), 58.20 (2 x CH), 61.72 (2 x 
CH2CH3), 152.29 (2 x NC=ON), 171.50 (2 x NC=O), 176.48 (2 x C=OO). IR (cm-1) νmax: 1694 
(C=O), 1721 (br C=O), 3317 (NH). MS: m/z (%): 455.7 (M+H+, 100). HRMS: calcd for 
C20H30N4O8 (M + H+), 455.21364; found, 455.21475. Yield: 97%. 
 
Ethyl 1-({[6-({[2-(ethoxycarbonyl)-5-oxopyrrolidin-1-yl]carbonyl}amino)hexyl]amino} 
carbonyl)-5-oxopyrrolidine-2-carboxylate (379b) 
1H-NMR (300 MHz, CDCl3) δ: 1.29 (t, J = 7.1 Hz, 
6H, 2 x CH3), 1.35 (t, J = 6.9 Hz, 4H, 2 x N(CH2)2CH2), 
1.55 (p, J = 6.9 Hz, 4H, 2 x NCH2CH2), 2.04 (dddd, J = 
13.3 Hz, J = 9.7 Hz, J = 3.2 Hz, J = 3.0 Hz, 2H, 2 x 
CHCHAHB), 2.34 (dddd, J = 13.3 Hz, J = 9.8 Hz, J = 9.7 Hz, J = 9.6 Hz, 2H, 2 x CHCHAHB), 2.57 
(ddd, J = 17.6 Hz, J = 9.7 Hz, J = 3.2 Hz, 2H, 2 x COCHAHB), 2.74 (ddd, J = 17.6 Hz, J = 9.7 Hz, 
J = 9.8 Hz, 2H, 2 x COCHAHB), 3.23 (ddt, J = 13.3 Hz, J = 6.9 Hz, J = 5.4 Hz, 2H, 2 x NCHAHB), 
3.32 (ddt, J = 13.3 Hz, J = 6.9 Hz, J = 5.4 Hz, 2H, 2 x NCHAHB), 4.24 (q, J = 7.1 Hz, 4H, 2 x 
CH2CH3), 4.78 (dd, J = 3.0 Hz, J = 9.6 Hz, 2H, 2 x CH), 8.29 (t, J = 5.4 Hz, 2H, 2 x NH). 13C-
NMR (75 MHz, CDCl3) δ: 14.18 (2 x CH3), 21.32 (2 x CHCH2), 26.55 (2 x N(CH2)2CH2), 29.58 (2 
x NCH2CH2), 31.93 (2 x COCH2), 39.87 (2 x NCH2), 58.23 (2 x CH), 61.75 (2 x CH2CH3), 152.29 
(2 x NC=ON), 171.56 (2 x NC=O), 176.46 (2 x C=OO). IR (cm-1) νmax: 1693 (C=O), 1721 
(C=O), 1743 (C=O), 3319 (NH). MS: m/z (%): 483.8 (M+H+, 100). HRMS: calcd for 
C22H34N4O8 (M + H+), 483.24494; found, 483.24594. Yield: 99%. 
 
Ethyl 1-({[8-({[2-(ethoxycarbonyl)-5-oxopyrrolidin-1-yl]carbonyl}amino)octyl]amino} 
carbonyl)-5-oxopyrrolidine-2-carboxylate (379c) 
1H-NMR (300 MHz, CDCl3) δ: 1.29 (t, J = 7.2 
Hz, 6H, 2 x CH3), 1.30 (m, 8H, 2 x 
N(CH2)2CH2CH2), 1.53 (p, J = 6.7 Hz, 4H, 2 x 
NCH2CH2), 2.05 (ddt, J = 13.1 Hz, J = 9.9 Hz, J = 3.1 Hz, 2H, 2 x CHCHAHB), 2.34 (ddt, J = 13.1 
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Hz, J = 9.6 Hz, J = 9.8 Hz, 2H, 2 x CHCHAHB), 2.57 (ddd, J = 17.6 Hz, J = 9.6 Hz, J = 3.1 Hz, 
2H, 2 x COCHAHB), 2.74 (ddd, J = 17.6 Hz, J = 9.8 Hz, J = 9.9 Hz, 2H, 2 x COCHAHB), 3.23 (ddt, 
J = 13.3 Hz, J = 6.7 Hz, J = 5.4 Hz, 2H, 2 x NCHAHB), 3.32 (ddt, J = 13.3 Hz, J = 6.6 Hz, J = 5.4 
Hz, 2H, 2 x NCHAHB), 4.24 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 4.78 (dd, J = 3.1 Hz, J = 9.6 Hz, 2H, 
2 x CH), 8.28 (t, J = 5.4 Hz, 2H, 2 x NH). 13C-NMR (75 MHz, CDCl3) δ: 14.18 (2 x CH3), 21.32 
(2 x CHCH2), 26.82 (2 x N(CH2)2CH2), 29.19 (2 x N(CH2)3CH2), 29.61 (2 x NCH2CH2), 31.95 (2 x 
COCH2), 39.98 (2 x NCH2), 58.23 (2 x CH), 61.75 (2 x CH2CH3), 152.26 (2 x NC=ON), 171.58 (2 x 
NC=O), 176.46 (2 x C=OO). IR (cm-1) νmax: 1694 (C=O), 1723 (C=O), 1746 (C=O), 3318 (NH). 
MS: m/z (%): 511.7 (M+H+, 100). HRMS: calcd for C24H38N4O8 (M + H+), 511.27624; found, 
511.27666. Yield: 99%. 
 
Ethyl 1-({[12-({[2-(ethoxycarbonyl)-5-oxopyrrolidin-1-yl]carbonyl}amino)dodecyl] 
amino}carbonyl)-5-oxopyrrolidine-2-carboxylate (379c) 
1H-NMR (300 MHz, CDCl3) δ: 1.25-
1.31 (m, 16H, 2 x N(CH2)2(CH2)4), 1.29 (t, 
J = 7.2 Hz, 6H, 2 x CH3), 1.54 (p, J = 6.7 
Hz, 4H, 2 x NCH2CH2), 2.05 (ddt, J = 13.1 Hz, J = 9.9 Hz, J = 2.9 Hz, 2H, 2 x CHCHAHB), 2.33 
(ddt, J = 13.1 Hz, J = 9.8 Hz, J = 9.4 Hz, 2H, 2 x CHCHAHB), 2.57 (ddd, J = 17.6 Hz, J = 9.8 Hz, 
J = 2.9 Hz, 2H, 2 x COCHAHB), 2.74 (ddd, J = 17.6 Hz, J = 9.9 Hz, J = 9.4 Hz, 2H, 2 x COCHAHB), 
3.24 (br dt, J = 13.2 Hz, J = 6.7 Hz, 2H, 2 x NCHAHB), 3.31 (br dt, J = 13.2 Hz, J = 6.7 Hz, 2H, 2 
x NCHAHB), 4.24 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 4.78 (dd, J = 9.4 Hz, J = 2.9 Hz, 2H, 2 x CH), 
8.28 (t, J = 5.3 Hz, 2H, 2 x NH). 13C-NMR (75 MHz, CDCl3) δ: 14.18 (2 x CH3), 21.34 (2 x 
CHCH2), 26.94 (2 x N(CH2)2CH2), 29.34 (2 x N(CH2)3CH2), 29.58 (2 x N(CH2)4CH2), 29.61 (2 x 
N(CH2)5CH2), 29.66 (2 x NCH2CH2), 31.95 (2 x COCH2), 40.04 (2 x NCH2), 58.24 (2 x CH), 61.75 
(2 x CH2CH3), 152.28 (2 x NC=ON), 171.58 (2 x NC=O), 176.45 (2 x C=OO). IR (cm-1) νmax: 
1694 (C=O), 1723 (C=O), 1746 (C=O), 3318 (NH). MS: m/z (%): 567.5 (M+H+, 100). MP 
(°C): 99.4-101. HRMS: calcd for C28H46N4O8 (M + H+), 567.33884; found, 567.34103. Yield: 
99%. 
4.8.2 Synthesis of bis-hydantoins 382 
The general procedure of this synthesis can be found in paper VI. 
 
3-(1-{4-[4-(2-Ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-butyl}-2,5-dioxo-
imidazolidin-4-yl)-propionic acid ethyl ester (382a) 
1H-NMR (300 MHz, CDCl3) δ: 1.26 (t, J = 7.2 Hz, 
6H, 2 x CH3), 1.63 (br s, 4H, 2 x NCH2CH2), 2.03 (ddt, 
J = 13.9 Hz, J = 7.2 Hz, J = 7.3 Hz, 2H, 2 x 
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CHAHBCH), 2.20 (ddt, J = 13.9 Hz, J = 7.3 Hz, J = 6.3 Hz, 2H, 2 x CHAHBCH), 2.47 (t, J = 7.3 Hz, 
2H, COCH2), 3.52 (br s, 4H, 2 x NCH2), 4.14 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 4.10 (dd, J = 7.2 
Hz, J = 6.3 Hz, 2H, 2 x CH), 6.29 (s, 2H, 2 x NH). 13C-NMR (75 MHz, CDCl3) δ: 14.25 (2 x 
CH3), 25.16 (2 x NCH2CH2), 26.94 (2 x CHCH2), 29.87 (2 x COCH2), 38.03 (2 x NCH2), 56.44 (2 x 
CH), 61.07 (2 x CH2CH3), 157.38 (2 x NC=ON), 172.92 (2 x C=OO), 173.73 (2 x NC=O). IR (cm-
1) νmax: 1713 (br C=O), 1764 (C=O), 3249 (NH). MS: m/z (%): 455.7 (M+H+, 100). MP (°C): 
124-127. HRMS: calcd for C20H30N4O8 (M + H+), 455.21364; found, 455.21467. Yield: 98%. 
 
3-(1-{6-[4-(2-Ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-hexyl}-2,5-dioxo-
imidazolidin-4-yl)-propionic acid ethyl ester (382b) 
1H-NMR (300 MHz, CDCl3) δ: 1.26 (t, J = 7.1 
Hz, 6H, 2 x CH3), 1.33 (br s, 4H, 2 x N(CH2)2CH2), 
1.61 (br p, J = 6.9 Hz, 4H, 2 x NCH2CH2), 2.02 
(ddt, J = 14.3 Hz, J = 7.1 Hz, J = 6.4 Hz, 2H, 2 x 
CHCHAHB), 2.22 (ddt, J = 14.3 Hz, J = 5.5 Hz, J = 7.1 Hz, 2H, 2 x CHCHAHB), 2.46 (t, J = 7.1 Hz, 
4H, 2 x COCH2), 3.48 (t, J = 6.9 Hz, 4H, 2 x NCH2), 4.10 (dd, J = 5.5 Hz, J = 6.4 Hz, 2H, 2 x 
CH), 4.15 (q, J = 7.1 Hz, 4H, 2 x CH2CH3), 6.16 (s, 2H, 2 x NH). 13C-NMR (75 MHz, CDCl3) δ: 
14.25 (2 x CH3), 26.21 (2 x N(CH2)2CH2), 26.93 (2 x CHCH2), 27.90 (2 x NCH2CH2), 29.81 (2 x 
COCH2), 38.56 (2 x NCH2), 56.36 (2 x CH), 61.05 (2 x CH2CH3), 157.48 (2 x NC=ON), 172.89 (2 x 
C=OO), 173.71 (2 x NC=O). IR (cm-1) νmax: 1712 (C=O), 1774 (C=O), 3338 (NH). MS: m/z 
(%): 483.3 (M+H+, 100). MP (°C): 95-98. HRMS: calcd for C22H34N4O8 (M + H+), 483.24494; 
found, 483.24577. Yield: 97%. 
 
3-(1-{8-[4-(2-Ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-octyl}-2,5-dioxo-
imidazolidin-4-yl)-propionic acid ethyl ester (382c) 
1H-NMR (300 MHz, CDCl3) δ: 1.26 (t, J = 
7.2 Hz, 6H, 2 x CH3), 1.30 (br s, 8H, 2 x 
N(CH2)2(CH2)2), 1.59 (p, J = 6.8 Hz, 4H, 2 x 
NCH2CH2), 2.03 (ddt, J = 14.7 Hz, J = 7.5 
Hz, J = 6.2 Hz, 2H, 2 x CHCHAHB), 2.22 (ddt, J = 14.7 Hz, J = 7.5 Hz, J = 6.7 Hz, 2H, 2 x 
CHCHAHB), 2.46 (t, J = 7.5 Hz, 4H, 2 x COCH2), 3.47 (t, J = 6.8 Hz, 4H, 2 x NCH2), 4.11 (dd, J = 
6.2 Hz, J = 6.7 Hz, 2H, 2 x CH), 4.15 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 6.41 (s, 2H, 2 x NH). 13C-
NMR (75 MHz, CDCl3) δ: 14.24 (2 x CH3), 26.61 (2 x N(CH2)2CH2CH2), 26.91 (2 x CHCH2), 
28.03 (2 x NCH2CH2), 28.99 (2 x N(CH2)3CH2), 29.74 (2 x COCH2), 38.73 (2 x NCH2), 56.35 (2 x 
CH), 61.04 (2 x CH2CH3), 157.73 (2 x NC=ON), 172.86 (2 x C=OO), 173.76 (2 x NC=O). IR (cm-
1) νmax: 1709 (br. C=O), 1774 (C=O), 3331 (NH). MS: m/z (%): 511.7 (M+H+, 100). MP (°C): 
102.5-103.5. HRMS: calcd for C24H38N4O8 (M + H+), 511.27624; found, 511.27767. Yield: 99%. 
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3-(1-{12-[4-(2-Ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-dodecyl}-2,5-dioxo-
imidazolidin-4-yl)-propionic acid ethyl ester (382d) 
1H-NMR (300 MHz, CDCl3) δ: 
1.24-1.29 (br s, 16H, 2 x 
N(CH2)2(CH2)4), 1.26 (t, J = 7.0 Hz, 
6H, 2 x CH3), 1.60 (p, J = 6.9 Hz, 
4H, 2 x NCH2CH2), 2.03 (ddt, J = 13.8 Hz, J = 7.0 Hz, J = 6.4 Hz, 2H, 2 x CHCHAHB), 2.22 (ddt, J 
= 13.8 Hz, J = 7.0 Hz, J = 6.0 Hz, 2H, 2 x CHCHAHB), 2.46 (t, J = 7.0 Hz, 4H, 2 x COCH2), 3.48 
(t, J = 6.9 Hz, 4H, 2 x NCH2), 4.10 (dd, J = 6.4 Hz, J = 6.0 Hz, 2H, 2 x CH), 4.15 (q, J = 7.0 Hz, 
4H, 2 x CH2CH3), 6.24 (s, 2H, 2 x NH). 13C-NMR (75 MHz, CDCl3) δ: 14.25 (2 x CH3), 26.74 (2 
x NCH2CH2CH2), 26.89 (2 x CHCH2), 28.09 (2 x NCH2CH2), 29.16 (2 x N(CH2)3CH2), 29.48 (2 x 
N(CH2)4CH2CH2), 29.77 (2 x COCH2), 38.84 (2 x NCH2), 56.36 (2 x CH), 61.05 (2 x CH2CH3), 
157.62 (2 x NC=ON), 172.87 (2 x C=OO), 173.73 (2 x NC=O). IR (cm-1) νmax: 1703 (br. C=O), 
1773 (C=O), 3314 (NH). MS: m/z (%): 567.5 (M+H+, 100). MP (°C): 94-96. HRMS: calcd for 
C28H46N4O8 (M + H+), 567.33884; found, 567.34079. Yield: 99%. 
4.8.3 Synthesis of bis-hydantoins 36 by N(1) alkylation of 382 
The general procedure of this synthesis can be found in paper VI. 
 
3-(3-Allyl-1-{4-[3-allyl-4-(2-ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-butyl}-
2,5-dioxo-imidazolidin-4-yl)-propionic acid ethyl ester (36a) 
1H-NMR (300 MHz, CDCl3) δ: 1.26 (t, J = 7.2 Hz, 
6H, 2 x CH3), 1.64 (br s, 4H, 2 x NCH2CH2), 2.00-2.12 
(m, 2H, 2 x CHAHBCH), 2.18-2.42 (m, 6H, 2 x 
CH2CHAHBCH), 3.53 (br s, 4H, 2 x NCH2), 3.62 (dd, J 
= 15.7 Hz, J = 7.4 Hz, 2H, 2 x NCHAHB), 4.01 (dd, J = 3.0 Hz, J = 6.6 Hz, 2H, 2 x CH), 4.13 (q, J 
= 7.2 Hz, 4H, 2 x CH2CH3), 4.34 (dd, J = 15.7 Hz, J = 5.0 Hz, 2H, 2 x NCHAHB), 5.24 (d, J = 4.7 
Hz, 2H, 2 x HC=CHAHB), 5.28 (s, 2H, 2 x HC=CHAHB), 5.70-5.83 (m, 2H, 2 x HC=CH2). 13C-NMR 
(75 MHz, CDCl3) δ: 14.25 (2 x CH3), 23.80 (2 x CHCH2), 25.29 (2 x NCH2CH2), 28.24 (2 x 
COCH2), 38.29 (2 x NCH2), 43.54 (2 x NCH2CH), 57.78 (2 x CH), 60.90 (2 x CH2CH3), 119.45 (2 x 
HC=CH2), 131.80 (2 x HC=CH2), 156.25 (2 x NC=ON), 172.39 (2 x C=O), 172.57 (2 x C=O). IR 
(cm-1) νmax: 1645 (C=C), 1709 (br C=O), 1769 (C=O). MS: m/z (%): 535.7 (M+H+, 100). 
HRMS: calcd for C26H38N4O8 (M + H+), 535.27624; found, 535.27686. Yield: 98%. 
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3-(3-Allyl-1-{6-[3-allyl-4-(2-ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-hexyl}-
2,5-dioxo-imidazolidin-4-yl)-propionic acid ethyl ester (36b) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 7.1 
Hz, 6H, 2 x CH3), 1.34 (br s, 4H, 2 x N(CH2)2CH2), 
1.61-1,66 (m, 4H, 2 x NCH2CH2), 2.01-2.13 (m, 
2H, 2 x CHCHAHB), 2.19-2.42 (m, 6H, 2 x 
CHCHAHBCH2), 3.49 (t, J = 7.1 Hz, 4H, 2 x NCH2), 3.61 (dd, J = 15.7 Hz, J = 7.7 Hz, 2H, 2 x 
NCHAHB), 4.01 (dd, J = 6.3 Hz, J = 2.8 Hz, 2H, 2 x CH), 4.13 (q, J = 7.1 Hz, 4H, 2 x CH2CH3), 
4.35 (dd, J = 15.7 Hz, J = 4.7 Hz, 2H, 2 x NCHAHB), 5.24 (d, J = 4.4 Hz, 2H, 2 x HC=CHAHB), 
5.28 (s, 2H, 2 x HC=CHAHB), 5.70-5.83 (m, 2H, 2 x HC=CH2). 13C-NMR (75 MHz, CDCl3) δ: 
14.24 (2 x CH3), 23.74 (2 x CHCH2), 26.27 (2 x N(CH2)2CH2), 27.98 (2 x NCH2CH2), 28.18 (2 x 
COCH2), 38.84 (2 x NCH2), 43.48 (NCH2CH), 57.71 (2 x CH), 60.88 (2 x CH2CH3), 119.39 (2 x 
HC=CH2), 131.80 (2 x HC=CH2), 156.37 (2 x NC=ON), 172.39 (2 x C=O), 172.57 (2 x C=O). IR 
(cm-1) νmax: 1645 (C=C), 1709 (C=O), 1737 (C=O), 1768 (C=O). MS: m/z (%): 563.3 (M+H+, 
100). HRMS: calcd for C28H42N4O8 (M + H+), 563.30754; found, 563.30994. Yield: 98%. 
 
3-(3-Allyl-1-{8-[3-allyl-4-(2-ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-octyl}-
2,5-dioxo-imidazolidin-4-yl)-propionic acid ethyl ester (36d) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 
7.2 Hz, 6H, 2 x CH3), 1.30 (br s, 8H, 2 x 
N(CH2)2(CH2)2), 1.60 (p, J = 7.1 Hz, 4H, 2 x 
NCH2CH2), 2.04-2.13 (m, 2H, 2 x CHCHAHB), 2.18-2.38 (m, 6H, 2 x CHCHAHBCH2), 3.47 (dt, J = 
13.5 Hz, J = 7.1 Hz, 2H, 2 x NCHAHBCH2), 3.50 (dt, J = 13.5 Hz, J = 7.1 Hz, 2H, 2 x NCHAHBCH2), 
3.61 (dd, J = 15.6 Hz, J = 7.6 Hz, 2H, 2 x NCHAHBCH), 4.00 (dd, J = 3.2 Hz, J = 6.5 Hz, 2H, 2 x 
CH), 4.13 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 4.35 (dd, J = 15.6 Hz, J = 5.0 Hz, 2H, 2 x NCHAHBCH), 
5.23 (d, J = 6.3 Hz, 2H, 2 x HC=CHAHB), 5.28 (s, 2H, 2 x HC=CHAHB), 5.69-5.83 (m, 2H, 2 x 
HC=CH2). 13C-NMR (75 MHz, CDCl3) δ: 14.25 (2 x CH3), 23.77 (2 x CHCH2), 26.71 (2 x 
N(CH2)2CH2), 28.10 (2 x NCH2CH2), 28.19 (2 x COCH2), 29.05 (2 x N(CH2)3CH2), 39.02 (2 x 
NCH2CH2), 43.49 (2 x NCH2CH), 57.72 (2 x CH), 60.90 (2 x CH2CH3), 119.38 (2 x HC=CH2), 
131.82 (2 x HC=CH2), 156.43 (2 x NC=ON), 172.40 (2 x C=O), 172.58 (2 x C=O). IR (cm-1) 
νmax: 1645 (C=C), 1709 (C=O), 1732 (C=O), 1769 (C=O). MS: m/z (%): 591.8 (M+H+, 100). 
HRMS: calcd for C30H46N4O8 (M + H+), 591.33884; found, 591.34042. Chromatography: 
Hex/EtOAc (4/6) Rf = 0.47. Yield: 98%. 
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3-(3-Allyl-1-{12-[3-allyl-4-(2-ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-1-yl]-
dodecyl}-2,5-dioxo-imidazolidin-4-yl)-propionic acid ethyl ester (36g) 
1H-NMR (300 MHz, CDCl3) δ: 
1.25 (t, J = 7.2 Hz, 6H, 2 x CH3), 
1.25-1.28 (m, 16H, 2 x 
NCH2CH2(CH2)4), 1.60 (p, J = 6.3 Hz, 4H, 2 x NCH2CH2), 2.05-2.13 (m, 2H, 2 x CHCHAHB), 2.18-
2.36 (m, 6H, 2 x CHCHAHBCH2), 3.48 (dt, J = 8.4 Hz, J = 6.3 Hz, 2H, 2 x NCHAHBCH2), 3.49 (dt, J 
= 8.4 Hz, J = 6.3 Hz, 2H, 2 x NCHAHBCH2), 3.61 (dd, J = 15.6 Hz, J = 3.6 Hz, 2H, 2 x 
NCHAHBCH), 4.01 (dd, J = 3.0 Hz, J = 6.3 Hz, 2H, 2 x CH), 4.13 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 
4.35 (dd, J = 15.6 Hz, J = 4.8 Hz, 2H, 2 x NCHAHBCH), 5.23 (d, J = 5.0 Hz, 2H, 2 x HC=CHAHB), 
5.28 (s, 2H, 2 x HC=CHAHB), 5.69-5.82 (m, 2H, 2 x HC=CH2). 13C-NMR (75 MHz, CDCl3) δ: 
14.24 (2 x CH3), 23.74 (2 x CHCH2), 26.80 (2 x N(CH2)2CH2), 28.16 (2 x NCH2CH2), 29.20 (2 x 
COCH2), 29.52 (2 x N(CH2)3CH2), 29.57 (2 x N(CH2)4(CH2)2), 39.07 (2 x NCH2CH2), 43.46 (2 x 
NCH2CH), 57.69 (2 x CH), 60.87 (2 x CH2CH3), 119.33 (2 x HC=CH2), 131.83 (2 x HC=CH2), 
156.45 (2 x NC=ON), 172.39 (2 x C=O), 172.57 (2 x C=O). IR (cm-1) νmax: 1645 (C=C), 1710 
(C=O), 1732 (C=O), 1770 (C=O). MS: m/z (%): 647.5 (M+H+, 100). HRMS: calcd for 
C34H54N4O8 (M + H+), 647.40144; found, 647.40224. Chromatography: Hex/EtOAc (4/6) Rf = 
0.44. Yield: 98%. 
 
3-(3-But-2-ynyl-1-{6-[3-but-2-ynyl-4-(2-ethoxycarbonyl-ethyl)-2,5-dioxo-imidazolidin-
1-yl]-hexyl}-2,5-dioxo-imidazolidin-4-yl)-propionic acid ethyl ester (36c) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 7.1 
Hz, 6H, 2 x CH3), 1.27 (br s, 4H, 2 x N(CH2)2CH2), 
1.60 (p, J = 7.1 Hz, 4H, 2 x NCH2CH2), 1.80 (t, J 
= 2.3 Hz, 6H, 2 x CCH3), 2.13-2.37 (m, 8H, 2 x 
CHCH2CH2), 3.46 (dt, J = 13.3 Hz, J = 7.1 Hz, 2H, 2 x NCHAHB), 3.49 (dt, J = 13.3 Hz, J = 7.1 
Hz, 2H, 2 x NCHAHB), 3.79 (dq, J = 17.6 Hz, J = 2.3 Hz, 2H, 2 x NCHAHBC), 4.12 (q, J = 7.1 Hz, 
4H, 2 x CH2CH3), 4.19 (dd, J = 5.5 Hz, J = 3.3 Hz, 2H, 2 x CH), 4.46 (dq, J = 17.6 Hz, J = 2.3 
Hz, 2H, 2 x NCHAHBC). 13C-NMR (75 MHz, CDCl3) δ: 3.54 (2 x CCH3), 14.25 (2 x CH3), 23.75 (2 
x CHCH2), 26.29 (2 x N(CH2)2CH2), 27.97 (2 x NCH2CH2), 28.45 (2 x COCH2), 31.22 (2 x NCH2C), 
38.96 (NCH2CH2), 57.92 (2 x CH), 60.87 (2 x CH2CH3), 72.07 (2 x CCH3), 81.50 (2 x NCH2C), 
156.37 (2 x NC=ON), 172.42 (4 x C=O). IR (cm-1) νmax: 1710 (br C=O), 1771 (C=O), 2231 
(alkyne). MS: m/z (%): 587.7 (M+H+, 100). HRMS: calcd for C30H42N4O8 (M + H+), 
587.30754; found, 587.30760. Chromatography: Hex/EtOAc (4/6) Rf = 0.35. Yield: 99%. 
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3-[1-{8-[4-(2-Ethoxycarbonyl-ethyl)-3-(3-fluoro-benzyl)-2,5-dioxo-imidazolidin-1-yl]-
octyl}-3-(3-fluoro-benzyl)-2,5-dioxo-imidazolidin-4-yl]-propionic acid ethyl ester (36f) 
1H-NMR (300 MHz, CDCl3) δ: 1.24 (t, J = 
7.2 Hz, 6H, 2 x CH3), 1.33 (br s, 8H, 2 x 
N(CH2)2(CH2)2), 1.62 (p, J = 7.2 Hz, 4H, 2 x 
NCH2CH2), 2.00-2.40 (m, 8H, 2 x CHCH2CH2), 
3.50 (dt, J = 13.5 Hz, J = 7.2 Hz, 2H, 2 x 
NCHAHBCH2), 3.53 (dt, J = 13.5 Hz, J = 7.2 Hz, 2H, 2 x NCHAHBCH2), 3.83 (dd, J = 3.2 Hz, J = 
6.5 Hz, 2H, 2 x CH), 4.12 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 4.13 (d, J = 14.9 Hz, 2H, 2 x 
NCHAHBPh), 4.95 (d, J = 14.9 Hz, 2H, 2 x NCHAHBPh), 6.97-7.06 (m, 3H, CHarom), 7.29-7.36 (m, 
1H, CHarom). 13C-NMR (75 MHz, CDCl3) δ: 14.25 (2 x CH3), 23.67 (2 x CHCH2), 26.73 (2 x 
N(CH2)2CH2), 28.10 (2 x NCH2CH2), 28.18 (2 x COCH2), 29.06 (2 x N(CH2)3CH2), 39.16 (2 x 
NCH2CH2), 44.24 (2 x NCH2Ph), 57.59 (2 x CH), 60.96 (2 x CH2CH3), 115.12 (d, J = 4.6 Hz, 2 x 
CHarom), 115.40 (d, J = 3.5 Hz, 2 x CHarom), 123.88 (d, J = 2.3 Hz, 2 x CHarom), 130.71 (d, J = 8.1 
Hz, 2 x CHarom), 138.32 (d, J = 6.9 Hz, 2 x Carom), 163.15 (d, J = 246.9 Hz, 2 x FCarom), 156.83 (2 
x NC=ON), 172.34 (4 x C=O). IR (cm-1) νmax: 1708 (C=O), 1769 (C=O). 19F-NMR (282 MHz, 
CDCl3) δ: -111.74 (dt, J = 8.7 Hz, J = 6.1 Hz). MS: m/z (%): 727.8 (M+H+, 100). HRMS: 
calcd for C38H48F2N4O8 (M + H+), 727.35130 found, 727.35429. Chromatography: Hex/EtOAc 
(3/7) Rf = 0.61. Yield: 86%. 
 
3-(3-(2-Bromo-benzyl)-1-{8-[3-(2-bromo-benzyl)-4-(2-ethoxycarbonyl-ethyl)-2,5-dioxo-
imidazolidin-1-yl]-octyl}-2,5-dioxo-imidazolidin-4-yl)-propionic acid ethyl ester (36e) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 
7.1 Hz, 6H, 2 x CH3), 1.32 (br s, 8H, 2 x 
N(CH2)2(CH2)2), 1.62 (p, J = 7.4 Hz, 4H, 2 x 
NCH2CH2), 2.11-2.39 (m, 8H, 2 x CHCH2CH2), 
3.50 (dt, J = 13.5 Hz, J = 7.4 Hz, 2H, 2 x 
NCHAHBCH2), 3.53 (dt, J = 13.5 Hz, J = 7.4 Hz, 2H, 2 x NCHAHBCH2), 3.84 (dd, J = 3.3 Hz, J = 
5.8 Hz, 2H, 2 x CH), 4.12 (q, J = 7.1 Hz, 4H, 2 x CH2CH3), 4.37 (d, J = 15.5 Hz, 2H, 2 x 
NCHAHBPh), 5.00 (d, J = 15.5 Hz, 2H, 2 x NCHAHBPh), 7.15-7.22 (m, 1H, CHarom), 7.28-7.37 (m, 
2H, CHarom), 7.54-7.59 (m, 1H, CHarom). 13C-NMR (75 MHz, CDCl3) δ: 14.27 (2 x CH3), 24.03 (2 
x CHCH2), 26.74 (2 x N(CH2)2CH2), 28.12 (2 x NCH2CH2), 28.26 (2 x COCH2), 29.09 (2 x 
N(CH2)3CH2), 39.13 (2 x NCH2CH2), 44.65 (2 x NCH2Ph), 57.94 (2 x CH), 60.91 (2 x CH2CH3), 
123.70 (2 x BrCarom), 128.17 (2 x CHarom), 129.94 (2 x CHarom), 130.75 (2 x CHarom), 133.35 (2 x 
CHarom), 135.01 (2 x Carom), 156.77 (2 x NC=ON), 172.31 (2 x C=OO), 172.40 (2 x NC=O). IR 
(cm-1) νmax: 1709 (C=O), 1732 (C=O), 1770 (C=O). MS: m/z (%): 847.5;849.5;851.5 (M+H+, 
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100). HRMS: calcd for C38H4879Br2N4O8 (M + H+), 847.19116; found, 847.19501. 
Chromatography: Hex/EtOAc (3/7) Rf = 0.61. Yield: 84%. 
4.8.4 Synthesis of macrocycles 37 by RCM 
The general procedure of this synthesis can be found in paper VI. 
 
3-[16-(2-Ethoxycarbonyl-ethyl)-8,15,17,18-tetraoxo-1,6,9,14-tetraaza-tricyclo 
[12.2.1.16,9]octadec-3-en-7-yl]-propionic acid ethyl ester (37a) (diastereomer 1, 
diastereomer 2, not assigned) 
1H-NMR (300 MHz, CDCl3) δ: 1.25 (t, J = 7.1 Hz, 6H, 
2 x CH3), 1.26 (t, J = 7.1 Hz, 6H, 2 x CH3), 1.46-1.75 
(m, 8H, 2 x NCH2CH2), 2.03-2.23 (m, 8H, 2 x CHCH2), 
2.26-2.64 (m, 8H, 2 x CHCH2CH2), 3.35 (d, J = 13.8 Hz, 2H, 2 x NCHAHBCH2), 3.40 (d, J = 17.6 
Hz, 2H, 2 x NCHAHBCH), 3.56-3.65 (m, 6H, NCHAHBCH2 + NCH2CH2), 3.70-3.90 (m, 2H, 2 x 
NCHAHBCH), 4.06-4.19 (m, 8H, 2 x NCHAHBCH + 2 x NCHAHBCH + 2 x CH + 2 x CH), 4.12 (q, J = 
7.1 Hz, 8H, 2 x CH2CH3), 5.83 (t, J = 3.4 Hz, 2H, HC=CH), 5.90 (t, J = 3.7 Hz, 2H, HC=CH). 13C-
NMR (75 MHz, CDCl3) δ: 14.24 (2 x CH3), 22.71 (2 x NCH2CH2), 23.23 (2 x NCH2CH2), 23.74 (2 
x CHCH2), 28.58 (2 x COCH2), 28.76 (2 x COCH2), 37.72 (2 x NCH2CH2), 38.00 (2 x NCH2CH2), 
42.55 (2 x NCH2CH), 58.01 (2 x CH), 58.72 (2 x CH), 60.87 (2 x CH2CH3), 128.61 (HC=CH), 
157.33 (2 x NC=ON), 172.60 (2 x C=OO), 172.75 (2 x C=OO), 172.91 (2 x NC=O). 173.18 (2 x 
NC=O). IR (cm-1) νmax: 1709 (C=O), 1767 (C=O). MS: m/z (%): 507.7 (M+H+, 100). HRMS: 
calcd for C24H34N4O8 (M + H+), 507.24494; found, 507.24700. Chromatography: Hex/EtOAc 
(3/7) Rf = 0.24. Yield: 46%. 
 
3-[18-(2-Ethoxycarbonyl-ethyl)-8,17,19,20-tetraoxo-1,6,9,16-tetraaza-tricyclo 
[14.2.1.16,9]icos-3-en-7-yl]-propionic acid ethyl ester (37b) (diastereomer 1) 
1H-NMR (300 MHz, CDCl3) δ: 1.15-1.30 (m, 4H, 2 x 
N(CH2)2CH2), 1.24 (t, J = 7.2 Hz, 6H, 2 x CH3), 1.62-
1.74 (m, 4H, 2 x NCH2CH2), 2.00-2.16 (m, 2H, 2 x 
CHCHAHB), 2.17-2.52 (m, 6H, 2 x CHCHAHBCH2), 3.43-3.49 (m, 4H, 2 x NCHAHBCH2 + 
NCHAHBCH), 3.57 (ddd, J = 13.8 Hz, J = 6.3 Hz, J = 3.9 Hz, 2H, 2 x NCHAHBCH2), 4.04 (dd, J = 
2.9 Hz, J = 6.5 Hz, 2H, 2 x CH), 4.11 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 4.35 (d, J = 16.0 Hz, 2H, 2 
x NCHAHB), 5.35 (t, J = 2.2 Hz, 2H, HC=CH). 13C-NMR (75 MHz, CDCl3) δ: 14.24 (2 x CH3), 
23.60 (2 x CHCH2), 27.48 (2 x N(CH2)2CH2), 27.83 (2 x NCH2CH2), 28.45 (2 x COCH2), 39.58 (2 x 
NCH2CH2), 41.83 (2 x NCH2CH), 57.71 (2 x CH), 60.91 (2 x CH2CH3), 126.31 (HC=CH), 156.97 (2 
x NC=ON), 172.57 (2 x C=OO), 172.71 (2 x NC=O). IR (cm-1) νmax: 1709 (C=O), 1769 (C=O). 
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MS: m/z (%): 535.2 (M+H+, 100). HRMS: calcd for C26H38N4O8 (M + H+), 535.27624; found, 
535.27723. Chromatography: Hex/EtOAc (2/8) Rf = 0.42. 
 
3-[18-(2-Ethoxycarbonyl-ethyl)-8,17,19,20-tetraoxo-1,6,9,16-tetraaza-tricyclo 
[14.2.1.16,9]icos-3-en-7-yl]-propionic acid ethyl ester (37b) (diastereomer 2) 
1H-NMR (300 MHz, CDCl3) δ: 1.16-1.35 (m, 4H, 2 x 
N(CH2)2CH2), 1.26 (t, J = 7.2 Hz, 6H, 2 x CH3), 1.58-
1.75 (m, 4H, 2 x NCH2CH2), 1.97-2.09 (m, 2H, 2 x 
CHCHAHB), 2.13-2.55 (m, 6H, 2 x CHCHAHBCH2), 3.43-3.49 (m, 4H, 2 x NCHAHBCH2 + 
NCHAHBCH), 3.48 (ddd, J = 13.3 Hz, J = 6.4 Hz, J = 3.8 Hz, 2H, 2 x NCHAHBCH2), 3.58 (ddd, J = 
13.3 Hz, J = 3.9 Hz, J = 3.8 Hz, 2H, 2 x NCHAHBCH2), 3.68 (dt, J = 16.2 Hz, J = 2.4 Hz, 2H, 2 x 
NCHAHB), 4.04 (dd, J = 3.6 Hz, J = 7.2 Hz, 2H, 2 x CH), 4.09 (d, J = 16.2 Hz, 2H, 2 x NCHAHB), 
4.14 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 5.63 (t, J = 2.4 Hz, 2H, HC=CH). 13C-NMR (75 MHz, 
CDCl3) δ: 14.27 (2 x CH3), 24.25 (2 x CHCH2), 26.79 (2 x N(CH2)2CH2), 27.58 (2 x NCH2CH2), 
28.56 (2 x COCH2), 38.94 (2 x NCH2CH2), 42.35 (2 x NCH2CH), 58.10 (2 x CH), 60.88 (2 x 
CH2CH3), 128.22 (HC=CH), 156.86 (2 x NC=ON), 172.71 (2 x C=OO), 172.97 (2 x NC=O). IR 
(cm-1) νmax: 1709 (C=O), 1768 (C=O). MS: m/z (%): 535.2 (M+H+, 100). HRMS: calcd for 
C26H38N4O8 (M + H+), 535.27624; found, 535.27786. Chromatography: Hex/EtOAc (2/8) Rf = 
0.38. (Still contains 14% of diastereomer 1). Total yield: 58%. 
 
3-[20-(2-Ethoxycarbonyl-ethyl)-8,19,21,22-tetraoxo-1,6,9,18-tetraaza-tricyclo 
[16.2.1.16,9]docos-3-en-7-yl]-propionic acid ethyl ester (37c) (diastereomer 1) 
1H-NMR (300 MHz, CDCl3) δ: 1.16-1.36 (m, 8H, 2 x 
N(CH2)2(CH2)2, 1.25 (t, J = 7.2 Hz, 6H, 2 x CH3), 1.52-
1.74 (m, 4H, 2 x NCH2CH2), 1.97-2.09 (m, 2H, 2 x 
CHCHAHB), 2.17-2.43 (m, 6H, 2 x CHCHAHBCH2), 3.47-3.63 (m, 6H, 2 x NCH2CH2 + 2 x 
NCHAHBCH), 4.03 (dd, J = 2.9 Hz, J = 6.5 Hz, 2H, 2 x CH), 4.12 (q, J = 7.2 Hz, 4H, 2 x CH2CH3), 
4.47 (d, J = 16.2 Hz, 2H, 2 x NCHAHBCH), 5.42 (t, J = 1.9 Hz, 2H, HC=CH). 13C-NMR (75 MHz, 
CDCl3) δ: 14.24 (2 x CH3), 23.46 (2 x CHCH2), 25.83 (2 x N(CH2)2CH2), 27.93 (2 x NCH2CH2), 
28.26 (2 x COCH2), 29.06 (2 x N(CH2)3CH2), 39.23 (2 x NCH2CH2), 41.08 (2 x NCH2CH), 57.10 (2 
x CH), 60.94 (2 x CH2CH3), 126.37 (HC=CH), 156.69 (2 x NC=ON), 172.46 (2 x C=OO), 172.52 
(2 x NC=O). IR (cm-1) νmax: 1709 (C=O), 1770 (C=O). MS: m/z (%): 563.7 (M+H+, 100). 
HRMS: calcd for C28H42N4O8 (M + H+), 563.30754; found, 563.30876. Chromatography: 
Hex/EtOAc (3/7) Rf = 0.26. 
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3-[20-(2-Ethoxycarbonyl-ethyl)-8,19,21,22-tetraoxo-1,6,9,18-tetraaza-tricyclo 
[16.2.1.16,9]docos-3-en-7-yl]-propionic acid ethyl ester (37c) (diastereomer 2) 
1H-NMR (300 MHz, CDCl3) δ: 1.14-1.29 (m, 8H, 2 x 
N(CH2)2(CH2)2, 1.26 (t, J = 7.1 Hz, 6H, 2 x CH3), 1.50-
1.73 (m, 4H, 2 x NCH2CH2), 1.96-2.08 (m, 2H, 2 x 
CHCHAHB), 2.16-2.56 (m, 6H, 2 x CHCHAHBCH2), 3.56 
(t, J = 5.7 Hz, 4H, 2 x NCH2CH2), 3.81 (d, J = 5.7 Hz, 2H, NCHAHB), 4.02 (dd, J = 3.5 Hz, J = 7.1 
Hz, 2H, 2 x CH), 4.09-4.16 (m, 2H, 2 x NCHAHB), 4.14 (q, J = 7.1 Hz, 4H, 2 x CH2CH3), 5.53 (t, J 
= 2.3 Hz, 2H, HC=CH). 13C-NMR (75 MHz, CDCl3) δ: 14.24 (2 x CH3), 24.10 (2 x CHCH2), 
25.66 (2 x N(CH2)2CH2), 27.80 (2 x NCH2CH2), 28.27 (2 x COCH2), 29.02 (2 x N(CH2)3CH2), 38.97 
(2 x NCH2CH2), 41.97 (2 x NCH2CH), 58.13 (2 x CH), 60.85 (2 x CH2CH3), 127.06 (HC=CH), 
156.60 (2 x NC=ON), 172.54 (2 x C=OO), 172.77 (2 x NC=O). IR (cm-1) νmax: 1710 (C=O), 
1770 (C=O). MS: m/z (%): 563.7 (M+H+, 100). HRMS: calcd for C28H42N4O8 (M + H+), 
563.30754; found, 563.30774. Chromatography: Hex/EtOAc (3/7) Rf = 0.22. Still contains 17% 
of diastereomer 1). Total yield: 54%. 
 
3-[24-(2-Ethoxycarbonyl-ethyl)-8,23,25,26-tetraoxo-1,6,9,22-tetraaza-tricyclo 
[20.2.1.16,9]hexacos-3-en-7-yl]-propionic acid ethyl ester (37d) (50:50 mixture of 
diastereomers) 
1H-NMR (300 MHz, CDCl3) δ: 1.23-1.28 (m, 44H, 2 x 
N(CH2)2(CH2)8 + 4 x CH3), 1.50-1.75 (m, 8H, 4 x 
NCH2CH2), 1.93-2.07 (m, 4H, 4 x CHCHAHB), 2.18-2.52 
(m, 12H, 4 x CHCHAHBCH2), 3.39-3.55 (m, 8H, 4 x NCH2CH2), 3.61 (d, J = 16.4 Hz, 2H, 2 x 
NCHAHB), 3.76 (d, J = 15.6 Hz, 2H, 2 x NCHAHB), 4.03 (dd, J = 3.2 Hz, J = 7.0 Hz, 4H, 4 x CH), 
4.13 (q, J = 7.1 Hz, 8H, 4 x CH2CH3), 4.22 (d, J = 15.6 Hz, 2H, 2 x NCHAHB), 4.40 4.22 (d, J = 
16.4 Hz, 2H, 2 x NCHAHB), 5.56 (br t, J = 2.9 Hz, 2H, HC=CH), 5.60 (br t, J = 2.6 Hz, 2H, 
HC=CH). 13C-NMR (75 MHz, CDCl3) δ: 14.25 (4 x CH3), 23.69 (2 x CHCH2), 24.07 (2 x CHCH2), 
26.21 (2 x N(CH2)2CH2), 26.41 (2 x N(CH2)2CH2), 27.21 (2 x NCH2CH2), 27.35 (2 x NCH2CH2), 
27.66 (2 x COCH2), 27.84 (4 x N(CH2)3CH2), 27.89 (2 x COCH2), 28.22 ((4 x N(CH2)4(CH2)2), 
39.00 (2 x NCH2CH2), 39.19 (2 x NCH2CH2), 41.34 (2 x NCH2CH), 42.06 (2 x NCH2CH), 57.57 (2 x 
CH), 58.10 (2 x CH), 60.90 (2 x CH2CH3), 60.94 (2 x CH2CH3), 127.24 (HC=CH), 127.54 
(HC=CH), 156.49 (2 x NC=ON), 156.52 (2 x NC=ON), 172.39 (2 x C=O), 172.43 (2 x C=O), 
172.52 (2 x C=O), 172.65 (2 x C=O). IR (cm-1) νmax: 1713 (C=O), 1732 (C=O), 1770 (C=O). 
MS: m/z (%): 619.8 (M+H+, 100). HRMS: calcd for C32H50N4O8 (M + H+), 619.37014; found, 
619.37291. Chromatography: Hex/EtOAc (4/6) Rf = 0.17. Yield: 41%. 
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4.8.5 Synthesis of 385a and 385c by reduction of compound 37c 
One diastereomer of 37c (100 mg, 0.18 mmol) was dissolved in absolute ethanol (5 ml) and 
subjected to catalytic reduction using H2 (3 bar) and Pd/C (10%) at room temperature for 16 
hours. After this time the mixture was filtered over a small silica plug and the solvent was 
removed in vacuo. The reduced compounds are obtained quantitatively. 
 
10,21,25,26-tetraoxo-1,6,11,20-tetraaza-tricyclo[18.4.1.16,11]hexacosane-7,24-
dicarboxylic acid diethyl ester (385a) (reduction 37c diastereomer 1) 
1H-NMR (300 MHz, CDCl3) δ: 1.14-1.36 (m, 8H, 2 x 
N(CH2)2(CH)2, 1.25 (t, J = 7.1 Hz, 6H, 2 x CH3), 1.50 
(br s, 4H, 2 x NCH2CH2), 1.54-1.69 (m, 4H, 2 x 
NCH2CH2), 1.97-2.10 (m, 2H, 2 x CHCHAHB), 2.18-2.45 
(m, 6H, 2 x CHCHAHBCH2), 2.99 (br d, J = 14.2 Hz, 2H, 2 x NCHAHB), 3.42-3.62 (m, 4H, 2 x 
NCH2CH2), 3.80 (br d, J = 14.2 Hz, 2H, 2 x NCHAHB), 4.08 (dd, J = 2.8 Hz, J = 6.6 Hz, 2H, 2 x 
CH), 4.12 (q, J = 7.1 Hz, 4H, 2 x CH2CH3). 13C-NMR (75 MHz, CDCl3) δ: 14.28 (2 x CH3), 
23.54 (2 x CHCH2), 24.85 (2 x NCH2CH2), 28.19 (2 x NCH2CH2), 28.30 (2 x COCH2), 29.40 (2 x 
N(CH2)3CH2), 39.16 (2 x NCH2CH2), 39.94 (2 x NCH2CH2), 56.81 (2 x CH), 61.01 (2 x CH2CH3), 
156.90 (2 x NC=ON), 172.49 (2 x C=OO), 172.66 (2 x NC=O). IR (cm-1) νmax: 1706 (C=O), 
1731 (C=O), 1768 (C=O). MS: m/z (%): 565.8 (M+H+, 100). HRMS: calcd for C28H44N4O8 (M 
+ H+), 565.32319; found, 565.32582. 
 
10,21,25,26-tetraoxo-1,6,11,20-tetraaza-tricyclo[18.4.1.16,11]hexacosane-7,24-
dicarboxylic acid diethyl ester (385b) (reduction 37c diastereomer 2) 
1H-NMR (300 MHz, CDCl3) δ: 1.14-1.36 (m, 8H, 2 x 
N(CH2)2(CH)2, 1.27 (t, J = 7.1 Hz, 6H, 2 x CH3), 1.51-
1.66 (m, 8H, 2 x NCH2CH2 + 2 x NCH2CH2), 1.98-2.11 
(m, 2H, 2 x CHCHAHB), 2.23-2.50 (m, 6H, 2 x 
CHCHAHBCH2), 3.26 (br d, J = 14.3 Hz, 2H, 2 x NCHAHB), 3.52 (br d, J = 14.3 Hz, 2H, 2 x 
NCHAHB), 3.54 (t, J = 5.6 Hz, 4H, 2 x NCH2CH2), 4.02 (dd, J = 3.0 Hz, J = 6.9 Hz, 2H, 2 x CH), 
4.15 (q, J = 7.1 Hz, 4H, 2 x CH2CH3). 13C-NMR (75 MHz, CDCl3) δ: 14.25 (2 x CH3), 24.29 (2 x 
CHCH2), 25.78 (2 x NCH2CH2), 28.10 (2 x NCH2CH2), 28.18 (2 x COCH2), 29.34 (2 x N(CH2)3CH2), 
38.81 (2 x NCH2CH2), 40.81 (2 x NCH2CH2), 58.26 (2 x CH), 60.88 (2 x CH2CH3), 156.93 (2 x 
NC=ON), 172.54 (2 x C=OO), 172.69 (2 x NC=O). IR (cm-1) νmax: 1709 (C=O), 1731 (C=O), 
1768 (C=O). MS: m/z (%): 565.8 (M+H+, 100). HRMS: calcd for C28H44N4O8 (M + H+), 
565.32319; found, 565.32452. 
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4.9 Synthesis of 1-phosphonylated benzazepines 
General procedures for the synthesis of compounds 397a-c and 395a-c as well as their 
complete spectroscopic description can be found in paper VII. 
4.9.1 Synthesis of dimethyl (prop-2-ynylamino)(2-vinylphenyl)methylphosphonate 
(400) 
The synthesis of 1-bromo-2-vinyl-benzene 397 and 2-vinyl-benzaldehyde 398 was performed 
following a literature procedure.212 Aldehyde 398 (1.54 g, 11.6 mmol) was dissolved in dry 
CH2Cl2 (30 ml) and 1.1 equivalents of propargylamine (0.71 g, 12.8 mmol) and MgSO4 (4.21 g) 
were added. The mixture was allowed to stir at room temperature for 24 hours. After filtration of 
the solids and removal of the volatiles, the obtained imine was directly used for the synthesis of 
the α-aminophosphonate 400. Thus the imine is dissolved in 30 ml of MeOH in a round bottom 
flask. Then, 2 equivalents of dimethyl phosphite (DMP) (2.57 g, 23 mmol) is added and the 
mixture is refluxed for 2 hours. After removing the solvent under vacuum, the resulting oil is 
dissolved in 20 ml of diethyl ether and added to a separatory funnel containing 20 ml of 1 M HCl. 
Both phases are vigorously mixed and the organic phase is removed from the funnel. The 
aqueous phase is washed twice with 10 ml of diethyl ether, added to 20 ml of dichloromethane 
and then neutralized using 3 M NaOH until slightly alkaline. Both phases are vigorously mixed 
and the organic phase is now collected. The aqueous phase is extracted twice more with 10 ml of 
dichloromethane and the combined organic phases are dried using MgSO4. The compound is 
obtained in pure form after filtration and evaporation of the solvent in 82% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 2.19 (br s, 1H, NH), 2.23 (t, J = 2.3 Hz, 1H, 
CCHalkyne), 3.15 (br d, J = 17.1 Hz, 1H, NCHAHBC), 3.44 (dd, J = 2.3 Hz, J = 
17.1 Hz, 3H, NCHAHBC), 3.56 (d, J = 10.5 Hz, 3H, OCH3), 3.72 (d, J = 10.5 Hz, 
3H, OCH3),4.79 (d, J = 18.5 Hz, 1H, CHP), 5.36 (d, J = 10.9 Hz, 1H, HC=CHAHB), 5.61 (d, J = 
17.3 Hz, 1H, HC=CHAHB), 7.18 (dd, J = 10.9 Hz, J = 17.3 Hz, 1H, HC=CH2), 7.27-7.37 (m, 2H, 2 
x CHarom), 7.46 (d, J = 7.2 Hz, 1H, PCHCCCHarom), 7.59-7.62 (m, 1H, PCHCCHarom). 13C-NMR (75 
MHz, CDCl3): δ 35.86 (d, J = 18.5 Hz), 53.59 (d, J = 5.8 Hz), 53.67 (d, J = 5.8 Hz), 53.88 (d, J 
= 155.8 Hz), 72.50, 81.08, 117.38, 127.06 (d, J = 2.3 Hz), 128.12 (d, J = 3.5 Hz), 128.21 (d, J = 
5.8 Hz), 128.67 (d, J = 3.5 Hz), 131.52 (d, J = 5.8 Hz), 134.63, 138.96 (d, J = 6.9 Hz). 31P-
NMR (MHz, CDCl3): δ 26.44. IR (cm-1) υmax: 1031 (br P-O), 1247 (P=O), 2104 (alkyne), 3293 
(br NH). MS (ESI): m/z (%): 280.2 (M+H+, 87), 170.2 (M+-P(O)(OMe)2, 100). 
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4.9.2 Synthesis of dimethyl [(4-bromobenzyl)(prop-2-ynyl)amino](2-vinylphenyl) 
methylphosphonate (46) 
To a roundbottom flask, compound 400 (0.7 g, 2.5 mmol) is added together with K2CO3 (1.38 g, 
10 mmol), NaI (0.04 g, 0.25 mmol) and 10 ml of acetone. Then 4-bromobenzyl bromide (1.25 g, 
5.0 mmol) is added and the mixture is refluxed during 24h. After this time the solids are removed 
by filtration and the solvent by evaporation under reduced pressure. The compound was obtained 
in pure form as a pale yellow oil after column chromatography in 69% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 2.26 (t, J = 2.2 Hz, 1H, CCHalkyne), 3.16 
(dd, J = 2.2 Hz, J = 17.6 Hz, 1H, NCHAHBC), 3.27 (d, J = 10.5 Hz, 3H, 
OCH3), 3.44 (dt, J = 2.2 Hz, J = 17.6 Hz, 3H, NCHAHBC), 3.74-3.92 (m, 2H, 
NCH2Ph), 3.79 (d, J = 10.8 Hz, 3H, OCH3), 4.69 (d, J = 17.3 Hz, 1H, CHP), 
5.36 (dd, J = 1.0 Hz, J = 11.0 Hz, 1H, HC=CHAHB), 5.63 (dd, J = 1.0 Hz, J = 16.8 Hz, 1H, 
HC=CHAHB), 7.23 (dd, J = 11.0 Hz, J = 16.8 Hz, 1H, HC=CH2), 7.26-7.54 (m, 7H, 7 x CHarom), 7-
87-7.90 (m, 1H, PCHCCHarom). 13C-NMR (75 MHz, CDCl3): δ 39.52 (d, J = 10.4 Hz), 52.55 (d, J 
= 8.1 Hz), 53.23 (d, J = 6.9 Hz), 54.09 (d, J = 6.9 Hz), 58.94 (d, J = 155.8 Hz), 73.71, 78.38, 
117.04, 120.78, 126.72, 127.60, 128.22, 130.02 (d, J = 3.5 Hz), 130.48, 131.12, 131.48 (d, J = 
3.5 Hz), 134.46, 137.33, 138.80 (d, J = 8.1 Hz). 31P-NMR (MHz, CDCl3): δ 26.20. IR (cm-1) 
υmax: 1031 (P-O), 1058 (P-O), 1250 (P=O), 2101 (alkyne). MS (ESI): m/z (%): 448.2/450.2 
(M+H+, 100), 422.2/424.2 (M+-vinyl, 8), 338.3/340.3 (M+-P(O)(OMe)2, 20). Chromatography: 
Hex/EtOAc 6/4 Rf = 0.23. 
4.9.3 Synthesis of dimethyl (allylbenzylamino)(2-ethynylphenyl)methylphosphonate 
(47) 
In a dry flask, 2-ethynylbenzaldehyde (0.5 g, 3.84 mmol) is dissolved into dry diethylether (6 ml). 
To this solution is added LiClO4 (3.07 g, 28.8 mmol, dried for 24h at 110 °C). This mixture is 
stirred for 5 minutes. Subsequently allylbenzylamine (1.13 g, 7.69 mmol, dissolved in 1 ml dry 
diethylether) is added. This mixture is stirred for 20 minutes after which P(OMe)3 is added (0.71 
g, 5.76 mmol). The reaction is stirred for 30 minutes after which water is very carefully added 
(20 ml). The mixture is extracted with CH2Cl2 (3 x 20 ml) and dried using MgSO4. After filtration 
of the solids and removal of the volatiles, the obtained compound was purified using column 
chromatography and obtained in 68% yield as a white solid. 
 
1H-NMR (300 MHz, CDCl3): δ 3.04 (s, 1H, CCH), 3.06 (dd, J = 7.2 Hz, J = 
14.6 Hz, 1H, NCHAHBCH), 3.44 (d, J = 10.5 Hz, 3H, OCH3), 3.52 (d, J = 14.2 
Hz, 1H, NCHAHBPh), 3.66 (ddd, J = 1.5 Hz, J = 4.5 Hz, J = 14.6 Hz, 1H, 
NCHAHBCH), 3.96 (d, J = 10.7 Hz, 3H, OCH3), 4.23 (d, J = 14.2 Hz, 1H, 
N
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NCHAHBPh), 5.03 (d, J = 24.5 Hz, 1H, CHP), 5.09 (d, J = 10.8 Hz, 1H, HC=CHAHB), 5.18 (dd, J = 
1.5 Hz, J = 17.3 Hz, 1H, HC=CHAHB), 5.83 (dddd, J = 4.5 Hz, J = 7.2 Hz, J = 10.5 Hz, J = 17.3 
Hz, 1H, HC=CH2), 7.19-7.44 (m, 7H, 7 x CHarom), 7.56 (d, J = 7.7 Hz, 1H, PCHCCH), 7.97 (d, J = 
8.0 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 52.94 (d, J = 6.9 Hz, OCH3), 53.72 (d, J 
= 6.9 Hz, OCH3), 54.28 (d, J = 8.1 Hz, NCH2CH), 55.18 (d, J = 8.1 Hz, NCH2Ph), 58.64 (d, J = 
161.5 Hz, CHP), 81.98 (CCH), 82.08 (CCH), 117.41 (HC=CH2), 124.18 (d, J = 12.7 Hz, PCHCC), 
126.80 (CHpara, Ph), 128.11 (3 x CHarom), 128.64 (3 x CHarom), 130.74 (d, J = 3.5 Hz, PCHCCH), 
133.39 (PCHCCCH), 135.77 (d, J = 5.8 Hz, PCHC), 135.99 (HC=CH2), 139.96 (Cq, Ph). 31P-NMR 
(MHz, CDCl3): δ 26.25. IR (cm-1) υmax: 1035 (P-O),1058 (P-O), 1246 (P=O), 1642 (C=C), 
2099 (alkyne). MS (ESI): m/z (%): 370.2 (M+H+, 100). MP (°C): 86-87. Chromatography: 
Hex/EtOAc 4/6 Rf = 0.27. 
4.9.4 Dimethyl 2-benzyl-5-vinyl-2,3-dihydro-1H-2-benzazepin-1-ylphosphonate (407) 
During the synthesis of compounds 395a-c about 10% of side product 407 is formed. This 
compound can be isolated using column chromatography. 
 
1H-NMR (300 MHz, CDCl3): δ 2.77 (dd, J = 7.0 Hz, J = 12.0 Hz, 1H, 
NCHAHBCH), 3.05 (dd, J = 7.0 Hz, J = 12.0 Hz, 1H, NCHAHBCH), 3.48 (d, J = 
10.2 Hz, 3H, OCH3), 3.63 (d, J = 12.9 Hz, 1H, NCHAHBPh), 3.65 (d, J = 10.5 Hz, 
3H, OCH3), 4.00 (d, J = 12.9 Hz, 1H, NCHAHBPh), 4.30 (d, J = 25.1 Hz, 1H, 
CHP), 5.23 (dd, J = 1.2 Hz, J = 10.8 Hz, 1H, HC=CHAHB), 5.35 (dd, J = 1.2 Hz, J = 17.5 Hz, 1H, 
HC=CHAHB), 6.19 (t, J = 7.0 Hz, 1H, NCH2CH), 6.58 (dd, J = 10.8 Hz, J = 17.5 Hz, 1H, 
HC=CHAHB), 7.24-7.47 (m, 9H, 9 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 50.00 (d, J = 5.8 Hz, 
NCH2CH), 52.97 (d, J = 6.9 Hz, OCH3), 53.07 (d, J = 6.9 Hz, OCH3), 61.59 (d, J = 10.4 Hz, 
NCH2Ph), 65.10 (d, J = 170.8 Hz, CHP), 116.57 (HC=CH2), 127.38 (CHpara, Ph), 127.83 (CHarom), 
127.91 (CHarom), 128.05 (NCH2CH), 128.38 (2 x CHarom), 129.27 (CHarom), 129.47 (2 x CHarom), 
131.69 (d, J = 10.4 Hz, PCHCCH), 133.07 (d, J = 2.3 Hz, PCHC), 137.77 (HC=CH2), 137.81 (d, J 
= 5.8 Hz, PCHCC), 138.63 (Cq, Ph), 143.51 (NCH2CHC). 31P-NMR (MHz, CDCl3): δ 26.06. IR 
(cm-1) υmax: 1031 (P-O),1057 (P-O), 1249 (P=O), 1601 (C=C). MS (ESI): m/z (%): 370.2 
(M+H+, 100), 260.2 (M+-P(O)(OMe)2, 30). Chromatography: Hex/EtOAc 2/8 Rf = 0.33. 
4.10 Attempted synthesis of other benzo-fused heterocycles 
4.10.1 Synthesis of 1-(allyloxy)-2-bromo-4-methylbenzene (415) 
In a dry flask 2-bromo-4-methylphenol (5 g, 27 mmol) is dissolved in acetone (100 ml). To this 
solution allylbromide (12.94 g, 107 mmol) and K2CO3 (14.76 g, 107 mmol) are added. The 
mixture is refluxed for 48 hours. After cooling, the mixture is filtered and all the volatiles are 
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removed in vacuo. The residue is dissolved in CH2Cl2 (50 ml) and washed with NaHCO3 (20 ml, 
aq, sat). After drying of the organic layer with MgSO4 the compound is obtained pure as an oil in 
91% yield. 
1H-NMR (300 MHz, CDCl3): δ 2.26 (s, 3H, CH3), 4.57 (dt, J = 1.9 Hz, J = 5.0 
Hz, 2H, OCH2), 5.29 (dq, J = 1.9 Hz, J = 10.5 Hz, 1H, HC=CHAHB), 5.47 (dq, J 
= 1.9 Hz, J = 17.2 Hz, 1H, HC=CHAHB), 6.05 (ddt, J = 5.0 Hz, J = 10.5 Hz, J = 17.2 Hz, 1H, 
HC=CHAHB), 6.78 (d, J = 8.5 Hz, 1H, CHarom), 7.02 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H, CHarom), 7.36 
(d, J = 2.2 Hz, 1H, CHarom). 13C-NMR (75 MHz, CDCl3): δ 20.32 (CH3), 69.89 (OCH2), 112.11 
(BrCq,arom), 113.71 (CHarom), 117.62 (HC=CH2), 128.95 (CHarom), 131.76 (Cq,arom), 132.99 (CHarom), 
133.88 (HC=CH2), 152.93 (OCq,arom). IR (cm-1) υmax: 1648 (C=C). MS (ESI): m/z (%): 226/228 
(M+H+, 100). 
4.10.2 Synthesis of 2-(allyloxy)-5-methylbenzaldehyde (416) 
In a dry flask compound 415 (5 g, 22 mmol) is dissolved in dry THF (100 ml). The flask is placed 
under inert N2 atmosphere in an acetone bath at -78 °C. To this solution BuLi (9 ml of a 2.5 M 
solution in hexanes, 22 mmol) is added and the mixture is stirred for 30 minutes at -78 °C. Next 
DMF (1.77 g, 24 mmol) is added and the mixture is stirred for 1 hour at -78 °C and 1 hour at 
room temperature. After that time very carefully brine is added (30 ml) and NaHCO3 (30 ml, aq, 
sat). The mixture is extracted with EtOAc (3 x 50 ml). After drying with MgSO4 the compound is 
obtained pure as an oil after column chromatography in 50% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 2.31 (s, 3H, CH3), 4.63 (dt, J = 1.4 Hz, J = 4.9 
Hz, 2H, OCH2), 5.33 (dq, J = 1.4 Hz, J = 10.5 Hz, 1H, HC=CHAHB), 5.44 (dq, J 
= 1.4 Hz, J = 17.3 Hz, 1H, HC=CHAHB), 6.07 (ddt, J = 4.9 Hz, J = 10.5 Hz, J = 
17.3 Hz, 1H, HC=CHAHB), 6.88 (d, J = 8.5 Hz, 1H, CHarom), 7.33 (dd, J = 2.2 Hz, J = 8.5 Hz, 1H, 
CHarom), 7.64 (d, J = 2.2 Hz, 1H, CHarom), 10.51 (s, 1H, HC=O). 13C-NMR (75 MHz, CDCl3): δ 
20.35 (CH3), 69.37 (OCH2), 113.01 (CHarom), 118.02 (HC=CH2), 124.86 (Cq,arom), 128.49 (CHarom), 
130.37 (Cq,arom), 132.66 (HC=CH2), 136.60 (CHarom), 159.15 (OCq,arom), 190.02 (C=O). IR (cm-1) 
υmax: 1613 (C=C), 1686 (C=O). MS (ESI): m/z (%): 177.3 (M+H+, 100). Chromatography: 
Hex/EtOAc 10/1 Rf = 0.41. 
4.10.3 Synthesis of dimethyl [2-(allyloxy)-5-methylphenyl](prop-2-ynylamino) 
methylphosphonate (418) 
Aldehyde 416 (1.9 g, 11 mmol) was dissolved in dry CH2Cl2 (30 ml) and propargylamine (0.89 g, 
16 mmol) and MgSO4 (2.59 g) were added. The mixture was allowed to stir at room temperature 
for 24 hours. After filtration of the solids and removal of the volatiles, the obtained imine was 
directly used for the synthesis of the α-aminophosphonate 417. Thus the imine is dissolved in 50 
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ml of MeOH in a round bottom flask. Then, dimethyl phosphite (DMP) (2.37 g, 22 mmol) is added 
and the mixture is refluxed for 2 hours. After removing the solvent under vacuum, the resulting 
oil is dissolved in 20 ml of diethyl ether and added to a separatory funnel containing 20 ml of 1 M 
HCl. Both phases are vigorously mixed and the organic phase is removed from the funnel. The 
aqueous phase is washed twice with 10 ml of diethyl ether, added to 20 ml of dichloromethane 
and then neutralized using 3 M NaOH until slightly alkaline. Both phases are vigorously mixed 
and the organic phase is now collected. The aqueous phase is extracted twice more with 10 ml of 
dichloromethane and the combined organic phases are dried using MgSO4. The compound is 
obtained in pure form after filtration and evaporation of the solvent in 91% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 2.13 (br s, 1H, NH), 2.18 (t, J = 2.1 Hz, 1H, 
CHalkyne), 2.29 (s, 3H, CH3), 3.22 (dd, J = 2.5 Hz, J = 17.1 Hz, 1H, NCHAHB), 
3.43 (ddd, J = 1.2 Hz, J = 2.1 Hz, J = 17.1 Hz, 1H, NCHAHB), 3.59 (d, J = 
10.6 Hz, 3H, OCH3), 3.79 (d, J = 10.7 Hz, 3H, OCH3), 4.55 (dt, J = 1.5 Hz, J = 5.0 Hz, 2H, 
OCH2), 4.96 (d, J = 19.6 Hz, CHP), 5.26 (dq, J = 1.5 Hz, J = 10.5 Hz, 1H, HC=CHAHB), 5.43 (dq, 
J = 1.5 Hz, J = 17.3 Hz, 1H, HC=CHAHB), 6.05 (ddt, (dq, J = 5.0 Hz, J = 10.5 Hz, J = 17.3 Hz, 
1H, OCH2CH), 6.78 (d, J = 8.3 Hz, 1H, CHarom), 7.04 (d, J = 8.3 Hz, 1H, CHarom), 7.31 (s, 1H, 1 x 
CHarom). 13C-NMR (75 MHz, CDCl3): δ 20.74 (CH3), 36.38 (d, J = 18.5 Hz, NCH2), 50.83 (d, J = 
158.1 Hz, PCH), 53.48 (d, J = 6.9 Hz, OCH3), 53.68 (d, J = 6.9 Hz, OCH3), 69.51 (OCH2), 71.92 
(CHalkyne), 81.36 (Calkyne), 112.41 (CHarom), 117.22 (HC=CH2), 123.12 (d, J = 3.5 Hz, Cq,arom), 
129.47 (d, J = 4.6 Hz, CHarom), 129.59 (d, J = 2.3 Hz, CHarom), 130.51 (d, J = 2.3 Hz, Cq,arom), 
133.48 (OCH2CH), 154.84 (d, J = 6.9 Hz, OCq,arom). 31P-NMR (121 MHz, CDCl3): δ 27.01. IR 
(cm-1) υmax: 1034 (br P-O), 1245 (P=O), 1644 (C=C), 2100 (alkyne). MS (ESI): m/z (%): 
324.3 (M+H+, 100). 
4.10.4 Synthesis of Dimethyl [2-(allyloxy)-5-methylphenyl][benzyl(prop-2-ynylamino)] 
methylphosphonate (419) 
In a flask compound 418 (3.14 g, 9.71 mmol) is dissolved in acetone (50 ml) and K2CO3 (5.05 g, 
39 mmol), NaI (0.15 g, 0.97 mmol) and benzylbromide (3.32 g, 19 mmol) are added and the 
mixture is refluxed during 24h. After this time the solids are removed by filtration and the solvent 
by evaporation under reduced pressure. The compound was obtained in pure form as a pale 
yellow oil after column chromatography in 75% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 2.12 (t, J = 2.2 Hz, 1H, CHalkyne), 2.32 (s, 3H, 
CH3), 3.27 (dd, J = 2.2 Hz, J = 17.2 Hz, 1H, NCHAHB), 3.47 (d, J = 10.5 Hz, 
3H, OCH3), 3.55 (d, J = 13.1 Hz, 1H, NCHAHBPh), 3.56 (dt, J = 2.2 Hz, J = 
17.2 Hz, 1H, NCHAHB), 3.88 (d, J = 10.5 Hz, 3H, OCH3), 4.16 (d, J = 13.1 Hz, 
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1H, NCHAHBPh), 4.54 (dt, J = 1.5 Hz, J = 5.2 Hz, 2H, OCH2), 5.11 (d, J = 21.5 Hz, CHP), 5.25 
(dq, J = 1.5 Hz, J = 10.7 Hz, 1H, HC=CHAHB), 5.40 (dq, J = 1.5 Hz, J = 17.3 Hz, 1H, 
HC=CHAHB), 6.05 (ddt, (dq, J = 5.2 Hz, J = 10.7 Hz, J = 17.3 Hz, 1H, OCH2CH), 6.81 (dd, J = 
1.1 Hz, J = 8.3 Hz, 1H, CHarom), 7.07 (d, J = 8.3 Hz, 1H, CHarom), 7.21-7.42 (m, 5H, 5 x CHarom), 
7.66 (s, 1H, 1 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 20.87 (CH3), 40.71 (d, J = 10.4 Hz, 
NCH2), 53.04 (d, J = 6.9 Hz, OCH3), 53.88 (d, J = 8.1 Hz, OCH3), 54.38 (d, J = 163.8 Hz, PCH), 
55.41 (d, J = 8.1 Hz, NCH2Ph), 69.60 (OCH2), 72.62 (CHalkyne), 80.14 (Calkyne), 112.20 (CHarom), 
117.36 (HC=CH2), 121.89 (Cq,arom), 127.13 (CHarom), 128.25 (2 x CHarom), 129.25 (2 x CHarom), 
131.96 (d, J = 4.6 Hz, CHarom), 133.61 (OCH2CH), 139.10 (Cq,arom), 155.13 (d, J = 9.2 Hz, 
OCq,arom). 31P-NMR (121 MHz, CDCl3): δ 26.35. IR (cm-1) υmax: 1033 (P-O), 1059 (P-O), 1240 
(br P=O), 1608 (C=C). MS (ESI): m/z (%): 414.2 (M+H+, 100). Chromatography: 
Hex/EtOAc 4/7 Rf = 0.39. 
4.10.5 Synthesis of 1-(allyloxy)-2-bromobenzene (426) 
The synthesis of this compound follows the same procedure as for compound 415. The 
compound was obtained in 99% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 4.60 (dt, J = 1.6 Hz, J = 4.9 Hz, 2H, OCH2), 5.31 
(dq, J = 1.7 Hz, J = 10.5 Hz, 1H, HC=CHAHB), 5.49 (dq, J = 1.7 Hz, J = 17.2 Hz, 
1H, HC=CHAHB), 6.06 (ddt, J = 4.9 Hz, J = 10.5 Hz, J = 17.2 Hz, 1H, HC=CHAHB), 6.80-7.55 (m, 
4H, 4 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 69.72 (OCH2), 112.40 (BrCq,arom), 113.68 
(CHarom), 117.83 (HC=CH2), 122.09 (CHarom), 128.48 (CHarom), 132.72 (HC=CH2), 133.51 (CHarom), 
155.03 (OCq,arom). IR (cm-1) υmax: 1649 (C=C). MS (GCMS): m/z (%): 212/214 (M+, 100). 
4.10.6 Synthesis of 1-(allyloxy)benzaldehyde (427) 
The synthesis of this compound follows the same procedure as for compound 416. The 
compound was obtained in 72% yield. 
 
1H-NMR (300 MHz, CDCl3): δ 4.66 (dt, J = 1.4 Hz, J = 5.2 Hz, 2H, OCH2), 5.34 
(dq, J = 1.4 Hz, J = 10.6 Hz, 1H, HC=CHAHB), 5.46 (dq, J = 1.4 Hz, J = 17.3 Hz, 
1H, HC=CHAHB), 6.08 (ddt, J = 5.2 Hz, J = 10.6 Hz, J = 17.3 Hz, 1H, HC=CHAHB), 
6.97-7.06 (m, 2H, 2 x CHarom), 7.50-7.56 (m, 1H, 1 x CHarom), 7.83-7.86 (m, 1H, CHarom), 10.54 
(s, 1H, HC=O). 13C-NMR (75 MHz, CDCl3): δ 69.23 (OCH2), 112.91 (CHarom), 118.17 
(HC=CH2), 122.09 (CHarom), 125.15 (Cq,arom), 128.52 (CHarom), 132.46 (HC=CH2), 133.96 (CHarom), 
161.03 (OCq,arom), 189.90 (C=O). IR (cm-1) υmax: 1689 (br C=O). MS (ESI): m/z (%): 163.2 
(M+H+, 100). Chromatography: Hex/EtOAc 10/1 Rf = 0.31. 
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4.10.7 Synthesis of dimethyl allylamino[2-(allyloxy)phenyl]methylphosphonate (429) 
The synthesis of this compound follows the same procedure as for compound 418. The 
compound was obtained in 83% yield. 
1H-NMR (300 MHz, CDCl3): δ 2.01 (br s, 1H, NH), 3.05 (dd, J = 6.6 Hz, J = 
13.8 Hz, 1H, NCHAHB), 3.21 (dd, J = 5.2 Hz, J = 13.8 Hz, 1H, NCHAHB), 3.54 (d, 
J = 10.5 Hz, 3H, OCH3), 3.80 (d, J = 10.5 Hz, 3H, OCH3), 4.57 (br d, J = 4.6 
Hz, 2H, OCH2), 4.78 (d, J = 21.5 Hz, CHP), 5.05-5.46 (m, 4H, 2 x HC=CH2), 5.78-5.91 (m, 1H, 
NCH2CH), 5.98-6.11 (m, 1H, OCH2CH), 6.88 (d, J = 8.3 Hz, 1H, CHarom), 7.01 (t, J = 7.4 Hz, 1H, 
CHarom), 7.22-7.28 (m, 1H, 1 x CHarom), 7.51 (d, J = 7.4 Hz, 1H, CHarom). 13C-NMR (75 MHz, 
CDCl3): δ 50.23 (d, J = 16.2 Hz, NCH2), 51.42 (d, J = 158.1 Hz, PCH), 53.36 (d, J = 6.9 Hz, 
OCH3), 53.68 (d, J = 6.9 Hz, OCH3), 69.22 (OCH2), 112.08 (CHarom), 116.69 (HC=CH2), 117.41 
(HC=CH2), 121.22 (d, J = 6.9 Hz, CHarom), 124.67 (Cq,arom), 128.92 (2 x CHarom), 132.27 
(OCH2CH), 136.23 (NCH2CH), 156.72 (d, J = 6.9 Hz, OCq,arom). 31P-NMR (121 MHz, CDCl3): δ 
27.47. IR (cm-1) υmax: 1032 (br P-O), 1242 (P=O), 1599 (C=C), 1644 (C=C). MS (ESI): m/z 
(%): 312.3 (M+H+, 100). 
 
4.10.8 Synthesis of dimethyl (allylbenzylamino)[2-(allyloxy)phenyl]methyl phosphonate 
(430) 
The synthesis of this compound follows the same procedure as for compound 419. The 
compound was obtained in 95% yield. 
1H-NMR (300 MHz, CDCl3): δ 2.92 (dd, J = 7.8 Hz, J = 14.1 Hz, 1H, 
NCHAHB), 3.29 (d, J = 14.0 Hz, 1H, NCHAHBPh), 3.46 (d, J = 10.5 Hz, 3H, 
OCH3), 3.62 (ddd, J = 1.9 Hz, J = 4.1 Hz, J = 14.1 Hz, 1H, NCHAHB), 3.88 (d, J 
= 10.5 Hz, 3H, OCH3), 4.24 (d, J = 14.0 Hz, 1H, NCHAHBPh), 4.53 (dt, J = 1.4 Hz, J = 5.4 Hz, 
2H, OCH2), 5.04 (d, J = 25.3 Hz, CHP), 5.07-5.34 (m, 4H, 2 x HC=CH2), 5.76-5.91 (m, 1H, 
NCH2CH), 5.95 (ddt, J = 5.4 Hz, J = 10.6 Hz, J = 17.2 Hz, 1H, OCH2CH), 6.92 (d, J = 8.3 Hz, 1H, 
CHarom), 7.00 (t, J = 7.7 Hz, 1H, CHarom), 6.91-7.39 (m, 6H, 6 x CHarom), 7.88 (d, J = 7.7 Hz, 1H, 
CHarom). 13C-NMR (75 MHz, CDCl3): δ 52.43 (d, J = 167.3 Hz, PCH), 52.67 (d, J = 6.9 Hz, 
OCH3), 53.91 (d, J = 6.9 Hz, OCH3), 54.61 (d, J = 9.2 Hz, NCH2CH), 55.52 (d, J = 8.1 Hz, 
NCH2Ph), 69.43 (OCH2), 112.25 (CHarom), 117.25 (HC=CH2), 117.71 (HC=CH2), 120.46 (CHarom), 
121.62 (d, J = 6.9 Hz, Cq,arom), 126.75 (CHarom), 128.09 (2 x CHarom), 128.87 (2 x CHarom), 129.41 
(CHarom), 132.22 (d, J = 4.6 Hz, CHarom), 133.22 (OCH2CH), 136.74 (NCH2CH), 140.28 (Cq,arom), 
157.18 (d, J = 11.5 Hz, OCq,arom). 31P-NMR (121 MHz, CDCl3): δ 27.23. IR (cm-1) υmax: 1035 
(P-O), 1058 (P-O), 1238 (P=O), 1598 (C=C), 1643 (C=C). MS (ESI): m/z (%): 402.2 (M+H+, 
100). 
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4.10.9 Synthesis of (1Z) and (1E) dimethyl (benzylamino)[2-(prop-1-enyloxy)phenyl] 
methylphosphonate (433) 
Compound 430 (0.15 g, 0.374 mmol) is dissolved in benzene (7.5 ml). Next ClRu(CO)H(PPh3)3 
(0.0178 g, 5 mol%) is added and the mixture is refluxed for 2 hours under N2 atmosphere. After 
this period the second generation Grubbs’ catalyst (0.016 g, 5 mol%) is added and refluxing is 
continued for 16 hours. Silica gel is added on which the product is coated by removal of the 
solvent in vacuo. The compound is obtained as an E/Z mixture (3:7) in 63% combined yield. 
 
MAJOR: 1H-NMR (300 MHz, CDCl3): δ 1.63 (dd, J = 1.7 Hz, J = 6.9 Hz, 3H, 
CH3), 2.27 (br s, 1H, NH), 3.54 (d, J = 10.5 Hz, 3H, OCH3), 3.55-3.77 (m, 2H, 
NCH2 major + minor), 3.78 (d, J = 10.5 Hz, 3H, OCH3), 4.72 (d, J = 21.2 Hz, 
CHP), 4.87 (p, J = 6.3 Hz, 1H, OCHCH), 6.31 (dq, J = 1.7 Hz, J = 6.3 Hz, 1H, 
OCHCH), 6.91-7.70 (m, 9H, 9 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 9.46 (CH3), 51.43 (d, J = 
156.9 Hz, PCH), 51.50 (d, J = 17.3 Hz, NCH2), 53.37 (d, J = 6.9 Hz, OCH3), 53.84 (d, J = 6.9 Hz, 
OCH3), 107.83 (OCHCH), 114.95 (CHarom), 122.97 (d, J = 3.5 Hz, CHarom), 125.12 (Cq,arom), 127.18 
(CHarom), 128.40 (2 x CHarom), 128.52 (2 x CHarom), 129.09 (CHarom), 132.19 (d, J = 9.2 Hz, 
CHarom), 139.42 (Cq,arom), 140.98 (OCH), 155.82 (d, J = 6.9 Hz, OCq,arom). 31P-NMR (121 MHz, 
CDCl3): δ 26.87. IR (cm-1) υmax: 1031 (br P-O), 1251 (P=O), 1669 (C=C). MS (ESI): m/z 
(%): 362.3 (M+H+, 100). Chromatography: Hex/EtOAc 4/6 Rf = 0.26. 
 
MINOR: 1H-NMR (300 MHz, CDCl3): δ 1.65 (dd, J = 1.5 Hz, J = 6.7 Hz, 3H, 
CH3), 2.27 (br s, 1H, NH), 3.54 (d, J = 10.5 Hz, 3H, OCH3), 3.79 (d, J = 10.7 
Hz, 3H, OCH3), 3.55-3.77 (m, 2H, NCH2 major + minor), 4.66 (d, J = 21.2 Hz, 
CHP), 5.29 (dq, J = 6.7 Hz, J = 12.4 Hz, 1H, OCHCH), 6.33 (dq, J = 1.5 Hz, J 
= 12.4 Hz, 1H, OCHCH), 6.91-7.70 (m, 9H, 9 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 12.33 
(CH3), 51.59 (d, J = 17.3 Hz, NCH2), 51.63 (d, J = 156.9 Hz, PCH), 53.37 (d, J = 6.9 Hz, OCH3), 
53.93 (d, J = 5.8 Hz, OCH3), 108.61 (OCHCH), 115.57 (CHarom), 123.07 (d, J = 2.3 Hz, CHarom), 
125.25 (Cq,arom), 127.18 (CHarom), 128.40 (2 x CHarom), 128.52 (2 x CHarom), 129.09 (CHarom), 
132.05 (d, J = 2.3 Hz, CHarom), 139.50 (Cq,arom), 142.20 (OCH), 155.77 (d, J = 8.1 Hz, OCq,arom). 
31P-NMR (121 MHz, CDCl3): δ 26.82. IR (cm-1) υmax: 1031 (br P-O), 1251 (P=O), 1669 
(C=C). MS (ESI): m/z (%): 362.3 (M+H+, 100). Chromatography: Hex/EtOAc 4/6 Rf = 0.26. 
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4.11 Synthesis of phosphonylated isoindoles 
4.11.1 Synthesis of secondary amines 454 
All secondary amines were synthesized using a reductive amination. A suitable aldehyde was 
dissolved in dry CH2Cl2 and 1 equivalent of amine and 2 equivalents of MgSO4 were added. The 
mixture was allowed to stir at room temperature for 24 hours. After filtration of the solids and 
removal of the volatiles, the obtained aldimines were dissolved in dry MeOH. To this solution 1.1 
equivalent of NaBH4 was carefully added and stirring was continued for 4 hours. The reaction 
was quenched by the addition of NaHCO3 (sat, aq) and the MeOH was removed under reduced 
pressure. The residue was extracted with CH2Cl2 and dried using MgSO4. After filtration of the 
solids and removal of the volatiles, the obtained amines 184a-h were obtained pure. 
 
N-[(2E)-3-(4-methoxyphenyl)prop-2-enyl]-N-propylamine (454c) 
1H-NMR (300 MHz, CDCl3): δ 0.93 (t, J = 7.3 Hz, 3H, CH3), 1.55 
(sextet, J = 7.3 Hz, 2H, CH2CH3), 1.94 (s, 1H, NH), 2.63 (t, J = 7.3 Hz, 
2H, NCH2CH2), 3.40 (dd, J = 1.2 Hz, J = 6.5 Hz, 2H, NCH2CH), 3.80 (s, 3H, PhOCH3), 6.18 (dt, J 
= 15.7 Hz, J = 6.5 Hz, 1H, HC=CHPh), 6.47 (d, J = 15.7 Hz, 1H, HCPh), 6.84 (d, J = 8.8 Hz, 2H, 
2 x CHarom), 7.31 (d, J = 8.5 Hz, 2H, 2 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 11.86 (CH2CH3), 
23.28 (CH2CH3), 51.40 (NCH2CH2), 52.03 (NCH2CH), 55.04 (OCH3), 113.91 (2 x CHarom), 126.41 
(HC=CHPh), 127.36 (2 x CHarom), 129.96 (Cq,arom), 130.54 (HC=CHPh), 159.01 (Cq, Ph). IR (cm-
1) νmax: 1608 (C=C), 3300 (br NH). MS (ESI): m/z (%): No M+H+, 147.2 (M+-NC3H8, 100). 
Yield: 97%. 
 
N-(4-methylbenzyl)-N-(3-methylbut-2-enyl)amine (454d) 
1H-NMR (300 MHz, CDCl3): δ 1.62 (br s, 3H, CH3), 1.72 (br s, 3H, CH3), 
1.77 (s, 1H, NH), 2.33 (s, 3H, CH3), 3.22 (d, J = 6.9 Hz, NCH2CH), 3.74 (s, 
2H, NCH2C), 5.28 (t x septet, J = 6.9 Hz, J = 1.4 Hz, 1H, NCH2CH), 7.11-
7.26 (m, 4H, 4 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 14.16 (CH2CH3), 16.73 (CCH3), 20.65 
(CH2CH3), 32.44 (NCH2CH2), 49.10 (NCH2CH2), 58.35 (NCH2C), 125.51 (CHPh), 126.20 (CHarom), 
128.14 (2 x CHarom), 128.96 (2 x CHarom), 137.33 (CCH3), 138.20 (Cq,arom). IR (cm-1) νmax: 1655 
(C=C), 2950 (br NH). MS (ESI): m/z (%): 204.5 (M+H+, 100). Yield: 68%. 
 
N-[(2E)-4-methylpent-2-enyl]-N-(2-phenylethyl) amine (454e) 
1H-NMR (300 MHz, CDCl3): δ 0.97 (d, J = 6.8 Hz, 6H, 2 x CH3), 1.30 
(br s, 1H, NH), 2.26 (octet, J = 6.8 Hz, 1H, CH), 2.78-2.90 (m, 4H, 
CH2CH2), 3.19 (d, J = 5.8 Hz, 2H, NCH2CH), 5.39-5.58 (m, 2H, 
HC=CHPh), 7.17-7.32 (m, 5H, 5 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 22.51 (2 x CH3), 
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30.91 (CH(CH3)2), 36.53 (CH2Ph), 50.65 (NCH2CH2), 51.75 (NCH2CH), 125.24 (HC=CHPh), 126.18 
(CHarom), 128.38 (2 x CHarom), 128.80 (2 x CHarom), 139.73 (HC=CHPh), 140.22 (Cq, Ph). IR (cm-
1) νmax: 1604 (C=C), 2958 (br NH). MS (ESI): m/z (%): 204.5 (M+H+, 100). Yield: 86%. 
 
Allyl-(3-fluorobenzyl)amine (454f) 
1H-NMR (300 MHz, CDCl3): δ 1.53 (br s, 1H, NH), 3.27 (dt, J = 1.2 Hz, J 
= 6.1 Hz, 2H, NCH2CH), 3.79 (s, 2H, NCH2Ph), 5.31 (dq, J = 1.2 Hz, J = 10.2 
Hz, 1H, HC=CHAHB), 5.20 (dq, J = 1.2 Hz, J = 17.1 Hz, 1H, HC=CHAHB), 5.92 (ddt, J = 6.1 Hz, J 
= 10.2 Hz, J = 17.1 Hz, 1H, HC=CH2), 6.91-7.32 (m, 4H, 4 x CHarom). 13C-NMR (75 MHz, 
CDCl3): δ 51.74 (NCH2CH), 52.65 (NCH2Ph), 113.83 (d, J = 21.9 Hz, CHarom), 114.96 (d, J = 
20.8 Hz, CHarom), 116.21 (HC=CH2), 123.70 (d, J = 3.5 Hz, CHarom), 129.86 (d, J = 8.1 Hz, 
CHarom), 136.67 (HC=CH2), 143.12 (d, J = 6.9 Hz, CHq,arom), 163.08 (d, J = 245.8 Hz, FCq,arom). 
19F-NMR (282 MHz, CDCl3): δ -113.41 (dd, J = 9.8 Hz, J = 16.8 Hz). IR (cm-1) νmax: 1590 
(C=C), 1616 (C=C), 1644 (C=C), 2823 (br NH). MS (ESI): m/z (%): 166.3 (M+H+, 100). 
Yield: 94%. 
 
N-(4-methylbenzyl)-N-(3-methylbut-2-enyl)amine (454g) 
1H-NMR (300 MHz, CDCl3): δ 1.48 (br s, 1H, NH), 1.52-1.67 (m, 4H, 
CH2CH2), 1.87-1.94 (m, 2H, CCH2), 1.96-2.05 (m, 2H, HCCH2), 2.74-2.84 
(m, 4H, NCH2CH2), 3.11 (s, 2H, NCH2), 5.54 (br s, HC), 7.14 (d, 2H, J = 
8.4 Hz, 2H, 2 x CHarom), 7.26 (d, 2H, J = 8.4 Hz, 2H, 2 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 
22.61 (CH2), 22.82 (CH2), 25.14 (HCCH2), 26.96 (CCH2), 35.81 (CH2Ph), 50.32 (NCH2CH2), 56.13 
(NCH2C), 122.86 (HC=C), 128.61 (2 x CHarom), 130.14 (2 x CHarom), 131.93 (ClCq,arom), 135.97 
(Cq,arom), 138.77 (C=CH). IR (cm-1) νmax: 1670 (C=C), 2925 (NH). MS (ESI): m/z (%): 
250.2/252.2 (M+H+, 100). Yield: 88%. 
 
N-butyl-N-[(2E)-2-methyl-3-phenylprop-2-enyl]amine (454h) 
1H-NMR (300 MHz, CDCl3): δ 0.93 (t, J = 7.3 Hz, 3H, CH3), 1.36 (s, 
1H, NH), 1.37 (sextet, J = 7.3 Hz, 2H, CH2CH3), 1.47-1.57 (m, 2H, 
NCH2CH2), 1.89 (d, J = 1.1 Hz, 3H, CH3), 2.63 (t, J = 7.2 Hz, NCH2CH2), 3.32 (s, 2H, NCH2C), 
6.34 (br s, 1H, CHPh), 7.17-7.35 (m, 5H, 5 x CHarom). 13C-NMR (75 MHz, CDCl3): δ 14.16 
(CH2CH3), 16.73 (CCH3), 20.65 (CH2CH3), 32.44 (NCH2CH2), 49.10 (NCH2CH2), 58.35 (NCH2C), 
125.51 (CHPh), 126.20 (CHarom), 128.14 (2 x CHarom), 128.96 (2 x CHarom), 137.33 (CCH3), 138.20 
(Cq,arom). IR (cm-1) νmax: 1655 (C=C), 2950 (br NH). MS (ESI): m/z (%): 204.5 (M+H+, 100). 
Yield: 49%. 
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4.11.2 Synthesis of α-aminophosphonates 434 
In a dry flask, 2-ethynylbenzaldehyde (0.5g, 3.84 mmol) is dissolved into diethylether (6 ml). To 
this solution is added LiClO4 (3.06 g, 28.8 mmol, dried for 24h at 110 °C). This mixture is stirred 
for 5 minutes. Subsequently secondary amine 454 is added (7.69 mmol, dissolved in 1ml dry 
diethylether). This mixture is stirred for 20 minutes after which P(OMe)3 is added (0.71 g, 5.76 
mmol). The reaction is stirred for 30 minutes after which water is very carefully added (20 ml). 
The mixture is extracted with CH2Cl2 (3 x 20ml) and dried using MgSO4. After filtration of the 
solids and removal of the volatiles, the obtained compounds were purified using either 
crystallization, column chromatography or acid/base extraction. 
 
Dimethyl [benzyl-(3-phenylprop-2-enyl)amino](2-ethynylphenyl)methylphosphonate 
(434a) 
1H-NMR (300 MHz, CDCl3): δ 3.01 (s, 1H, CCH), 3.20 (dd, J = 7.4 Hz, J = 
14.6 Hz, 1H, NCHAHBCH), 3.45 (d, J = 10.5 Hz, 3H, OCH3), 3.63 (d, J = 14.0 
Hz, 1H, NCHAHBPh), 3.75 (ddt, J = 2.5 Hz, J = 5.2 Hz, J = 14.6 Hz, 1H, 
NCHAHBCH), 3.91 (d, J = 10.5 Hz, 3H, OCH3), 4.33 (d, J = 14.2 Hz, 1H, 
NCHAHBPh), 5.12 (d, J = 24.0 Hz, 1H, CHP), 6.18 (ddd, J = 15.7 Hz, J = 7.4 
Hz, J = 5.2 Hz, 1H, HC=CHPh), 6.48 (d, J = 15.7 Hz, 1H, HCPh), 7.17-7.58 (m, 13H, 13 x 
CHarom), 8.00 (d, J = 8.0 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 53.04 (d, J = 6.9 
Hz, OCH3), 53.63 (d, J = 6.9 Hz, OCH3), 53.70 (d, J = 8.1 Hz, NCH2CH), 55.48 (d, J = 6.9 Hz, 
NCH2Ph), 58.85 (d, J = 160.1 Hz, CHP), 82.11 (CCH), 82.17 (CCH), 124.15 (d, J = 12.7 Hz, 
PCHCC), 126.34 (2 x CHarom), 126.86 (CHarom), 127.35 (CHarom), 127.70 (HC=CHPh), 128.11 
(CHarom), 128.18 (2 x CHarom), 128.57 (3 x CHarom), 128.72 (3 x CHarom), 130.73 (d, J = 3.5 Hz, 
PCHCCH), 132.58 (CHPh), 133.45 (PCHCCCH), 135.98 (d, J = 5.8 Hz, PCHC), 137.38 (Cq, Ph), 
140.00 (Cq, Ph). 31P-NMR (121 MHz, CDCl3): δ 26.47. IR (cm-1) νmax: 1032 (P-O), 1056 (P-
O), 1248 (P=O), 1641 (C=C), 2090 (alkyne). MS (ESI): m/z (%): 446.3 (M+H+, 100). 
Chromatography: Hex/EtOAc 4/6 Rf = 0.18. Yield: 68%. 
 
Dimethyl (allylbenzylamino)(2-ethynylphenyl)methylphosphonate (434b) 
1H-NMR (300 MHz, CDCl3): δ 3.04 (s, 1H, CCH), 3.06 (dd, J = 7.2 Hz, J = 
14.6 Hz, 1H, NCHAHBCH), 3.44 (d, J = 10.5 Hz, 3H, OCH3), 3.52 (d, J = 14.2 
Hz, 1H, NCHAHBPh), 3.66 (ddd, J = 1.5 Hz, J = 4.5 Hz, J = 14.6 Hz, 1H, 
NCHAHBCH), 3.96 (d, J = 10.7 Hz, 3H, OCH3), 4.23 (d, J = 14.2 Hz, 1H, 
NCHAHBPh), 5.03 (d, J = 24.5 Hz, 1H, CHP), 5.09 (d, J = 10.8 Hz, 1H, HC=CHAHB), 5.18 (dd, J = 
1.5 Hz, J = 17.3 Hz, 1H, HC=CHAHB), 5.83 (dddd, J = 4.5 Hz, J = 7.2 Hz, J = 10.5 Hz, J = 17.3 
Hz, 1H, HC=CH2), 7.19-7.44 (m, 7H, 7 x CHarom), 7.56 (d, J = 7.7 Hz, 1H, PCHCCH), 7.97 (d, J = 
8.0 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 52.94 (d, J = 6.9 Hz, OCH3), 53.72 (d, J 
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= 6.9 Hz, OCH3), 54.28 (d, J = 8.1 Hz, NCH2CH), 55.18 (d, J = 8.1 Hz, NCH2Ph), 58.64 (d, J = 
161.5 Hz, CHP), 81.98 (CCH), 82.08 (CCH), 117.41 (HC=CH2), 124.18 (d, J = 12.7 Hz, PCHCC), 
126.80 (CHpara, Ph), 128.11 (3 x CHarom), 128.64 (3 x CHarom), 130.74 (d, J = 3.5 Hz, PCHCCH), 
133.39 (PCHCCCH), 135.77 (d, J = 5.8 Hz, PCHC), 135.99 (HC=CH2), 139.96 (Cq, Ph). 31P-NMR 
(121 MHz, CDCl3): δ 26.25. IR (cm-1) νmax: 1035 (P-O),1058 (P-O), 1246 (P=O), 1642 (C=C), 
2099 (alkyne). MS (ESI): m/z (%): 370.2 (M+H+, 100). MP (°C): 86-87. Chromatography: 
Hex/EtOAc 4/6 Rf = 0.27. Yield: 68%. 
 
Dimethyl (2-ethynylphenyl) [(propyl)[(2E)-3-(4-methoxyphenyl)prop-2-enyl]amino] 
methylphosphonate (434c) 
1H-NMR (300 MHz, CDCl3): δ 0.86 (t, J = 7.3 Hz, 3H, CH3), 1.55 
(sextet, J = 7.3 Hz, 2H, CH2CH3), 2.51 (ddd, J = 5.5 Hz, J = 7.3 Hz, J = 
12.9 Hz, 1H, NCHAHBCH2), 2.74-2.81 (m, 1H, NCHAHBCH2), 3.07 (dd, J = 
7.6 Hz, J = 14.3 Hz, 1H, NCHAHBCH), 3.22 (s, 1H, CCH), 3.47 (d, J = 9.6 
Hz, 3H, OCH3), 3.79 (s, 3H, PhOCH3), 3.90-3.94 (m, 1H, NCHAHBCH), 
3.92 (d, J = 10.5 Hz, 3H, OCH3), 5.02 (d, J = 24.8 Hz, 1H, CHP), 6.04 (ddd, J = 14.7 Hz, J = 7.6 
Hz, J = 5.5 Hz, 1H, HC=CHPh), 6.41 (d, J = 14.7 Hz, 1H, HCPh), 6.83 (d, J = 8.2 Hz, 2H, 2 x 
CHarom), 7.25-7.41 (m, 2H, 2 x CHarom), 7.26 (d, J = 8.3 Hz, 2H, 2 x CHarom), 7.56 (d, J = 7.4 Hz, 
1H, PCHCCH), 7.93 (d, J = 7.7 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 11.74 
(CH2CH3), 21.31 (CH2CH3), 52.76 (d, J = 6.9 Hz, OCH3), 53.07 (d, J = 10.4 Hz, NCH2CH2), 54.10 
(d, J = 6.9 Hz, OCH3), 54.20 (d, J = 5.8 Hz, NCH2CH), 58.95 (d, J = 162.7 Hz, CHP), 81.54 
(CCH), 82.38 (CCH), 114.00 (2 x CHarom), 124.01 (d, J = 12.7 Hz, PCHCC), 126.32 (HC=CHPh), 
127.42 (2 x CHarom), 127.91 (CHarom), 128.66 (CHarom), 130.32 (Cq,arom), 130.73 (d, J = 3.5 Hz, 
PCHCCH), 131.30 (HC=CHPh), 133.39 (PCHCCCH), 136.12 (d, J = 6.9 Hz, PCHC), 159.01 (Cq, 
Ph). 31P-NMR (121 MHz, CDCl3): δ 26.11. IR (cm-1) νmax: 1034 (P-O),1058 (P-O), 1248 
(P=O), 1607 (C=C), 2098 (alkyne). MS (ESI): m/z (%): 428.3 (M+H+, 100). MP (°C): 99-
101. Yield: 81%. 
 
Dimethyl [(4-methylbenzyl)-(3-methylbut-2-enyl)amino](2-ethynylphenyl)methyl 
phosphonate (434d) 
1H-NMR (300 MHz, CDCl3): δ 1.41 (s, 3H, CH3), 1.65 (s, 3H, CH3), 2.32 
(s, 3H, CH3), 3.03 (dd, J = 6.7 Hz, J = 13.5 Hz, 1H, NCHAHBCH), 3.06 (s, 
1H, CCH), 3.40-3.51 (m, 1H, NCHAHBCH), 3.44 (d, J = 10.4 Hz, 3H, OCH3), 
3.53 (d, J = 13.8 Hz, 1H, NCHAHBPh), 3.89 (d, J = 10.5 Hz, 3H, OCH3), 4.15 
(d, J = 13.8 Hz, 1H, NCHAHBPh), 5.04 (d, J = 24.2 Hz, 1H, CHP), 5.26 (t*septet, J = 6.6 Hz, J = 
1.2 Hz, 1H, HC=C), 7.06-7.43 (m, 6H, 6 x CHarom), 7.55 (d, J = 7.7 Hz, 1H, PCHCCH), 7.96 (d, J 
= 8.0 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 18.19 (CH3), 21.22 (CH3), 26.06 (CH3), 
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49.05 (d, J = 9.2 Hz, NCH2CH), 52.87 (d, J = 6.9 Hz, OCH3), 53.75 (d, J = 6.9 Hz, OCH3), 55.15 
(d, J = 8.1 Hz, NCH2Ph), 58.86 (d, J = 160.4 Hz, CHP), 81.77 (CCH), 82.91 (CCH), 122.14 
(HC=C), 124.08 (d, J = 11.5 Hz, PCHCC), 127.88 (CHarom), 128.63 (CHarom), 128.70 (4 x CHarom), 
130.79 (d, J = 3.5 Hz, PCHCCH), 133.33 (PCHCCCH), 134.95 (Cq,arom), 136.17 (d, J = 6.8 Hz, 
PCHC), 136.28 (Cq), 137.19 (Cq,arom). 31P-NMR (121 MHz, CDCl3): δ 26.56. IR (cm-1) νmax: 
1035 (P-O), 1057 (P-O), 1245 (P=O), 1637 (C=C), 2101 (alkyne). MS (ESI): m/z (%): 412.3 
(M+H+, 100). Chromatography: Hex/EtOAc 1/1 Rf = 0.32. MP (°C): 101.5. Yield: 48%. 
 
Dimethyl (2-ethynylphenyl)[[(2E)-4-methylpent-2-enyl(2-phenylethyl)]amino]methyl 
phosphonate (434e) 
1H-NMR (300 MHz, CDCl3): δ 0.95 (d, J = 6.9 Hz, 3H, CH3), 0.96 (d, J = 
6.9 Hz, 3H, CH3), 2.26 (octet, J = 6.9 Hz, 1H, CH), 2.69-2.85 (m, 3H, 
CH2Ph + NCHAHBCH2), 2.99-3.11 (m, 2H, NCHAHBCH2 + NCHAHBCH), 3.33 
(s, 1H, CCH), 3.45 (d, J = 10.4 Hz, 3H, OCH3), 3.80 (d, J = 10.4 Hz, 3H, 
OCH3), 3.76-3.84 (m, 1H, NCHAHBCH), 5.05 (d, J = 24.5 Hz, 1H, CHP), 5.33 
(ddd, J = 15.4 Hz, J = 7.0 Hz, J = 5.6 Hz, 1H, NCH2CH), 5.52 (dd, J = 15.4 Hz, J = 6.9 Hz, 1H, 
CHCH(CH3)2), 7.12-7.51 (m, 7H, 7 x CHarom), 7.55 (d, J = 7.4 Hz, 1H, PCHCCH), 7.89 (d, J = 7.7 
Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 22.51 (CH3), 22.56 (CH3), 30.99 (CH), 34.23 
(CH2Ph), 52.49 (d, J = 10.4 Hz, NCH2CH2), 52.80 (d, J = 8.1 Hz, OCH3), 54.16 (d, J = 5.8 Hz, 
NCH2CH + OCH3), 59.51 (d, J = 163.8 Hz, CHP), 81.91 (CCH), 82.55 (CCH), 123.81 (d, J = 12.7 
Hz, PCHCC), 124.78 (NCH2CH), 125.89 (CHarom), 127.96 (CHarom), 128.26 (2 x CHarom), 128.78 
(CHarom), 129.18 (2 x CHarom), 130.60 (d, J = 3.5 Hz, PCHCCH), 133.44 (CHarom), 136.25 (d, J = 
4.6 Hz, PCHC), 140.54 (HCCH(CH3)2), 140.58 (Cq,arom). 31P-NMR (MHz, CDCl3): δ 25.95. IR 
(cm-1) νmax: 1035 (P-O), 1060 (P-O), 1246 (P=O), 1604 (C=C), 2100 (alkyne). MS (ESI): m/z 
(%): 426.2 (M+H+, 100). Chromatography: Hex/EtOAc 1/1 Rf = 0.56. Yield: 56%. 
 
Dimethyl [allyl(3-fluorobenzyl)amino](2-ethynylphenyl)methylphosphonate (434f) 
1H-NMR (300 MHz, CDCl3): δ 3.05 (dd, J = 7.6 Hz, J = 14.3 Hz, 1H, 
NCHAHBCH), 3.06 (s, 1H, CCH), 3.44 (d, J = 10.7 Hz, 3H, OCH3), 3.53 (d, J = 
14.4 Hz, 1H, NCHAHBPh), 3.71 (ddd, J = 2.0 Hz, J = 4.6 Hz, J = 14.3 Hz, 1H, 
NCHAHBCH), 3.91 (d, J = 10.7 Hz, 3H, OCH3), 4.21 (d, J = 14.4 Hz, 1H, 
NCHAHBPh), 4.99 (d, J = 24.8 Hz, 1H, CHP), 5.10 (dd, J = 10.6 Hz, J = 1.0 Hz, 1H, HC=CHAHB), 
5.18 (dd, J = 1.0 Hz, J = 17.0 Hz, 1H, HC=CHAHB), 5.83 (dddd, J = 4.6 Hz, J = 7.6 Hz, J = 10.6 
Hz, J = 17.0 Hz, 1H, HC=CH2), 6.87-7.44 (m, 6H, 6 x CHarom), 7.56 (d, J = 7.7 Hz, 1H, PCHCCH), 
7.96 (d, J = 7.7 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 53.00 (d, J = 6.9 Hz, OCH3), 
53.62 (d, J = 6.9 Hz, OCH3), 54.47 (d, J = 6.9 Hz, NCH2CH), 54.65 (d, J = 8.1 Hz, NCH2Ph), 
58.53 (d, J = 161.5 Hz, CHP), 81.91 (CCH), 82.11 (CCH), 113.62 (d, J = 20.8 Hz, CHarom), 115.26 
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(d, J = 21.9 Hz, CHarom), 117.60 (HC=CH2), 124.08 (d, J = 2.3 Hz, CHarom), 124.18 (d, J = 12.7 
Hz, PCHCC), 128.17 (CHarom), 128.75 (CHarom), 129.38 (d, J = 8.1 Hz, CHarom), 130.64 (d, J = 3.5 
Hz, PCHCCH), 133.45 (PCHCCCH), 135.48 (d, J = 5.8 Hz, PCHC), 135.79 (HC=CH2), 142.90 (d, J 
= 6.9 Hz, Cq, Ph), 163.03 (d, J = 224.6 Hz, FCq,arom). 31P-NMR (121 MHz, CDCl3): δ 26.03. 
19F-NMR (282 MHz, CDCl3): δ -113.90 (dt, J = 6.6 Hz, J = 9.2 Hz). IR (cm-1) νmax: 1035 (P-
O), 1058 (P-O), 1248 (P=O), 1615 (C=C), 2100 (alkyne). MS (ESI): m/z (%): 388.3 (M+H+, 
100). Chromatography: Hex/EtOAc 6/4 Rf = 0.13. Yield: 72%. 
 
Dimethyl {[(cyclohex-1-en-1-ylmethyl)[2-(4-chlorophenyl)ethyl]]amino}(2-ethynyl 
phenyl)methylphosphonate (434g) 
1H-NMR (300 MHz, CDCl3): δ 1.53-1.61 (m, 4H, CH2CH2), 1.86-1.97 (m, 
4H, HCCH2 + CCH2), 2.57-2.68 (m, 1H, NCHAHBCH2), 2.74 (t, J = 6.6 Hz, 2H, 
NCH2CH2), 2.84 (d, J = 12.9 Hz, NCHAHB), 2.96-3.05 (m, 1H, NCHAHBCH2), 
3.31 (s, 1H, CHalkyne), 3.44 (d, J = 10.5 Hz, 3H, OCH3), 3.65 (d, J = 12.9 Hz, 
NCHAHB), 3.82 (d, J = 10.7 Hz, 3H, OCH3), 5.03 (d, J = 24.8 Hz, 1H, CHP), 
5.52 (br s, 1H, CH), 7.09 (d, J = 8.4 Hz, 2H, 2 x CHarom), 7.21 (d, J = 8.4 Hz, 
2H, 2 x CHarom), 7.29-7.39 (m, 2H, 2 x CHarom), 7.57 (d, J = 7.4 Hz, 1H, PCHCCH), 7.85 (d, J = 
8.0 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 22.73 (CH2), 22.91 (CH2), 25.38 (CH2), 
26.77 (CH2), 33.74 (CH2Ph), 52.58 (d, J = 10.4 Hz, NCH2CH2), 52.91 (d, J = 6.9 Hz, OCH3), 53.59 
(d, J = 6.9 Hz, OCH3), 59.00 (d, J = 162.7 Hz, CHP), 59.26 (d, J = 5.8 Hz, NCH2C), 81.71 (CCH), 
82.55 (CCH), 123.87 (d, J = 12.7 Hz, PCHCC), 124.72 (CH), 127.96 (CHarom), 128.32 (2 x CHarom), 
128.73 (CHarom), 130.37 (2 x CHarom), 130.64 (d, J = 3.5 Hz, PCHCCH), 131.57 (ClCq,arom), 133.44 
(CHarom), 135.96 (Cq,arom), 136.06 (d, J = 5.8 Hz, PCHC), 139.24 (C=CH). 31P-NMR (MHz, 
CDCl3): δ 26.21. IR (cm-1) νmax: 1035 (P-O), 1060 (P-O), 1244 (P=O), 2097 (alkyne). MS 
(ESI): m/z (%): 472.2/474.2 (M+H+, 100). MP (°C): 103-104. Yield: 59%. 
 
Dimethyl (2-ethynylphenyl){butyl[(2E)-2-methyl-3-phenylprop-2-enyl]amino}methyl 
phosphonate (434h) 
 
For purification of 434h, the mixture obtained after drying with MgSO4 was dissolved in ether 
(100 ml) and washed twice with HCl (3N, 25 ml) to remove the excess of secondary amine. 
Afterwards the organic layer is made basic with NaOH (aq, 3N),extracted with ether three times 
(50 ml) and dried with MgSO4. 
 
1H-NMR (300 MHz, CDCl3): δ 0.89 (t, J = 7.3 Hz, 3H, CH2CH3), 1.20-1.43 
(m, 2H, CH2CH3), 1.54 (m, 2H, NCH2CH2), 1.92 (s, 3H, CCH3), 2.44 (ddd, J = 
6.1 Hz, J = 6.9 Hz, J = 12.9 Hz, 1H, NCHAHBCH2), 2.81-2.92 (m, 1H, 
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NCHAHBCH2), 2.90 (d, J = 13.8 Hz, 1H, NCHAHBC), 3.21 (s, 1H, CCH), 3.46 (d, J = 10.5 Hz, 3H, 
OCH3), 3.84 (d, J = 13.8 Hz, 1H, NCHAHBC), 3.91 (d, J = 10.7 Hz, 3H, OCH3), 5.05 (d, J = 25.6 
Hz, 1H, CHP), 6.43 (s, 1H, HC=C), 7.17-7.43 (m, 7H, 7 x CHarom), 7.57 (d, J = 7.4 Hz, 1H, 
PCHCCH), 7.93 (d, J = 8.0 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 14.27 (CH2CH3), 
16.65 (CCH3), 20.56 (CH2CH3), 30.47 (NCH2CH2), 51.00 (d, J = 11.5 Hz, NCH2CH2), 52.84 (d, J = 
6.9 Hz, OCH3), 53.63 (d, J = 6.9 Hz, OCH3), 58.30 (d, J = 163.8 Hz, CHP), 60.97 (d, J = 5.8 Hz, 
NCH2C), 81.45 (CCH), 82.32 (CCH), 124.19 (d, J = 12.7 Hz, PCHCC), 126.11 (HC=C), 126.81 
(CHarom), 127.94 (CHarom), 128.12 (2 x CHarom), 128.63 (CHarom), 128.93 (2 x CHarom), 130.80 (d, J 
= 3.5 Hz, PCHCCH), 133.42 (PCHCCCH), 135.76 (d, J = 6.9 Hz, PCHC), 137.35 (C=CH), 138.45 
(Cq, Ph). 31P-NMR (121 MHz, CDCl3): δ 26.38. IR (cm-1) νmax: 1036 (P-O),1059 (P-O), 1244 
(P=O), 1598 (C=C), 2099 (alkyne). MS (ESI): m/z (%): 426.2 (M+H+, 100). Yield: 88%. 
 
Dimethyl (diallylamino)(2-ethynylphenyl)methylphosphonate (434i) 
1H-NMR (300 MHz, CDCl3): δ 3.06 (dd, J = 7.2 Hz, J = 14.6 Hz, 2H, 2 x 
NCHAHBCH), 3.26 (s, 1H, CCH), 3.46 (d, J = 10.5 Hz, 3H, OCH3), 3.66 (ddt, J = 
2.2 Hz, J = 2.5 Hz, J = 14.6 Hz, 2H, 2 x NCHAHBCH), 3.90 (d, J = 10.5 Hz, 3H, 
OCH3), 4.97 (d, J = 24.2 Hz, 1H, CHP), 5.10 (d, J = 10.5 Hz, 2H, 2 x 
HC=CHaHb), 5.19 (d, J = 17.2 Hz, 2H, 2 x HC=CHaHb), 5.75-5.88 (m, 2H, 2 x HC=CH2), 7.27-7.41 
(m, 2H, 2 x CHarom), 7.72 (d, J = 7.5 Hz, 1H, PCHCCH), 7.92 (d, J = 7.7 Hz, 1H, PCHCCCH). 13C-
NMR (75 MHz, CDCl3): δ 52.82 (d, J = 6.9 Hz, OCH3), 54.05 (d, J = 8.1 Hz, 2 x NCH2CH), 
54.15 (d, J = 6.9 Hz, OCH3), 58.91 (d, J = 163.8 Hz, CHP), 81.97 (CCH), 82.26 (CCH), 117.04 (2 
x HC=CH2), 123.95 (d, J = 12.7 Hz, PCHCC), 127.99 (CHarom), 128.70 (CHarom), 130.66 (d, J = 
4.6 Hz, PCHCCH), 133.42 (CHarom), 136.00 (d, J = 4.6 Hz, PCHC), 136.15 (2 x HC=CH2). 31P-
NMR (121 MHz, CDCl3): δ 26.16. IR (cm-1) νmax: 1047 (br P-O), 1239 (P=O), 1642 (C=C), 
2095 (alkyne). MS (ESI): m/z (%): 320.2 (M+H+, 100). MP (°C): 97. Yield: 79%. 
 
Dimethyl (2-ethynylphenyl) [(butyl)(3-fluorobenzyl)amino]methylphosphonate (434j) 
1H-NMR (300 MHz, CDCl3): δ 0.81 (t, J = 7.4 Hz, 3H, CH3), 1.09-1.36 (m, 
2H, CH2CH3), 1.48 (p, J = 7.2 Hz, 2H, NCH2CH2), 2.45 (dt, J = 6.6 Hz, J = 
13.0 Hz, 1H, NCHAHBCH2), 2.70-2.80 (m, 1H, NCHAHBCH2), 3.14 (s, 1H, CCH), 
3.37 (d, J = 14.3 Hz, 1H, NCHAHBPh), 3.46 (d, J = 10.5 Hz, 3H, OCH3), 3.92 
(d, J = 10.7 Hz, 3H, OCH3), 4.37 (d, J = 14.3 Hz, 1H, NCHAHBPh), 5.02 (d, J = 25.3 Hz, 1H, 
CHP), 6.87-7.43 (m, 6H, 6 x CHarom), 7.57 (d, J = 7.5 Hz, 1H, PCHCCH), 7.95 (d, J = 7.7 Hz, 1H, 
PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 14.10 (CH3), 20.32 (CH2CH3), 30.32 (NCH2CH2), 
51.32 (d, J = 10.4 Hz, NCH2CH2), 52.92 (d, J = 8.1 Hz, OCH3), 53.63 (d, J = 6.9 Hz, OCH3), 
55.61 (d, J = 5.8 Hz, NCH2Ph), 58.30 (d, J = 163.8 Hz, CHP), 81.62 (CCH), 82.11 (CCH), 113.56 
(d, J = 20.8 Hz, CHarom), 115.37 (d, J = 21.9 Hz, CHarom), 124.17 (d, J = 2.3 Hz, CHarom), 124.23 
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(d, J = 11.5 Hz, PCHCC), 128.09 (CHarom), 128.70 (CHarom), 129.38 (d, J = 8.1 Hz, CHarom), 
130.71 (d, J = 3.5 Hz, PCHCCH), 133.47 (PCHCCCH), 135.47 (d, J = 6.9 Hz, PCHC), 143.36 (d, J 
= 6.9 Hz, Cq, Ph), 163.00 (d, J = 224.6 Hz, FCq,arom). 31P-NMR (121 MHz, CDCl3): δ 26.37. 
19F-NMR (282 MHz, CDCl3): δ -114.00 (dt, J = 5.3 Hz, J = 9.5 Hz). IR (cm-1) νmax: 1036 (P-
O),1058 (P-O), 1249 (P=O), 1614 (C=C), 2099 (alkyne). MS (ESI): m/z (%): 404.2 (M+H+, 
100). MP (°C): 67. Yield: 65%. 
 
Dimethyl (2-ethynylphenyl)[(4-methoxybenzyl)(propyl)amino]methylphosphonate 
(434k) 
1H-NMR (300 MHz, CDCl3): δ 0.77 (t, J = 7.3 Hz, 3H, CH3), 1.42-1.57 
(m, 2H, CH2CH3), 2.41 (ddd, J = 4.8 Hz, J = 8.3 Hz, J = 13.0 Hz, 1H, 
NCHAHBCH2), 2.61-2.72 (m, 1H, NCHAHBCH2), 3.16 (s, 1H, CCH), 3.27 (d, 
J = 13.5 Hz, 1H, NCHAHBPh), 3.47 (d, J = 10.5 Hz, 3H, OCH3), 3.79 (s, 
3H, PhOCH3), 3.91 (d, J = 10.7 Hz, 3H, OCH3), 4.32 (d, J = 13.5 Hz, 1H, NCHAHBPh), 5.04 (d, J 
= 25.3 Hz, 1H, CHP), 6.83 (d, J = 8.7 Hz, 2H, 2 x CHarom), 7.26-7.56 (m, 2H, 2 x CHarom), 7.28 (d, 
J = 8.7 Hz, 2H, 2 x CHarom), 7.57 (d, J = 6.0 Hz, 1H, PCHCCH), 7.96 (d, J = 7.7 Hz, 1H, 
PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 11.66 (CH2CH3), 21.17 (CH2CH3), 52.82 (d, J = 6.9 
Hz, OCH3), 52.98 (d, J = 10.4 Hz, NCH2CH2), 53.80 (d, J = 6.9 Hz, OCH3), 55.31 (PhOCH3), 55.39 
(d, J = 5.8 Hz, NCH2), 58.44 (d, J = 163.8 Hz, CHP), 81.50 (CCH), 82.20 (CCH), 113.42 (2 x 
CHarom), 124.19 (d, J = 12.7 Hz, PCHCC), 127.97 (CHarom), 128.66 (CHarom), 129.89 (2 x CHarom), 
130.82 (d, J = 3.5 Hz, PCHCCH), 132.37 (Cq,arom), 133.41 (Cq,arom), 135.77 (d, J = 6.9 Hz, PCHC), 
158.51 (Cq,arom). 31P-NMR (121 MHz, CDCl3): δ 26.31. IR (cm-1) νmax: 1034 (P-O), 1057 (P-
O), 1246 (P=O), 1612 (C=C), 2099 (alkyne). MS (ESI): m/z (%): 402.2 (M+H+, 100). MP 
(°C): 82. Yield: 71%. 
 
Dimethyl [(2-ethynylphenyl)-(4-phenyl-3,6-dihydro-2H-pyridin-1-yl)methyl] 
phosphonate (434l) 
1H-NMR (300 MHz, CDCl3): δ 2.44-2.66 (m, 2H, NCH2CH2), 2.75 (ddd, J 
= 4.4 Hz, J = 7.3 Hz, J = 11.4 Hz, 1H, NCHAHBCH2), 3.31 (dt, J = 4.6 Hz, J 
= 11.4 Hz, 1H, NCHAHBCH2), 3.34 (s, 1H, CCH), 3.43 (d, J = 2.9 Hz, 1H, 
NCHAHB), 3.44 (d, J = 2.9 Hz, 1H, NCHAHB), 3.50 (d, J = 10.5 Hz, 3H, 
OCH3), 3.88 (d, J = 10.5 Hz, 3H, OCH3), 4.92 (d, J = 22.0 Hz, 1H, CHP), 6.02 (br s, 1H, CH), 
7.18-7.41 (m, 7H, 7 x CHarom), 7.57 (dt, J = 7.7 Hz, J = 1.1 Hz, 1H, PCHCCH), 7.94 (dt, J = 7.9 
Hz, J = 2.5 Hz, 1H, PCHCCCH). 13C-NMR (75 MHz, CDCl3): δ 28.29 (NCH2CH2), 47.97 (d, J = 
6.9 Hz, NCH2CH2), 51.57 (d, J = 11.5 Hz, NCH2CH), 53.06 (d, J = 8.1 Hz, OCH3), 54.06 (d, J = 
6.9 Hz, OCH3), 63.07 (d, J = 161.5 Hz, CHP), 82.15 (CCH), 82.24 (CCH), 122.00 (HC=C), 123.85 
(d, J = 11.5 Hz, PCHCC), 124.84 (2 x CHarom), 127.02 (CHarom), 128.06 (CHarom), 128.37 (2 x 
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CHarom), 128.83 (CHarom), 130.33 (d, J = 3.5 Hz, PCHCCH), 133.27 (PCHCCCH), 134.54 (Cq,arom), 
135.12 (d, J = 2.0 Hz, PCHC), 140.80 (HC=C). 31P-NMR (121 MHz, CDCl3): δ 24.96. IR (cm-
1) νmax: 1036 (P-O), 1058 (P-O), 1245 (P=O), 1654 (C=C), 2100 (alkyne). MS (ESI): m/z (%): 
382.3 (M+H+, 100). Chromatography: Hex/EtOAc 1/1 Rf = 0.16. Yield: 75%. 
 
Dimethyl [(2-ethynylphenyl)-(4-(4-fluorophenyl)-3,6-dihydro-2H-pyridin-1-yl)methyl] 
phosphonate (434m) 
1H-NMR (300 MHz, CDCl3): δ 2.42-2.61 (m, 2H, NCH2CH2), 2.74 (ddd, 
J = 4.4 Hz, J = 7.4 Hz, J = 11.4 Hz, 1H, NCHAHBCH2), 3.30 (dt, J = 3.3 
Hz, J = 11.4 Hz, 1H, NCHAHBCH2), 3.34 (s, 1H, CCH), 3.43 (br s, 2H, 
NCH2), 3.50 (d, J = 10.5 Hz, 3H, OCH3), 3.88 (d, J = 10.5 Hz, 3H, OCH3), 
4.91 (d, J = 22.0 Hz, 1H, CHP), 5.96 (br s, 1H, CH), 6.98 (t, J = 8.5 Hz, 2H, 2 x CHarom), 7.26-
7.44 (m, 4H, 4 x CHarom), 7.57 (d, J = 7.6 Hz, 1H, PCHCCH), 7.93 (d, J = 8.0 Hz, 1H, PCHCCCH). 
13C-NMR (75 MHz, CDCl3): δ 28.53 (NCH2CH2), 47.91 (d, J = 8.1 Hz, NCH2CH2), 51.49 (d, J = 
11.5 Hz, NCH2CH), 53.09 (d, J = 8.1 Hz, OCH3), 54.00 (d, J = 6.9 Hz, OCH3), 63.04 (d, J = 161.5 
Hz, CHP), 82.12 (CCH), 82.24 (CCH), 115.13 (d, J = 20.8 Hz, 2 x CHarom), 121.86 (HC=C), 123.83 
(d, J = 11.5 Hz, PCHCC), 126.36 (d, J = 20.8 Hz, 2 x CHarom), 128.08 (CHarom), 128.84 (CHarom), 
130.30 (d, J = 3.5 Hz, PCHCCH), 133.28 (PCHCCCH), 133.64 (HC=C), 135.11 (Cq,arom), 136.91 (d, 
J = 3.5 Hz, PCHC), 162.06 (d, J = 245.8 Hz, FCq,arom). 31P-NMR (121 MHz, CDCl3): δ 24.93. 
19F-NMR (282 MHz, CDCl3): δ -115.83 (tt, J = 9.8 Hz, J = 5.7 Hz). IR (cm-1) νmax: 1035 (P-
O), 1057 (P-O), 1227 (P=O), 1602 (C=C), 2100 (alkyne). MS (ESI): m/z (%): 400.2 (M+H+, 
100). MP (°C): 76-77. Chromatography: Hex/EtOAc 4/6 Rf = 0.21. Yield: 62%. 
4.11.3 Microwave induced synthesis of isoindoles 435 
In a dry reaction tube, compounds 434 (0.5 mmol) are dissolved into a mixture of acetonitrile (3 
ml) and benzene (3 ml). This solution is heated in a microwave to 165 °C for 60 minutes. After 
this period of time the progress of the reaction is checked by 31P NMR from a sample taken 
directly from the mixture. If this reveals the presence of remaining starting material, the reaction 
is placed back inside the microwave and is again heated to 165 °C. After complete conversion the 
compound is coated on silica gel by removal of the volatiles in vacuo and purified by column 
chromatography. 
 
Dimethyl 2-benzyl-3-(2-phenylbut-3-enyl)-2H-isoindol-1-ylphosphonate (435a) 
1H-NMR (300 MHz, CDCl3): δ 3.17 (dd, J = 7.5 Hz, J = 15.1 Hz, 1H, 
CHAHBCH), 3.43 (dd, J = 7.5 Hz, J = 15.1 Hz, 1H, CHAHBCH), 3.48 (d, J = 11.6 
Hz, 3H, OCH3), 3.49 (d, J = 11.6 Hz, 3H, OCH3), 3.62 (ps q, J = 7.5 Hz, 
CHPh), 4.98 (1H, d, J = 17.1 Hz, HC=CHAHB), 5.07 (1H, d, J = 10.3 Hz, 
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HC=CHAHB), 5.19 (d, J = 16.8 Hz, 1H, NCHAHBPh), 5.53 (d, J = 16.8 Hz, 1H, NCHAHBPh), 6.10 
(ddd, J = 17.1 Hz, J = 10.3 Hz, J = 7.5 Hz, 1H, HC=CH2), 6.74-7.53 (m, 13H, 13 x CHarom), 7.95 
(d, J = 8.5 Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 32.18 (CH2CH), 49.63 (NCH2), 
50.20 (CHPh), 52.33 (d, J = 3.5 Hz, 2 x OCH3), 103.63 (d, J = 231.9 Hz, PC), 115.71 (HC=CH2), 
119.89 (CHarom), 120.15 (CHarom), 121.13 (CHarom), 124.05 (d, J = 12.7 Hz, PCCC), 124.84 
(CHarom), 125.74 (2 x CHarom), 127.02 (CHarom), 127.39 (CHarom), 127.65 (2 x CHarom), 128.69 (4 x 
CHarom), 131.07 (d, J = 9.2 Hz, NC), 133.00 (d, J = 17.3 Hz, PCC), 137.79 (Cq, Ph), 140.06 
(HC=CH2), 142.80 (Cq, Ph). 31P-NMR (121 MHz, CDCl3): δ 14.66. IR (cm-1) νmax: 1022 (P-
O), 1049 (P-O), 1242 (P=O), 1702 (C=C). MS (ESI): m/z (%): 446.3 (M+H+, 100). 
Chromatography: Hex/EtOAc 1/1 Rf = 0.34. Yield: 82%. 
 
Dimethyl 2-benzyl-3-but-3-enyl-2H-isoindol-1-ylphosphonate (435b) 
1H-NMR (300 MHz, CDCl3): δ 2.25 (ps q, J = 7.5 Hz, 2H, CH2CH), 3.02 (t, J 
= 7.3 Hz, 2H, CH2CH2), 3.55 (d, J = 11.5 Hz, 6H, 2 x OCH3), 4.97 (d, J = 10.7 
Hz, 1H, HC=CHAHB), 4.98 (d, J = 16.3 Hz, 1H, HC=CHAHB), 5.77 (ddt, J = 7.3 
Hz, J = 10.7 Hz, J = 16.3 Hz, 1H, HC=CH2), 5.84 (s, 2H, NCH2), 6.87 (d, J = 
6.6 Hz, 2 x CHarom), 7.05 (t, J = 7.6 Hz, CHarom), 7.17-7.29 (m, 4H, 4 x CHarom), 7.62 (d, J = 8.5 
Hz, PCCCH), 7.93 (d, J = 8.8 Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 24.93 (NCCH2), 
33.97 (CH2CH), 50.12 (NCH2), 52.48 (d, J = 5.8 Hz, 2 x OCH3), 103.57 (d, J = 234.2 Hz, PC), 
116.05 (HC=CH2), 119.86 (CHarom), 120.03 (CHarom), 121.04 (CHarom), 123.43 (d, J = 12.7 Hz, 
PCCC), 124.94 (CHarom), 125.93 (2 x CHarom), 127.48 (CHarom), 128.72 (2 x CHarom), 132.80 (d, J = 
9.2 Hz, NC), 132.82 (d, J = 17.3 Hz, PCC), 137.01 (HC=CH2), 137.80 (Cq, Ph). 31P-NMR (121 
MHz, CDCl3): δ 14.80. IR (cm-1) νmax: 1023 (P-O), 1049 (P-O), 1241 (P=O), 1698 (C=C). MS 
(ESI): m/z (%): 370.2 (M+H+, 100). Chromatography: Hex/EtOAc 55/45 Rf = 0.25. Yield: 
76%. 
 
Dimethyl 3-[2-(4-methoxyphenyl)but-3-enyl]-2-propyl-2H-isoindol-1-ylphosphonate 
(435c) 
1H-NMR (300 MHz, CDCl3): δ 0.92 (t, J = 7.4 Hz, 3H, CH3), 1.66-1.80 (m, 
2H, CH2CH3), 3.24 (dd, J = 8.0 Hz, J = 14.6 Hz, 1H, CHAHBCH), 3.47 (dd, J = 
7.2 Hz, J = 14.6 Hz, 1H, CHAHBCH), 3.67 (d, J = 11.8 Hz, 3H, OCH3), 3.68 (d, J 
= 11.6 Hz, 3H, OCH3), 3.67-3.74 (m, 1H, CHPh), 3.76 (s, 3H, PhOCH3), 4.00 
(ddd, J = 6.3 Hz, J = 9.5 Hz, J = 14.0 Hz, 1H, NCHAHB), 4.22 (ddd, J = 6.3 Hz, 
J = 9.5 Hz, J = 14.0 Hz, 1H, NCHAHB), 5.01 (dt, J = 1.3 Hz, J = 17.1 Hz, 1H, 
HC=CHAHB), 5.08 (dt, J = 1.3 Hz, J = 10.2 Hz, HC=CHAHB), 6.11 (ddd, J = 
17.1 Hz, J = 10.2 Hz, J = 7.0 Hz, 1H, HC=CH2), 6.74-7.51 (m, 7H, 7 x CHarom), 7.85 (d, J = 8.5 
Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 11.38 (CH2CH3), 25.58 (CH2CH3), 32.22 
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(CH2CH), 48.25 (NCH2), 49.39 (CHPh), 52.37 (d, J = 5.8 Hz, 2 x OCH3), 55.34 (PhOCH3), 102.33 
(d, J = 234.2 Hz, PC), 114.05 (2 x CHarom), 115.30 (HC=CH2), 119.77 (2 x CHarom), 120.69 
(CHarom), 123.77 (d, J = 13.8 Hz, PCCC), 124.52 (CHarom), 128.54 (2 x CHarom), 130.41 (d, J = 9.2 
Hz, NC), 132.64 (d, J = 18.5 Hz, PCC), 134.84 (Cq, Ph), 140.51 (HC=CH2), 158.60 (Cq, Ph). 31P-
NMR (121 MHz, CDCl3): δ 15.23. IR (cm-1) νmax: 1024 (P-O), 1049 (P-O), 1246 (P=O), 1698 
(C=C). MS (ESI): m/z (%): 428.3 (M+H+, 100). Chromatography: Hex/EtOAc 1/1 Rf = 0.15. 
Yield: 68%. 
 
Dimethyl 3-(2,2-dimethylbut-3-enyl)-2-(4-methylbenzyl)-2H-isoindol-1-ylphosphonate 
(435d) 
1H-NMR (300 MHz, CDCl3): δ 1.12 (s, 6H, 2 x CH3), 2.27 (s, 3H, CH3), 3.47 
(d, J = 11.5 Hz, 6H, 2 x OCH3), 4.93 (dd, J = 17.4 Hz, J = 1.1 Hz, 1H, 
HC=CHAHB), 4.97 (dd, J = 10.7 Hz, J = 1.1 Hz, 1H, HC=CHAHB), 5.82 (s, 2H, 
NCH2), 5.84 (dd, J = 10.7 Hz, J = 17.4 Hz, 1H, HC=CH2), 6.58 (d, J = 7.8 Hz, 
2 x CHarom), 7.02 (d, J = 7.8 Hz, 2 x CHarom), 7.05-7.21 (m, 2H, 2 x CHarom), 
7.62-7.65 (m, 1H, PCCCH), 7.93 (d, J = 8.8 Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 
21.09 (CH3), 27.57 (2 x CH3), 37.52 (NCCH2), 39.81 (C(CH3)2), 50.21 (NCH2), 52.30 (d, J = 4.6 
Hz, 2 x OCH3), 104.03 (d, J = 233.1 Hz, PC), 111.82 (HC=CH2), 120.02 (CHarom), 120.93 (CHarom), 
121.19 (CHarom), 124.64 (CHarom), 123.94 (d, J = 12.7 Hz, PCCC), 125.50 (2 x CHarom), 129.28 (2 
x CHarom), 130.86 (d, J = 9.2 Hz, NC), 132.11 (d, J = 17.3 Hz, PCC), 134.84 (Cq, Ph), 136.95 (Cq, 
Ph), 147.04 (HC=CH2). 31P-NMR (121 MHz, CDCl3): δ 14.79. IR (cm-1) νmax: 1023 (P-O), 
1051 (P-O), 1243 (P=O), 1638 (C=C). MS (ESI): m/z (%): 412.3 (M+H+, 100). 
Chromatography: Hex/EtOAc 1/1 Rf = 0.22. Yield: 47%. 
 
Dimethyl 3-[2-isopropylbut-3-enyl]-2-(2-fenylethyl)-2H-isoindol-1-ylphosphonate (435e) 
 
1H-NMR (300 MHz, CDCl3): δ 0.95 (d, J = 6.4 Hz, 3H, CH3), 0.96 (d, J 
= 6.4 Hz, 3H, CH3), 1.70 (octet, J = 6.4 Hz, 1H, CH(CH3)2), 2.24 (tt, J = 
6.4 Hz, J = 9.8 Hz, 1H, CH2CH), 2.76 (dd, J = 9.8 Hz, J = 14.9 Hz, 1H, 
CHAHBCH), 2.98 (dd, J = 6.4 Hz, J = 14.9 Hz, 1H, CHAHBCH), 3.05-3.20 (m, 
2H, CH2Ph), 3.74 (d, J = 11.6 Hz, 3H, OCH3), 3.75 (d, J = 11.5 Hz, 3H, 
OCH3), 4.61 (dd, J = 1.7 Hz, J = 17.1 Hz, 1H, HC=CHAHB), 4.61-4.79 (m, 2H, NCH2), 4.82 (dt, J 
= 1.7 Hz, J = 9.8 Hz, HC=CHAHB), 5.63 (dt, J = 17.1 Hz, J = 9.8 Hz, 1H, HC=CH2), 6.98-7.33 (m, 
7H, 7 x CHarom), 7.52 (d, J = 8.5 Hz, 1H, PCCCH), 7.86 (d, J = 8.8 Hz, 1H, PCCCCH). 13C-NMR 
(75 MHz, CDCl3): δ 18.85 (CH3), 20.90 (CH3), 27.90 (CH2CH), 31.46 (CH(CH3)2), 38.88 
(CH2Ph), 48.90 (NCH2), 51.51 (CHCH=CH2), 52.53 (d, J = 4.6 Hz, 2 x OCH3), 101.81 (d, J = 
234.2 Hz, PC), 116.76 (HC=CH2), 119.60 (CHarom), 120.14 (CHarom), 120.54 (CHarom), 123.73 (d, J 
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= 12.7 Hz, PCCC), 124.73 (CHarom), 126.90 (CHarom), 128.81 (2 x CHarom), 129.01 (2 x CHarom), 
132.13 (d, J = 10.4 Hz, NC), 132.73 (d, J = 17.3 Hz, PCC), 138.23 (Cq, Ph), 138.58 (HC=CH2). 
31P-NMR (121 MHz, CDCl3): δ 15.44. IR (cm-1) νmax: 1025 (P-O), 1049 (P-O), 1247 (P=O), 
1660 (C=C). MS (ESI): m/z (%): 426.2 (M+H+, 100). Chromatography: Hex/EtOAc 1/1 Rf = 
0.32. Yield: 71%. 
 
Dimethyl 3-but-2-enyl-2-(3-fluorobenzyl)-2H-isoindol-1-ylphosphonate (435f) 
1H-NMR (300 MHz, CDCl3): δ 2.26 (ps q, J = 7.4 Hz, 2H, CH2CH), 3.01 (t, J 
= 7.4 Hz, 2H, NCCH2), 3.59 (d, J = 11.6 Hz, 6H, 2 x OCH3), 4.95-5.01 (m, 2H, 
HC=CH2), 5.77 (ddt, J = 7.4 Hz, J = 9.9 Hz, J = 17.3 Hz, 1H, HC=CH2), 5.85 
(s, 2H, NCH2Ph), 6.57 (d, J = 9.6 Hz, 1H, CHarom), 6.69 (d, J = 7.7 Hz, 1H, 
CHarom), 6.92 (dt, J = 8.4 Hz, J = 0.8 Hz, 1H, CHarom), 7.04-7.26 (m, 3H, 3 x 
CHarom), 7.62 (d, J = 8.5 Hz, 1H, PCCCH), 7.90 (d, J = 8.8 Hz, 1H, PCCCCH). 13C-NMR (75 
MHz, CDCl3): δ 24.88 (NCCH2), 33.97 (CH2CH), 49.60 (NCH2), 52.52 (d, J = 5.8 Hz, 2 x OCH3), 
103.69 (d, J = 234.2 Hz, PC), 113.04 (d, J = 23.1 Hz, CHarom), 114.45 (d, J = 21.9 Hz, CHarom), 
116.18 (HC=CH2), 119.89 (CHarom), 119.96 (CHarom), 121.21 (CHarom), 121.58 (d, J  3.5 Hz, 
CHarom), 123.48 (d, J = 13.9 Hz, PCCC), 125.13 (CHarom), 130.30 (d, J = 8.1 Hz, CHarom), 132.64 
(d, J = 17.3 Hz, NC), 132.70 (d, J = 17.3 Hz, PCC), 136.86 (HC=CH2), 140.49 (d, J = 6.9 Hz, 
Cq,arom), 163.23 (d, J = 245.8 Hz, FCq,arom). 31P-NMR (121 MHz, CDCl3): δ 14.56. 19F-NMR 
(282 MHz, CDCl3): δ -112.48 (dt, J = 5.3 Hz, J = 7.2 Hz). IR (cm-1) νmax: 1025 (P-O), 1050 
(P-O), 1243 (P=O), 1617 (C=C). MS (ESI): m/z (%): 388.3 (M+H+, 100). Chromatography: 
Hex/EtOAc 4/6 Rf = 0.36. Yield: 63%. 
 
Dimethyl [2-[2-(4-chlorophenyl)-ethyl]-3-(2-methylene-cyclohexylmethyl)--2H-isoindol-
1-yl]-phosphonate (435g) 
1H-NMR (300 MHz, CDCl3): δ 1.12-1.70 (m, 6H, 3 x CH2), 1.99-2.10 
(m, 1H, CHAHB), 2.30-2.38 (m, 2H, CH2CH + CHAHB), 2.88 (dd, J = 10.3 
Hz, J = 14.7 Hz, 1H, NCCHAHB), 3.03 (dd, J = 4.3 Hz, J = 14.7 Hz, 1H, 
NCCHAHB), 3.09-3.17 (m, 2H, CH2Ph), 3.77 (d, J = 11.5 Hz, 3H, OCH3), 
3.78 (d, J = 11.5 Hz, 3H, OCH3), 4.62 (1H, s, C=CHAHB), 4.64 (dt, J = 
8.0 Hz, J = 13.8 Hz, 1H, NCHAHB), 4.74 (dt, J = 7.9 Hz, J = 13.8 Hz, 1H, NCHAHB), 4.76 (1H, s, 
C=CHAHB), 6.99-7.28 (m, 6H, 6 x CHarom), 7.53 (d, J = 8.5 Hz, 1H, PCCCH), 7.82 (d, J = 8.5 Hz, 
1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 24.97 (CH2), 27.90 (NCCH2), 28.47 (CH2), 33.39 
(CH2), 35.75 (CH2), 38.23 (NCH2CH2), 43.49 (CH), 48.53 (NCH2), 52.68 (d, J = 3.5 Hz, 2 x OCH3), 
102.27 (d, J = 235.4 Hz, PC), 105.92 (C=CH2), 119.45 (CHarom), 120.22 (CHarom), 120.78 
(CHarom), 123.93 (d, J = 12.7 Hz, PCCC), 124.93 (CHarom), 128.89 (2 x CHarom), 130.44 (2 x 
CHarom), 132.02 (d, J = 9.2 Hz, NC), 132.45 (d, J = 17.3 Hz, PCC), 132.78 (ClCq,arom), 136.57 
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(Cq,arom), 152.22 (C=CH2). 31P-NMR (121 MHz, CDCl3): δ 15.25. IR (cm-1) νmax: 1024 (P-O), 
1049 (P-O), 1245 (P=O), 1644 (C=C). MS (ESI): m/z (%): 472.2/474.2 (M+H+, 100). 
Chromatography: Hex/EtOAc 1/1 Rf = 0.26. Yield: 40%. 
 
Dimethyl 2-butyl-3-(3-methyl-2-phenylbut-3-enyl)-2H-isoindol-1-ylphosphonate (435h) 
1H-NMR (300 MHz, CDCl3): δ 0.89 (t, J = 7.6 Hz, 3H, CH3), 1.29 (sextet, J 
= 7.6 Hz, 2H, CH2CH3), 1.59 (p, J = 7.6 Hz, 2H, NCH2CH2), 1.66 (s, 3H, CH3), 
3.22 (dd, J = 9.5 Hz, J = 13.3 Hz, 1H, CHAHBCH), 3.54-3.77 (m, 3H, CHAHBCH 
+ NCHAHB), 3.64 (d, J = 11.5 Hz, 3H, OCH3), 3.65 (d, J = 11.6 Hz, 3H, OCH3), 
4.10 (dt, J = 7.6 Hz, J = 14.0 Hz, 1H, NCHAHB), 5.08 (s, 1H, HC=CHAHB), 5.11 
(s, 1H, HC=CHAHB), 6.85-7.20 (m, 7H, 7 x CHarom), 7.42 (d, J = 8.3 Hz, 1H, PCCCH), 7.86 (d, J = 
8.5 Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 13.77 (CH2CH3), 20.17 (CH2CH3), 22.79 
(CCH3), 30.83 (CH2CH), 34.12 (NCH2CH2), 46.13 (NCH2), 52.36 (d, J = 3.5 Hz, 2 x OCH3), 52.87 
(CHPh), 101.90 (d, J = 234.2 Hz, PC), 111.05 (C=CH2), 119.54 (CHarom), 119.82 (CHarom), 120.58 
(CHarom), 123.63 (d, J = 12.7 Hz, PCCC), 124.46 (CHarom), 127.01 (CHarom), 127.82 (2 x CHarom), 
128.44 (2 x CHarom), 130.75 (d, J = 9.2 Hz, NC), 132.77 (d, J = 17.3 Hz, PCC), 141.86 (Cq, Ph), 
147.09 (C=CH2). 31P-NMR (121 MHz, CDCl3): δ 15.24. IR (cm-1) νmax: 1022 (P-O), 1048 (P-
O), 1251 (P=O), 1701 (C=C). MS (ESI): m/z (%): 426.5 (M+H+, 100). Chromatography: 
Hex/EtOAc 1/1 Rf = 0.20. Yield: 40%. 
 
Dimethyl 2-allyl-3-but-3-enyl-2H-isoindol-1-ylphosphonate (435i) 
1H-NMR (300 MHz, CDCl3): δ 2.43 (ps q, J = 7.4 Hz, 2H, CH2CH2CH), 3.07 
(t, J = 7.4 Hz, 2H, CH2CH2), 3.71 (d, J = 11.6 Hz, 6H, 2 x OCH3), 4.74 (br d, J 
= 17.1 Hz, J = 1.5 Hz, 1H, NCH2HC=CHAHB), 5.03 (br d, J = 10.3 Hz, 1H, 
HC=CHAHB), 5.09 (br d, J = 17.1 Hz, 1H, HC=CHAHB), 5.16 (dq, J = 10.5 Hz, J 
= 1.5 Hz, 1H, NCH2HC=CHAHB), 5.23 (dt, J = 1.5 Hz, J = 4.8 Hz, 2H, NCH2), 5.86 (ddt, J = 7.4 
Hz, J = 10.3 Hz, J = 17.1 Hz, 1H, HC=CH2), 6.03 (ddt, J = 4.8 Hz, J = 10.5 Hz, J = 17.1 Hz, 1H, 
NCH2HC=CH2), 7.00-7.06 (m, 1H, CHarom), 7.15-7.20 (m, 1H, CHarom), 7.15-7.20 (m, 1H, CHarom), 
7.58-7.62 (m, 1H, CHarom), 7.87 (d, J = 8.5 Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 
24.68 (NCCH2), 34.06 (CH2CH2CH), 48.96 (NCH2), 52.62 (d, J = 4.6 Hz, 2 x OCH3), 102.77 (d, J 
= 234.2 Hz, PC), 116.00 (HC=CH2), 116.14 (NCH2CH=CH2), 119.79 (CHarom), 119.83 (CHarom), 
120.84 (CHarom), 123.25 (d, J = 12.7 Hz, PCCC), 124.80 (CHarom), 132.44 (d, J = 9.2 Hz, NC), 
132.57 (d, J = 18.5 Hz, PCC), 134.31 (NCH2HC=CH2), 137.12 (HC=CH2). 31P-NMR (121 MHz, 
CDCl3): δ 14.97. IR (cm-1) νmax: 1022 (P-O), 1050 (P-O), 1241 (P=O), 1641 (C=C). MS (ESI): 
m/z (%): 320.2 (M+H+, 100). Chromatography: Hex/EtOAc 55/45 Rf = 0.25. Yield: 98%. 
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Dimethyl 2-phenyl-2-vinyl-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6-ylphosphonate 
(471a) 
1H-NMR (300 MHz, CDCl3): δ 2.41 (ddd, J = 5.6 Hz, J = 7.1 Hz, J = 13.3 
Hz, 1H, NCH2CHAHB), 2.57 (ddd, J = 5.3 Hz, J = 7.7 Hz, J = 13.3 Hz, 1H, 
NCH2CHAHB), 3.49 (s, 2H, NCCH2), 3.64 (d, J = 11.5 Hz, 3H, OCH3), 3.66 (d, J 
= 11.6 Hz, 3H, OCH3), 4.30 (ddd, J = 5.3 Hz, J = 7.1 Hz, J = 14.1 Hz, 1H, 
NCHAHB), 4.50 (ddd, J = 5.6 Hz, J = 7.7 Hz, J = 14.1 Hz, 1H, NCHAHB), 5.01 
(d, J = 17.4 Hz, 1H, HC=CHAHB), 5.17 (d, J = 10.7 Hz, 1H, HC=CHAHB), 6.03 (dd, J = 10.7 Hz, J 
= 17.4 Hz, 1H, HC=CH2), 7.03-7.36 (m, 7H, 7 x CHarom), 7.61-7.65 (m, 1H, CHarom), 7.89 (d, J = 
8.4 Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 32.70 (NCCH2), 32.81 (NCH2CH2), 42.24 
(Cq), 43.66 (NCH2), 52.39 (d, J = 3.5 Hz, OCH3), 52.44 (d, J = 4.6 Hz, OCH3), 101.65 (d, J = 
235.4 Hz, PC), 114.32 (HC=CH2), 119.12 (CHarom), 119.51 (CHarom), 120.49 (CHarom), 121.74 (d, J 
= 13.9 Hz, PCCC), 126.47 (2 x CHarom), 129.96 (CHarom), 128.44 (d, J = 9.2 Hz, NC), 128.73 (2 x 
CHarom), 133.28 (d, J = 18.5 Hz, PCC), 143.47 (HC=CH2), 144.08 (Cq, Ph). 31P-NMR (121 MHz, 
CDCl3): δ 15.29. IR (cm-1) νmax: 1021 (P-O), 1047 (P-O), 1243 (P=O), 1623 (C=C). MS (ESI): 
m/z (%): 382.3 (M+H+, 100). Chromatography: Hex/EtOAc 1/1 Rf = 0.14. Yield: 68%. 
 
Dimethyl 2-(4-fluorophenyl)-2-vinyl-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6-
ylphosphonate (471b) 
1H-NMR (300 MHz, CDCl3): δ 2.38 (dt, J = 6.3 Hz, J = 13.8 Hz, 1H, 
NCH2CHAHB), 2.52 (dt, J = 6.3 Hz, J = 13.8 Hz, 1H, NCH2CHAHB), 3.45 (s, 2H, 
NCCH2), 3.65 (d, J = 11.5 Hz, 3H, OCH3), 3.67 (d, J = 11.5 Hz, 3H, OCH3), 
4.27 (dt, J = 6.3 Hz, J = 14.7 Hz, 1H, NCHAHB), 4.51 (dt, J = 6.3 Hz, J = 14.7 
Hz, 1H, NCHAHB), 4.99 (d, J = 17.6 Hz, 1H, HC=CHAHB), 5.17 (d, J = 10.7 Hz, 
1H, HC=CHAHB), 5.99 (dd, J = 10.7 Hz, J = 17.6 Hz, 1H, HC=CH2), 6.93-7.26 
(m, 6H, 6 x CHarom), 7.62 (dt, J = 0.9 Hz, J = 8.5 Hz, 1H, CHarom), 7.89 (dt, J = 0.9 Hz, J = 8.5 
Hz, 1H, PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 32.85 (NCCH2), 32.94 (NCH2CH2), 41.87 (Cq), 
43.60 (NCH2), 52.39 (d, J = 4.6 Hz, OCH3), 52.42 (d, J = 4.6 Hz, OCH3), 101.84 (d, J = 236.5 Hz, 
PC), 114.46 (HC=CH2), 115.47 (d, J = 21.9 Hz, 2 x CHarom), 119.05 (CHarom), 119.51 (CHarom), 
120.58 (CHarom), 121.73 (d, J = 12.7 Hz, PCCC), 125.13 (CHarom), 128.09 (d, J = 11.5 Hz, NC), 
128.22 (d, J = 8.1 Hz, 2 x CHarom), 133.24 (d, J = 18.5 Hz, PCC), 139.77 (d, J = 3.5 Hz, Cq,arom), 
143.38 (HC=CH2), 161.64 (d, J = 246.9 Hz, FCq,arom). 31P-NMR (121 MHz, CDCl3): δ 15.17. 
19F-NMR (282 MHz, CDCl3): δ -115.68 - -155.78 (m). IR (cm-1) νmax: 1024 (P-O), 1048 (P-
O), 1238 (P=O), 1602 (C=C), 1623 (C=C), 1636 (C=C), 1702 (C=C). MS (ESI): m/z (%): 
400.2 (M+H+, 100). Chromatography: Hex/EtOAc 4/6 Rf = 0.17. Yield: 82%. 
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4.11.4 Synthesis of dimethyl 2-(4-chlorobutyl)-3-methyl-2H-isoindol-1-ylphosphonate 
(466) 
In a dry flask, 2-ethynylbenzaldehyde (0.5 g, 3.84 mmol) is dissolved into diethylether (6 ml). To 
this solution is added LiClO4 (3.06 g, 28.8 mmol, dried for 24h at 110 °C). This mixture is stirred 
for 5 minutes. Subsequently pyrrolidine is added (0.55 g, 7.69 mmol) dissolved in 1 ml dry 
diethylether. This mixture is stirred for 20 minutes after which P(OMe)3 is added (0.71 g, 5.76 
mmol). The reaction is stirred for 4 hours after which HCl (3N, 20 ml) is very carefully added. The 
mixture is extracted with CH2Cl2 (3 x 20 ml) and dried using MgSO4. After filtration of the solids 
and removal of the volatiles, the obtained compound was purified using column chromatography. 
 
1H-NMR (300 MHz, CDCl3): δ 1.88-2.02 (m, 4H, NCH2CH2CH2), 2.61 (s, 
3H, CH3), 3.59 (t, J = 6.2 Hz, 2H, CH2Cl), 3.73 (d, J = 11.3 Hz, 6H, 2 x 
OCH3), 4.55 (t, J = 7.6 Hz, 2H, NCH2), 7.02 (t, J = 8.0 Hz, 1H, CHarom), 7.17 
(t, J = 8.0 Hz, 1H, CHarom), 7.56 (d, J = 8.0 Hz, 1H, PCCCH), 7.80 (d, J = 8.0 Hz, 1H, PCCCCH). 
13C-NMR (75 MHz, CDCl3): δ 10.41 (CH3), 28.96 (CH2), 29.75 (CH2), 44.53 (ClCH2), 46.21 
(NCH2), 52.61 (d, J = 4.6 Hz, 2 x OCH3), 102.16 (d, J = 235.4 Hz, PC), 119.47 (CHarom), 119.67 
(CHarom), 120.67 (CHarom), 123.51 (d, J = 12.7 Hz, PCCC), 124.89 (CHarom), 128.44 (d, J = 10.4 
Hz, NC), 132.35 (d, J = 17.3 Hz, PCC). 31P-NMR (121 MHz, CDCl3): δ 15.16. IR (cm-1) νmax: 
1024 (P-O), 1048 (P-O), 1245 (P=O), 1710 (C=C). MS (ESI): m/z (%): 330.2/332.3 (M+H+, 
100). Chromatography: EtOAc Rf = 0.59. Yield: 8%. 
4.11.5 Synthesis of dimethyl 10,11-dihydro-7H-azepino[2,1-a]isoindol-5-ylphosphonate 
(472) 
Compound 435i (0.2 g, 0.63 mmol) was dissolved in benzene (20 ml) and the second generation 
Grubbs’ catalyst (5 mol%, 0.011 g, 0.013 mmol) was added. The reaction was allowed to reflux 
for 16h under a N2-atmosphere. The product was coated on silica gel by removal of the solvent in 
vacuo and purified by column chromatography. 
 
1H-NMR (300 MHz, CDCl3): δ 2.42-2.48 (m, 2H, CH2CH2CH), 3.38 (t, J = 
6.0 Hz, 2H, CH2CH2CH), 3.72 (d, J = 11.5 Hz, 6H, 2 x OCH3), 5.24-5.28 (m, 
2H, NCH2), 5.75-5.94 (m, 2H, HC=CH), 7.03 (ddd, J = 1.0 Hz, J = 6.6 Hz, J = 
8.4 Hz, 1H, CHarom), 7.16 (ddd, J = 1.0 Hz, J = 6.6 Hz, J = 8.7 Hz, 1H, CHarom), 
7.58 (ddt, J = 1.0 Hz, J = 2.2 Hz, J = 8.4 Hz, 1H, PCCCH), 7.90 (dt, J = 1.0 Hz, J = 8.7 Hz, 1H, 
PCCCCH). 13C-NMR (75 MHz, CDCl3): δ 21.86 (NCCH2), 28.13 (CH2CH2CH), 43.98 (NCH2), 
52.59 (d, J = 4.6 Hz, 2 x OCH3), 102.46 (d, J = 234.2 Hz, PC), 119.08 (CHarom), 119.75 (CHarom), 
120.72 (CHarom), 122.26 (d, J = 12.7 Hz, PCCC), 122.62 (HC=CH), 124.44 (CHarom), 132.09 (d, J 
= 17.3 Hz, PCC), 133.15 (NCH2CH), 133.87 (d, J = 9.2 Hz, NC). 31P-NMR (121 MHz, CDCl3): δ 
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15.26. IR (cm-1) νmax: 1025 (P-O), 1047 (P-O), 1224 (P=O), 1694 (C=C). MS (ESI): m/z 
(%): 292.3 (M+H+, 100). Chromatography: Hex/EtOAc 4/6 Rf = 0.20. Yield: 95%. 
 
 
Summary and Perspectives 
-158- 
5 Summary and Perspectives 
Almost 80% of all processes in the modern chemical industry use catalysts. This can be 
attributed to a continuing quest of researchers to achieve a specific chemical transformation in 
the most efficient way in order to limit the amount of waste and used energy. Catalysts are found 
in many different forms. Roughly, catalysis can be divided into three classes: homogeneous 
catalysis, heterogeneous catalysis and biocatalysis. The best known biocatalysts are called 
enzymes which are responsible for many fundamentally important reactions in living organisms. 
In heterogeneous catalysis the catalyst and the involved reaction components are present in a 
different phase (e.g. solid catalyst in liquid). In homogeneous catalysis both the catalyst and 
reaction components are distributed to the molecular level in a single phase. 
 
In this work homogeneous catalysis was used to target compounds that are very difficult to 
synthesize in a non-catalytic way and that are biologically important or closely related to a 
biologically important group of compounds. Attention was focussed on three major groups: 
pyrroles, hydantoins and benzo-fused heterocycles. Furthermore, successful efforts were made to 
achieve multiple transformations (both catalytic and non-catalytic) in a single synthetic operation 
thus decreasing the amount of steps needed to obtain a certain compound. 
 
The key reaction in this thesis is ring-closing metathesis, a process in which two carbon-carbon 
double bonds are broken and one new carbon-carbon double bond is formed, catalyzed by 
certain ruthenium complexes. In 2005, three researchers, namely Yves Chauvin, Robert H. 
Grubbs and Richard R. Schrock, received the Nobel Prize in Chemistry for the development of the 
metathesis method in organic synthesis. Although the discovery of catalyzed metathesis dates 
from the 1950s in industry, it was only in 1992 that Grubbs and co-workers reported the first well 
defined ruthenium carbene complex that did not only show good metathesis activity, but was 
also air-stable and could be used under standard lab conditions. Three years later, an even more 
active catalyst i, which would later be called the “first-generation Grubbs’ catalyst”, was 
described. The “second-generation Grubbs’ catalyst” ii with increased activity and greater 
thermal stability, was presented in 1999. 
 
N N
RuCl
Cl
PCy3
PCy3
RuCl
Cl
PCy3
Ph
Mes
Ph
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i ii  
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The starting point of this research was the special activity of a new ruthenium based bimetallic 
catalyst. Earlier work had suggested that this catalyst converts diallylamines iii directly to the 
corresponding pyrroles iv instead of to the expected pyrrolines v. It was proven, however, that 
this hypothesis was not correct and that rather RuCl3 x H2O, present as impurity in the catalyst, 
facilitates the conversion of pyrrolines to pyrroles. Thus, in a first part of this PhD a new entry to 
this interesting azaheterocyclic compound was developed comprising the ring-closing of 
diallylamines iii using the commercially available second generation Grubbs’ catalyst ii in 
combination with catalytic oxidative aromatization using RuCl3 x H2O. Although this reaction 
works fine, it usually takes more than 12 hours to obtain satisfactory conversion to the pyrroles 
at 60 °C under ultrasound conditions. Especially the oxidative dehydrogenation step proved to 
proceed very slowly. The reaction time could be dramatically reduced by adding a strong 
hydrogen acceptor, namely tetrachloroquinone vi which is reduced to vii, to the reaction 
mixture. The correct choice of the oxidizing agent, however, is crucial since duroquinone didn’t 
influence the oxidation rate and DDQ caused decomposition of the metathesis catalyst. This 
illustrates the delicate balance of this one-pot reaction sequence. It was also found that in this 
case RuCl3 x H2O is no longer required as a hydrogen transfer catalyst. The reaction time is 
reduced to about 2 hours in this fashion. In this case, obviously, a stoichiometric amount of 
oxidant is consumed. Substrates bearing a strong electron withdrawing group on the N-atom, 
however, could not be oxidized. This explains why no direct pyrrole formation was observed by 
researchers working with a tosyl-, Boc-, or SES-protecting group on nitrogen. 
N
R1
N
R1
R2 R2
iv
7 examples
30-74%
iii
N
R1
R2
5% cat. ii
ClCH2CH2Cl
70°C, 2h
N
R1
R2
OH
OH
Cl
Cl Cl
Cl
O
O
Cl
Cl Cl
Cl
v iv
6 examples
90-100% conversion
5% cat. ii, 1% RuCl3 x H2O
ClCH2CH2Cl, 60°C, 12h
vi
vii  
 
Phosphonylated azaheterocycles are an important class of compounds with high biological 
potential as conformationally restricted bioisosteres of amino acids. Some interesting activities 
are shown by azaheterocyclic five-membered rings with phosphonates at various positions. The 
synthesis of the aromatic counterparts of phosphonylated five-membered rings, however, has 
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received far less attention over the years. Application of the developed RCM/oxidation 
methodology on α-aminophosphonates x containing two double bonds allowed the 
straightforward synthesis of phosphonylated pyrrolines and pyrroles. In a first step, imines viii 
were phosphonylated with complete 1,2-regioselectivity by treatment with dialkyl phosphites in 
refluxing methanol. The N-atom of the obtained α-aminophosphonates ix was protected with a 
benzyl group by refluxing in acetone with K2CO3 as a base, benzylbromide as electrophile and NaI 
as catalyst. These compounds x could easily be converted, under very mild conditions, to the 
corresponding pyrrolines xi or pyrroles xii, depending on the addition of TCQ to the reaction 
mixture. When the RCM was attempted on secondary amines ix, the reaction stops at about 30% 
conversion. This proves that especially pyrrolines tend to poison the catalyst. In the pyrrole ring, 
the nitrogen lone pair is no longer nucleophilic since it is part of the aromatic system. When TCQ 
is added to the secondary amines ix together with the metathesis catalyst ii, the ‘poisonous’ 
pyrrolines are immediately oxidized to the ‘benign’ pyrroles. In this fashion, 100% conversion 
could be obtained. Unfortunately, an immense drop in yield is observed during purification by 
column chromatography. 
R1 H
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R3 R1 P(OMe)2
R2
HN
O
R3
viii
R1 P(OMe)2
R2
N
O
R3Ph
2 equiv HP(O)(OMe)2
MeOH, Δ, 2-4h
ix
7 examples
27-95%
x
7 examples
35-92%
1.5 equiv BnBr
0.5 equiv NaI
4 equiv K2CO3
acetone, Δ, 24h
N P(OMe)2
R2
Ph
R3
O
N P(OMe)2
R2
R
R3
O
5% cat. ii
CH2Cl2, RT, 3-5h
xi
6 examples
70-84%
xii
7 examples
27-70%
5% cat. ii
1 equiv TCQ
CH2Cl2, RT, 5-7h
5% cat. ii
1 equiv TCQ
CH2Cl2, RT, 5-7h
 
 
In a control experiment, it was demonstrated that oxidation of the isolated pyrrolines with TCQ in 
the absence of the second generation catalyst ii proceeds significantly slower than in the domino 
reaction. Probably, both hydrogen donor and acceptor are brought together by simultaneous 
coordination to the metal centre, followed by direct hydrogen transfer from the pyrroline to the 
TCQ. It seems that the phosphonate group is just electron withdrawing enough to lower the 
nucleophilicity of the N-atom to allow the RCM to occur at room temperature while still allowing 
oxidation of the pyrrolines to the corresponding pyrroles. 
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The substrates ix and x bear one terminal and one non-terminal alkene. Initiation of the 
metathesis occurs, for steric reasons, on the terminal double bond. The cyclobutane xiii 
fragments with formation of a new carbene xiv and styrene xv. The new carbene cyclizes to xvi 
which forms the pyrroline and regenerates the active species of catalyst ii upon cycloreversion. 
No ethylene is formed in this cycle which is unconventional since the formation of ethylene is 
considered to be crucial to shift the equilibrium to the end product. The styrene xv builds up in 
the reaction mixture, however, and starts to compete with the substrate for reaction with the 
catalyst. Thus, in a second catalytic cycle, styrene is dimerized to stilbene xviii, which 
precipitates from the mixture, and methylidene carbene xix is generated. This carbene can react 
either with styrene to xx or with substrate to xxi. Both cyclobutanes generate ethylene upon 
cycloreversion. Thus, in contrast to the normal metathesis cycle, in this case ethylene is 
generated in two secondary catalytic pathways. 
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Enyne metathesis, involving reaction between an alkene and an alkyne, has received far less 
attention than RCM. Sequential reactions, for example, have hardly been developed for enyne 
metathesis. So far, only a one-pot combination of enyne metathesis with a Diels-Alder reaction or 
a cyclopropanation has been reported. Unlike olefin metathesis, all carbon atoms from the 
starting material are retained in the end product which contains a synthetically useful 1,3-diene 
moiety. Despite its usefulness, however, little is known about the mechanism of the reaction. 
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More precisely, the question whether the reaction proceeds via the “yne-then-ene” or the “ene-
then-yne” mechanism is still often raised. 
The first combination of ring-closing enyne metathesis with oxidation was developed by 
treatment of α-aminophosphonates xxiv containing a double and a triple bond with the second 
generation Grubbs’ catalyst ii in refluxing benzene in the presence of TCQ. The substrates for 
this reaction were made in two straightforward steps starting from imines xxii. In a first step 
these imines were phosphonylated with complete 1,2-regioselectivity by treatment with dialkyl 
phosphites in refluxing methanol. The N-atom of the obtained α-aminophosphonates xxiii was 
protected with a benzyl group by refluxing in acetone with K2CO3 as a base, benzylbromide as 
electrophile and NaI as catalyst. 
 
R1 H
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R1 P(OMe)2
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O
xxii
R1 P(OMe)2
R2
N
O
2 equiv HP(O)(OMe)2
MeOH, Δ, 2-3h
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6 examples
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xxiv
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48-85%
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C6H6, Δ, 1h
5% cat. ii
1 equiv TCQ
C6H6, Δ, 1h
R1R1
xxv
5 examples
68-88%
xxvi
4 examples
48-85%  
 
This RCEYM/oxidation sequence on substrates xxiv allows the synthesis of highly functionalized 
2-phosphonylated pyrrolines xxv and pyrroles xxvi. A detailed mechanistic investigation revealed 
that the reaction follows the “yne-then-ene” pathway. The proof of this reaction mechanism is 
based on the formation of certain end and sideproducts, spectroscopic data and finally on the 
difference in reactivity of different substrates. During the initiation phase, the Grubbs’ carbene is 
converted to a new ruthenium-carbene which continues the propagation cycle. 
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In the second part of this thesis entries towards new polycyclic hydantoin derivatives were 
developed starting from pyroglutamates. Hydantoins have been extensively studied and are 
reported to possess a wide range of biological activities. Furthermore, several hydantoin 
derivatives with an extra fused ring show some interesting medicinal properties. 
When a mixture of a pyroglutamate xxvii and an isocyanate xxviii is treated with NaH in diethyl 
ether, a precipitate is formed during the reaction, which after workup proved to be the sodium 
salt of the expected carbamoyllactam xxix in high purity. If the reaction is performed in THF on 
the other hand, no precipitate is formed since intermediate xxix reacts intramolecularly by a 
nucleophilic attack on the carbonyl of the ester function followed by expulsion of an alkoxide 
anion, resulting in the formation of bicyclic intermediate xxx. The alkoxide anion in turn can 
open this bicyclic intermediate with formation of anions xxxi and xxxii. These anions are in 
equilibrium with each other, causing racemization of the chiral centre. Work up results in 
hydantoin derivatives xxxiii as a 1:1 mixture of their enantiomers. 
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O
X
R2
R1OOC
xxxiii
8 examples
42-89%
xxviii
1.1 equiv NaH
THF, RT, 16h
 
 
This ring-transformation was successfully used in a short 4-step approach for the synthesis of 
hydantoin derivatives xxxviii that are annelated to a six-membered ring. In a first step, 
pyroglutamates xxvii are alkylated at the 2-position using LiHMDS and a proper electrophile. It 
was found that excellent results can be obtained when a mixture of the pyroglutamate and the 
electrophile is treated with 2.1 equivalents of LiHMDS at –40 °C. Even when using several 
equivalents of electrophile, no N-alkylation was observed. Treatment of a solution of xxxiv and 
an isocyanate in THF with NaH results in the formation of carbamoylated lactam xxxv which 
rearranges with formation of the hydantoin nucleus xxxvi. These compounds are cleanly 
alkylated at N(1) towards xxxvii in good yield by refluxing them with 2 equivalents of 
electrophile and 5 equivalents of finely ground K2CO3 in acetone for several days. Treatment of 
these compounds with 5% second generation catalyst ii in refluxing CH2Cl2 resulted in clean 
conversion to the desired compounds xxxviii. 
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5 examples
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8 examples
45-99%
NN
O
O
R3
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xxxviii
8 examples
55-93%
R2
R4
xxxv
2.1 equiv LiHMDS
4 equiv electrophile
THF, -40°C, 30min
then 2h, RT
1.1 equiv R3NCO
1.1 equiv NaH
THF, RT, 16h
3 equiv electrophile
5 equiv K2CO3
acetone, Δ
5% cat. ii
CH2Cl2, Δ, 4h
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Also a new entry towards N(3),N'(3)-polymethylene-bis-hydantoins was developed. Bis-
hydantoins, usually dimers of phenetoin or related compounds, have in the past been tested as 
analogues of HMBA and might prove effective in cancer treatment. In this work, bis-hydantoins 
xli were obtained by reaction of pyroglutamate xxvii with bis-isocyanates xxxix and subsequent 
ring-transformation of bis-carbamoylated lactams xl using KOtBu in ethanol. 
 
N Nn
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N NnN N
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R R
xlii
7 examples
84-99%
xliii
4 examples
41-58%
0.5 equiv xxxix
1.2 equiv NaH
ether, RT, 1h
4 equiv electrophile
5 equiv K2CO3
acetone, Δ
5% cat. ii
CH2Cl2, Δ, 16h
 
These compounds xli are cleanly alkylated at N(1) towards xlii in good yield by refluxing with 4 
equivalents of electrophile and 5 equivalents of finely ground K2CO3 in acetone. The compounds 
with allyl groups at N(1) could be converted to their macrocyclic derivatives xliii using the 
second generation Grubbs’ catalyst ii in refluxing CH2Cl2. It was proven that only the trans-
isomers are isolated. The presence of only one isomer around the double bound can be explained 
by secondary metathesis reactions since it is known that macrocycles isomerise to produce a 
thermodynamically controlled (E/Z) ratio regardless the stereochemistry of the initial alkene. 
A number of the synthesized hydantoins were screened for their anti-invasive activity on human 
breast cancer cell lines. The screening assay chosen is based on the in vitro confrontation of 
cancer cells with a fragment of normal heart tissue dissected from 9-days old chicken embryos. It 
can be stated that some of the synthesized bis-hydantoins show some good anti-invasive activity 
at a concentration of 100 μm and 10 μm. Furthermore, these compounds can be very easily 
prepared on a large scale and are non-toxic to the heart tissue used in the in vitro tests. 
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Unfortunately, the activity of these compounds cannot be accurately predicted using a nonlinear 
QSAR model. Further research is therefore needed to shed light on the mode of action of these 
structures in order to allow the synthesis of more active compounds. In a further stage, in vivo 
tests will have to be performed to validate these results. 
 
In the third part of this thesis, entries towards new benzo-fused compounds, namely 1H-2-
benzazepine-1-ylphosphonates and phosphonylated isoindoles, were developed. Benzo-fused 
compounds, and especially seven-membered ring systems with famous examples like diazepam 
(Valium®) and flurazepam (Dalmadorm®), have received a lot of attention over the years 
because of their ubiquitous appearance in natural products and modern pharmaceuticals. 
The first protocol for the synthesis of 1H-2-benzazepine-1-ylphosphonates xliv uses a 
combination of enyne-metathesis with cross-metathesis. A refluxing mixture of compound xlv 
and 5 equivalents of an alkene in CH2Cl2 was treated with 10 mol% of the second generation 
Grubbs’ catalyst ii. An additional amount of alkene (5 equiv) has to be added after 2 hours. This 
observation was explained by looking at the complete reaction cycle. During the course of the 
reaction, the alkene is not only incorporated in the end product but also dimerized in the “alkene 
sink” with regeneration of the methylidene carbene and production of ethylene. Upon evaluation 
of the reaction between xlvi and alkenes, it was found that in this case it is not necessary to add 
an extra amount of alkene. The advantage of this strategy is that it required the synthesis of only 
two substrates, with a terminal double and triple bond, that depending on the addition of a 
certain alkene to the reaction mixture are transformed into different seven-membered rings. 
 
P(O)(OMe)2
N
PG N
PG(MeO)2(O)P
P(O)(OMe)2
N
PG
R2R
1
xliv
6 examples
50-78%
xlvi xlv
5 equiv 
10% cat. ii
CH2Cl2, Δ, 4h
R2 5 equiv 
10% cat. ii
CH2Cl2, Δ, 1h
5 equiv
Δ, 4h
R1
R1
 
 
The treatment of very similar substrates xlvii containing a non-terminal double bond with a 
metathesis catalyst did not lead to the expected seven-membered rings but produced 
phosphonylated isoindoles instead. Phosphonylated isoindoles and related compounds are rarely 
described in the literature. In fact, only one low yielding entry to phosphonylated isoindoles could 
be found. Furthermore, few entries towards related compounds like phosphonylated dihydro 
isoindoles and isoindolinones have been reported in the literature. The latter are known for their 
plant growth regulating properties. 
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It was found that this rearrangement is thermally driven. After a number of experiments the yield 
and conversion rate could be optimized by heating the substrates in a mixture of benzene/CH3CN 
in a 1/1 ratio at 165 °C under microwave conditions. The first step in this transformation 
probably involves a direct addition of the nitrogen lone pair onto the triple bond in a 5-exo-dig 
fashion to xlviii. The zwitterionic intermediate xlviii subsequently fragments with formation of 
anion xlix and cations la and lb. Anion xlix reacts with lb with formation of li. The overall result 
of the fragmentation and recombination corresponds to a [1,3]-alkyl shift. The rearrangement 
ends with a [1,5]-H shift resulting in aromatization towards lii. This pathway represents the first 
ever high yielding entry to phosphonylated isoindoles. 
 
N
P(O)(OMe)2
Bn
N
P(O)(OMe)2
Bn
Ph
5-exo-dig
N
P(O)(OMe)2
Bn
N
P(O)(OMe)2
Bn
Ph
N
P(O)(OMe)2
Bn
Ph
H
[1,3]-alkyl shift
[1,5]-H shift
Ph
Ph
Ph
la lb
xlix
liliia
xlviiixlviia
 
 
The general nature of this rearrangement was proven by preparing a number of α-
aminophosphonates xlvii and subjecting them to the same conditions. These α-
aminophosphonates were prepared using a three component coupling between 
ethynylbenzaldehyde, secondary amines and trimethyl phosphite mediated by LiClO4. The 
isoindoles lii were isolated in good yield. 
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MW (165 °C)
lii
9 examples
40-98%
xlvii
9 examples
48-88%  
 
When the allylic group that migrates is incorporated in an extra ring, the anion and cation will 
remain attached to each other during the reaction. As expected, heating liii under microwave 
conditions resulted in the formation of tricyclic compounds lvii. The fragmentation of the 
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zwitterionic intermediate liv results in the formation of lva and resonance form lvb. An 
intramolecular attack forms an additional six-membered ring lvi. Finally, aromatization produces 
isoindoles lvii. 
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From the results in this research, some perspectives to future work have to be formulated. 
Firstly, a new entry towards pyrroles using a combination of RCM or RCEYM with oxidation has 
been developed. This will allow researchers to efficiently construct this interesting azaheterocyclic 
compound and its phosphonylated derivatives. In order to evaluate the biological potential of 
these compounds, deprotection of the phosphonates might be necessary. New catalytic systems, 
for example on a solid support, may allow the synthesis of these compounds on a larger scale. 
Possibly, this methodology can also be extended for the synthesis of other heterocycles. It is 
unlikely, however, that for example furans or thiophenes can be made in a one-pot sequence 
since most probably the metathesis catalyst will be destroyed by the use of stronger oxidants. In 
the future, development of other metathesis catalysts could allow the synthesis of more 
substituted derivatives and allow the use of other oxidants. The mechanistic insights in RCEYM 
will help researchers to explain the formation of certain end and byproducts in the reaction 
mixture. 
The new entry to hydantoin derivatives might prove very powerful when combined with 
enantioselective reactions on the pyroglutamate. Future biological screening of compounds 
obtained in this thesis might reveal their working mechanisms and can possibly direct the 
synthesis to more active structures. The hydrolysis of the ester moiety in the screened 
compounds will produce more polar compounds with even better water solubility and possibly 
increased activity. 
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The combination of enyne-metathesis with cross-metathesis for the synthesis of 1H-2-
benzazepine-1-ylphosphonates allows the synthesis of a variety of benzo-fused azepines 
depending on the addition of a certain alkene. The obtained diene could be further functionalized 
by a Diels-Alder reaction with a variety of dienophiles, leading to more complex structures in one 
synthetic effort. 
The rearrangement towards phosphonylated isoindoles is a very promising reaction since it could 
possibly be applied to the synthesis of other heterocycles. Thus, instead of starting from 2-
ethynylbenzaldehyde one could envisage routes starting from 3-ethynyl-furan-2-carbaldehyde or 
3-ethynyl-pyridine-2-carbaldehyde. Reactions with internal alkynes instead of terminal ones, 
might lead to isoquinoline derivatives after a rearrangement that starts with a 6-endo-dig attack 
instead of the 5-exo-dig attack described in this work. 
 
 
In conclusion, a large variety of azaheterocyclic compounds has been made accessible by ring-
closing metathesis reactions. These include five-, six- and seven-membered rings next to a 
number of macrocyclic derivatives. Furthermore, the combination of RCM with oxidative 
dehydrogenation provides a new straightforward entry to aromatic compounds. The results 
obtained in this thesis offer the possibility to other researchers to further develop this interesting 
chemistry. 
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6 Samenvatting en Perspectieven 
Bijna 80% van alle processen in de moderne chemische industrie maken gebruik van 
katalysatoren. Dit kan verklaard worden door de voortdurende zoektocht van onderzoekers om 
een specifieke chemische transformatie te verwezenlijken op de meest efficiënte manier teneinde 
zowel de hoeveelheid afval als de hoeveelheid gebruikte energie te beperken. Katalysatoren 
komen voor onder veel verschillende vormen. Ruwweg kan katalyse ingedeeld worden in drie 
klassen: homogene katalyse, heterogene katalyse en biokatalyse. De best gekende 
biokatalysatoren zijn enzymes die instaan voor een aantal fundamenteel belangrijke processen in 
levende organismen. Bij heterogene katalyse zijn de katalysator en de reactiecomponenten 
aanwezig in een verschillende fase (bijvoorbeeld een vaste katalysator in een vloeistof). Bij 
homogene katalyse zijn de katalysator en de reactiecomponenten in dezelfde fase tot op het 
moleculaire niveau verdeeld. 
 
In dit werk werd gebruikt gemaakt van homogene katalyse om verbindingen aan te maken die 
heel moeilijk te bereiden zijn op niet-katalytische wijze en die tevens een zeker biologisch belang 
hebben of nauw verwant zijn aan een biologisch belangrijke klasse van verbindingen. De 
aandacht werd gefocust op drie grote groepen: pyrrolen, hydantoines en benzo-gefuseerde 
heterocyclische verbindingen. Bovendien werden een aantal succesvolle pogingen ondernomen 
om meerdere transformaties (zowel katalytische als niet-katalytische) te verwezenlijken in één 
enkele synthetische handeling, waardoor dus het aantal stappen nodig om een bepaald product 
te bekomen, verminderd werd. 
 
De sleutelreactie in deze thesis is ringsluitings metathese, een proces waarbij twee koolstof-
koolstof dubbele bindingen gebroken worden en één nieuwe koolstof-koolstof dubbele binding 
gevormd wordt, gekatalyseerd door bepaalde ruthenium complexen. In 2005 ontvingen drie 
onderzoekers, namelijk Yves Chauvin, Robert H. Grubbs en Richard R. Schrock, de Nobelprijs 
Chemie voor de ontwikkeling van de metathese methodologie in de organische synthese. 
Alhoewel de ontdekking van gekatalyseerde metathese reeds dateert van de jaren 1950, werd er 
pas in 1992 een goed gedefinieerd ruthenium complex ontwikkeld door Grubbs en zijn 
medewerkers dat niet alleen hoge metathese activiteit vertoonde maar tevens luchtstabiel was en 
gebruikt kon worden onder standaard labo condities. Drie jaar later werd een nog actievere 
katalysator i beschreven die later de “eerste-generatie Grubbs katalysator” genoemd zou worden. 
De “tweede-generatie Grubbs katalysator” ii met verhoogde activiteit en grotere thermische 
stabiliteit werd voorgesteld in 1999. 
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Het oorspronkelijke uitgangspunt van dit onderzoek was de speciale activiteit van een nieuwe 
bimetallische ruthenium katalysator. Eerder onderzoek had immers gesuggereerd dat deze 
katalysator diallylamines iii rechtstreeks kon omzetten tot de overeenkomstige pyrrolen iv in 
plaats van tot de verwachte pyrrolines v. Het werd echter aangetoond dat deze hypothese niet 
correct was en dat eerder RuCl3 x H2O, aanwezig als onzuiverheid in de katalysator, de omzetting 
van pyrrolines naar pyrrolen veroorzaakt. In een eerste deel van dit doctoraat werd er dus een 
nieuwe toetreding tot deze interessante heterocyclische verbindingen ontwikkeld die bestaat uit 
de ringsluiting van diallylamines iii, door de commercieel beschikbare tweede generatie Grubbs 
katalysator ii, in combinatie met een katalytische oxidatieve aromatizatie door RuCl3 x H2O. 
Alhoewel deze reactie betrekkelijk goed werkt, duurt het doorgaans meer dan 12 uren om een 
aanvaardbare omzetting tot de pyrrolen te verkrijgen bij 60 °C onder ultrasone condities. Er werd 
opgemerkt dat vooral de oxidatieve dehydrogenatie zeer traag verloopt. De reactietijd kon enorm 
gereduceerd worden door een sterke waterstof acceptor, namelijk tetrachloorchinon vi dat 
gereduceerd wordt tot vii, toe te voegen aan het reactiemengsel. De correcte keuze van het 
oxidans is echter cruciaal aangezien durochinon de oxidatiesnelheid niet beïnvloedt en DDQ 
afbraak van de metathese katalysator veroorzaakt. 
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N
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ClCH2CH2Cl
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Cl Cl
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v iv
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5% kat. ii, 1% RuCl3 x H2O
ClCH2CH2Cl, 60°C, 12u
vi
vii
 
Dit illustreert de delicate balans van deze eenpotsreactie. Het werd tevens opgemerkt dat RuCl3 x 
H2O niet langer nodig was als waterstoftransfer katalysator. Op deze wijze werd de reactietijd 
teruggebracht tot ongeveer 2 uren. Natuurlijk wordt er in dit geval een stoichiometrische 
hoeveelheid oxidans verbruikt. Substraten met een sterke elektronenzuigende groep op het N-
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atoom konden echter niet geoxideerd worden. Dit verklaart waarom directe pyrrool vorming niet 
geobserveerd werd door onderzoekers die werkten met een tosyl-, Boc-, of SES-beschermende 
groep op stikstof. 
 
Gefosfonyleerde heterocyclische producten zijn een interessante klasse van verbindingen met 
groot biologisch potentieel als conformationeel beperkte bio-isosteren van aminozuren. Sommige 
azaheterocyclische vijfringen met een fosfonaatgroep op variabele positie vertonen interessante 
biologische activiteit. De synthese van de aromatische tegenhangers van gefosfonyleerde 
azaheterocyclische vijfringen heeft echter heel wat minder aandacht gekregen over de jaren. 
Toepassing van de ontwikkelde RCM/oxidatie methodologie op α-aminofosfonaten x, die twee 
dubbele bindingen bevatten, liet de synthese toe van gefosfonyleerde pyrrolines en pyrrolen. In 
een eerste stap werden imines viii gefosfonyleerd met complete 1,2-regioselectiviteit door 
behandeling met dialkyl fosfieten in kokende methanol. Het N-atoom van de verkregen α-
aminofosfonaten ix werd beschermd met een benzyl groep door te refluxen in aceton met K2CO3 
als base, benzylbromide als elektrofiel en NaI als katalysator. Deze verbindingen x konden 
eenvoudig en onder heel milde omstandigheden omgezet worden tot de overeenkomstige 
pyrrolines xi of pyrrolen xii, afhankelijk van de toevoeging van TCQ aan het reactiemengsel. 
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R3
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N
O
R3Ph
2 equiv HP(O)(OMe)2
MeOH, Δ, 2-4u
ix
7 voorbeelden
27-95%
x
7 voorbeelden
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0.5 equiv NaI
4 equiv K2CO3
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R
R3
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5% kat. ii
CH2Cl2, RT, 3-5u
xi
6 voorbeelden
70-84%
xii
7 voorbeelden
27-70%
5% kat. ii
1 equiv TCQ
CH2Cl2, RT, 5-7u
5% kat. ii
1 equiv TCQ
CH2Cl2, RT, 5-7u
 
 
Wanneer de RCM geëvalueerd werd op secundaire amines ix, werd opgemerkt dat de reactie 
stilvalt bij ongeveer 30% omzetting. Dit duidt op het feit dat vooral pyrrolines de katalysator 
vergiftigen. In de pyrroolring is het vrije elektronenpaar op stikstof immers niet meer nucleofiel 
aangezien het deel uitmaakt van het aromatisch systeem. Wanneer TCQ samen met de 
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secundaire amines ix wordt toegevoegd aan de metathese katalysator ii, worden de 
complexerende pyrrolines onmiddellijk geoxideerd tot de niet-complexerende pyrrolen. Op deze 
wijze kon 100% conversie bekomen worden. Jammer genoeg daalde het rendement enorm 
tijdens de opzuivering via kolom chromatografie. 
In een controle experiment werd aangetoond dat de oxidatie van de geïsoleerde pyrrolines met 
TCQ opvallend trager verloopt in afwezigheid van de tweede generatie katalysator ii dan in de 
domino sequentie. Waarschijnlijk worden zowel waterstofdonor als –acceptor bij elkaar gebracht 
door simultane coördinatie aan het metallisch centrum, gevolgd door directe waterstof transfer 
van het pyrroline naar TCQ. Het lijkt dat de fosfonaatgroep net elektronenzuigend genoeg is om 
de nucleofiliciteit van het N-atoom te verlagen zodat de RCM bij kamertemperatuur kan 
plaatsgrijpen terwijl toch nog steeds de oxidatie van het pyrroline tot het pyrrool mogelijk is. 
De substraten ix en x bezitten één eindstandige en één niet-eindstandige dubbele binding. 
Initiatie van de metathese gebeurt, omwille van sterische redenen, aan de eindstandige dubbele 
binding. Het cyclobutaan xiii fragmenteert met vorming van een nieuw carbeen xiv en styreen 
xv. Dit nieuwe carbeen cycliseert tot xvi dat het pyrroline vormt en het actieve species van de 
katalysator regenereert na cycloreversie. In deze cyclus wordt geen etheen gevormd en dat is 
merkwaardig aangezien de vorming van etheen als cruciaal aanzien wordt om het evenwicht van 
de reactie naar het eindproduct te verschuiven. 
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Styreen xv accumuleert echter in het reactiemengsel en begint in competitie te treden met het 
substraat om met de katalysator te reageren. Zo wordt in een tweede katalytische cyclus styreen 
omgezet tot stilbeen xviii dat neerslaat uit het mengsel en wordt het methylideen carbeen xix 
gegenereerd. Dit carbeen kan ofwel reageren met styreen tot xx of met substraat tot xxi. Beide 
cyclobutanen genereren etheen tijdens de cycloreversie. In tegenstelling dus tot de normale 
metathese cyclus, wordt in dit geval etheen gegenereerd in twee secundaire katalytische cycli. 
 
Enyne metathese (RCEYM), dat reactie inhoudt tussen een alkeen en een alkyn, heeft in het 
verleden veel minder aandacht gekregen dan RCM. Sequentiële reacties, bijvoorbeeld, zijn 
nauwelijks ontwikkeld voor RCEYM. Tot nu toe zijn enkel een eenpotsreactie van RCEYM met een 
Diels-Alder reactie of een cyclopropanering beschreven. In tegenstelling tot de olefiene 
metathese, worden bij RCEYM alle koolstof atomen van het uitgangsproduct ingebouwd in het 
eindproduct dat een synthetisch bruikbaar 1,3-dieen bevat. Ondanks het grote nut van deze 
reactie is echter nog relatief weinig bekend over het mechanisme ervan. Meer precies wordt nog 
vaak de vraag gesteld of de reactie geschiedt via het “yn-dan-een” of via het “een-dan-yn” 
mechanisme. 
De allereerste combinatie van RCEYM met een oxidatie werd ontwikkeld door α-aminofosfonaten 
xxiv, die zowel een dubbele als een driedubbele binding bevatten, te behandelen met de tweede 
generatie Grubbs katalysator in kokende benzeen in aanwezigheid van TCQ. De substraten voor 
deze reactie werden bereid in twee eenvoudige stappen uit imines xxii. Als eerste stap werden 
deze imines gefosfonyleerd met volledige 1,2-regioselectiviteit door ze te behandelen met dialkyl 
fosfiet in kokende methanol. 
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MeOH, Δ, 2-3u
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6 voorbeelden
65-95%
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6 voorbeelden
48-85%
1.5 equiv BnBr
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4 equiv K2CO3
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1 equiv TCQ
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5 voorbeelden
68-88%
xxvi
4 voorbeelden
48-85%  
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Het N-atoom van de verkregen α-aminofosfonaten xxiii werd beschermd met een benzylgroep 
door te refluxen in aceton met K2CO3 als base, benzylbromide als elektrofiel en NaI als 
katalysator. 
Deze RCEYM/oxidatie sequentie laat de synthese toe van sterk gefunctionaliseerde 2-
gefosfonyleerde pyrrolines xxv en pyrrolen xxvi. Een gedetailleerd mechanistisch onderzoek 
bracht aan het licht dat de reactie de “yn-dan-een” pathway volgt. Het bewijs voor dit 
reactiemechanisme is gebaseerd op de vorming van bepaalde eind- en nevenproducten, 
spectroscopische gegevens en tenslotte op het verschil in reactiviteit van verschillende 
substraten. Tijdens de initiatie fase wordt het Grubbs carbeen omgezet tot een nieuw ruthenium 
carbeen dat de propagatie cyclus verder zet. 
 
 
 
In het tweede deel van deze thesis werd een toetreding tot nieuwe polycyclische hydantoines 
ontwikkeld vertrekkend van pyroglutamaten. Hydantoines zijn reeds uitgebreid bestudeerd en 
vertonen een breed gamma aan biologische activiteiten. Tevens vertonen een reeks hydantoine 
derivaten, die gefuseerd zijn met een extra ring, een aantal interessante medicinale 
eigenschappen. 
Wanneer een mengsel van een pyroglutamaat xxvii en een isocyanaat xxviii in ether behandeld 
wordt met NaH, wordt een neerslag gevormd tijdens de reactie die na opwerking het natrium 
zout bleek te zijn van het verwachte carbamoyl lactam xxix in hoge zuiverheid. Indien deze 
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reactie echter uitgevoerd wordt in THF, wordt er geen neerslag gevormd omdat intermediair 
xxix intramoleculair reageert door een nucleofiele aanval op de carbonylfunctie van het ester, 
gevolgd door uitstoot van een alkoxide anion en vorming van het bicyclisch intermediair xxx. Het 
alkoxide anion kan op zijn beurt dit bicyclisch intermediair openen met vorming van de anionen 
xxxi en xxxii. Deze anionen zijn met elkaar in evenwicht waardoor racemisatie van het chirale 
centrum optreedt en de hydantoines xxxiii geïsoleerd worden als een 1:1 mengsel van 
enantiomeren. 
 
N
H
O
O
OR1
CX N
R2
NO
O
OR1
NX
R2
N
N
O X
R2
O
OR1
N N
O
X
R2
R1OOC
xxvii
xxix xxx
xxxi
HN N
O
X
R2
R1OOC
xxxii
HN N
O
X
R2
R1OOC
xxxiii
8 voorbeelden
42-89%
1.1 equiv NaH
THF, RT, 16u
xxviii
 
 
Deze ringtransformatie werd succesvol toegepast in een korte vierstapssequentie voor de 
synthese van hydantoinederivaten xxxviii die gefuseerd zijn met een zesring. In een eerste stap 
werden pyroglutamaten xxvii gealkyleerd op de 2-positie door gebruik te maken van LiHMDS en 
een gepast elektrofiel. 
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O COOR1
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O COOR1
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NN
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R4
R2
xxvii xxxiv
9 voorbeelden
20-84%
xxxvi
5 voorbeelden
45-70%
xxxvii
8 voorbeelden
45-99%
NN
O
O
R3
R1OOC
xxxviii
8 voorbeelden
55-93%
R2
R4
xxxv
2.1 equiv LiHMDS
4 equiv elektrofiel
THF, -40°C, 30min
dan 2u, RT
1.1 equiv R3NCO
1.1 equiv NaH
THF, RT, 16u
3 equiv elektrofiel
5 equiv K2CO3
aceton, Δ
5% kat. ii
CH2Cl2, Δ, 4u
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De studie toonde aan dat uitstekende resultaten bekomen kunnen worden wanneer een mengsel 
van het pyroglutamaat en elektrofiel behandeld wordt met 2.1 equivalenten LiHMDS bij -40 °C. 
Zelfs indien meerdere equivalenten elektrofiel gebruikt werden, werd er nooit reactie vastgesteld 
op het stikstof atoom. Behandeling van een oplossing van xxxiv en een isocyanaat in THF met 
NaH leidt vervolgens tot de vorming van het carbamoyl lactam xxxv dat een omlegging 
ondergaat tot hydantoine xxxvi. Deze verbindingen kunnen eenvoudig gealkyleerd worden op 
N(1) tot xxxvii door ze enkele dagen te refluxen met 2 equivalenten elektrofiel en 5 
equivalenten fijngemalen K2CO3 in aceton. Behandeling van deze verbindingen met 5% 
katalysator ii in kokende CH2Cl2 leidt tot omzetting naar de gewenste derivaten xxxviii. 
 
Tevens werd een nieuwe toetreding tot N(3),N'(3)-polymethyleen-bis-hydantoines ontwikkeld. 
Bis-hydantoines, meestal dimeren van phenetoin of gelijkaardige producten, zijn in het verleden 
reeds met succes getest als analogen van HMBA en kunnen mogelijks hun nut bewijzen bij de 
behandeling van kanker. In dit werk werden bis-hydantoines xli verkregen door reactie van 
pyroglutamaat xxvii met bis-isocyanaten en daaropvolgende ringtransformatie van bis-carbamoyl 
lactamen xl in ethanol met KOtBu als base. 
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R R
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7 voorbeelden
84-99%
xliii
4 voorbeelden
41-58%
0.5 equiv xxxix
1.2 equiv NaH
ether, RT, 1u
4 equiv elektrofiel
5 equiv K2CO3
aceton, Δ
5% kat. ii
CH2Cl2, Δ, 16u
 
Deze verbindingen xli kunnen eenvouding gealkyleerd worden op N(1) tot xlii door ze te 
refluxen met 4 equivalenten elektrofiel en 5 equivalenten fijngemalen K2CO3 in aceton. De 
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derivaten met een allyl substituent op N(1) konden omgezet worden tot de overeenkomstige 
macrocyclische derivaten xliii door behandeling met de tweede generatie Grubbs katalysator ii in 
kokende CH2Cl2. Er werd aangetoond dat enkel de trans isomeren geïsoleerd werden. De 
aanwezigheid van een enkel isomeer ter hoogte van de dubbele binding kan verklaard worden 
door secundaire metathese reacties, aangezien het geweten is dat macrocyclische verbindingen 
isomeriseren naar een thermodynamisch gecontroleerde (E/Z) verhouding los van de 
stereochemie van het initieel gevormde alkeen. 
 
Een aantal van de gesynthetiseerde hydantoines werd gescreend op hun anti-invasieve activiteit 
tegen een humane borstkanker cellijn. De gekozen screening assay is gebaseerd op de in vitro 
confrontatie van kankercellen met een fragment normaal hartweefsel dat gedissecteerd werd uit 
kuiken embryo’s van 9 dagen oud. Er kan gesteld worden dat sommige van de aangemaakte bis-
hydantoines goede anti-invasieve activiteit vertonen bij een concentratie van 100 μm en 10 μm. 
Tevens kunnen deze producten heel eenvoudig op grote schaal aangemaakt worden en zijn ze 
niet toxisch voor het hartweefsel dat gebruikt werd in de in vitro test. Jammer genoeg kon de 
activiteit van deze componenten niet correct voorspeld worden door een niet-lineair QSAR model. 
Daarom is er verder onderzoek nodig om het exacte werkingsmechanisme van deze structuren te 
ontrafelen zodat de synthese van meer actieve verbindingen mogelijk wordt. In een verder 
stadium zullen in vivo testen dienen te gebeuren om deze resultaten te valideren. 
 
In het derde deel van deze thesis werden nieuwe toetredingen ontwikkeld naar benzo-gefuseerde 
verbindingen namelijk 1H-2-benzazepine-1-ylfosfonaten en gefosfonyleerde isoindolen. Benzo-
gefuseerde verbindingen, en in het bijzonder zevenringen met bekende voorbeelden als 
diazepam (Valium®) en flurazepam (Dalmadorm®), hebben over de jaren heen veel aandacht 
gekregen omwille van hun alomtegenwoordigheid in natuurproducten en moderne farmaceutica. 
Het eerste protocol voor de synthese van 1H-2-benzazepine-1-ylfosfonaten xliv maakt gebruik 
van een combinatie van RCEYM met cross-metathese. Hiertoe werd een refluxend mengsel van 
xlv en 5 equivalenten alkeen in CH2Cl2 behandeld met 10 mol% tweede generatie Grubbs’ 
katalysator ii. Een extra hoeveelheid alkeen (5 equiv) dient toegevoegd te worden na 2 uren. 
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N
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PG(MeO)2(O)P
P(O)(OMe)2
N
PG
R2R
1
xliv
6 voorbeelden
50-78%
xlvi xlv
5 equiv 
10% kat. ii
CH2Cl2, Δ, 4u
R2 5 equiv 
10% kat. ii
CH2Cl2, Δ, 1u
5 equiv
Δ, 4u
R1
R1
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Deze observatie werd verklaard door te kijken naar de volledige reactie cyclus. Tijdens het 
verloop van de reactie wordt het alkeen immers niet enkel ingebouwd in het eindproduct, maar 
ook gedimeriseerd in de zogenaamde “alkeen-sink” met regeneratie van het methylideen carbeen 
en productie van etheen. Bij evaluatie van de reactie tussen xlvi en alkenen werd vastgesteld dat 
het in dit geval niet nodig is een extra hoeveelheid alkeen toe te voegen. Het voordeel van deze 
strategie is dat het slechts de synthese vereist van twee substraten, met een eindstandige 
dubbele en driedubbele binding, die worden omgezet tot verschillende zevenringen afhankelijk 
van de toevoeging van een bepaald alkeen aan het reactiemengsel. 
 
De behandeling van zeer gelijkaardige substraten xlvii die een niet-eindstandige dubbele binding 
bevatten met een metathese katalysator leidde niet tot de verwachte zevenring maar leverde 
gefosfonyleerde isoindolen. Gefosfonyleerde isoindolen zijn nog maar zelden beschreven in de 
literatuur. Er werd immers maar één toetreding tot deze producten gevonden, die echter een 
laag rendement gaf. Bovendien zijn er slechts weinig toetredingen gerapporteerd tot verwante 
verbindingen zoals gefosfonyleerde dihydroisoindolen en isoindolinonen. Deze laatste zijn gekend 
omwille van hun plantengroei regulerende eigenschappen. 
Er werd gevonden dat deze omlegging thermisch gedreven is. Na een aantal experimenten 
konden het rendement en de conversiesnelheid geoptimaliseerd worden door de substraten te 
verhitten in een mengsel van benzeen/CH3CN in een 1/1 verhouding tot 165 °C onder microgolf 
condities. De eerste stap in deze transformatie omvat waarschijnlijk een directe aanval van het 
vrije elektronenpaar van stikstof op de niet geactiveerde driedubbele binding op een 5-exo-dig 
wijze met vorming van xlviii. 
 
N
P(O)(OMe)2
Bn
N
P(O)(OMe)2
Bn
Ph
5-exo-dig
N
P(O)(OMe)2
Bn
N
P(O)(OMe)2
Bn
Ph
N
P(O)(OMe)2
Bn
Ph
H
[1,3]-alkyl shift
[1,5]-H shift
Ph
Ph
Ph
la lb
xlix
liliia
xlviiixlviia
 
 
Het zwitterion xlviii fragmenteert vervolgens met vorming van anion xlix en kationen la en lb. 
Anion xlix reageert met lb met vorming van li. Het resultaat van deze fragmentatie en 
recombinatie komt overeen met een [1,3]-alkyl shift. De omlegging eindigt met een [1,5]-H shift 
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die resulteert in aromatisering tot lii. Deze reactieweg vertegenwoordigt de eerste efficiënte 
toetreding tot gefosfonyleerde isoindolen. 
 
De algemene aard van deze omlegging werd aangetoond door een aantal α-aminofosfonaten 
xlvii te bereiden en te onderwerpen aan dezelfde condities. Deze α-aminofosfonaten werden 
bereid door gebruik te maken van een driecomponent koppeling tussen ethynylbenzaldehyde, 
secundaire amines en trimethyl fosfiet in aanwezigheid van LiClO4. De isoindolen lii werden 
geïsoleerd in goed rendement. 
 
N
P(O)(OMe)2
R1
R3
R2
N
P(O)(OMe)2
R1
R2
R4 R
4
R3
C6H6/CH3CN (1:1)
MW (165 °C)
lii
9 voorbeelden
40-98%
xlvii
9 voorbeelden
48-88%  
 
Wanneer de migrerende allylische groep geïncorporeerd wordt in een extra ring, blijven het anion 
en het kation aan mekaar verbonden tijdens de reactie. Zoals verwacht, resulteerde de verhitting 
van liii onder microgolfcondities in de vorming van tricyclische verbindingen lvii. De fragmentatie 
van het zwitterion liv resulteert in de vorming van lva en resonantie vorm lvb. Een 
intramoleculaire aanval vormt een extra zesring lvi. Uiteindelijk zorgt aromatisering voor de 
vorming van isoindolen lvii. 
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Vanuit de resultaten behaald in dit werk, kunnen een aantal perspectieven voor toekomstig werk 
geformuleerd worden. Initieel werd een nieuwe toetreding tot pyrrolen ontwikkeld, gebruik 
makend van een combinatie van RCM of RCEYM met oxidatie. Dit zal onderzoekers toelaten deze 
interessante azaheterocyclische verbindingen, en gefosfonyleerde derivaten, op efficiente wijze te 
construeren. Teneinde het biologisch potentieel van deze producten te evalueren, kan een 
ontscherming van het fosfonaat wenselijk zijn. Nieuwe katalytische systemen, bijvoorbeeld op 
een vaste drager, kunnen toelaten de synthese op een grotere schaal uit te voeren. Mogelijks 
kan deze methodologie uitgebreid worden voor de synthese van andere heterocyclische 
verbindingen. Het is echter onwaarschijnlijk dat furanen of thiofenen gemaakt kunnen worden via 
een éénstapssequentie aangezien waarschijnlijk de metathese katalysator vernietigd zal worden 
door het gebruik van sterkere oxidanten. In de toekomst zou de ontwikkeling van nieuwe 
katalysatoren de synthese van meer gesubstitueerde derivaten en het gebruik van sterkere 
oxidanten kunnen toelaten. Het mechanistisch inzicht in RCEYM zal onderzoekers toelaten de 
vorming van bepaalde neven- en eindproducten in reactiemengsels te verklaren. 
De nieuwe toetreding tot hydantoines kan zich ontpoppen tot een heel krachtige methode indien 
gecombineerd met enantioselectieve reacties op het pyroglutamaat. Toekomstige biologische 
screening van de producten gesynthetiseerd in deze thesis zou het exacte werkingsmechanisme 
aan het licht kunnen brengen en zo de synthese kunnen bijsturen naar meer actieve structuren. 
De verzeping van het ester kan meer polaire structuren leveren met een hogere 
wateroplosbaarheid en mogelijks verhoogde activiteit. 
De combinatie van RCEYM met cross-metathese voor de synthese van 1H-2-benzazepine-1-
ylfosfonaten laat de synthese toe van een brede waaier aan benzo-gefuseerde azepines, 
afhankelijk van de toevoeging van een specifiek alkeen. Het verkregen dieen zou tevens verder 
gefunctionaliseerd kunnen worden door middel van een Diels-Alder reactie, wat leidt tot meer 
complexe structuren in één synthetische inspanning. 
De omlegging tot gefosfonyleerde isoindolen is een veelbelovende reactie omdat ze mogelijks 
kan toegepast worden voor de synthese van andere heterocyclische verbindingen. Zo zou gestart 
kunnen worden van 3-ethynyl-furan-2-carbaldehyde of 3-ethynyl-pyridine-2-carbaldehyde in 
plaats van 2-ethynylbenzaldehyde. Reacties met interne alkynen in plaats van eindstandige, zou 
kunnen leiden tot isoquinoline derivaten na een omlegging die begint met een 6-endo-dig aanval 
in plaats van de 5-exo-dig aanval zoals hier beschreven. 
 
Samengevat werd een waaier aan azaheterocyclische verbindingen bereid gebruik makend van 
RCM. Er werden onder andere vijf-, zes-, en zevenringen gesynthetiseerd naast een aantal 
macrocyclische derivaten. Bovendien biedt de combinatie van RCM met oxidatieve aromatisering 
een nieuwe toetreding tot aromatische verbindingen. De resultaten uit deze thesis bieden de 
mogelijkheid aan andere onderzoekers om deze interessante chemie verder te ontwikkelen. 
References 
-182- 
7 References 
 
1 Stevens, C. V.; Verhé, R. 2004, Renewable Bioresources: Scope and Modicifcation for Non-Food Applications, 
John Wiley & Sons, Ltd, West Sussex, 310pp. 
2 Hagen, J. 1999, Industrial Catalysis, a practical approach, John Wiley & Sons, Ltd, West Sussex, 230pp. 
3 De Vos, D. Master Thesis, Faculty of Bioscience Engineering 2002, 70pp. 
4 The synthesis, reactivity, and physical properties of substituted pyrroles, Volume 48, Part 2, Pyrroles; R. Alan 
Jones, Ed.; John Wiley & Sons, 1992, US, 640pp. 
5 Leroux, P. Pestic. Sci. 1996, 47, 191. 
6 Della Bella, D.; Carenzi, A.; Cibin, M.; Gentile, N. Eur. Pat. Appl. 1992; EP 480458 A 19920415; Chem. Abstr. 
1992, 117, 14434. 
7 Biava, M.; Porretta, G. C.; Deidda, D.; Pompei, R.; Tafi, A.; Manetti, F. Bioorg. Med. Chem. 2004, 12, 1453-
1458. 
8 Sbardella, G.; Mai, A.; Artico, M.; Loddo, R.; Setzu, M. G.; La Colla, P. Bioorg. Med. Chem. Lett. 2004, 14, 
1537-1541. 
9 Moonen, K.; Laureyn, I.; Stevens, C. V. Chem. Rev. 2004, 104, 6177-6215. 
10 Tehrani, A. T.; De Kimpe, N. Science of Synthesis, Houben-Weyl Methods of Molecular Transformations; 2004 
Vol. 27: Heteroatom Analogues of Aldehydes and Ketones, Product Class 7: Imines, pp245-321. 
11 Claeys, D. D. unpublished results. 
12 Biltz, H. Ber. Dtsch. Chem. Ges. 1908, 1379-1393. 
13 Sircar, I.; Furth, P.; Teegarden, B. R.; Morningstar, M.; Smith, N.; Griffith R. 2001 WO 0130781. 
14 Salvati, M.; Balog, A.; Shan, W. Geise, S. US Patent 885,798,2003. 
15 Gassiot, A. C.; Charton, J.; Girault-Mizzi, S.; Gilleron, P.; Debreu-Fontaine, M.-A.; Sergheraert, C.; Melnyk, P. 
Bioorg. Med. Chem. Lett. 2005, 15, 4828-4832. 
16 Haces, A.; Breitman, T. R. Driscoll, J. S. J. Med. Chem. 1987, 30, 405-409. 
17 Breslow, R.; Belvedere, S.; Gershell, L. Helv. Chim. Act. 2000, 83, 1685-1692. 
18 Horton, D. A.; Bourne, G. T.; Smythe, M. L. Chem. Rev. 2003, 103, 893-930. 
19 van den Worm, E.; de Vries, A.; Nijkamp, F. P.; Engels, F. Eur. J. Pharm. 2005, 518, 77-78. 
20 Toda, N.; Tago, K.; Marumoto, S.; Takami, K.; Ori, M.; Yamada, N.; Koyama, K.; Naruto, S.; Abe, K.; 
Yamazaki, R.; Hara, T.; Aoyagi, A.; Abe, Y.; Kaneko, T.; Kogen, H. Bioorg. Med. Chem. 2003, 11, 4389-4415. 
21 Danikiewicz, W.; Makosza, M. J. Org. Chem. 1991, 56, 1283-1286. 
22 Gaffar, A. US 5753633, 1998; Chem. Abstr. 1998, 129, 8161. 
23 Calderon, N. Acc. Chem. Res. 1972, 5, 127-132. 
24 Calderon, N.; Chen, H. Y.; Scott, K. W. Tetrahedron Lett. 1967, 8, 3327-3329. 
25 Grubbs, R. H.; Brunck, T. K. J. Am. Chem. Soc. 1972, 94, 2538-2540. 
26 Hérisson, J.-L.; Chauvin, Y. Makromol. Chem. 1971, 141, 161-176. 
27 Grubbs, R. H.; Burk, P. L.; Carr, D. D. J. Am. Chem. Soc. 1975, 97, 3265-3267. 
28 Grubbs, R. H.; Carr, D. D.; Hoppin, C.; Burk, P. L. J. Am. Chem. Soc. 1976, 98, 3478-3483. 
29 Katz, T. J.; McGinnis, J. J. Am. Chem. Soc. 1977, 99, 1903-1912. 
30 Schaverien, C. J.; Dewan, J. C.; Schrock, R. R. J. Am. Chem. Soc. 1986, 108, 2771-2773. 
31 Murdzek, J. S.; Schrock, R. R. Organometallics 1987, 6, 1373-1374. 
 
References 
-183- 
 
32 Schrock, R. R.; Krouse, S. A.; Knoll, K.; Feldman, J.; Murdzek, J. S.; Yang, D. C. J. Mol. Catal. 1988, 46, 243-
253. 
33 Schrock, R. R.; Murdzek, J. S.; Barzan, G. C.; Robbis, J.; DiMare, M.; O’Regan, M. J. Am. Chem. Soc. 1990, 
112, 3875-3886. 
34 Nguyen, S. T.; Johnsson, L. K.; Grubbs, R. H. J. Am. Chem. Soc. 1992, 114, 3974-3975. 
35 Schwab, P.; France, M. B.; Ziller, J. W.; Grubbs, R. H. Angew. Chem. Int. Ed. Engl. 1995, 34, 2039-2041. 
36 Scholl, M.; Ding, S.; Lee, C. W.; Grubbs, R. H. Org. Lett. 1999, 1, 953-956. 
37 Dias, E. L.; Nguyen, S. T.; Grubbs, R. H. J. Am. Chem. Soc. 1997, 119, 3887-3897. 
38 Sanford, M. S.; Ulman, M.; Grubbs, R. H. J. Am. Chem. Soc. 2001, 123, 749-750. 
39 Sanford, M. S.; Love, J.; Grubbs, R. H. J. Am. Chem. Soc. 2001, 123, 6543-6554. 
40 Schmalz, H.-G. Angew. Chem. Int. Ed. Engl. 1995, 34, 1833-1836. 
41 Schuster, M.; Blechert, S. Angew. Chem. Int. Ed. Engl. 1997, 36, 2036-2056. 
42 Dragutan, I.; Dragutan, V.; Filip, P. Arkivoc 2005, x, 105-129. 
43 Fürstner, A. Angew. Chem. Int. Ed. 2000, 39, 3012-3043. 
44 Grubbs, R. H.; Chang, S. Tetrahedron 1998, 54, 4413-4450. 
45 Alcaide, B.; Almendros, P. Chem. Eur. J. 2003, 9, 1259-1262. 
46 Hoveyda, A. H.; Gillingham, D. G.; Van Veldhuizen, J. J.; Kataoka, O.; Garber, S. B.; Kingsbury, J. S.; Harrity, J. 
P. A. Org. Biomol. Chem. 2004, 2, 8-23. 
47 Poulsen, C. S.; Madsen, R. Synthesis 2003, 1-18. 
48 Diver, S. T.; Giessert, A. J. Chem. Rev. 2004, 104, 1317-1382. 
49 Maifeld, S. V.; Lee, D. Chem. Eur. J. 2005, 11, 6118-6126. 
50 Drozdzak, R.; Allaert, B.; Ledoux, N.; Dragutan, I.; Dragutan, V.; Verpoort, F. Coordin. Chem. Rev. 2005, 249, 
3055-3074. 
51 Dragutan, V.; Dragutan, I. J. Organomet. Chem. 2006, 691, 5129-5147. 
52 Dragutan, V.; Dragutan, I.; Delaude, L.; Demonceau A. Coordin. Chem. Rev. 2007, 251, 765-794. 
53 Schrock, R. R.; Hoveyda, A. H. Angew. Chem. Int. Ed. 2003, 42, 4592-4633. 
54 Nicolaou, K. C.; Bulger, P. G.; Sarlah, D. Angew. Chem. Int. Ed. 2005, 44, 4490-4527. 
55 Donohoe, T. J.; Orr, A. J.; Bingham, M. Angew. Chem. Int. Ed. 2006, 45, 2664-2670. 
56 Grubbs, R. H. Tetrahedron 2004, 60, 7117-7140. 
57 Astruc, D. New. J. Chem. 2005, 29, 42-56. 
58 Deiters, A.; Martin, S. F. Chem. Rev. 2004, 104, 2199-2238. 
59 McReynolds, M. D.; Dougherty, J. M.; Hanson, P. R. Chem. Rev. 2004, 104, 2239-2258. 
60 Schmidt, B. Eur. J. Org. Chem. 2004, 1865-1880. 
61 Martin, W. H. C.; Blechert, S. Curr. Top. Med. Chem. 2005, 5, 1521-1540. 
62 Ghosh, S.; Ghosh, S.; Sarkar, N. J. Chem. Sci. 2006, 118, 223-235. 
63 Connon, S. J.; Blechert, S. Angew. Chem. Int. Ed. 2003, 42, 1900-1923. 
64 Nguyen Van, T.; De Kimpe, N. Tetrahedron Lett. 2004, 45, 3443-3446. 
65 Stragies, R.; Blechert, S. Tetrahedron 1999, 55, 8179-8188. 
66 Fürstner, A.; Thiel, O. R. J. Org. Chem. 2000, 65, 1738-1742. 
67 Nguyen Van, T.; Debenedetti, S.; De Kimpe, N. Tetrahedron Letters 2003, 44, 4199-4201 and references cited 
therein. 
68 Chatterjee, A. K.; Toste, F. D.; Goldberg, S. D.; Grubbs, R. H. Pure Appl. Chem. 2003, 75, 421-425. 
 
References 
-184- 
 
69 Fürstner, A.; Leitner, A. Angew. Chem. Int. Ed. 2003, 42, 309-311. 
70 Zuercher, W. J.; Scholl, M.; Grubbs, R. H. J. Org. Chem. 1998, 63, 4291-4298. 
71 Nicola, T.; Brenner, M.; Donsbach, K.; Kreye, P. Org. Process Res. Develop. 2005, 9, 513-515. 
72 Tsantrizos, Y. S.; Ferland, J.-M.; McClory, A.; Poirier, M.; Farina, V.; Yee, N. K.; Wang, X.-j.; Haddad, N.; Wei, 
X.; Xu, J.; Zhang, L. J. Organomet. Chem. 2006, 691, 5163-5171. 
73 Van Veldhuizen, J. J.; Gillingham, D. G.; Garber, S. B.; Kataoka, O.; Hoveyda, A. H. J. Am. Chem. Soc. 2003, 
125, 12502-12508. 
74 Hong, S. H.; Grubbs, R. H. J. Am. Chem. Soc. 2006, 128, 3508-3509. 
75 Varray, S.; Lazaro, R.; Martinez, J.; Lamaty, F. Organometallics 2003, 22, 2426-2435. 
76 Fujimura, O.; Fu, G. C.; Grubbs, R. H. J. Org. Chem. 1994, 59, 4029-4031. 
77 Arisawa, M.; Terada, Y.; Nakagawa, M.; Nishida, A. Angew. Chem. Int. Ed. 2002, 41, 4732-4734. 
78 Iuliano, A.; Piccioli, P.; Fabbri, D. Org. Lett. 2004, 6, 3711-3714. 
79 Walker, E. R.; Leung, S. Y.; Barret, A. G. M. Tetrahedron Lett. 2005, 46, 6537-6540. 
80 Pelly, S. C.; Parkinson, C. J.; van Otterlo, W. A. L.; de Koning, C. B. J. Org. Chem. 2005, 70, 10474-10481. 
81 Huang, K. S.; Wang, E. C. Tetrahedron Lett. 2001, 42, 6155-6157. 
82 Chen, Y. Z.; Dias, H. V. R.; Lovely, C. J. Tetrahedron Lett. 2003, 44, 1379-1382. 
83 Declerck, V.; Ribière, P.; Martinez, J.; Lamaty, F. J. Org. Chem. 2004, 69, 8372-8381. 
84 For a review on the SES-group see: Ribiere, P.; Declerck, V.; Martinez, J.; Lamaty, F. Chem. Rev. 2006, 106, 
2249-2269. 
85 Varray, S.; Lazaro, R.; Martinez, J.; Lamaty, F. Eur. J. Org. Chem. 2002, 2308-2316. 
86 Donohoe, T. J.; Orr, A. J.; Gosby, K.; Bingham, M. Eur. J. Org. Chem. 2005, 1969-1971. 
87 Robertson, J.; Kuhnert, N.; Zhao, Y. Heterocycles 2000, 53, 2415-2420. 
88 Arisawa, M.; Theeraladanon, C.; Nishida, A.; Nakagawa, M. Tetrahedron Lett. 2001, 42, 8029-8033. 
89 Nguyen Van, T.; D’hooghe, M.; Pattyn, S.; De Kimpe, N. Synlett 2004, 1913-1916. 
90 Bennasar, M. L.; Roca, T.; Monerris, M.; Garcia-Diaz, D. Tetrahedron Lett. 2005, 46, 4035-4038. 
91 Bennasar, M. L.; Roca, T.; Monerris, M.; Carcia-Diaz, D. J. Org. Chem. 2006, 71, 7028-7034. 
92 Sanchez, I.; Pujol, M. D. Synthesis 2006, 1823-1828. 
93 Kotha, S.; Mandal, K. Tetrahedron Lett. 2004, 45, 2585-2588. 
94 Evans, P.; Grigg, R.; Monteith, M. Tetrahedron Lett. 1999, 40, 5247-5250. 
95 Yang, C.; Murray, W. V.; Wilson, L. J. Tetrahedron Lett. 2003, 44, 1783-1786. 
96 Evanno, L.; Nay, B.; Bodo, B. Synthetic Commun. 2005, 35, 1559-1565. 
97 van Otterlo, W. A. L.; Coyanis, E. M.; Panayides, J.-L.; de Koning, C. B.; Fernandes, M. A. Synlett 2005, 501-
505. 
98 van Otterlo, W. A. L.; Ngidi, E. L.; Coyanis, E. M.; de Koning, C. B. Tetrahedron Lett. 2003, 44, 311-313. 
99 Yoshida, K.; Imamoto, T. J. Am. Chem. Soc. 2005, 127, 10470-10471. 
100 Louie, J.; Bielawski, C. W.; Grubbs, R. H. J. Am. Chem. Soc. 2001, 123, 11312-11313. 
101 Krompiec, S.; Kuznic, N.; Bieg, T.; Adamus, B.; Majnusz, J.; Grymel, M. Polish J. Chem. 2000, 74, 1197-1200. 
102 Krompiec, S.; Pigulla, M.; Bieg, T.; Szczepankiewicz, W.; Kuznic, N.; Krompiec, M.; Kubicki, M. J. Mol. Catal. A 
2002, 189, 169-185. 
103 van Otterlo, W. A. L.; Ngidi, E. L.; de Koning, C. B. Tetrahedron Lett. 2003, 44, 6483-6486. 
104 van Otterlo, W. A. L.; Morgans, G. L.; Khanye, S. D.; Aderibigde, B. A. A.; Michael, J. P.; Billing, D. G. 
Tetrahedron Lett. 2004, 45, 9171-9175. 
 
References 
-185- 
 
105 van Otterlo, W. A. L.; Morgans, G. L.; Madeley, L. G.; Kuzvidza, S.; Moleele, S. S.; Thornton, N.; de Koning, C. 
B. Tetrahedron 2005, 61, 7746-7755. 
106 Sutton, A. E.; Seigal, B. A.; Finnegan, D. F.; Snapper, M. L. J. Am. Chem. Soc. 2002, 124, 13390-13391. 
107 Schmidt, B. J. Org. Chem. 2004, 69, 7672-7687. 
108 Schmidt, B. Synlett 2004, 1541-1544. 
109 Fustero, S.; Sanchez-Rosello, M.; Jimenez, D.; Sanz-Cervera, J. F.; del Pozo, C.; Acena, J. L. J. Org. Chem. 
2006, 71, 2706-2714. 
110 Gonzalez-Perez, P.; Perez-Serrano, L.; Casarrubios, L.; Dominguez, G.; Perez-Castells J. Tetrahedron Lett. 
2002, 43, 4765-4767. 
111 Tissot-Croset, K.; Polet, D.; Gille, S.; Hawner, C.; Alexakis, A. Synthesis 2004, 2586-2590. 
112 Beligny, S.; Eibauer, S.; Maechling, S.; Blecherd, S. Angew. Chem. Int. Ed. 2006, 45, 1900-1903. 
113 Scholte, A. A.; An, M. H.; Snapper, M. L. Org. Lett. 2006, 8, 4759-4762. 
114 Kim, B. G.; Snapper, M. L. J. Am. Chem. Soc. 2006, 128, 52-53. 
115 Mori, M.; Sakakibara, N.; Kinoshita, A. J. Org. Chem. 1998, 63, 6082-6083. 
116 Monnier, F.; Castillo, D.; Dérien, S.; Toupet, L.; Dixneuf, P. H. Angew. Chem. Int. Ed. 2003, 42, 5474-5477. 
117 Eckert, M.; Monnier, F.; Shchetnikov, G. T.; Titanyuk, I. D.; Oipov, S. N.; Toupet, L.; Dérien, S. Dixneuf, P. H. 
Org. Lett. 2005, 7, 3741-3743. 
118 Quayle, P.; Fengas, D.; Richards, S. Synlett 2003, 1797-1800. 
119 Faulkner, J.; Edlin, C. D.; Fengas, D.; Preece, I.; Quayle, P.; Richards, S. N. Tetrahedron Lett. 2005, 46, 
2381-2385. 
120 Schmidt, B.; Pohlern M. J. Organomet. Chem. 2005, 690, 5552-5555 
121 Edlin, C. D.; Faulkner, J.; Quayle, P. Tetrahedron Lett. 2006, 47, 1145-1151. 
122 Seigal, B. A.; Fajardo, C. Snapper, M. L. J. Am. Chem. Soc. 2005, 127, 16329. 
123 Kinderman, S. S.; Van Maarseven, J. H.; Schoenmaker, H. E.; Hiemstra, A. Rutjes, F. P. J. T. Org. Lett. 2001, 
3, 2045-2048. 
124 Dondas, H. A.; Balme, G.; Clique, B.; Grigg, R.; Hodgeson, A.; Morris, J.; Sridharan, V. Tetrahedron Lett. 
2001, 42, 8673-8675. 
125 Grigg, R.; Hodgson, A.; Morris, J.; Sridharan, V. Tetrahedron Lett. 2003, 44, 1023-1026. 
126 Grigg, R.; Martin, W.; Morris, J.; Sridharan, V. Tetrahedron 2005, 61, 11380-11392. 
127 Bentz, D.; Laschat, S. Synthesis 2000, 1766-1773. 
128 Moreno-Manas, M.; Pleixats, R.; Santamaria, A. Synlett 2001, 1784-1786. 
129 Desroy, N.; Robert-Peillaert, F.; Toueg, J.; Hénaut, C.; Duboc, R.; Rager, M.-N.; Savignac, M.; Genêt, J.-P. 
Synthesis 2004, 16, 2665-2672. 
130 Kaliappan, K. P.; Ravikumar, V.; Pujari, S. A. Tetrahedron Lett. 2006, 47, 981-984. 
131 Lee, H.-Y.; Kim, H. Y.; Tae, H.; Kim, B. G.; Lee, J. Org. Lett. 2003, 5, 3439-3442. 
132 Schramm, M. P.; Reddy, D. S.; Kozmin, S. A. Angew. Chem. Int. Ed. 2001, 40, 4274-4277. 
133 Kowalski, C. J.; Haque, M. S.; Fields, K. W. J. Am. Chem. Soc. 1985, 107, 1429-1430. 
134 Shindo, M. Chem. Soc. Rev. 1998, 27, 367-374. 
135 Van de Weghe, P.; Aoun, D.; Boiteau, J.-G.; Eutache, J. Org. Lett. 2002, 4, 4105-4108. 
136 Denmark, S. E.; Yang, S.-M. Tetrahedron 2004, 60, 9695-9708. 
137 Hara, O.; Sugimoto, K.; Hamada, Y. Tetrahedron 2004, 60, 9381-9390. 
138 Chien, T.-C.; Meade, E. A.; Hinkley, J. M.; Townsend, L. B. Org. Lett. 2004, 6, 2875-2859. 
 
References 
-186- 
 
139 De Kimpe, N.; Tehrani, K. A.; Stevens, C.; De Cooman, P. Tetrahedron 1997, 53, 3693-3706. 
140 Tehrani, K. A.; Borremans, D.; De Kimpe, N. Tetrahedron 1999, 55, 4133-4152. 
141 Aelterman, W.; De Kimpe, N.; Tyvorskii, V.; Kulinkovich, O. J. Org. Chem. 2001, 66, 53-58. 
142 Verniest, G.; Claessens, S.; Bombeke, F.; Van Thienen, T.; De Kimpe, N. Tetrahedron 2005, 61, 2879-2887. 
143 Verniest, G.; Claessens, S.; De Kimpe, N. Tetrahedron 2005, 61, 4631-4637. 
144 Byers, J. H.; DeWitt, A.; Nasveschuk, C. G.; Swigor, J. E. Tetrahedron Lett. 2004, 45, 6587-6590. 
145 Metten, B.; Kostermans, M.; Van Baelen, G.; Smet, M.; Dehaen, W. Tetrahedron 2006, 62, 6018-6028. 
146 Rao, H. S. P.; Jothilingam, S.; Scheeren, H. W. Tetrahedron 2005, 60, 1625-1630. 
147 Shen, H.-C.; Li, C.-W.; Liu, R.-S. Tetrahedron Lett. 2004, 45, 9245-9247. 
148 Dhawan, R.; Arndtsen, B. A. J. Am. Chem. Soc. 2004, 126, 468-459. 
149 Ramanathan, B.; Keith, A. J.; Armstrong, D.; Odom, A. L. Org. Lett. 2004, 6, 2957-2960. 
150 Ferreira, V. F.; de Souza, M. C. B. V.; Cunha, A. C.; Pereira, L. O. R.; Ferreira, M. L. G. Org. Prep. Proced. Int. 
2001, 33, 411-454. 
151 Gilchrist, T. L. J. Chem. Soc., Perkin Trans. 1 1998, 615-628. 
152 Fogg, D. E.; dos Santos, E. N. Coord. Chem. Rev. 2004, 248, 2365-2379. 
153 De Clercq, B.; Verpoort, F. Adv. Synth. Catal. 2002, 344, 1-11. 
154 Nishiguchi, T.; Kurooka, A.; Fukuzumi, K. J. Org. Chem. 1974, 39, 2403-2405. 
155 Junge, H.; Beller, M. Tetrahedron Lett. 2005, 46, 1031-1034. 
156 Adair, G. R. A.; Williams, J. M. J. Tetrahedron Lett. 2005, 46, 8233-8235. 
157 Ulman, M.; Grubbs, R. H. J. Org. Chem. 1999, 64, 7202-7207. 
158 Bert, S. H.; Dabbagh, G.; Williams, L. M. J. Org. Chem. 1985, 50, 4415-4417. 
159 Padwa, A.; Norman, B. H. J. Org. Chem. 1990, 55, 4801-4807. 
160 Ezquerra, J.; Pedregal, C.; Rubio, A.; Valenciano, J.; Navio, J. L. G.; Alvarez-Builla, J.; Vaquero, J. J. 
Tetrahedron Lett. 1993, 34, 6317-6320. 
161 Hanessian, S.; McNaughton-Smith, G.; Lombart, H. G.; Lubell, W. D. Tetrahedron 1997, 38, 12789-12854. 
162 Maison, W.; Prenzel, A. H. G. P. Synthesis 2005, 1031-1048. 
163 Adams, A.; Tehrani, K. A.; Kersiene, M.; De Kimpe, N. J. Agric. Food Chem. 2004, 52, 5685-5693. 
164 For a comprehensive review on a number of Maillard flavor compounds see: Adams, A.; De Kimpe, N. Chem. 
Rev. 2006, 106, 2299-2319. 
165 Wang, P.; Zhang, Z.; Ma, X.; Huang, Y.; Liu, X.; Tu, P.; Tong, T. Mech. Ageing Dev. 2003, 124, 1025-1034. 
166 Stevens, C. V.; Rammeloo, T.; De Kimpe, N. Synlett 2001, 1519-1522. 
167 Dieltiens, N.; Stevens, C. V.; Masschelein, K. G. R.; Rammeloo, T. Tetrahedron 2005, 61, 6749-6756. 
168 Najera, C.; Yus, M. Tetrahedron: Asymmetry 1999, 10, 2245-2303. 
169 Kwon, T. W.; Keusenkothen, P. F.; Smith, M. B. J. Org. Chem. 1992, 57, 6169-6173. 
170 Moonen, K.; Van Meenen, E.; Verwée, A.; Stevens, C. V. Angew. Chem. Int. Ed. 2005, 44, 7407-7411. 
171 Van Meenen, E.; Moonen, K.; Acke, D.; Stevens, C. V. Arkivoc 2006, i, 31-35. 
172 Van Meenen, E.; Moonen, K.; Verwee, A.; Stevens, C. V. J. Org. Chem. 2006, 71, 7903-7906 
173 Giessert, A. J.; Diver, S. T. Org. Lett. 2005, 7, 351-354. 
174 Lloyd-Jones, G. C.; Margue, R. G.; de Vries, J. G. Angew. Chem. Int. Ed. 2005, 44, 7442-7447. 
175 Baeyer, A. Justus Liebigs Ann. Chem. 1861, 119, 126. 
176 Urech, F. Justus Liebigs Ann. Chem. 1873, 165, 99. 
177 Bucherer, H. T.; Brandt, W. J. Prakt. Chem. 1934, 140, 129. 
 
References 
-187- 
 
178 Meusel, M.; Gütschow, M. Org. Prep. Proc. Int. 2004, 36, 391-443. 
179 Stevens, C. V.; Dieltiens, N.; Claeys, D. D. Org. Lett. 2005, 7, 1117-1119. Additions and Corrections 2005, 7, 
5347-5348. 
180 Marquez, V. E.; Kelley, J. A.; Driscoll, J. S. J. Org. Chem. 1980, 45, 5308-5312. 
181 Guillon, J.; Sonnet, P.; Boulouard, M.; Dallemagne, P.; Miel, H.; Daoust, M.; Rault, S. J. Het. Chem. 1998, 35, 
535-539. 
182 Heckendorn, R.; Winkler, T. J. Het. Chem. 2000, 37, 111-114. 
183 Dieltiens, N.; Claeys, D. D.; Allaert, B.; Verpoort, F. Stevens, C. V. Chem. Commun. 2005, 35, 4477-4478. 
184 Braña, M. F.; Garranzo, M.; Pérez-Castells, J. Tetrahedron Lett. 1998, 39, 6569-6572. 
185 Masschelein, K. G. R.; Stevens, C. V.; Dieltiens, N.; Claeys, D. D. Tetrahedron 2007, in press 
186 Dieltiens, N. 2003 Master thesis, Faculty of bioscience engineering, 75pp. 
187 De Kimpe, N.; De Smaele, D. Tetrahedron 1995, 51, 5465-5478. 
188 For the first example of RCM of vinyl chlorides see: Chao, W.; Weinreb, S. M. Org. Lett. 2003, 5, 2505-2507. 
189 For the first example of RCM of vinyl fluorides see: Marhold, M.; Buer, A.; Hiemstra, H.; van Maarseveen, J. 
H.; Haufe, G. Tetrahedron Lett. 2004, 45, 57-60. 
190 Royer, F.; Vilain, C.; Elkaïm, L.; Grimaud, L. Org. Lett. 2003, 5, 2007-2009. 
191 Poupaert, J. H.; Mergen, F.; Lerot, T. Bull. Soc. Chim. Belg. 1988, 97, 469-470. 
192 Fürstner, A.; Langemann, K. Synthesis 1997, 792-803. 
193 Fürstner, A.; Thiel, O. R.; Lehmann, C. W. Organometallics 2002, 21, 331-335. 
194 Vlaamse Liga Tegen Kanker, http://www.tegenkanker.net. 
195 Breslow, R. Jursic, B.; Yan, Z. F.; Friedman, E.; Leng, L.; Ngo, L.; Rifkind, R. A.; Marks, P. A. Proc. Natl. Acad. 
Sci. USA 1991, 88, 5542-5546. 
196 Vanhoecke, B. W.; Bracke, M. E.; Kloosterboer, H. J.; Depypere, H. T. Maturitas 2006, 54, 229-237. 
197 Katritzky, A. R.; Kuanar, M.; Dobchev, D. A.; Vanhoecke, B. W. A.; Karelson, M.; Parmar, V. S.; Stevens, C. V.; 
Bracke, M. E. Bioorg. Med. Chem. 2006, 14, 6933-6939. 
198 Asao, N.; Iso, K.; Yudha, S. S. Org. Lett. 2006, 8, 4149-4151. 
199 Azizi, N.; Saidi, M. R. Tetrahedron 2003, 59, 5329-5332. 
200 Lee, C. W.; Grubbs, R. H. Org. Lett. 2000, 2, 2145-2147. 
201 Hennebel, G. 2007 Master thesis, Faculty of bioscience engineering, in progress. 
202 Hansen, E. C.; Lee, D. J. Am. Chem. Soc. 2003, 125, 9582-9583. 
203 Hansen, E. C.; Lee, D. J. Am. Chem. Soc. 2004, 126, 15074-15080. 
204 Abdou, W. A.; Kamel, A. A.; Khidre, M. D. Heteroatom Chem. 2004, 15, 77-84. 
205 Houbion, J. A. (Monsanto CO., USA) 1978, CAN 90:137674. 
206 Phillips, W. G. (Monsanto CO., USA) 1979, CAN 91:175521. 
207 Haunin, R. (Hoffman-La Roche, F., und Co. A.-G., Switz.) 1979, CAN 91:193175. 
208 Lloyd-Jones, G. C. Org. Biomol. Chem. 2003, 1, 215-236. 
209 Nevado, C.; Echavarren, A. M. Chem. Eur. J. 2005, 11, 3155-3164. 
210 De Kimpe, N.; Stanoeva, E.; Verhé, N.; Schamp, N. Synthesis 1988, 587-592. 
211 Wipf, P.; Fritch, P. C. J. Org. Chem. 1994, 59, 4875-4886. 
212 Hibino, S.; Sugino, E.; Adachi, Y.; Nomi, K.; Sato, K. Heterocycles 1989, 28, 275-282. 
Appendix 2 – Overview of Structures 
Appendix 2 – Overview of Structures 
 
About 213 compounds have been described in this thesis. In this appendix a location (page 
number or paper) is given to each structure which allows the interested reader to quickly retrieve 
the procedure and spectral data of a certain compound. The synthesized compounds are divided 
into 9 classes: 
 
1. Diallylamines, propargylamines, pyrroles, pyrrolines (42 compounds) 
2. α-Aminophosphonates (46 compounds) 
3. 2-Phosphonopyrrolines and 2-phosphonopyrroles (23 compounds) 
4. Phosphonylated isoindoles (13 compounds) 
5. Phosphonylated benzazepines (7 compounds) 
6. Hydantoins and bicyclic derivatives (33 compounds) 
7. Bis-hydantoins and bis-carbamoyllactams (20 compounds) 
8. Pyroglutamate derivatives (14 compounds) 
9. Miscellaneous (15 compounds) 
 
1. Diallylamines, propargylamines, pyrroles, pyrrolines 
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2. α-Aminophosphonates 
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3. 2-Phosphonopyrrolines and 2-phosphonopyrroles
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4. Phosphonylated isoindoles
 
Structure Location Structure Location 
N
P(O)(OMe)2
Cl
 
153 N
P(O)(OMe)2
Cl
 
156 
N
P(O)(OMe)2
Bn
Ph
 
150 
N
P(O)(OMe)2
F
 
153 
N
P(O)(OMe)2
Bn
 
151 
N
P(O)(OMe)2
Ph
 
154 
N
P(O)(OMe)2
O
 
151 N
P(O)(OMe)2  
155 
N
P(O)(OMe)2 
152 N
P(O)(OMe)2
F
 
155 
N
P(O)(OMe)2
Ph
 
152 N
P(O)(OMe)2 
156 
N
P(O)(OMe)2 
154   
 
 
 
 
 
 
 
 
 
 
 
-201- 
Appendix 2 – Overview of Structures 
5. Phosphonylated benzazepines
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6. Hydantoins
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Structure Location Structure Location 
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7. Bis-hydantoins and bis-carbamoyllactams
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8. Pyroglutamate derivatives
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9. Miscellaneous
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